COMPOUNDS AND MEDICAMENTS USING SAME

Information

  • Patent Application
  • 20210214356
  • Publication Number
    20210214356
  • Date Filed
    February 14, 2020
    4 years ago
  • Date Published
    July 15, 2021
    3 years ago
Abstract
The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB:
Description
TECHNICAL FIELD

The present disclosure relates to a novel fused tricyclic compound that is useful as a medicament, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. More specifically, the present disclosure relates to a pharmaceutical composition comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. The present disclosure also relates to a therapeutic agent comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof.


BACKGROUND ART

Rabies is an infection induced by a rabies virus. The mortality after the onset in humans is almost 100%. While over 15 million people worldwide are vaccinated postexposure for the prophylaxis of rabies every year, the worldwide number of fatalities due to rabies is about 55000 annually. An effective therapeutic method for rabies still has not been established. There is still a demand for the establishment thereof.


SUMMARY OF INVENTION
Solution to Problem

The present disclosure provides a compound and a method for the treatment of rabies and other diseases.


The present disclosure was completed by the inventors from finding that compounds represented by the following formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB and the structural formulas related thereto, or a pharmaceutically acceptable salt thereof (hereinafter, also referred to as “the compound(s) of the present disclosure” or “the present compound(s)”) can achieve the objects as a result of diligent study.


The present disclosure provides the following items.


[Item 1]

A compound represented by formula XXIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R3, and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, and


R2A and R2B are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, or R2A and R2B, together with the nitrogen atom to which they are attached, form a heterocycle, wherein the heterocycles are each independently and optionally substituted.


[Item 1B]

The compound represented by formula XXIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof according to item 1, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl,


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 2]

A compound represented by formula XXIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R3, and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group,


R2A and R2B are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, or R2A and R2B, together with the nitrogen atom to which they are attached, form a heterocycle, wherein the heterocycles are each independently and optionally substituted.


[Item 2B]

The compound represented by formula XXIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof according to item 2, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl,


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 3]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R1, R3, and R4 are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and


the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R2A and R2B are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.


[Item 4]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 4B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C6-10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C6-10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 5]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.


[Item 5B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and


R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group V.


[Item 6]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 6B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 7]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally substituted alkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 7B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, carbamoyl, or optionally substituted C1-12 alkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 8]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; substituted carbonyl; or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 8B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, C3-10 cycloalkyl, and substituted C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; substituted carbonyl; or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 9]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; alkylcarbonyl; arylalkylcarbonyl; arylalkyloxycarbonyl; alkoxycarbonyl; arylcarbonyl; aryloxycarbonyl; carbamoyl; alkylcarbamoyl; or arylalkylcarbamoyl, wherein the substituted amino each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 9B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R4 are each independently hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; C1-12 alkylcarbonyl; C6-10 aryl C1-6 alkylcarbonyl; C6-10 aryl C1-6 alkyloxycarbonyl; C1-12 alkoxycarbonyl; C6-10 arylcarbonyl; C6-10 aryloxycarbonyl; carbamoyl; C1-12 alkylcarbamoyl; or C6-10 aryl C1-6 alkylcarbamoyl, wherein the substituted amino have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 10]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R3 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 11]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy.


[Item 11B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, amino, C1-6 alkoxycarbonylamino, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 alkoxycarbonyl, and hydroxy.


[Item 12]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy; heteroarylalkyl; substituted heteroarylalkyl; cycloalkyl; or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group VI.


[Item 13]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; heteroarylalkyl; alkoxycarbonyl-substituted heteroarylalkyl; or cycloalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


[Item 13B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, and 5- to 10-membered heterocycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and hydroxy; 5- to 10-membered heteroaryl C1-6 alkyl; C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl; or C3-10 cycloalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


[Item 14]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 14B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 15]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A is hydrogen, and R2B is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl.


[Item 15B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A is hydrogen, and R2B is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and hydroxy; or C3-10 cycloalkyl.


[Item 16]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.


[Item 16B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of C1-6 alkyl and hydroxy.


[Item 17]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl.


[Item 17B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, C1-12 alkyl, C1-12 alkylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, C6-10 aryl C1-6 alkyloxycarbonyl, C1-12 alkoxycarbonyl, carbamoyl, or C6-10 aryl C1-6 alkylcarbamoyl.


[Item 17C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is hydrogen, methyl, ethyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, tert-butylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, ethoxybenzyl, tert-butoxybenzyl, aminobenzyl, (cyclopentylcarbonylamino)benzyl, (cyclopentylmethylamino)benzyl, (dimethylamino)benzyl, (carbamoylethylcarbonylamino)benzyl, (carboxyethylcarbonylamino)benzyl, nitrobenzyl, hydroxybenzyl, 3-methylbutanoyl, isobutylcarbonyl, 2-phenylacetyl, isopropyloxycarbonyl, benzoyl, or phenyloxycarbonyl.


[Item 17D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A is hydrogen, R2B is methyl, isopropyl, isobutyl, n-pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, carbamoylmethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, (tetrahydro-2H-pyran-2-yl)methyl, benzyl, phenylethyl, naphthalenylmethyl, naphthalenylethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, tert-butoxybenzyl, hydroxybenzyl, α-hydroxymethylphenethyl, β-hydroxyphenethyl, pyridinylmethyl, (1H-indol-3-yl)ethyl, (1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, cyclopentyl, or cyclohexyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.


[Item 17E]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxymethyl, hydroxyethyl, (tert-butyldimethylsilyloxy)ethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, or hydroxybenzyl.


[Item 17F]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, methyl, ethyl, isobutyl, formyl, acetyl, 3-methylbutanoyl, 2-phenylacetyl, methoxycarbonyl, ethoxycarbonyl, 2-methylpropyloxycarbonyl, tert-butoxycarbonyl, benzoyl, benzyl, benzyloxycarbonyl, aminocarbonyl, N-benzylaminocarbonyl, propylcarbamoyl, N-isobutylaminocarbonyl, or N-benzylaminocarbonyl.


[Item 17G]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is a compound selected from the group consisting of compound numbers IB-1 to IB-995 and IF-1 to IF-931.


[Item 18]

A compound represented by formula XXIIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 19]

A compound represented by formula XXIIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 20]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R1 and R3 are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and


the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R2A and R2B are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.


[Item 21]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


[Item 22]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.


[Item 23]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 24]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 25B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


[Item 25]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is hydrogen; alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, hydroxy, substituted oxy, formyl, substituted carbonyl, cycloalkyl, and substituted cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; or substituted carbonyl, wherein the substituted amino, substituted oxy, substituted carbonyl, substituted cycloalkyl, and substituted alkyl in R1 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 26]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is hydrogen; alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl-substituted amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; alkylcarbonyl; arylalkylcarbonyl; alkoxycarbonyl; arylcarbonyl; aryloxycarbonyl; carbamoyl; alkylcarbamoyl; or arylalkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 27B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; C1-12 alkylcarbonyl; C6-10 aryl C1-6 alkylcarbonyl; C1-12 alkoxycarbonyl; C6-10 arylcarbonyl; C6-10 aryloxycarbonyl; carbamoyl; C1-12 alkylcarbamoyl; or C6-10 aryl C1-6 alkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 27C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, substituted amino, nitro, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 28]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; alkyl; formyl; substituted carbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl; heteroarylalkyl; or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R3 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 29B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; alkyl; formyl; alkylcarbonyl; arylalkylcarbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino; heteroarylalkyl; or alkoxycarbonyl-substituted heteroarylalkyl.


[Item 29C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is hydrogen; C1-12 alkyl; formyl; C1-6 alkylcarbonyl; C6-10 aryl C1-6 alkylcarbonyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-6 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino; 5- to 10-membered heteroaryl C1-6 alkyl; or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl.


[Item 29D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-6 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


[Item 29]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; alkyl; formyl; substituted carbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl; heteroarylalkyl; or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R2A and Rn, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


[Item 30B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; alkyl; formyl; alkylcarbonyl; arylalkylcarbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino; heteroarylalkyl; or alkoxycarbonyl-substituted heteroarylalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


[Item 30C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; C1-12 alkyl; formyl; C1-6 alkylcarbonyl; C6-10 aryl C1-6 alkylcarbonyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C6-10 aryl C1-12 alkyl; C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino; 5- to 10-membered heteroaryl C1-12 alkyl; or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-12 alkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C1-6alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


[Item 30D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently hydrogen; C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C6-10 aryl C1-12 alkyl; C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino; 5- to 10-membered heteroaryl C1-12 alkyl; or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-12 alkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C1-6alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


[Item 30]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 31B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


[Item 31]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A is hydrogen, and R2B is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen and alkyl.


[Item 32B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A is hydrogen, and R2B is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen and C1-6 alkyl.


[Item 32]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; or arylalkyl.


[Item 32B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is C1-12 alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; C6-10 aryl C1-6 alkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.


[Item 32C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is methyl, n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, aminopropyl, 2-(tert-butyl-dimethylsilyloxy)ethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, (tert-butyl)benzyl, methoxybenzyl, ethoxybenzyl, (tert-butoxy)benzyl, (trifluoromethoxy)benzyl, (dimethylamino)benzyl, nitrobenzyl, or hydroxybenzyl.


[Item 32D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2A and R2B are each independently isopropyl, isobutyl, sec-butyl, pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, (tert-butoxycarbonyl)ethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminopropyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, (1,2,3,4-tetrahydronaphthalenyl)methyl, (tetrahydro-2H-pyranyl)methyl, benzyl, phenylethyl, naphthalenylmethyl, (naphthalenyl)ethyl, β,-hydroxyphenethyl, α-(hydroxymethyl)phenethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, (tert-butoxy)benzyl, hydroxybenzyl, pyridinylmethyl, quinolinylethyl, (1-(tert-butoxycarbonyl)-1H-indolyl)ethyl, cyclopentyl, or cyclohexyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.


[Item 32E]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, aminopropyl, (tert-butyldimethylsilyloxy)ethyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, (tert-butoxy)benzyl, or hydroxybenzyl.


[Item 32F]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is a compound selected from the group consisting of compound numbers IIB-1 to IIB-1129 and IIF-1 to IIF-1047.


[Item 33]

An antiviral agent for a virus in the Lyssavirus genus, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.


[Item 34]

The antiviral agent according to any one of the preceding items, wherein the virus in the Lyssavirus genus comprises a rabies virus.


[Item 35]

A medicament comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.


[Item 36]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for rabies.


[Item 37]

A pharmaceutical composition comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


[Item 38]

A pharmaceutical composition for the prophylaxis or treatment of rabies, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


[Item 39]

An anticancer agent comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.


[Item 40]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for cancer.


[Item 41]

A pharmaceutical composition for the prophylaxis or treatment of cancer, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


[Item 42]

A method for the prophylaxis or treatment of rabies, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the antiviral agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof.


[Item 43]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of rabies.


[Item 44]

A method for the prophylaxis or treatment of cancer, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the anticancer agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof.


[Item 45]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the anticancer agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of cancer.


[Item 46]

A method for the prophylaxis or treatment of rabies, comprising administering an effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof to a subject in need thereof.


[Item 47]

A method for the prophylaxis or treatment of cancer, comprising administering an effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof to a subject in need thereof.


The present disclosure also provides the following items.


[Item A1]

A compound represented by formula IF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and


R4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.


[Item A2]

A compound represented by formula IB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and


R4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.


[Item A3]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and


R4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted alkoxycarbonyl, or optionally substituted carbamoyl.


[Item A3a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and


R4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, or optionally substituted alkoxycarbonyl.


[Item A4]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl C1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C1-6 alkyl, or optionally substituted C3-6 cycloalkyl C1-6 alkyl, and


R4 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkylcarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C1-6 alkoxycarbonyl, or optionally substituted C1-6 alkylcarbamoyl.


[Item A4b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl C1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C1-6 alkyl, or optionally substituted C3-6 cycloalkyl C1-6 alkyl, and


R4 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkylcarbonyl, optionally substituted C6-10 arylcarbonyl, or optionally substituted C1-6 alkoxycarbonyl.


[Item A5]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, (optionally substituted amino)-C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6 alkyl, or C3-6 cycloalkyl C1-6 alkyl.


[Item A5a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6 alkyl, or C3-6 cycloalkyl C1-6 alkyl.


[Item A5b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkylcarbonyl, optionally substituted C6-10 aryl C1-6 alkylcarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C1-6 alkoxycarbonyl, optionally substituted C6-10 aryl C1-6 alkoxycarbonyl, carbamoyl, optionally substituted C1-6 alkylcarbamoyl, or optionally substituted C6-10 aryl C1-6 alkylcarbamoyl.


[Item A5c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted alkyl or optionally substituted arylalkyl.


[Item A5d]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


[Item A5e]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, or (optionally substituted amino)-C6-10 aryl C1-6 alkyl.


[Item A5f]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is naphthalen-1-ylmethyl or optionally substituted benzyl.


[Item A5g]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently alkyl or optionally substituted benzyl, and R2 is optionally substituted benzyl.


[Item A5h]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently C1-6 alkyl, benzyl, C1-4 alkyl-substituted benzyl, chloro-substituted benzyl, C1-4 alkoxy-substituted benzyl, or amino-substituted benzyl, and R2 is benzyl or chloro-substituted benzyl.


[Item A5i]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 and R3 are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R2 is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.


[Item A6]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C6-lo arylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C6-10 aryl C1-6 alkoxycarbonyl, carbamoyl, C1-6 alkylcarbamoyl, or C6-10 aryl C1-6 alkylcarbamoyl.


[Item A6b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C6-10 arylcarbonyl, or C1-6 alkoxycarbonyl.


[Item A7]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, C1-4 alkyl, C1-4 alkylcarbonyl, C6 arylcarbonyl, C6 aryl C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl, C6 aryl C1-4 alkoxycarbonyl, carbamoyl, C1-4 alkylcarbamoyl, or C6 aryl C1-4 alkylcarbamoyl.


[Item A7b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, C1-4 alkyl, C1-4 alkylcarbonyl, C6 arylcarbonyl, or C1-4 alkoxycarbonyl.


[Item A8]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.


[Item A8b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.


[Item A9]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, halogen-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C1-4 alkoxycarbonylamino-substituted C1-4 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A9b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.


[Item A10]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.


[Item A10b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.


[Item A11]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.


[Item A11b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.


[Item A12]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-6 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, halo-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A12b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.


[Item A13]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.


[Item A14]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.


[Item A14b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, or hydroxyethyl.


[Item A14c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.


[Item A15]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A15b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, which is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 3-methoxy-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.


[Item A16]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl. [Item A17] The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.


[Item A17b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, hydroxymethyl, or naphthalen-1-ylmethyl.


[Item A17c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.


[Item A18]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen or alkyl.


[Item A18a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen or C1-6 alkyl.


[Item A18b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen or ethyl.


[Item A19]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R4 is hydrogen.


[Item A20]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein R1 is C1-6 alkyl or C6-10 aryl C1-6 alkyl, and R2 and R3 are each independently C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


[Item A21]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, isopentyl, or benzyl, R2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.


[Item A22]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is a compound of formula IF, R1 is isobutyl, R2 is benzyl, and R3 is benzyl.


[Item A23]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is compound of formula IF, R1 is benzyl, R2 is benzyl, and R3 is isobutyl.


[Item A24]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is a compound of formula IF, R1 is isobutyl, R2 is benzyl, and R3 is 3-methylbenzyl.


[Item A25]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


the compound is a compound of formula IF, R1 is benzyl, R2 is 3,4-dichlorobenzyl, and R3 is isobutyl.


[Item A26]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IF is a compound selected from the group consisting of IF-1, IF-2, IF-3, IF-4, IF-5, IF-6, IF-7, IF-8, IF-9, IF-10, IF-11, IF-12, IF-13, IF-14, IF-15, IF-16, IF-17, IF-18, IF-19, IF-20, IF-22, IF-23, IF-24, IF-25, IF-26, IF-27, IF-28, IF-29, IF-30, IF-31, IF-32, IF-33, IF-34, IF-35, IF-36, IF-38, IF-39, IF-40, IF-41, IF-42, IF-43, IF-44, IF-45, IF-46, IF-47, IF-49, IF-50, IF-54, IF-57, IF-58, IF-68, IF-69, IF-70, IF-71, IF-72, IF-73, IF-74, IF-76, IF-77, IF-80, and IF-81 to IF-884.


[Item A26b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IF is (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl-N-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N,1-dibenzyl-7-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isopentyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(3-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(4-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N-(3,4-dichlorobenzyl)-7-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, or (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-4-ethyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide.


[Item A27]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IB is a compound selected from the group consisting of IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, IB-8, IB-9, IB-10, IB-11, IB-12, IB-13, IB-14, IB-15, IB-16, IB-17, IB-18, IB-19, IB-20, IB-21, IB-22, IB-23, IB-24, IB-25, IB-26, IB-27, IB-28, IB-29, IB-30, IB-31, IB-32, IB-33, IB-34, IB-35, IB-36, IB-37, IB-38, IB-39, IB-40, IB-41, IB-42, IB-43, IB-44, IB-45, IB-46, IB-47, IB-49, IB-50, IB-54, IB-57, IB-58, IB-64, IB-68, IB-69, IB-70, IB-71, IB-72, IB-73, IB-74, IB-75, IB-76, IB-77, IB-78, IB-79, IB-80, and IB-81 to IB-923.


[Item A27b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IB is (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-1,7-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isopentyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7-isobutyl-N-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(3-methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, or (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide.


[Item A28]

A compound represented by formula IIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl.


[Item A29]

A compound represented by formula IIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl.


[Item A30]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.


[Item A31]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl C1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C1-6 alkyl, or optionally substituted C3-6 cycloalkyl C1-6 alkyl.


[Item A32]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, (optionally substituted amino)-C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6 alkyl, or C3-6 cycloalkyl C1-6 alkyl.


[Item A32a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-20 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6 alkyl, or C3-6 cycloalkylC1-6alkyl.


[Item A32b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted alkyl or optionally substituted arylalkyl.


[Item A32c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2 and R3 are each independently optionally substituted C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


[Item A33]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, halogen-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C1-4 alkoxycarbonylamino-substituted C1-4 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A33b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, cyclohexylmethyl, or




embedded image


[Item A34]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.


[Item A35]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.


[Item A35b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R2 is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


[Item A36]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-6 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, halo-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A36b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or




embedded image


[Item A37]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.


[Item A38]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, or hydroxyethyl.


[Item A38b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


[Item A39]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


[Item A39b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or




embedded image


[Item A40]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.


[Item A41]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, hydroxymethyl, or naphthalen-1-ylmethyl.


[Item A41b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R3 is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


[Item A42]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-6 alkyl or C6-10 aryl C1-6 alkyl, R2 and R3 are each independently C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


[Item A42b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2, and R3 are each independently C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


[Item A42c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1, R2, and R3 are each independently C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkyl-substituted C6-20 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, or (optionally substituted amino)-C6-10 aryl C1-6 alkyl.


[Item A42d]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is C1-6 alkyl or C6 aryl C1-4 alkyl, R2 is C1-6 alkyl or C1-4 alkyl-substituted benzyl, and R3 is C1-6 alkyl or C6 aryl C1-4 alkyl.


[Item A43]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, R2 is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R3 is isobutyl, isopentyl, or benzyl.


[Item A43b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein


R1 is isobutyl, isopentyl, or benzyl, R2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.


[Item A44]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound is a compound of formula IIF, R1 is isobutyl, R2 is 4-methylbenzyl, and R3 is benzyl.


[Item A45]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound is a compound of formula IIB, R1 is benzyl, R2 is isobutyl, and R3 is isobutyl.


[Item A46]

An antiviral agent for a virus in the Lyssavirus genus, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.


[Item A47]

The antiviral agent according to any one of the preceding items, wherein the virus in the Lyssavirus genus comprises a rabies virus.


[Item A48]

A medicament comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items.


[Item A49]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for rabies.


[Item A50]

A pharmaceutical composition comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.


[Item A51]

A pharmaceutical composition for the prophylaxis or treatment of rabies, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.


[Item A52]

The compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof for use as an antiviral agent for a virus in the Lyssavirus genus, preferably a rabies virus, or for the prophylaxis or treatment of rabies.


[Item A53]

A method for the prophylaxis or treatment of rabies, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the antiviral agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof


[Item A54]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of rabies.


The present disclosure is intended so that one or more of the features described above can be provided not only as the explicitly disclosed combinations, but also as other combinations thereof. Additional embodiments and advantages of the present disclosure are recognized by those skilled in the art by reading and understanding the following detailed description as needed.


Advantageous Effects of Invention

The compounds of the present disclosure exhibit an excellent antiviral action on viruses in the Lyssavirus genus including the rabies virus. Therefore, the compounds of the present disclosure are useful as a therapeutic agent and/or prophylactic agent for rabies.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 shows an ORTEP diagram for the results of X-ray crystallography in Synthesis Example: IF-1.



FIG. 2 shows a chromatogram upon separation of the racemate in Synthesis Example: IF-1 using a chiral column, CHIRALPAK IG (5 μm, 4.6×150 mm), mobile phase: methanol:diethylamine (100:0.1).



FIG. 3 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 4 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 5 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 6 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 7 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 8 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 9 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 10 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 11 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 12 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 13 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 14 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 15 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 16 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 17 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 18 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 19 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 20 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 21 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 22 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 23 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 24 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 25 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 26 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 27 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 28 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 29 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 30 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 31 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 32 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 33 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 34 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 35 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 36 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 37 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 38 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 39 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 40 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 41 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 42 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 43 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 44 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 45 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 46 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 47 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 48 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 49 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 50 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 51 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 52 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 53 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 54 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 55 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 56 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 57 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 58 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 59 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 60 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 61 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 62 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 63 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 64 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 65 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 66 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 67 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 68 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 69 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 70 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 71 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 72 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 73 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 74 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 75 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 76 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 77 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 78 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 79 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 80 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).



FIG. 81 shows the 1H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).





DESCRIPTION OF EMBODIMENTS

Hereinafter, the present disclosure is described in more detail.


Throughout the entire specification, a singular expression should be understood as encompassing the concept thereof in the plural form, unless specifically noted otherwise. Thus, singular articles (e.g., “a”, “an”, “the”, and the like in the case of English) should also be understood as encompassing the concept thereof in the plural form, unless specifically noted otherwise. The terms used herein should also be understood as being used in the meaning that is commonly used in the art, unless specifically noted otherwise. Thus, unless defined otherwise, all terminologies and scientific technical terms that are used herein have the same meaning as the general understanding of those skilled in the art to which the present disclosure pertains. In case of a contradiction, the present specification (including the definitions) takes precedence.


Definitions

The terms and the general technology used in the present disclosure are first described.


As used herein, the term “group” refers to a monovalent group, unless especially noted otherwise. Examples of a group that is not a monovalent group include alkylene group (divalent) and the like. The term “group” may also be abbreviated in the following description of substituents or the like.


As used herein, the number of substituents when a group is defined as “optionally substituted” or “substituted” is not particularly limited as long as it is substitutable and is one or more. The description for each group is also applicable when the substituent is a part of or a substituent on another substituent, unless specifically noted otherwise.


As used herein, “maximum substitutable number” is the maximum number of substituents that a group can have. The number can vary for each group. For example, the number is 3 for a methyl group, 5 for an ethyl group, 7 for a benzyl group, and 10 for a naphthalenyl ethyl group.


For a group that is modified by “optionally substituted” or “substituted” herein, any portion of the group can be substituted. For example, “optionally substituted arylalkyl” and “substituted arylalkyl” can have the aryl moiety substituted, the alkyl moiety substituted, or both the aryl moiety and the alkyl moiety substituted.


As used herein, the substituent used when “optionally substituted” can be one or more of the same or different substituents selected from any one of the following substituent groups I to VI. While the types of atoms within a substituent associated with attachment are not particularly limited by the type of substituent, if the atom to which a substituent attaches is an oxygen atom, a nitrogen atom, or a sulfur atom, the atom is limited to and selected from those with an attachment point in the following substituents that is a carbon atom.


Substituent group I consists of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted alkyloxy, unsubstituted or substituted alkenyloxy, unsubstituted or substituted alkynyloxy, unsubstituted or substituted aryl-LX-oxy, unsubstituted or substituted cycloalkyl-LX-oxy, unsubstituted or substituted heteroaryl-LX-oxy, unsubstituted or substituted heterocycloalkyl-LX-oxy, unsubstituted or substituted alkyloxyalkyl, unsubstituted or substituted alkenyloxyalkyl, unsubstituted or substituted alkynyloxyalkyl, unsubstituted or substituted aryloxyalkyl, unsubstituted or substituted cycloalkyloxyalkyl, unsubstituted or substituted heteroaryloxyalkyl, unsubstituted or substituted heterocycloalkyloxyalkyl, unsubstituted or substituted alkyloxyalkyloxy, unsubstituted or substituted alkenyloxyalkyloxy, unsubstituted or substituted alkynyloxyalkyloxy, unsubstituted or substituted aryloxyalkyloxy, unsubstituted or substituted cycloalkyloxyalkyloxy, unsubstituted or substituted heteroaryloxyalkyloxy, unsubstituted or substituted heterocycloalkyloxyalkyloxy, unsubstituted or substituted alkylcarbonyl, unsubstituted or substituted alkenylcarbonyl, unsubstituted or substituted alkynylcarbonyl, unsubstituted or substituted aryl-LX-carbonyl, unsubstituted or substituted cycloalkyl-LX-carbonyl, unsubstituted or substituted heteroaryl-LX-carbonyl, unsubstituted or substituted heterocycloalkyl-LX-carbonyl, unsubstituted or substituted alkylcarbonyloxy, unsubstituted or substituted alkenylcarbonyloxy, unsubstituted or substituted alkynylcarbonyloxy, unsubstituted or substituted aryl-LX-carbonyloxy, unsubstituted or substituted cycloalkyl-LX-carbonyloxy, unsubstituted or substituted heteroaryl-LX-carbonyloxy, unsubstituted or substituted heterocycloalkyl-LX-carbonyloxy, unsubstituted or substituted alkylcarbonylamino, unsubstituted or substituted alkenylcarbonylamino, unsubstituted or substituted alkynylcarbonylamino, unsubstituted or substituted aryl-LX-carbonylamino, unsubstituted or substituted cycloalkyl-LX-carbonylamino, unsubstituted or substituted heteroaryl-LX-carbonylamino, unsubstituted or substituted heterocycloalkyl-LX-carbonylamino, unsubstituted or substituted alkylcarbonylthio, unsubstituted or substituted alkenylcarbonylthio, unsubstituted or substituted alkynylcarbonylthio, unsubstituted or substituted aryl-LX-carbonylthio, unsubstituted or substituted cycloalkyl-LX-carbonylthio, unsubstituted or substituted heteroaryl-LX-carbonylthio, unsubstituted or substituted heterocycloalkyl-LX-carbonylthio, unsubstituted or substituted alkylcarbonylimino, unsubstituted or substituted alkenylcarbonylimino, unsubstituted or substituted alkynylcarbonylimino, unsubstituted or substituted aryl-LX-carbonylimino, unsubstituted or substituted cycloalkyl-LX-carbonylimino, unsubstituted or substituted heteroaryl-LX-carbonylimino, unsubstituted or substituted heterocycloalkyl-LX-carbonylimino, unsubstituted or substituted alkylthio, unsubstituted or substituted alkenylthio, unsubstituted or substituted alkynylthio, unsubstituted or substituted aryl-LX-thio, unsubstituted or substituted cycloalkyl-LX-thio, unsubstituted or substituted heteroaryl-LX-thio, unsubstituted or substituted heterocycloalkyl-LX-thio, unsubstituted or substituted alkylamino, unsubstituted or substituted alkenylamino, unsubstituted or substituted alkynylamino, unsubstituted or substituted alkynylamino, unsubstituted or substituted aryl-LX-amino, unsubstituted or substituted cycloalkyl-LX-amino, unsubstituted or substituted heteroaryl-LX-amino, unsubstituted or substituted heterocycloalkyl-LX-amino, unsubstituted or substituted alkylsulfonyl, unsubstituted or substituted alkenylsulfonyl, unsubstituted or substituted alkynylsulfonyl, unsubstituted or substituted aryl-LX-sulfonyl, unsubstituted or substituted cycloalkyl-LX-sulfonyl, unsubstituted or substituted heteroaryl-LX-sulfonyl, unsubstituted or substituted heterocycloalkyl-LX-sulfonyl, unsubstituted or substituted alkylsulfonylamino, unsubstituted or substituted alkenylsulfonylamino, unsubstituted or substituted alkynylsulfonylamino, unsubstituted or substituted aryl-LX-sulfonylamino, unsubstituted or substituted cycloalkyl-LX-sulfonylamino, unsubstituted or substituted heteroaryl-LX-sulfonylamino, unsubstituted or substituted heterocycloalkyl-LX-sulfonylamino, unsubstituted or substituted alkylimino, unsubstituted or substituted alkenylimino, unsubstituted or substituted alkynylimino, unsubstituted or substituted aryl-LX-imino, unsubstituted or substituted cycloalkyl-LX-imino, unsubstituted or substituted heteroaryl-LX-imino, unsubstituted or substituted heterocycloalkyl-LX-imino, unsubstituted or substituted alkyloxyimino, unsubstituted or substituted alkenyloxyimino, unsubstituted or substituted alkynyloxyimino, unsubstituted or substituted aryl-LX-oxyimino, unsubstituted or substituted cycloalkyl-LX-oxyimino, unsubstituted or substituted heteroaryl-LX-oxyimino, unsubstituted or substituted heterocycloalkyl-LX-oxyimino, unsubstituted or substituted alkyloxycarbonyl, unsubstituted or substituted alkenyloxycarbonyl, unsubstituted or substituted alkynyloxycarbonyl, unsubstituted or substituted aryl-LX-oxycarbonyl, unsubstituted or substituted cycloalkyl-LX-oxycarbonyl, unsubstituted or substituted heteroaryl-LX-oxycarbonyl, unsubstituted or substituted heterocycloalkyl-LX-oxycarbonyl, unsubstituted or substituted alkyloxycarbonylamino, unsubstituted or substituted alkenyloxycarbonylamino, unsubstituted or substituted alkynyloxycarbonylamino, unsubstituted or substituted aryl-LX-oxycarbonylamino, unsubstituted or substituted cycloalkyl-LX-oxycarbonylamino, unsubstituted or substituted heteroaryl-LX-oxycarbonylamino, unsubstituted or substituted heterocycloalkyl-LX-oxycarbonylamino, unsubstituted or substituted alkylsulfanyl, unsubstituted or substituted alkenylsulfanyl, unsubstituted or substituted alkynylsulfanyl, unsubstituted or substituted aryl-LX-sulfanyl, unsubstituted or substituted cycloalkyl-LX-sulfanyl, unsubstituted or substituted heteroaryl-LX-sulfanyl, unsubstituted or substituted heterocycloalkyl-LX-sulfanyl, unsubstituted or substituted alkylsulfinyl, unsubstituted or substituted alkenylsulfinyl, unsubstituted or substituted alkynylsulfinyl, unsubstituted or substituted aryl-LX-sulfinyl, unsubstituted or substituted cycloalkyl-LX-sulfinyl, unsubstituted or substituted heteroaryl-LX-sulfinyl, unsubstituted or substituted heterocycloalkyl-LX-sulfinyl, unsubstituted or substituted alkylcarbamoyl, unsubstituted or substituted alkenylcarbamoyl, unsubstituted or substituted alkynylcarbamoyl, unsubstituted or substituted aryl-LX-carbamoyl, unsubstituted or substituted cycloalkyl-LX-carbamoyl, unsubstituted or substituted heteroaryl-LX-carbamoyl, unsubstituted or substituted heterocycloalkyl-LX-carbamoyl, unsubstituted or substituted alkylsulfamoyl, unsubstituted or substituted alkenylsulfamoyl, unsubstituted or substituted alkynylsulfamoyl, unsubstituted or substituted aryl-LX-sulfamoyl, unsubstituted or substituted cycloalkyl-LX-sulfamoyl, unsubstituted or substituted heteroaryl-LX-sulfamoyl, and unsubstituted or substituted heterocycloalkyl-LX-sulfamoyl, wherein LX is a single bond or unsubstituted or substituted alkylene,


wherein the substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, substituted heteroaryl, substituted heterocycloalkyl, and substituted alkylene moieties (fully or partially) in the substituent group each independently have one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfa, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyloxy, alkenyloxy, alkynyloxy, aryl-LX-oxy, cycloalkyl-LX-oxy, heteroaryl-LX-oxy, heterocycloalkyl-LX-oxy, alkyloxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl, aryloxyalkyl, cycloalkyloxyalkyl, heteroaryloxyalkyl, heterocycloalkyloxyalkyl, alkyloxyalkyloxy, alkenyloxyalkyloxy, alkynyloxyalkyloxy, aryloxyalkyloxy, cycloalkyloxyalkyloxy, heteroaryloxyalkyloxy, heterocycloalkyloxyalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aryl-LX-carbonyl, cycloalkyl-LX-carbonyl, heteroaryl-LX-carbonyl, heterocycloalkyl-LX-carbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, aryl-LX-carbonyloxy, cycloalkyl-LX-carbonyloxy, heteroaryl-LX-carbonyloxy, heterocycloalkyl-LX-carbonyloxy, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, aryl-LX-carbonylamino, cycloalkyl-LX-carbonylamino, heteroaryl-LX-carbonylamino, heterocycloalkyl-LX-carbonylamino, alkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, aryl-LX-carbonylthio, cycloalkyl-LX-carbonylthio, heteroaryl-LX-carbonylthio, heterocycloalkyl-LX-carbonylthio, alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, aryl-LX-carbonylimino, cycloalkyl-LX-carbonylimino, heteroaryl-LX-carbonylimino, heterocycloalkyl-LX-carbonylimino, alkylthio, alkenylthio, alkynylthio, aryl-LX-thio, cycloalkyl-LX-thio, heteroaryl-LX-thio, heterocycloalkyl-LX-thio, alkylamino, alkenylamino, alkynylamino, alkynylamino, aryl-LX-amino, cycloalkyl-LX-amino, heteroaryl-LX-amino, heterocycloalkyl-LX-amino, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, aryl-LX-sulfonyl, cycloalkyl-LX-sulfonyl, heteroaryl-LX-sulfonyl, heterocycloalkyl-LX-sulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aryl-LX-sulfonylamino, cycloalkyl-LX-sulfonylamino, heteroaryl-LX-sulfonylamino, heterocycloalkyl-LX-sulfonylamino, alkylimino, alkenylimino, alkynylimino, aryl-LX-imino, cycloalkyl-LX-imino, heteroaryl-LX-imino, heterocycloalkyl-LX-imino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, aryl-LX-oxyimino, cycloalkyl-LX-oxyimino, heteroaryl-LX-oxyimino, heterocycloalkyl-LX-oxyimino, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryl-LX-oxycarbonyl, cycloalkyl-LX-oxycarbonyl, heteroaryl-LX-oxycarbonyl, heterocycloalkyl-LX-oxycarbonyl, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryl-LX-oxycarbonylamino, cycloalkyl-LX-oxycarbonylamino, heteroaryl-LX-oxycarbonylamino, heterocycloalkyl-LX-oxycarbonylamino, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, aryl-LX-sulfanyl, cycloalkyl-LX-sulfanyl, heteroaryl-LX-sulfanyl, heterocycloalkyl-LX-sulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, aryl-LX-sulfinyl, cycloalkyl-LX-sulfinyl, heteroaryl-LX-sulfinyl, heterocycloalkyl-LX-sulfinyl, alkylcarbamoyl, alkenylcarbamoyl, alkynylcarbamoyl, aryl-LX-carbamoyl, cycloalkyl-LX-carbamoyl, heteroaryl-LX-carbamoyl, heterocycloalkyl-LX-carbamoyl, alkylsulfamoyl, alkenylsulfamoyl, alkynylsulfamoyl, aryl-LX-sulfamoyl, cycloalkyl-LX-sulfamoyl, heteroaryl-LX-sulfamoyl, and heterocycloalkyl-LX-sulfamoyl.


Substituent group II consists of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, unsubstituted or substituted C1-12 alkyl, unsubstituted or substituted C2-12 alkenyl, unsubstituted or substituted C2-12 alkynyl, unsubstituted or substituted C0-10 aryl, unsubstituted or substituted C3-10 cycloalkyl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl, unsubstituted or substituted C1-12 alkyloxy, unsubstituted or substituted C2-12 alkenyloxy, unsubstituted or substituted C2-12 alkynyloxy, unsubstituted or substituted C6-10 aryl-LX-oxy, unsubstituted or substituted C3-10 cycloalkyl-LX-oxy, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-oxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-oxy, unsubstituted or substituted C1-12 alkyloxy C1-12 alkyl, unsubstituted or substituted C2-12 alkenyloxy C1-12 alkyl, unsubstituted or substituted C2-12 alkynyloxy C1-12 alkyl, unsubstituted or substituted C0-10 aryloxy C1-12 alkyl, unsubstituted or substituted C3-10 cycloalkyloxy C1-12 alkyl, unsubstituted or substituted 5- to 10-membered heteroaryloxy C1-12 alkyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyloxy C1-12 alkyl, unsubstituted or substituted C1-12 alkyloxy C1-12 alkyloxy, unsubstituted or substituted C2-12 alkenyloxy C1-12 alkyloxy, unsubstituted or substituted C2-12 alkynyloxy C1-12 alkyloxy, unsubstituted or substituted C6-10 aryloxy C1-12 alkyloxy, unsubstituted or substituted C3-10 cycloalkyloxy C1-12 alkyloxy, unsubstituted or substituted 5- to 10-membered heteroaryloxy C1-12 alkyloxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyloxy C1-12 alkyloxy, unsubstituted or substituted C1-12 alkylcarbonyl, unsubstituted or substituted C2-12 alkenylcarbonyl, unsubstituted or substituted C2-12 alkynylcarbonyl, unsubstituted or substituted C6-10 aryl-LX-carbonyl, unsubstituted or substituted C3-10 cycloalkyl-LX-carbonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbonyl, unsubstituted or substituted C1-12 alkylcarbonyloxy, unsubstituted or substituted C2-12 alkenylcarbonyloxy, unsubstituted or substituted C2-12 alkynylcarbonyloxy, unsubstituted or substituted C6-10 aryl-LX-carbonyloxy, unsubstituted or substituted C3-10 cycloalkyl-LX-carbonyloxy, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbonyloxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbonyloxy, unsubstituted or substituted C1-12 alkylcarbonylamino, unsubstituted or substituted C2-12 alkenylcarbonylamino, unsubstituted or substituted C2-12 alkynylcarbonylamino, unsubstituted or substituted C6-10 aryl-LX-carbonylamino, unsubstituted or substituted C3-10 cycloalkyl-LX-carbonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbonylamino, unsubstituted or substituted C1-12 alkylcarbonylthio, unsubstituted or substituted C2-12 alkenylcarbonylthio, unsubstituted or substituted C2-12 alkynylcarbonylthio, unsubstituted or substituted C6-10 aryl-LX-carbonylthio, unsubstituted or substituted C3-10 cycloalkyl-LX-carbonylthio, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbonylthio, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbonylthio, unsubstituted or substituted C1-12 alkylcarbonylimino, unsubstituted or substituted C2-12 alkenylcarbonylimino, unsubstituted or substituted C2-12 alkynylcarbonylimino, unsubstituted or substituted C6-10 aryl-LX-carbonylimino, unsubstituted or substituted C3-10 cycloalkyl-LX-carbonylimino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbonylimino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbonylimino, unsubstituted or substituted C1-12 alkylthio, unsubstituted or substituted C2-12 alkenylthio, unsubstituted or substituted C2-12 alkynylthio, unsubstituted or substituted C6-10 aryl-LX-thio, unsubstituted or substituted C3-10 cycloalkyl-LX-thio, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-thio, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-thio, unsubstituted or substituted C1-12 alkylamino, unsubstituted or substituted C2-12 alkenylamino, unsubstituted or substituted C2-12 alkynylamino, unsubstituted or substituted C2-12 alkynylamino, unsubstituted or substituted C6-10 aryl-LX-amino, unsubstituted or substituted C3-10 cycloalkyl-LX-amino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-amino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-amino, unsubstituted or substituted C1-12 alkylsulfonyl, unsubstituted or substituted C2-12 alkenylsulfonyl, unsubstituted or substituted C2-12 alkynylsulfonyl, unsubstituted or substituted C6-10 aryl-LX-sulfonyl, unsubstituted or substituted C3-10 cycloalkyl-LX-sulfonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-sulfonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-sulfonyl, unsubstituted or substituted C1-12 alkylsulfonylamino, unsubstituted or substituted C2-12 alkenylsulfonylamino, unsubstituted or substituted C2-12 alkynylsulfonylamino, unsubstituted or substituted C6-10 aryl-LX-sulfonylamino, unsubstituted or substituted C3-10 cycloalkyl-LX-sulfonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-sulfonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-sulfonylamino, unsubstituted or substituted C1-12 alkylimino, unsubstituted or substituted C2-12 alkenylimino, unsubstituted or substituted C2-12 alkynylimino, unsubstituted or substituted C6-10 aryl-LX-imino, unsubstituted or substituted C3-10 cycloalkyl-LX-imino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-imino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-imino, unsubstituted or substituted C1-12 alkyloxyimino, unsubstituted or substituted C2-12 alkenyloxyimino, unsubstituted or substituted C2-12 alkynyloxyimino, unsubstituted or substituted C6-10 aryl-LX-oxyimino, unsubstituted or substituted C3-10 cycloalkyl-LX-oxyimino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-oxyimino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-oxyimino, unsubstituted or substituted C1-12 alkyloxycarbonyl, unsubstituted or substituted C2-12 alkenyloxycarbonyl, unsubstituted or substituted C2-12 alkynyloxycarbonyl, unsubstituted or substituted C6-10 aryl-LX-oxycarbonyl, unsubstituted or substituted C3-10 cycloalkyl-LX-oxycarbonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-oxycarbonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-oxycarbonyl, unsubstituted or substituted C1-12 alkyloxycarbonylamino, unsubstituted or substituted C2-12 alkenyloxycarbonylamino, unsubstituted or substituted C2-12 alkynyloxycarbonylamino, unsubstituted or substituted C6-10 aryl-LX-oxycarbonylamino, unsubstituted or substituted C3-10 cycloalkyl-LX-oxycarbonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-oxycarbonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-oxycarbonylamino, unsubstituted or substituted C1-12 alkylsulfanyl, unsubstituted or substituted C2-12 alkenylsulfanyl, unsubstituted or substituted C2-12 alkynylsulfanyl, unsubstituted or substituted C6-10 aryl-LX-sulfanyl, unsubstituted or substituted C3-10 cycloalkyl-LX-sulfanyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-sulfanyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-sulfanyl, unsubstituted or substituted C1-12 alkylsulfinyl, unsubstituted or substituted C2-12 alkenylsulfinyl, unsubstituted or substituted C2-12 alkynylsulfinyl, unsubstituted or substituted C6-10 aryl-LX-sulfinyl, unsubstituted or substituted C3-10 cycloalkyl-LX-sulfinyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-sulfinyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-sulfinyl, unsubstituted or substituted C1-12 alkylcarbamoyl, unsubstituted or substituted C2-12 alkenylcarbamoyl, unsubstituted or substituted C2-12 alkynylcarbamoyl, unsubstituted or substituted C6-10 aryl-LX-carbamoyl, unsubstituted or substituted C3-10 cycloalkyl-LX-carbamoyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-carbamoyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-carbamoyl, unsubstituted or substituted C1-12 alkylsulfamoyl, unsubstituted or substituted C2-12 alkenylsulfamoyl, unsubstituted or substituted C2-12 alkynylsulfamoyl, unsubstituted or substituted C6-10 aryl-LX-sulfamoyl, unsubstituted or substituted C3-10 cycloalkyl-LX-sulfamoyl, unsubstituted or substituted 5- to 10-membered heteroaryl-LX-sulfamoyl, and unsubstituted or substituted 5- to 10-membered heterocycloalkyl-LX-sulfamoyl, wherein LX is a single bond or unsubstituted or substituted C1-12 alkylene,


wherein the substituted C1-12 alkyl, substituted C2-12 alkenyl, substituted C2-12 alkynyl, substituted C6-10 aryl, substituted C3-10 cycloalkyl, substituted 5- to 10-membered heteroaryl, substituted 5- to 10-membered heterocycloalkyl, and substituted alkylene moieties (fully or partially) in the substituent group each independently have one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfa, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C1-12 alkyloxy, C1-12 haloalkyloxy, C2-12 alkenyloxy, C2-12 alkynyloxy, C6-10 aryl-LX-oxy, C3-10 cycloalkyl-LX-oxy, 5- to 10-membered heteroaryl-LX-oxy, 5- to 10-membered heterocycloalkyl-LX-oxy, C1-12 alkyloxyalkyl, C2-12 alkenyloxyalkyl, C2-12 alkynyloxyalkyl, C6-10 aryloxyalkyl, C3-10 cycloalkyloxyalkyl, 5- to 10-membered heteroaryloxyalkyl, 5- to 10-membered heterocycloalkyloxyalkyl, C1-12 alkyloxyalkyloxy, C2-12 alkenyloxyalkyloxy, C2-12 alkynyloxyalkyloxy, C6-10 aryloxyalkyloxy, C3-10 cycloalkyloxyalkyloxy, 5- to 10-membered heteroaryloxyalkyloxy, 5- to 10-membered heterocycloalkyloxyalkyloxy, C1-12 alkylcarbonyl, C2-12 alkenylcarbonyl, C2-12 alkynylcarbonyl, C6-10 aryl-LX-carbonyl, C3-10 cycloalkyl-LX-carbonyl, 5- to 10-membered heteroaryl-LX-carbonyl, 5- to 10-membered heterocycloalkyl-LX-carbonyl, C1-12 alkylcarbonyloxy, C2-12 alkenylcarbonyloxy, C2-12 alkynylcarbonyloxy, C6-10 aryl-LX-carbonyloxy, C3-10 cycloalkyl-LX-carbonyloxy, 5- to 10-membered heteroaryl-LX-carbonyloxy, 5- to 10-membered heterocycloalkyl-LX-carbonyloxy, C1-12 alkylcarbonylamino, C2-12 alkenylcarbonylamino, C2-12 alkynylcarbonylamino, C6-10 aryl-LX-carbonylamino, C3-10 cycloalkyl-LX-carbonylamino, 5- to 10-membered heteroaryl-LX-carbonylamino, 5- to 10-membered heterocycloalkyl-LX-carbonylamino, C1-12 alkylcarbonylthio, C2-12 alkenylcarbonylthio, C2-12 alkynylcarbonylthio, C6-10 aryl-LX-carbonylthio, C3-10 cycloalkyl-LX-carbonylthio, 5- to 10-membered heteroaryl-LX-carbonylthio, 5- to 10-membered heterocycloalkyl-LX-carbonylthio, C1-12 alkylcarbonylimino, C2-12 alkenylcarbonylimino, C2-12 alkynylcarbonylimino, C6-10 aryl-LX-carbonylimino, C3-10 cycloalkyl-LX-carbonylimino, 5- to 10-membered heteroaryl-LX-carbonylimino, 5- to 10-membered heterocycloalkyl-LX-carbonylimino, C1-12 alkylthio, C2-12 alkenylthio, C2-12 alkynylthio, C6-10 aryl-LX-thio, C3-10 cycloalkyl-LX-thio, 5- to 10-membered heteroaryl-LX-thio, 5- to 10-membered heterocycloalkyl-LX-thio, C1-12 alkylamino, C2-12 alkenylamino, C2-12 alkynylamino, C2-12 alkynylamino, C6-10 aryl-LX-amino, C3-10 cycloalkyl-LX-amino, 5- to 10-membered heteroaryl-LX-amino, 5- to 10-membered heterocycloalkyl-LX-amino, C1-12 alkylsulfonyl, C2-12 alkenylsulfonyl, C2-12 alkynylsulfonyl, C6-10 aryl-LX-sulfonyl, C3-10 cycloalkyl-LX-sulfonyl, 5- to 10-membered heteroaryl-LX-sulfonyl, 5- to 10-membered heterocycloalkyl-LX-sulfonyl, C1-12 alkylsulfonylamino, C2-12 alkenylsulfonylamino, C2-12 alkynylsulfonylamino, C6-10 aryl-LX-sulfonylamino, C3-10 cycloalkyl-LX-sulfonylamino, 5- to 10-membered heteroaryl-LX-sulfonylamino, 5- to 10-membered heterocycloalkyl-LX-sulfonylamino, C1-12 alkylimino, C2-12 alkenylimino, C2-12 alkynylimino, C6-10 aryl-LX-imino, C3-10 cycloalkyl-LX-imino, 5- to 10-membered heteroaryl-LX-imino, 5- to 10-membered heterocycloalkyl-LX-imino, C1-12 alkyloxyimino, C2-12 alkenyloxyimino, C2-12 alkynyloxyimino, C6-10 aryl-LX-oxyimino, C3-10 cycloalkyl-LX-oxyimino, 5- to 10-membered heteroaryl-LX-oxyimino, 5- to 10-membered heterocycloalkyl-LX-oxyimino, C1-12 alkyloxycarbonyl, C2-12 alkenyloxycarbonyl, C2-12 alkynyloxycarbonyl, C6-10 aryl-LX-oxycarbonyl, C3-10 cycloalkyl-LX-oxycarbonyl, 5- to 10-membered heteroaryl-LX-oxycarbonyl, 5- to 10-membered heterocycloalkyl-LX-oxycarbonyl, C1-12 alkyloxycarbonylamino, C2-12 alkenyloxycarbonylamino, C2-12 alkynyloxycarbonylamino, C6-10 aryl-LX-oxycarbonylamino, C3-10 cycloalkyl-LX-oxycarbonylamino, 5- to 10-membered heteroaryl-LX-oxycarbonylamino, 5- to 10-membered heterocycloalkyl-LX-oxycarbonylamino, C1-12 alkylsulfanyl, C2-12 alkenylsulfanyl, C2-12 alkynylsulfanyl, C6-10 aryl-LX-sulfanyl, C3-10 cycloalkyl-LX-sulfanyl, 5- to 10-membered heteroaryl-LX-sulfanyl, 5- to 10-membered heterocycloalkyl-LX-sulfanyl, C1-12 alkylsulfinyl, C2-12 alkenylsulfinyl, C2-12 alkynylsulfinyl, C6-10 aryl-LX-sulfinyl, C3-10 cycloalkyl-LX-sulfinyl, 5- to 10-membered heteroaryl-LX-sulfinyl, 5- to 10-membered heterocycloalkyl-LX-sulfinyl, C1-12 alkylcarbamoyl, C2-12 alkenylcarbamoyl, C2-12 alkynylcarbamoyl, C6-10 aryl-LX-carbamoyl, C3-10 cycloalkyl-LX-carbamoyl, 5- to 10-membered heteroaryl-LX-carbamoyl, 5- to 10-membered heterocycloalkyl-LX-carbamoyl, C1-12 alkylsulfamoyl, C2-12 alkenylsulfamoyl, C2-12 alkynylsulfamoyl, C6-10 aryl-LX-sulfamoyl, C3-10 cycloalkyl-LX-sulfamoyl, 5- to 10-membered heteroaryl-LX-sulfamoyl, and 5- to 10-membered heterocycloalkyl-LX-sulfamoyl.


Substituent group III consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidinoamino, alkyl, aryl, cycloalkyl, heteroaryl, alkyloxy, alkylcarbonyl, cycloalkylcarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylamino, cycloalkylalkylamino, alkyloxycarbonyl, and trialkylsilyloxy, and these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, alkyl, haloalkyl, alkyloxy, haloalkyloxy, and alkyloxycarbonyl.


Substituent group III is preferably substituent group III′, which consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidinoamino, C1-12 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, C1-12 alkyloxy, C1-alkylcarbonyl, C3-10 cycloalkylcarbonyl, C1-12 alkylcarbonylamino, C3-10 cycloalkylcarbonylamino, C1-12 alkylamino, C3-10 cycloalkyl C1-6 alkylamino, C1-12 alkyloxycarbonyl, and tri-C1-6 alkylsilyloxy, wherein these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, C1-12 alkyl, C1-12 haloalkyl, C1-12 alkyloxy, C1-12 haloalkyloxy, and C1-12 alkyloxycarbonyl.


Substituent group IV consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidino, alkyl, aryl, cycloalkyl, heteroarylheterocycloalkyl, arylalkyl, cycloalkylalkyl, alkyloxy, aryloxy, alkylcarbonyl, cycloalkylcarbonyl, alkyloxycarbonyl, and trialkylsilyloxy, and these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, alkyl, haloalkyl, alkyloxy, haloalkyloxy, and alkyloxycarbonyl.


Substituent group IV is preferably substituent group IV′, which consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidino, C1-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C6-10 aryl C1-6 alkyl, C3-10 cycloalkyl C1-6 alkyl, C1-6 alkyloxy, C6-10 aryloxy, C1-6 alkylcarbonyl, C3-10 cycloalkylcarbonyl, C1-6 alkyloxycarbonyl, and tri-C1-6 alkylsilyloxy, and these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyloxy, C1-6 haloalkyloxy, and C1-6 alkyloxycarbonyl.


Substituent group V consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyloxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, alkyloxyoxy, alkylamino, arylamino, cycloalkylamino, heteroarylamino, heterocycloalkylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heteroarylcarbonyl, heterocycloalkylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkyloxycarbonyl, alkylcarbamoyl, arylcarbamoyl, cycloalkylcarbamoyl, heteroarylcarbamoyl, and heterocycloalkylcarbamoyl, wherein these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, alkyloxy, haloalkyl, haloalkyloxy, alkylamino, formyl, alkylcarbonyl, alkyloxycarbonyl, and alkylcarbamoyl.


Substituent group V is preferably substituent group V′, which consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C1-12 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C1-12 alkyloxy, C6-10 aryloxy, C3-10 cycloalkyloxy, 5- to 10-membered heteroaryloxy, 5- to 10-membered heterocycloalkyloxy, C1-12 alkylamino, C6-10 arylamino, C3-10 cycloalkylamino, 5- to 10-membered heteroarylamino, 5- to 10-membered heterocycloalkylamino, formyl, C1-12 alkylcarbonyl, C6-10 arylcarbonyl, C3-10 cycloalkylcarbonyl, 5- to 10-membered heteroarylcarbonyl, 5- to 10-membered heterocycloalkylcarbonyl, C1-12 alkyloxycarbonyl, C6-10 aryloxycarbonyl, C3-10 cycloalkyloxycarbonyl, 5- to 10-membered heteroaryloxycarbonyl, 5- to 10-membered heterocycloalkyloxycarbonyl, C1-12 alkylcarbamoyl, C6-10 arylcarbamoyl, C3-10 cycloalkylcarbamoyl, 5- to 10-membered heteroarylcarbamoyl, and 5- to 10-membered heterocycloalkylcarbamoyl, wherein these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C1-6 alkyl, C1-6 alkyloxy, C1-6 haloalkyl, C1-6 haloalkyloxy, C1-6 alkylamino, formyl, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, and C1-6 alkylcarbamoyl.


Substituent group VI consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, alkyloxy, haloalkyl, haloalkyloxy, alkylamino, formyl, alkylcarbonyl, alkyloxycarbonyl, and alkylcarbamoyl.


Substituent group VI is preferably substituent group VI′, which consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C1-6 alkyl, C1-6 alkyloxy, C1-6 haloalkyl, C1-6 haloalkyloxy, C1-6 alkylamino, formyl, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, and C1-6 alkylcarbamoyl.


As used herein, examples of substituents used when “optionally substituted” include substituent group α and substituent group β. Substituent group a can be substituent group α1, substituent group α2, or substituent group α3. Substituent group β can be substituent group β1, substituent group β2, or substituent group β3. Substituents used when “optionally substituted” can be selected from substituent group α1, and substitution can be performed with 1 to 5 of the same or different substituents. While the types of atoms within a substituent associated with attachment are not particularly limited by the type of substituent, if the atom to which a substituent attaches is an oxygen atom, a nitrogen atom, or a sulfur atom, the substituent is limited to those with an attaching atom that is a carbon atom from the following substituents.


Substituent group α1 includes


1) halogen atom


2) hydroxyl group


3) carboxyl group


4) cyano group


5) C1-6 alkyl


6) C2-6 alkenyl


7) C2-6 alkynyl


8) C1-6 alkoxy


9) C1-6 alkylthio


10) C1-6 alkylcarbonyl


11) C1-6 alkylsulfonyl


(however, each substituent from 5) to 11) is optionally substituted with 1 to 5 of the same or different substituents selected from substituent group (1)


12) C3-10 alicyclic group


13) C3-10 alicyclic oxy


14) C6-10 aryloxy


15) 5- to 6-membered heteroaryloxy


16) 4- to 10-membered non-aryl heterocyclyloxy


17) C3-10 alicyclic thio


18) C6-10 arylthio


19) 5- to 6-membered heteroarylthio


20) 4- to 10-membered non-aryl heterocyclylthio


21) C6-10 aryl


22) 5- to 6-membered heteroaryl


23) 4- to 10-membered non-aryl heterocycle


24) C3-10 alicyclic carbonyl


25) C6-10 arylcarbonyl


26) 5- to 6-membered heteroarylcarbonyl


27) 4- to 10-membered non-aryl heterocyclylcarbonyl


28) C3-10 alicyclic sulfonyl


29) C6-10 aryl sulfonyl


30) 5- to 6-membered heteroarylsulfonyl


31) 4- to 10-membered non-aryl heterocyclylsulfonyl


(however, each substituent from 12) to 31) is optionally substituted with 1 to 5 substituents in substituent group β1 or 5) C1-6 alkyl)


32) —NR10aR11a

33) —SO2—NR10bR11b

34) —NR10c—C(═O) R11c

35) —NR10d—C(═O) OR11d

36) —NR12a—C(═P) NR10eR11e

37) —NR10i—SO2—R11i

38) —NR12c—SO2—NR10jR11j


39) —C(═O) OR10k

40) —C(═O) NR10lR11k

41) —C(═O) NR10mOR11l

42) —C(═O)NR12d—NR10nR11m

43) —C(═NR13a)R10s

44) —C(═NR13c)NR10tR11q

45) —C(═NR13d) NR12f—NR10uR11r

46) —NR17c—C(═NR13k)R17d

47) —NR12g—C(═NR13e)—NR10vR11s

48) —NR14—C(═NR13f)—NR12h—NR10wR11t


49) —OC(═O)R10x
50) —OC(═O)OR10y

51) —OC(═O)—NR10z1R11u

52) —NR12i—NR10z2R11v

53) —NR10z3OR11w, and


54) protecting group, and


substituent group β1 is a group consisting of


1) halogen atom,


2) hydroxyl group,


3) carboxyl group,


4) cyano group,


5) C3-10 alicyclic group,


6) C1-6 alkoxy,


7) C3-10 alicyclic oxy,


8) C1-6 alkylthio,


9) 5- to 6-membered heteroarylthio,


10) C6-10 aryl,


11) 5- to 6-membered heteroaryl,


12) 4- to 10-membered non-aryl heterocycle,


13) C1-6 alkylcarbonyl,


14) C3-10 alicyclic carbonyl,


15) C6-10 arylcarbonyl,


16) 5- to 6-membered heteroarylcarbonyl,


17) 4- to 10-membered non-aryl heterocyclylcarbonyl,


18) —NR15aR16a,


19) —SO2—NR15bR16b,


20) —NR15c—C(═O)R16c

21) —NR17a—C(═O)NR15dR16d

22) —C(═O)NR15eR15e,


23) —C(═NR13g)R15f,


24) —C(═NR13h) NR15gR16f

25) —NR16g—C(═NR13i)R15h

26) —NR17b—C(═NR13j)—NR15iR16h, and


27) protecting group


(however, each substituent from 5) to 17) in substituent group β1 is optionally substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, carboxyl group, and —NR18aR18b), wherein


R13a, R13a2, R13c, R13c2, R13d, R13d2, R13e, R13f, R13g, R13g2, R13h, R13h2, R13i, R13j, and R13k are each independently the same or different hydrogen atom, hydroxyl group, C1-6 alkyl, C1-6 alkoxy, or C1-6 alkoxycarbonyl,


R10a, R10b, R10c, R10d, R10e, R10i, R10j, R10k, R10l, R10m, R10n, R10s, R10s2, R10t, R10t2, R10u, R10u2, R10v, R10w, R10x, R10y, R10z1, R10z2, R10z3, R11a, R11b, R11c, R11d, R11e, R11i, R11j, R11k, R11l, R11m, R11q, R11q2, R11r, R11r2, R11s, R11t, R11u, R11v, R11w, R12a, R12c, R12d, R12f, R12f2, R12g, R12h, R12i, R14, R15a, R15b, R15c, R15d, R15e, R15f, R15f2, R15g, R15g2, R15h, R15i, R16a, R16b, R16c, R16d, R16e, R16f, R16f2, R16g, R16h, R17a, R17b, R17c, and R17d are each independently the same or different hydrogen atom, C1-6 alkyl (the C1-6 alkyl is optionally substituted with 1 to 3 of the same or different substituents selected from a hydroxyl group, cyano group, C1-6 alkoxy, and —NR18aR18b), or C1-6 alkoxycarbonyl, and


R18a and R18b are each independently the same or different hydrogen atom or C1-6 alkyl.


In an exemplary embodiment, hydrogen of any hydroxyl group in substituent groups α1 and β1 is optionally substituted with a protecting group.


Examples of preferred substituents as the substituent used when “optionally substituted” herein include the following.


Substituent group α2 preferably includes


1) halogen atom


2) hydroxyl group


3) carboxyl group


4) cyano group


5) C1-6 alkyl


6) C1-6 alkoxy


7) C1-6 alkylthio


8) C1-6 alkylcarbonyl


(however, each substituent from 5) to 8) is optionally substituted with 1 to 5 same or different substituents selected from substituent group (2)


9) C3-10 alicyclic group


10) C3-10 alicyclic oxy


11) C6-10 aryloxy


12) 5- to 6-membered heteroaryloxy


13) 4- to 10-membered non-aryl heterocyclyloxy


14) C3-10 alicyclic thio


15) C6-10 arylthio


16) 5- to 6-membered heteroarylthio


17) 4- to 10-membered non-aryl heterocyclylthio


18) C6-10 aryl


19) 5- to 6-membered heteroaryl


20) 4- to 10-membered non-aryl heterocycle


21) C3-10 alicyclic carbonyl


22) C6-10 arylcarbonyl


23) 5- to 6-membered heteroarylcarbonyl


24) 4- to 10-membered non-aryl heterocyclylcarbonyl


(however, each substituent from 9) to 24) is optionally substituted with 1 to 5 substituents in substituent group β2 or 1) C1-6 alkyl)


25) —NR10aR11a

26) —SO2—NR10bR11b

27) —NR10c—C(═O)R11c

28) —NR12a—C(═O) NR10dR11d

29) —NR10e_SO2—R11e

30) —NR12b—SO2—NR10fR11f

31) —C(═O)—NR10gR11g

32) —C(═NR13a)R10h

33) —C(═NR13b)R10iR11h

34) —NR11f2—C(═NR13c)R10g2, and


35) —NR12c—C(═NR13d) and


substituent group (2 is preferably a group consisting of


1) halogen atom


2) hydroxyl group


3) cyano group


4) C3-10 alicyclic group


5) C1-6 alkoxy


6) C1-6 alkylthio


7) 5- to 6-membered heteroarylthio


8) 5- to 6-membered heteroaryl


9) 4- to 10-membered non-aryl heterocycle


10) C1-6 alkylcarbonyl


11) C3-10 alicyclic carbonyl


12) C6-10 arylcarbonyl


13) 5- to 6-membered heteroarylcarbonyl


14) 4- to 10-membered non-aryl heterocyclylcarbonyl


15) —NR15aR16a

16) —NR15b—C(═O)R16b

17) —NR17a—C(═O)NR15cR16c

18) —C(═O)NR15dR16d

19) —C(═NR13e)R15e

20) —C(═NR13f)NR15fR16e

21) —NR16f—C(═NR13g)R15g

22) —NR17b—C(═NR13h)—NR15hR16g

23) —C(═N—OR13e2)R15e2, and


24) —C(═N—OR13f2)NR15f2R16e2

(however, each substituent from 4) to 14) in substituent group β2 is optionally substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, carboxyl group, and —NR18aR18b,


R13a, R13a2, R13b, R13b2, R13c, R13d, R13e, R13e2, R13f, R13f2, R13g, and R13h are each independently the same or different hydrogen atom, hydroxyl group, C1-6 alkyl, C1-6 alkoxy, or C1-6 alkoxycarbonyl,


R10a, R10b, R10c, R10d, R10e, R10f, R10g, R10g2, R10h, R10h2, R10i, R10i2, R10j, R11a, R11b, R11c, R11d, R11e, R11f, R11f2, R11g, R11h, R11h2, R11i, R12a, R12b, R12c, R15a, R15b, R15c, R15d, R15e, R15e2, R15f, R15f2, R15g, R15h, R16a, R16b, R16c, R16d, R16e, R16e2, R16f, R16g, R17a, and R17b are each independently the same or different hydrogen atom, C1-6 alkyl (the C1-6 alkyl is optionally substituted with 1 to 3 same or different substituents selected from a hydroxyl group, cyano group, C1-6 alkoxy, and —NR18aR18b), or C1-6 alkoxycarbonyl, and


R18a and R18b are each independently the same or different hydrogen atom or C1-6 alkyl.


In an exemplary embodiment, hydrogen of any hydroxy group in substituent groups α2 and β2 is optionally substituted with a protecting group.


Examples of more preferred substituents used when “optionally substituted” herein include the following substituents.


Substituent group α3 more preferably includes


1) halogen atom


2) hydroxyl group


3) cyano group


4) C1-6 alkyl


5) C1-6 alkoxy


6) C1-6 alkylthio


7) C1-6 alkylcarbonyl


(however, each substituent from 4) to 7) is optionally substituted with 1 to 5 same or different substituents selected from substituent group β3)


8) C3-10 alicyclic group


9) 5- to 6-membered heteroaryloxy


10) 4- to 10-membered non-aryl heterocyclyloxy


11) 5- to 6-membered heteroarylthio


12) 4- to 10-membered non-aryl heterocyclylthio


13) C6-10 aryl


14) 5- to 6-membered heteroaryl


15) 4- to 10-membered non-aryl heterocycle


(however, each substituent from 8) to 15) is optionally substituted with 1 to 5 substituents in substituent group β3 or 1) C1-6 alkyl)


16) —NR10aR11a

17) —NR11b—C(═O)R10b

18) —NR12a—C(═O) NR10cR11c

19) —C(═O)—NR10dR11d

20) —C(═NR13a)R10e

21) —C(═NR13b)NR10fR11e

22) —NR11f—C(═NR13c) R10g, and


23) —NR12b—C(═NR13d)—NR10hR11g, and substituent group β3 is more preferably


1) halogen atom,


2) hydroxyl group,


3) cyano group,


4) —NR15aR16a,


5) —NR15b—C(═O)R16b,


6) —NR17a—C(═O) NR15cR16c,


7) —C(═O) NR15dR16d,


8) —C(═NR13e)R15e,


9) —C(═NR13f) NR15fR16e,


10) —NR16f—C(═NR13g)R15g, and


11) —NR17b—C(═NR13h)—NR15hR16g, wherein


R13a, R13a2, R13b, R13b2, R13c, R13d, R13e, R13e2, R13f, R13f2, R13g, and R13h are each independently the same or different hydrogen atom, hydroxyl group, C1-6 alkyl, C1-6 alkoxy, or C1-6 alkoxycarbonyl,


R10a, R10b, R10c, R10d, R10e, R10f, R10e2, R10f2, R10g, R10h, R11a, R11b, R11c, R11d, R11e, R11e2, R11f, R11g, R12a, R12b, R15a, R15b, R15c, R15d, R15e, R15e2, R15f, R15f2, R15g, R15h, R16a, R16b, R16c, R16d, R16e, R16e2, R16f, R16g, R17a, and R17b are each independently the same or different hydrogen atom, C1-6 alkyl (the C1-6 alkyl is optionally substituted with 1 to 3 same or different substituents selected from hydroxyl group, cyano group, C1-6 alkoxy, and —NR18aR18b), or C1-6 alkoxycarbonyl, and


R18a, and R18b are each independently the same or different hydrogen atom or C1-6 alkyl.


In an exemplary embodiment, hydrogen of any hydroxyl group in substituent groups α3 and β3 is optionally substituted with a protecting group.


In an exemplary embodiment, a hydroxyl group in the aforementioned substituent group (e.g., α (α1 or the like) β (β1 or the like), or I to VI) is also optionally substituted with a protecting group. In an exemplary embodiment, an amino group in substituent groups I to VI is also optionally protected with a nitrogen protecting group.


As used herein, “C1-6” means that the number of carbon atoms is 1 to 6. The same applies to other numbers. For example, “C1-4” means that the number of carbon atoms is 1 to 4, and “C1-3” means that the number of carbon atoms is 1 to 3. A description with a limitation in the number of carbons herein is only a preferred numerical range. It is intended so that groups with a substituent with a number of carbons other than the number of carbons specified in the present disclosure are also within the scope of the present disclosure.


As used herein, “hydrocarbon group” is also referred to as a hydrocarbyl group, referring to a group generated by removing at least one hydrogen from “hydrocarbon” comprising at least one carbon and at least one hydrogen.


As used herein, “functional group” refers to any group conferring some type of functionality, encompassing a carboxyl group, nitrile group, carbonyl group, hydroxyl group, amino group, imino group, nitro group, halogen group, as well as alkyl group, and more broadly acid anhydrides and groups formed by a bond such as an ester bond, amide bond, or ether bond.


As used herein, “heteroatom” refers to atoms other than carbon atoms and hydrogen atoms such as oxygen atoms, nitrogen atoms, and sulfur atoms. A group comprising a heteroatom is also known as a hetero . . . group (e.g., heteroaryl group (means that an aryl group comprises at least a heteroatom) or heterocyclic group (means that a cyclic group (carbon ring group) comprises at least one heteroatom)) or the like.


As used herein, “halogen atom” is an atom belonging to the halogen group, referring to a fluorine atom, chlorine atom, bromine atom, iodine atom, or the like, and is preferably a fluorine atom or chlorine atom, and still more preferably a fluorine atom. A “halogen atom” is also referred to as “halogen” or “halo”.


As used herein, “hydroxyl group” is a monovalent group of —OH. This group is also referred to as a “hydroxy group” or “hydroxy”.


As used herein, “carboxyl group” is a monovalent group of —COOH. This group is also referred to as a “carboxy group”, “carboxy”, or “carboxyl”.


As used herein, “cyano group” is a monovalent group of —CN.


As used herein, “amino” is a monovalent group of —NH2.


This group is also referred to as an “amino group”.


As used herein, “alkyl” refers to a linear or branched saturated aliphatic hydrocarbon group. “C1-12 alkyl” is an alkyl group with 1 to 12 carbon atoms. Examples thereof include, but are not limited to, C1-6 alkyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isnonyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecy, and the like. “C1-6 alkyl” is an alkyl group with 1 to 6 carbon atoms, which is preferably “C1-4 alkyl”, more preferably “C1-3 alkyl”, and still more preferably “C1-2 alkyl”. Specific examples of “C1-4 alkyl” include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, and the like. Specific examples of “C1-6alkyl” include, but are not limited to, C1-4 alkyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1,2-dimethylpropyl, n-hexyl, and the like.


As used herein, “alkenyl” refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon double bond. “C2-12 alkenyl” is an alkenyl group with 2 to 12 carbon atoms. Examples thereof include, but are not limited to, heptenyl, isoheptenyl, octenyl, isooctenyl, nonenyl, isononenyl, decenyl, isodecenyl, undecenyl, isoundecenyl, dodecenyl, isododecenyl, and the like. “C2-6 alkenyl” is an alkenyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C2-4 alkenyl”. Specific examples of “C2-6 alkenyl” include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, and the like.


As used herein, “alkynyl” refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon triple bond. “C2-12 alkynyl” is an alkynyl group with 2 to 12 carbon atoms. Examples thereof include, but are not limited to, heptynyl, isoheptynyl, octynyl, isooctynyl, nonynyl, isononynyl, decynyl, isodecynyl, undecynyl, isoundecynyl, dodecynyl, isododecynyl, and the like. “C2-6 alkynyl” is an alkynyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C2-4 alkynyl”. Specific examples of “C2-6 alkynyl” include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 1-methyl-2-propynyl, 3-butynyl, 1-pentynyl, 1-hexynyl, and the like.


As used herein, “aryl” refers to a monovalent group of a monocyclic or bicyclic aromatic hydrocarbon ring. “C6-10 aryl” refers to an aryl group with 6 to 10 carbon atoms. Examples of “aryl” include, but are not limited to, C6 aryl, C10 aryl, and the like. Specific examples of C6 aryl include, but are not limited to, phenyl and the like. Specific examples of C10 aryl include, but are not limited to, 1-naphthyl, 2-naphthyl, and the like.


An aryl group as a substituent or a portion thereof may be fused to an alicyclic group. For example, a phenyl group may be fused to a cyclohexane ring to form a 1,2,3,4-tetrahydronaphthalenyl group. In such a case, one of the possible carbon atoms on a benzene ring attaches to the backbone, or to a group near the backbone, or to its atom. An aryl group encompasses 5,6,7,8-tetrahydronaphthalen-1-yl and 5,6,7,8-tetrahydronaphthalen-2-yl.


As used herein, “arylalkyl” refers to alkyl substituted with at least one aryl. C06-1 aryl C1-6 alkyl” refers to C1-6 alkyl substituted with at least one C6-10 aryl. Specific examples of C6-10 aryl C1-6 alkyl include, but are not limited to, benzyl(phenyl-CH2—), phenethyl (phenyl-CH2CH2—), naphthalen-1-ylmethyl, naphthalen-2-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(naphthalen-2-yl)ethyl, and the like.


As used herein, “(optionally substituted amino)-arylalkyl” refers to arylalkyl substituted with an optionally substituted amino group, wherein the alkyl group, the aryl group, or both is substituted with an amino group. An amino group of such an arylalkyl group may be unsubstituted, or substituted with 1, 2, or 3 substituents, such as optionally substituted alkyl (e.g., unsubstituted C1-6 alkyl, C3-6 cycloalkyl-C1-6 alkyl, C3-6 cycloalkylcarbonyl, or the like). Examples of (optionally substituted amino)-C6-10 aryl C1-6 alkyl include, but are not limited to, (di(alkyl)amino)benzyl, ((cycloalkylalkyl)amino)benzyl, ((cycloalkylcarbonyl)amino)benzyl, ((carbamoylalkyl) carbonylamino)benzyl, ((carboxyalkyl)carbonyl)aminobenzyl, (di(alkyl)amino)naphthalenylmethyl, ((cycloalkylalkyl)amino)naphthalenylmethyl, ((cycloalkylcarbonyl)amino)naphthalenylmethyl, ((carbamoylalkyl)carbonylamino)naphthalenylmethyl, ((carboxyalkyl)carbonyl)aminonaphthalenylmethyl, and the like.


As used herein, the aryl moiety of “arylthio” is defined the same as the aforementioned aryl. Preferred examples of “C6-10 arylthio” include “C6 or C10 arylthio”. Specific examples of “C6-10 aryloxy” include, but are not limited to, phenylthio, 1-naphthylthio, 2-naphthylthio, and the like.


As used herein, “aryl sulfonyl” refers to sulfonyl substituted with the aforementioned “aryl”. “C6-10 aryl sulfonyl” is preferably “C6 or C10 aryl sulfonyl”. Specific examples of “C6-10 aryl sulfonyl” include, but are not limited to, phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, and the like.


As used herein, “heteroaryl” refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.


As used herein, “5- to 6-membered heteroaryl” refers to a monovalent group of a monocyclic aromatic heterocycle consisting 5 to 6 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom. Specific examples of “5- to 6-membered heteroaryl” include, but are not limited to, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, pyridyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, and the like.


As used herein, “5- to 10-membered heteroaryl” refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle consisting of 5 to 10 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom. Specific examples of “5- to 10-membered heteroaryl” include, but are not limited to, 5- to 6-membered heteroaryl, quinolyl, isoquinolyl, naphthyridinyl, quinoxalinyl, cinnolinyl, quinazolinyl, phthalazinyl, imidazopyridyl, imidazothiazolyl, imidazooxazolyl, benzothiazolyl, benzooxazolyl, benzoimidazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridyl, thienopyridyl, furopyridyl, benzothiadiazolyl, benzooxadiazolyl, pyridopyrimidinyl, benzofuryl, benzothienyl, benzo[1,3]dioxole, thienofuryl, chromenyl, chromanyl, coumarinyl, quinolonyl, and the like.


As used herein, “heteroarylalkyl” refers to alkyl substituted with at least one heteroaryl. “5- to 10-membered heteroaryl C1-6 alkyl” refers to C1-6 alkyl substituted with at least one 5- to 10-membered heteroaryl. Specific examples of 5- to 10-membered heteroaryl C1-6 alkyl include, but are not limited to, pyridin-2-ylmethyl, pyridin-4-ylmethyl, 2-(quinolin-8-yl)ethyl, 2-(quinolin-5-yl)ethyl, 2-(quinoxalin-5-yl)ethyl, 2-(1H-indol-3-yl)ethyl, and the like.


As used herein, “alicyclic group” refers to a monovalent group of a monocyclic, bicyclic, or tricyclic non-aromatic hydrocarbon ring, including those that have a partially unsaturated bond, those that have a partially crosslinked structure, those that are partially a spiro, and those having 1, 2, or more carbonyl structures. An “alicyclic group” encompasses cycloalkyl, cycloalkenyl, and cycloalkynyl. “C3-20 alicyclic group” is preferably a “C3-10 alicyclic group”, more preferably a “C3-6 alicyclic group”. Specific examples of “C3-20 alicyclic group” include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexadinyl, cycloheptadinyl, cyclooctadinyl, adamantyl, norbornyl, and the like.


An alicyclic group can be a fused ring between a non-aryl ring and an aryl and/or heteroaryl ring. For example, cycloalkyl fused with C6-10 aryl or 5- to 6-membered heteroaryl is encompassed by an alicyclic group. Examples of fused alicyclic groups include a monovalent group with one hydrogen atom removed from 1,2,3,4-tetrahydronaphthalene, indane, 1,2,3,4-tetrahydroanthracene, and 5,6,7,8-tetrahydroquinoline. Specific examples thereof include 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, indan-1-yl, indan-2-yl, 5,6,7,8-tetrahydroquinolin-5-yl, 5,6,7,8-tetrahydroquinolin-6-yl, and the like. A fused alicyclic group attaches from any one of the possible cyclic structure atoms on a non-aryl ring to the backbone.


As used herein, “C3-10 alicyclic group” refers to a substituent with “C3-10 alicyclic group” that is a monovalent group among the aforementioned C03-2 alicyclic group”.


As used herein, “alicyclic oxy” refers to an (alicyclic group)-O— group, and the alicyclic moiety is defined the same as an alicyclic group. “C3-6 alicyclic oxy” refers to a (C3-6 alicyclic group)-O— group, and the C3-6 alicyclic moiety is defined the same as a C3-6 alicyclic group. “C3-6 alicyclic oxy” is preferably “C3-5 alicyclic oxy”. Specific examples of “C3-6 alicyclic oxy” include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.


As used herein, “alicyclic carbonyl” refers to carbonyl substituted with the “alicyclic group” described above. “C3-10 alicyclic carbonyl” is preferably “C3-6 alicyclic carbonyl”. Specific examples of “C3-10 alicyclic carbonyl” include, but are not limited to, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, and the like.


As used herein, “alicyclic thio” refers to an (alicyclic group)-S— group, and the alicyclic moiety is defined the same as above. “C3-10 alicyclic thio” is preferably “C3-6 alicyclic thio”. Specific examples of “C3-6 alicyclic thio” include, but are not limited to, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.


As used herein, “alicyclic sulfonyl” refers to a sulfonyl group substituted with the “alicyclic group” described above. “C3-10 alicyclic sulfonyl” is preferably “C3-6 alicyclic sulfonyl”. Specific examples of “C3-10 alicyclic sulfonyl” include, but are not limited to, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl, and the like.


As used herein, “cycloalkyl” refers to a non-aromatic saturated hydrocarbon ring group, including those that have a partially crosslinked structure, those that are partially spiro, those having 1, 2, or more carbonyl structures. “C3-20 cycloalkyl” refers to monocyclic or bicyclic cycloalkyl with 3 to 20 carbon atoms. “C3-6 cycloalkyl” refers to monocyclic cycloalkyl with 3 to 6 carbon atoms. Specific examples of C3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.


A cycloalkyl group can be fused to aryl and/or heteroaryl ring as a substituent or a portion thereof. For example, a cyclohexyl group can be fused to a benzene ring to form a 1,2,3,4-tetrahydronaphthalenyl group. In such a case, one of the possible carbon atoms on the cyclohexane ring attaches to the backbone, to a group near the backbone, or to its atom. A cycloalkyl group encompasses 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, indan-1-yl, indan-2-yl, 5,6,7,8-tetrahydroquinolin-5-yl, and 5,6,7,8-tetrahydroquinolin-6-yl.


As used herein, “cycloalkylalkyl” refers to alkyl substituted with at least one cycloalkyl. “C3-6 cycloalkyl C1-6 alkyl” refers to C1-6 alkyl substituted with at least one C3-6 cycloalkyl. Specific examples of C3-6 cycloalkyl C1-6 alkyl include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, 3-cyclopropylpropyl, 3-cyclobutylpropyl, 3-cyclopentylpropyl, 3-cyclohexylpropyl, and the like.


As used herein, “heterocycloalkyl” refers to a non-aromatic saturated or partially unsaturated heterocycle comprised of 3 or more atoms, copmrising 1, 2, or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including those that have a partially crosslinked structure and those that are partially spiro. “Heterocycloalkyl” encompasses “non-aryl heterocycle”. Heterocycloalkyl can have a structure where a non-aromatic heterocycle is fused to an aryl ring and/or heteroaryl ring.


As used herein, “non-aryl heterocycle” refers to a monocyclic or bicyclic non-aromatic heterocycle comprised of 3 or more atoms, comprising 1, 2, or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including saturated non-aryl heterocycles, those that have a partially unsaturated attachment, those that have a partially crosslinked structure, and those that are partially spiro. A non-aryl heterocycle can form a fused ring with aryl or heteroaryl. For example, a non-aryl heterocycle fused to C6-10 aryl or 5- to 6-membered heteroaryl is also encompassed by a heterocycle. 1, 2, or more carbonyl, thiocarbonyl, sulfinyl, or sulfonyl can be comprised to constitute the non-aryl heterocycle. For example, lactam, thiolactam, lactone, thiolactone, cyclic imide, cyclic carbamate, cyclic thiocarbamate, and other cyclic groups are also encompassed by the non-aryl heterocycle. In this regard, an oxygen atom of carbonyl, sulfinyl, and sulfonyl and a sulfur atom of thiocarbonyl are not included in the number of members of the ring (ring size) or the number of heteroatoms constituting the ring.


As used herein, “4- to 10-membered non-aryl heterocycle” refers to a substituent with “4- to 10-membered non-aryl heterocycle” that is a monovalent group among the “non-aryl heterocycle” described above.


As used herein, the non-aryl heterocycle moiety of “non-aryl heterocyclyloxy” is defined the same as the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclyloxy” is preferably “4- to 6-membered non-aryl heterocyclyloxy”. Specific examples of “4- to 10-membered non-aryl heterocyclyloxy” include, but are not limited to, tetrahydrofuranyloxy, tetrahydropyranyloxy, azetidinyloxy, pyrrolidinyloxy, piperidinyloxy, and the like.


As used herein, the non-aryl heterocycle moiety of “non-aryl heterocyclylthio” is defined the same as the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylthio” is preferably “4- to 6-membered non-aryl heterocyclylthio”. Specific examples of “4- to 10-membered non-aryl heterocyclylthio” include, but are not limited to, tetrahydropyranylthio, piperidinylthio, and the like.


As used herein, “non-aryl heterocyclylcarbonyl” refers to a carbonyl group substituted with the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylcarbonyl” is preferably “4- to 6-membered non-aryl heterocyclylcarbonyl”. Specific examples of “4- to 10-membered non-aryl heterocyclylcarbonyl” include, but are not limited to, azetidinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, and the like.


As used herein, “non-aryl heterocyclylsulfonyl” refers to a sulfonyl group substituted with the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylsulfonyl” is preferably “4- to 6-membered non-aryl heterocyclylsulfonyl”. Specific examples of “4- to 10-membered non-aryl heterocyclylsulfonyl” include, but are not limited to, azetidinylsulfonyl, pyrrolidinylsulfonyl, piperidinylsulfonyl, morpholinylsulfonyl, and the like.


As used herein, “5- to 6-membered heterocycloalkyl” refers to heterocycloalkyl comprised of 5 to 6 cyclic atoms, comprising 1 or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.


As used herein, “heterocycloalkylalkyl” refers to alkyl substituted with at least one heterocycloalkyl.


As used herein, “alkylcarbonyl” is a monovalent group of —C(═O)-alkyl. Preferred examples of alkylcarbonyl include C1-6 alkylcarbonyl. Specific examples of C1-6 alkylcarbonyl include, but are not limited to, acetyl (CH3C(═O)—), n-propanoyl (CH3CH2C(═O)—), n-butanoyl (CH3CH2CH2C(═O)—), n-pentanoyl (CH3 (CH2)3C(═O)—), n-hexanoyl (CH3 (CH2)4C(═O)—), n-heptanoyl (CH3 (CH2)5C(═O)—), and the like.


As used herein, “alkoxy” is a monovalent group of —O-alkyl. Preferred examples of alkoxy include C1-6 alkoxy (i.e., C1-6 alkyl-O—), C1-4 alkoxy (i.e., C1-4 alkyl-O—), and the like. Specific examples of C1-4 alkoxy include methoxy (CH3O—), ethoxy (CH3CH2O—), n-propoxy (CH3(CH2)2O—), isopropoxy ((CH3)2CHO—), n-butoxy (CH3(CH2)3O—), isobutoxy ((CH3)2CHCH2O—), tert-butoxy ((CH3)3CO—), sec-butoxy (CH3CH2CH(CH3)O—), and the like. Specific examples of C1-6 alkoxy include, but are not limited to, C1-4 alkoxy, n-pentyloxy (CH3(CH2)4O—), isopentyloxy ((CH3)2CHCH2CH2O—), neopentyloxy ((CH3)3CCH2O—), tert-pentyloxy (CH3CH2C(CH3)2O—), 1,2-dimethylpropoxy (CH3CH(CH3)CH(CH3)O—), and the like.


As used herein, “alkoxycarbonyl” is a monovalent group of —C(═O)—O-alkyl. Examples of alkoxycarbonyl include, but are not limited to, C1-6 alkoxycarbonyl, preferably C1-4 alkoxycarbony. Specific examples of C1-4 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, and the like. Specific examples of C1-6 alkoxycarbonyl include, but are not limited to, C1-4 alkoxycarbonyl, n-pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert-pentyloxycarbonyl, 1,2-dimethylpropyloxycarbonyl, n-hexyloxycarbonyl, and the like.


As used herein, “alkoxycarbonylamino” is a monovalent group of —NH—C(═O)—O-alkyl. Examples of alkoxycarbonylamino include, but are not limited to, C1-6 alkoxycarbonylamino, preferably C1-4 alkoxycarbonylamino. Specific examples of C1-4 alkoxycarbonylamino include methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, n-butoxycarbonylamino, sec-butoxycarbonylamino, tert-butoxycarbonylamino, isobutoxycarbonylamino, and the like. Specific examples of C1-6 alkoxycarbonylamino include, but are not limited to, C1-4 alkoxycarbonylamino, n-pentyloxycarbonylamino, isopentyloxycarbonylamino, neopentyloxycarbonylamino, tert-pentyloxycarbonylamino, 1,2-dimethylpropyloxycarbonylamino, n-hexyloxycarbonylamino, and the like.


As used herein, “haloalkyl” is a monovalent group of halogenated alkyl, having one or more hydrogen on an alkyl group substituted with halogen. The term “perhaloalkyl” refers to haloalkyl with all hydrogen on the alkyl group substituted with halogen. For example, perfluoroethyl is —CF2CF3, and perchloro-n-propyl is —CCl2CCl2CCl3. Examples of haloalkyl include C1-6 haloalkyl, C1-4 haloalkyl, C1-3 haloalkyl, and the like. Specific examples of C1-3 alkyl include, but are not limited to, fluoromethyl, chloromethyl, bromomethyl, difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, fluorochloromethyl, difluorochloromethyl, fluorodichloromethyl, fluoroethyl, chloroethyl, bromoethyl, trifluoroethyl, trichloroethyl, tribromoethyl, perfluoroethyl, perchloroethyl, perbromoethyl, perfluoropropyl, perchloropropyl, perbromopropyl, perfluoroisopropyl, perchloroisopropyl, perbromoisopropyl, and the like. Specific examples of C1-4 alkyl include, but are not limited to, C1-3 haloalkyl, perfluorobutyl, perchlorobutyl, perbromobutyl, perfluoroisobutyl, perfluoro-t-butyl, and the like. Specific examples of C1-6 alkyl include, but are not limited to, C1-4 haloalkyl, perfluoro-n-pentyl, perfluoroisopentyl, perfluoroneopentyl, perfluorotert-pentyl, perfluoro-1,2-dimethylpropyl, and the like.


As used herein, “haloalkoxy” as well as “haloalkyloxy” is a monovalent group of —O-haloalkyl with one or more hydrogen on the alkyl group substitututed with halogen. The term “perhaloalkoxy” refers to haloalkoxy with all hydrogen on the alkyl group substituted with halogen. For example, perfluoroethoxy is —OCF2CF3, and perchloro-n-propoxy is —OCCl2CCl2CCl3. Preferred examples of haloalkoxy include C1-6 haloalkoxy, C1-4 haloalkoxy, C1-3 haloalkoxy, and the like. Specific examples of C1-3 alkoxy include, but are not limited to, fluoromethoxy, chloromethoxy, bromomethoxy, difluoromethoxy, dichloromethoxy, dibromomethoxy, tri fluoromethoxy, trichloromethoxy, tribromomethoxy, fluorochloromethoxy, difluorochloromethoxy, fluorodichloromethoxy, fluoroethoxy, chloroethoxy, bromoethoxy, trifluoroethoxy, trichloroethoxy, tribromoethoxy, perfluoroethoxy, perchloroethoxy, perbromoethoxy, perfluoropropoxy, perchloropropoxy, perbromopropoxy, perfluoroisopropoxy, perchloroisopropoxy, perbromoisopropoxy, and the like. Specific examples of C1-4 alkoxy include, but are not limited to, C1-3 haloalkoxy, perfluorobutoxy, perchlorobutoxy, perbromobutoxy, perfluoroisobutoxy, perfluoro-t-butoxy, and the like. Specific examples of C1-6 alkoxy include, but are not limited to, C1-4 haloalkoxy, perfluoro-n-pentyloxy, perfluoroisopentyloxy, perfluoroneopentyloxy, perfluorotert-pentyloxy, perfluoro-1,2-dimethylpropoxy, and the like.


As used herein, “alkylsulfonyl” refers to a sulfonyl group substituted with the “alkyl” described above. “C1-6 alkylsulfonyl” is preferably “C1-4 alkylsulfonyl”. Specific examples of “C1-6 alkylsulfonyl” include, but are not limited to, methylsulfonyl, propionylsulfonyl, butyrylsulfonyl, and the like.


As used herein, the alkyl moiety of “alkylthio” is defined the same as the alkyl described above. Examples of “C1-6 alkylthio” include “C1-4 alkylthio”, and preferred examples thereof include “C1-3 alkylthio”. Specific examples of “C1-6 alkylthio” include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, isopropylthio, isobutylthio, tert-butylthio, sec-butylthio, isopentylthio, neopentylthio, tert-pentylthio, 1,2-dimethylpropylthio, and the like.


As used herein, “arylcarbonyl” is a monovalent group of —C(═O)-aryl. Preferred examples of arylcarbonyl include C6-10 arylcarbonyl. Specific examples of C6-10 arylcarbonyl include, but are not limited to, benzoyl (i.e., phenyl-C(═O)—), 1-naphthylcarbonyl, 2-naphthylcarbonyl, and the like.


As used herein, the aryl moiety of “aryloxy” is defined the same as the aryl described above. Preferred examples of “C6-10 aryloxy” include “C6 or C10 aryloxy”. Specific examples of “C6-10 aryloxy group” include, but are not limited to, a phenoxy group, 1-naphthyloxy group, 2-naphthyloxy group, and the like.


As used herein, “heteroarylcarbonyl” is a monovalent group of —C(═O)-heteroaryl.


As used herein, “heteroarylcarbonyl group” refers to a carbonyl group substituted with the “heteroaryl” described above. Specific examples of “5- to 6-membered heteroarylcarbonyl group” include, but are not limited to, pyrazoylcarbonyl group, triazoylcarbonyl group, triazoylcarbonyl group, thiadiazoylcarbonyl group, pyridylcarbonyl group, pyridazoylcarbonyl group, and the like.


As used herein, the heteroaryl moiety of the “heteroaryloxy group” is defined the same as the “heteroaryl” described above. The 5- to 6-membered heteroaryl moiety of the “5- to 6-membered heteroaryloxy group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl”, respectively. Specific examples of “5- to 6-membered heteroaryloxy group” include, but are not limited to, a pyrazoyloxy group, triazoyloxy group, triazoyloxy group, thiadiazoyloxy group, pyridyloxy group, pyridazoyloxy group, and the like.


As used herein, the heteroaryl moiety of a “heteroarylthio group” is defined the same as the “heteroaryl” described above. The 5- to 6-membered heteroaryl moiety of “5- to 6-membered heteroarylthio group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl”, respectively. Specific examples of “5- to 6-membered heteroarylthio group” include, but are not limited to, pyrazoylthio group, triazoylthio group, thiazoylthio group, thiadiazoylthio group, pyridylthio group, pyridazoylthio group, and the like.


As used herein, the heteroaryl moiety of a “heteroarylsulfonyl group” is defined the same as the “heteroaryl” described above. A “5- to 6-membered heteroarylsulfonyl group” refers to a sulfonyl group substituted with a “5- to 6-membered heteroaryl”. Specific examples of “5- to 6-membered heteroarylsulfonyl group” include, but are not limited to, pyrazoylsulfonyl group, triazoylsulfonyl group, triazoylsulfonyl group, thiadiazoylsulfonyl group, pyridylsulfonyl group, pyridazoylsulfonyl group, and the like.


As used herein, “acyl” refers to a monovalent group of —C(═O)—Racyl, wherein Racyl is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl. Specific examples of acyl include, but are not limited to, formyl, groups exemplified as alkylcarbonyl, arylcarbonyl, and heteroarylcarbonyl, and the like.


As used herein, “optionally substituted carbonyl” group refers to a monovalent group of —C(═O)— (hydrogen or any group selected from a substituent group described herein). Examples of “optionally substituted carbonyl” group include, but are not limited to, formyl, and optionally substituted carbamoyl, alkylcarbonyl, alkoxycarbonyl, alkenylcarbonyl, alkenyloxycarbonyl, alkynylcarbonyl, alkynyloxycarbonyl, arylcarbonyl, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkyloxycarbonyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkyloxycarbonyl, and the like. A carbonyl group substituted with hydrogen is a formyl group. A carbonyl group substituted with amino is a carbamoyl group.


As used herein, “optionally substituted oxy” group refers to a monovalent group of —O— (hydrogen or any group selected from a substituent group described herein). Examples of “optionally substituted oxy” group include, but are not limited to, hydroxy, and optionally substituted alkyloxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, heterocycloalkylcarbonyloxy, and the like. An oxy group substituted with hydrogen is a hydroxy group.


As used herein, “carbamoyl” is a monovalent group of —C(═O)—NH2.


As used herein, “amidinoamino” is a monovalent group of —NH—C(═NH)—NH2.


As used herein, the phrase “a substituent-substituted group” means that the group is substituted with at least one substituent. For example, “hydroxy-substituted C1-6 alkyl” refers to C1-6 alkyl that has at least one hydroxy substitution.


As used herein, “carbamoyl-substituted C1-6alkyl” is C1-6 alkyl substituted with at least one —C(═O)—NH2 group. Examples of “carbamoyl-substituted C1-6 alkyl” include, but are not limited to, carbamoyl-substituted C1-4 alkyl. Specific examples of “carbamoyl-substituted C1-4 alkyl” include, but are not limited to, 2-amino-2-oxoethyl (i.e., H2NC(═O)—CH2— or carbamoylmethyl), 3-amino-3-oxopropyl (i.e., H2NC(═O)—CH2CH2— or carbamoylethyl), 4-amino-4-oxobutyl (i.e., H2NC(═O)—(CH2)3— or carbamoylpropyl), 5-amino-5-oxopentyl (i.e., H2NC(═O)—(CH2)4— or carbamoylbutyl), and the like. Specific examples of “carbamoyl-substituted C1-6 alkyl” include, but are not limited to, carbamoyl-substituted C1-4 alkyl, 6-amino-6-oxohexyl (i.e., H2NC(═O)—(CH2)5— or carbamoylpentyl), 7-amino-7-oxoheptyl (i.e., H2NC(═O)—(CH2)6— or carbamoylhexyl), and the like.


As used herein, “amidinoamino-substituted alkyl” or “guanidino-substituted alkyl” is alkyl substituted with at least one —NH—C(═NH)—NH2 group, wherein the nitrogen atom of the amidinoamino group can be protected with a nitrogen protecting group (e.g., tert-butoxycarbonyl group). Examples of “amidinoamino-substituted C1-6 alkyl” include, but are not limited to, “amidinoamino-substituted C1-4 alkyl” and the like. Specific examples of “amidinoamino-substituted C1-4 alkyl” include, but are not limited to, (amidinoamino)methyl, 2-(amidinoamino)ethyl, 3-(amidinoamino)propyl, 4-(amidinoamino)butyl, and the like. Specific examples of “amidinoamino-substituted C1-6 alkyl” include, but are not limited to, amidinoamino-substituted C1-4 alkyl, 5-(amidinoamino)pentyl, 6-(amidinoamino)hexyl, and the like. Examples of amidinoamino groups protected with a nitrogen protecting group include




embedded image


As used herein, “amidinoamino” is synonymous with “guanidino”.


As used herein, “carboxy-substituted alkyl” is alkyl substituted with at least one —COOH group. Examples of “carboxy-substituted C1-6 alkyl” include, but are not limited to, “carboxy-substituted C1-4 alkyl” and the like. Specific examples of “carboxy-substituted C1-4 alkyl” include, but are not limited to, carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, and the like. Specific examples of “carboxy-substituted C1-6 alkyl” include, but are not limited to, carboxy-substituted C1-4 alkyl, 5-carboxypentyl, 6-carboxyhexyl, and the like.


A “protecting group” refers to a group of atoms that blocks, reduces, or prevents reactivity of a functional group when attached to a reactive functional group in a molecule. The compound of the present disclosure can have a substitution with a protecting group when appropriate or needed at any of R1 to R4 or any position of a substituent thereof or other substituents or the like. Compounds comprising such a protecting group are also within the scope of the present disclosure. Typically, a protecting group can be selectively removed during a synthesis process if desired. Examples of protecting groups are found in Greene and Wuts, Protective Groups in Organic Chemistry, 5th Edition, 2014, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vol. 1 to 8, John Wiley & Sons, NY, or the like. As used herein, a “protecting group” can fall under the definitions for 1) to 53) of substituent a and 1) to 26) of substituent β. In such a case, “54) protecting group” can be described as “54) protecting group other than 1) to 53)” in substituent group α1, and “27) protecting group” can be described as “protecting group other than 1) to 26)” in substituent group β1. Representative examples of nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilylethanesulfonyl (“TES”), trityl and substituted trityl group, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro-veratryloxycarbonyl (“NVOC”), groups represented by “Protect” herein, and the like. Representative examples of hydroxyl protecting groups include, but are not limited to, groups that acylate (esterify) or alkylate a hydroxyl group, such as benzyl and trityl ether, as well as alkyl ether, tetrahydropyranyl ether, trialkylsilyl ether (e.g., TMS, triethylsilyl, t-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS)), alkyldiarylsilyl ether (e.g., t-butyldiphenylsilyl (TBDPS)), triarylsilyl ether (e.g., triphenylsilyl), glycol ether (e.g., ethylene glycol ether, propylene glycol ether, and the like), and allyl ether.


An amino group of the compound of the present disclosure (e.g., amino group of the backbone, amino group as a substituent, amino group in a substituent of said compound, or the like) can be protected with a nitrogen protecting group or a group represented by “Protect”. An amino group in a substituent listed in a substituent group can be further protected with a nitrogen protecting group or a group represented by “Protect”. A protected substituent can also be used as a substituent.


A hydroxy group of the compound of the present disclosure (e.g., hydroxy group as a substituent, a hydroxy group in a substituent of said compound, a hydroxy group in a substituent group described above, or the like) can also be protected with a protecting group of a hydroxy group. A hydroxy group in a substituent listed in a substituent group can be further protected with a hydroxyl protecting group described herein. A protected substituent can also be used as a substituent.


Preferred Embodiments

The preferred embodiments of the present disclosure are described hereinafter. It is understood that the embodiments provided hereinafter are provided for the better understanding of the present disclosure, so that the scope of the present disclosure should not be limited by the following descriptions. Thus, it is apparent that those skilled in the art can refer to the descriptions herein to make appropriate modifications within the scope of the present disclosure. It is also understood that the following embodiments of the present disclosure can be used individually or as a combination.


(Compound and Composition of the Present Disclosure)


In one aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R3, and R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and R23, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


If one of R2A or R2B is hydrogen herein, it is understood that the same definition as R2 described herein can be used.


In another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R1, R2a, R2B, and R3 are defined the same as those for formula XXIF described herein.


In still another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R1, R2A, R2B, and R3 are defined the same as those for formula XXIF described herein.


In still another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R1, R2, and R3 are defined the same as those for formula XXIF described herein.


In one embodiment, the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R1, R3, and if present R4 are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and


the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R2A and R2B are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.


In one embodiment, R1, R3, and if present R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and Rn, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


In some cases for substituents in this embodiment, R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl and/or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.


Alternatively, in another embodiment for (an imine form), R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R2A and Rn, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


In some cases, R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, and R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, and/or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.


In one embodiment, R1, R3, and if present R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C6-10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, and


R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C6-10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, or R2A and Rn, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.


In some cases, R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, and/or R2A and Rn, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.


In one embodiment, R1, R3, and if present R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and


R2A and R2B are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R2A and Rn, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.


In one embodiment, R1, R3, and if present R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and


R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group V.


In some cases, R2A and R2B are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, or formyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In some cases, R1 and if present R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, or formyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally substituted alkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, carbamoyl, or optionally substituted C1-12 alkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R1 and if present R4 are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, C3-10 cycloalkyl, and substituted C3-10 cycloalkyl, C6-10 aryl C1-6 alkyl, C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R1 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, and R3 are each independently hydrogen, optionally substituted C1-12 alkyl, optionally substituted C6-10 aryl C1-12 alkyl, optionally substituted C3-10 cycloalkyl, formyl, optionally substituted C1-12 alkylcarbonyl, optionally substituted C1-12 alkoxycarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C6-10 aryloxycarbonyl, optionally substituted C3-10 cycloalkylcarbonyl, optionally substituted C3-10 cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C1-12 alkylcarbamoyl, optionally substituted C1-12 alkoxycarbamoyl, optionally substituted C6-10 arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C3-10 cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R1 and R3 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.


In one embodiment, R1 and if present R4 are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, carbamoyl, alkylcarbamoyl, or arylalkylcarbamoyl, wherein the substituted amino each independently has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R1 and if present R4 are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, and C3-10 cycloalkyl, C6-10 aryl C1-6 alkyl, C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, C1-12 alkylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, C6-10 aryl C1-6 alkyloxycarbonyl, C1-12 alkoxycarbonyl, C6-10 arylcarbonyl, C6-10 aryloxycarbonyl, carbamoyl, C1-12 alkylcarbamoyl, or C6-10 aryl C1-6 alkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R1 and if present R4 are each independently, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, and C3-10 cycloalkyl, C6-10 aryl C1-6 alkyl, or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, substituted amino, nitro, and hydroxy, wherein the substituted amino optionally has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R3 is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R3 each independently and optionally have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In some cases, R3 is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R3 each independently and optionally have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R3 can be hydrogen, alkyl, formyl, alkylcarbonyl, arylalkylcarbonyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl.


In some cases, R3 can be hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl.


In one embodiment, R3 can be hydrogen, C1-12 alkyl, formyl, C1-6 alkylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-6 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-6 alkyl, C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino, 5- to 10-membered heteroaryl C1-6 alkyl, or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl.


In some cases, R3 can be hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-6 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-6 alkyl, C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino, 5- to 10-membered heteroaryl C1-6 alkyl, or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl.


In one embodiment, R3 can be C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-6 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-6 alkyl, or C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


In one embodiment, R3 is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R3 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R3 is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy.


In one embodiment, R3 is hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C1-6 alkylsilyloxy, amino, C1-6 alkoxycarbonylamino, and C3-10 cycloalkyl, C6-10 aryl C1-6 alkyl, or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 alkoxycarbonyl, and hydroxy.


In one embodiment, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In one embodiment, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, heteroarylalkyl, alkoxycarbonyl-substituted heteroarylalkyl, or cycloalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In one embodiment, R2A and R2B are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C1-6 alkoxy, C1-6 alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, and 5- to 10-membered heterocycloalkyl, C6-10 aryl C1-6 alkyl, C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and hydroxy, 5- to 10-membered heteroaryl C1-6 alkyl, C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, or C3-10 cycloalkyl, R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In one embodiment, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In some cases, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In one embodiment, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, alkylcarbonyl, arylalkylcarbonyl, hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In some cases, R2A and R2B are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.


In one embodiment, R2A and R2B are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, C1-6 alkylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-12 alkyl, C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino, 5- to 10-membered heteroaryl C1-12 alkyl, or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-12 alkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


In some cases, R2A and R2B are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-12 alkyl, C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino, 5- to 10-membered heteroaryl C1-12 alkyl, or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-12 alkyl, or R2A and Rn, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


In one embodiment, R2A and R2B are each independently hydrogen, C1-12 alkyl, C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C1-6 alkylsilyloxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonylamino, C3-10 cycloalkyl, carboxy, amino, amidinoamino, C1-6 alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C6-10 aryl C1-12 alkyl, C6-10 aryl C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C1-6 alkylamino, di-C1-6 alkylamino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, carboxy C1-6 alkylcarbonylamino, carbamoyl C1-6 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino, 5- to 10-membered heteroaryl C1-12 alkyl, or C1-6 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-12 alkyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group consisting of halogen, nitro, hydroxy, amino, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C3-6 cycloalkylcarbonylamino, and C3-6 cycloalkyl C1-6 alkylamino.


In one embodiment, R1 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV. Alternatively, R1 is alkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R1 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV. Alternatively, R1 is C1-12 alkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.


In one embodiment, R2A is hydrogen, and R2B is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl. Alternatively, R2A is hydrogen, and R2B is alkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl.


In one embodiment, R2A is hydrogen, and R2B is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and hydroxy; or C3-10 cycloalkyl. Alternatively, R2A is hydrogen, and R2B is C1-12 alkyl; C6-10 aryl C1-6 alkyl; C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and hydroxy; or C3-10 cycloalkyl.


In one embodiment, R3 is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy. Alternatively, R3 is alkyl or arylalkyl.


In one embodiment, R3 is C1-12 alkyl; C1-12 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C3-10 cycloalkyl; C6-10 aryl C1-6 alkyl; or C6-10 aryl C1-6 alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of C1-6 alkyl and hydroxy.


Alternatively, in one embodiment, R3 is C1-12 alkyl or C6-10 aryl C1-6 alkyl.


In one embodiment, R4 is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl.


In one embodiment, R4 is hydrogen, C1-12 alkyl, C1-12 alkylcarbonyl, C6-10 aryl C1-6 alkylcarbonyl, C6-10 aryl C1-6 alkyloxycarbonyl, C1-12 alkoxycarbonyl, carbamoyl, or C6-10 aryl C1-6 alkylcarbamoyl.


In one embodiment, R1 is hydrogen, methyl, ethyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, tert-butylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, ethoxybenzyl, tert-butoxybenzyl, aminobenzyl, (cyclopentylcarbonylamino)benzyl, (cyclopentylmethylamino)benzyl, (dimethylamino)benzyl, (carbamoylethylcarbonylamino)benzyl, (carboxyethylcarbonylamino)benzyl, nitrobenzyl, hydroxybenzyl, 3-methylbutanoyl, isobutylcarbonyl, 2-phenylacetyl, isopropyloxycarbonyl, benzoyl, or phenyloxycarbonyl.


In another embodiment, R1 is methyl, n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, aminopropyl, 2-(tert-butyl-dimethylsilyloxy)ethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, (tert-butyl)benzyl, methoxybenzyl, ethoxybenzyl, (tert-butoxy)benzyl, (trifluoromethoxy)benzyl, (dimethylamino)benzyl, nitrobenzyl, or hydroxybenzyl.


In one embodiment, R2A is hydrogen, and R2B is methyl, isopropyl, isobutyl, n-pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, carbamoylmethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, (tetrahydro-2H-pyran-2-yl)methyl, benzyl, phenylethyl, naphthalenylmethyl, naphthalenylethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, tert-butoxybenzyl, hydroxybenzyl, α-hydroxymethylphenethyl, 1-hydroxyphenethyl, pyridinylmethyl, (1H-indol-3-yl)ethyl, (1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, cyclopentyl, or cyclohexyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.


In one embodiment, R2A and R2B are each independently isopropyl, isobutyl, sec-butyl, pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, (tert-butoxycarbonyl)ethylcarbamoylethyl, carboxyethyl, hydroxyethyl, aminopropyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, (1,2,3,4-tetrahydronaphthalenyl)methyl, (tetrahydro-2H-pyranyl)methyl, benzyl, phenylethyl, naphthalenylmethyl, (naphthalenyl)ethyl, β-hydroxyphenethyl, α-(hydroxymethyl)phenethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, (tert-butoxy)benzyl, hydroxybenzyl, pyridinylmethyl, quinolinylethyl, (1-(tert-butoxycarbonyl)-1H-indolyl)ethyl, cyclopentyl, or cyclohexyl, or R2A and R2B, together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.


In one embodiment, R3 is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxymethyl, hydroxyethyl, (tert-butyldimethylsilyloxy)ethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, or hydroxybenzyl.


In one embodiment, R3 is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, aminopropyl, (tert-butyldimethylsilyloxy)ethyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, (tert-butoxy)benzyl, or hydroxybenzyl.


In one embodiment, R4 is hydrogen, methyl, ethyl, isobutyl, formyl, acetyl, 3-methylbutanoyl, 2-phenylacetyl, methoxycarbonyl, ethoxycarbonyl, 2-methylpropyloxycarbonyl, tert-butoxycarbonyl, benzoyl, benzyl, benzyloxycarbonyl, aminocarbonyl, N-benzylaminocarbonyl, propylcarbamoyl, N-isobutylaminocarbonyl, or N-benzylaminocarbonyl.


In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein


R1, R2, and R3 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and


R4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.


In one embodiment, R1, R2, and R3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.


In one embodiment, R1, R2, and R3 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl C1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C1-6 alkyl, or optionally substituted C3-6 cycloalkyl C1-6 alkyl.


In one embodiment, R1, R2, and R3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and R4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted alkoxycarbonyl, or optionally substituted alkylcarbamoyl.


In one embodiment, R1, R2, and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, (optionally substituted amino)-C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6alkyl, or C3-6 cycloalkyl C1-6 alkyl.


In one embodiment, R1, R2, and R3 are each independently C1-6 alkyl, hydroxy-substituted C1-6 alkyl, carbamoyl-substituted C1-6 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-6 alkyl, carboxy-substituted C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, hydroxy-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, (optionally substituted amino)-C6-10 aryl C1-6 alkyl, C1-4 alkoxycarbonyl-substituted C1-6 alkyl, C1-4 alkoxycarbonylamino-substituted C1-6 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-6 alkyl, or C3-6 cycloalkyl C1-6 alkyl.


In one embodiment, R1, R2, and R3 are each independently alkyl or optionally substituted arylalkyl.


In one embodiment, R1, R2, and R3 are each independently C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


In one embodiment, R1, R2, and R3 are each independently C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, halogen-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, or (optionally substituted amino)-C6-10 aryl C1-6 alkyl.


In one embodiment, R1, R2, and R3 are each independently C1-6 alkyl, C6-10 aryl C1-6 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-6 alkyl, chloro-substituted C6-10 aryl C1-6 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-6 alkyl, or (optionally substituted amino)-C6-10 aryl C1-6 alkyl.


In one embodiment, R1 is C1-6 alkyl or C6 aryl C1-4 alkyl, R2 is C1-6 alkyl or C1-4 alkyl-substituted benzyl, and R3 is C1-6 alkyl or C6 aryl C1-4 alkyl.


In one embodiment, R1 and R3 are each independently alkyl or optionally substituted benzyl, and R2 is optionally substituted benzyl.


In one embodiment, R1 and R3 are each independently C1-6 alkyl, benzyl, C1-4 alkyl-substituted benzyl, chloro-substituted benzyl, C1-4 alkoxy-substituted benzyl, or amino-substituted benzyl, and R2 is benzyl or chloro-substituted benzyl.


In one embodiment, R1 and R3 are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R2 is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.


In one embodiment, R1 is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, R2 is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R3 is isobutyl, isopentyl, or benzyl.


In one embodiment, R1 is C1-6 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-6 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, halo-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


In one embodiment, R1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.


In one embodiment, R1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or




embedded image


In one embodiment, R1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.


In one embodiment, R1 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.


In one embodiment, R1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, or hydroxyethyl.


In one embodiment, R1 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.


In one embodiment, R1 is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


In one embodiment, R1 is isobutyl, 3-hydroxypropyl, 3-amino-3-oxopropyl, 6-aminohexyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.


In one embodiment, R2 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, halogen-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxy-substituted C6-10 aryl C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, C1-4 alkoxycarbonylamino-substituted C1-4 alkyl, 5- to 6-membered heterocycloalkyl-substituted C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


In one embodiment, R2 is naphthalen-1-ylmethyl or optionally substituted benzyl.


In one embodiment, R2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.


In one embodiment, R2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, cyclohexylmethyl, or




embedded image


In one embodiment, R2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.


In one embodiment, R2 is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.


In one embodiment, R2 is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


In one embodiment, R2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.


In one embodiment, R2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, cyclohexylmethyl, or 2-(1H-indol-3-yl)ethyl.


In one embodiment, R2 is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino) propyl, or naphthalen-1-ylmethyl.


In one embodiment, R3 is C1-4 alkyl, hydroxy-substituted C1-4 alkyl, carbamoyl-substituted C1-4 alkyl, C1-4 alkoxycarbonyl-substituted C1-4 alkyl, amino-substituted C1-4 alkyl, amidinoamino-substituted C1-4 alkyl, carboxy-substituted C1-4 alkyl, C6-10 aryl C1-4 alkyl, C1-4 alkyl-substituted C6-10 aryl C1-4 alkyl, hydroxy-substituted C6-10 aryl C1-4 alkyl, or C5-6 cycloalkyl C1-4 alkyl.


In one embodiment, R3 is isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.


In one embodiment, R3 is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or




embedded image


In one embodiment, R3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.


In one embodiment, R3 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.


In one embodiment, R3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxymethyl, or naphthalen-1-ylmethyl.


In one embodiment, R3 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.


In one embodiment, R3 is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or




embedded image


In one embodiment, R3 is isobutyl, hydroxymethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, 2-naphthylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.


In one embodiment, R1 is C1-6 alkyl or C6-10 aryl C1-6 alkyl, and R2 and R3 are each independently C1-6 alkyl or optionally substituted C6-10 aryl C1-6 alkyl.


In one embodiment, R1 is isobutyl, isopentyl, or benzyl, R2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.


In one embodiment, R1 is isobutyl, R2 is benzyl, and R3 is benzyl.


In one embodiment, R1 is benzyl, R2 is benzyl, and R3 is isobutyl.


In one embodiment, R1 is isobutyl, R2 is benzyl, and R3 is 3-methylbenzyl.


In one embodiment, R1 is benzyl, R2 is 3,4-dichlorobenzyl, and R3 is isobutyl.


In one embodiment, R1 is isobutyl, R2 is 4-methylbenzyl, and R3 is benzyl.


In one embodiment, R1 is benzyl, R2 is isobutyl, and R3 is isobutyl.


In one embodiment, R4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, or optionally substituted alkoxycarbonyl.


In one embodiment, R4 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkylcarbonyl, optionally substituted C6-10 arylcarbonyl, optionally substituted C1-6 alkoxycarbonyl, or optionally substituted C1-6 alkylcarbamoyl.


In one embodiment, R4 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkylcarbonyl, optionally substituted C6-10 arylcarbonyl, or optionally substituted C1-6 alkoxycarbonyl.


In one embodiment, R4 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C6-10 arylcarbonyl, C1-6 alkoxycarbonyl, or C1-6 alkylcarbamoyl.


In one embodiment, R4 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C6-10 arylcarbonyl, or C1-6 alkoxycarbonyl.


In one embodiment, R4 is hydrogen, C1-4 alkyl, C1-4 alkylcarbonyl, C6 arylcarbonyl, C1-4 alkoxycarbonyl, or C1-4 alkylcarbamoyl.


In one embodiment, R4 is hydrogen, C1-4 alkyl, C1-4 alkylcarbonyl, C6 arylcarbonyl, or C1-4 alkoxycarbonyl.


In one embodiment, R4 is hydrogen or alkyl.


In one embodiment, R4 is hydrogen or C1-6 alkyl.


In one embodiment, R4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.


In one embodiment, R4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.


In one embodiment, R4 is hydrogen or ethyl. In a preferred embodiment, R4 is hydrogen.


A hydroxyl group, amino group, and/or carboxyl group in R1, R2, R3, and/or R4, when present, can be independently protected with a protecting group. Such a compound is also within the scope of the present disclosure.


In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof. R1, R2, and R3 in formula IB are defined the same as those in formula IF.


In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IIF:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof. R1, R2, and R3 in formula IIF are defined the same as those in formula IF.


In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IIB:




embedded image


or an enantiomer thereof, or a salt thereof, or a solvate thereof. R1, R2, and R3 in formula IIB are defined the same as those in formula IF.


The compound of the present disclosure is further described hereinafter.


While the compound of the present disclosure can have enantiomers and stereoisomers such as tautomers and geometric isomers depending on the type of substituent, they are also encompassed by the present disclosure. Specifically, if there is one or more asymmetric carbon atoms in the compound of the present disclosure, there is a diastereomer or enantiomer, and a mixture of such a diastereomer and enantiomer, and isolated diastereomers and enantiomers are also encompassed by the compound of the present disclosure.


The present disclosure is also intended to encompass various hydrates, solvates, and crystalline polymorphisms.


Furthermore, the compound of the present disclosure can be substituted with an isotope (e.g., 2H (or D), 3H (or T), 11C, 13C, 14C, 13N, 15N, 15O, 35S, 18F, 125I, or the like). These compounds are also encompassed by the compound of the present disclosure.


Furthermore, the scope of the present disclosure encompasses prodrugs of the compound of the present disclosure. In the present disclosure, a prodrug refers to a derivative that yields a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula by acid hydrolysis or enzymatic degradation in the body. For example, if a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula thereof has a functional group such as a hydroxyl group, amino group, or carboxyl group or other substituents, these groups can be modified by a conventional method to manufacture a prodrug. Prodrug technologies are described in, for example, C. G. Wermuth, “The Practice of Medicinal Chemistry”, 4th Ed., Academic Press, (2015), Chapter 28.


Examples for compounds having a carboxy group include compound whose carboxyl group is modified to be an alkoxycarbonyl group, alkylthiocarbonyl group, or alkylaminocarbonyl group.


Examples of compounds having an amino group include compounds whose amino group is substituted with an alkanoyl group to be an alkanoylamino group, compounds substituted with an alkoxycarbonyl group to be an alkoxycarbonylamino group, compounds modified to have an alkanoyloxymethylamino group, and compounds modified to have hydroxylamine.


Examples for compounds having a hydroxyl group include compounds whose hydroxyl group is substituted with an alkanoyl group to be an alkanoyloxy group, phosphate ester, or alkanoyloxymethyloxy group.


Examples of the alkyl moiety of a group used for preparing a prodrug thereof include the alkyl group. The alkyl group is optionally substituted with, for example, an alkoxy group or the like. Preferred examples thereof include the following.


For compounds whose carboxyl group is modified to be an alkoxycarbonyl group, examples thereof include alkoxycarbonyl such as methoxycarbonyl and ethoxycarbony, and alkoxycarbonyl substituted with an alkoxy group such as methoxymethoxycarbonyl, ethoxymethoxycarbonyl, 2-methoxyethoxycarbonyl, and 2-methoxyethoxymethoxycarbonyl, or privaloyloxymethoxycarbonyl.


As used herein, “pharmaceutically acceptable salt” refers to an acid addition salt or base addition salt which is pharmaceutically acceptable for use. Specific examples of “pharmaceutically acceptable salts” include, but are not limited to, acid addition salts such as acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonate, para-toluenesulfonate (tosylate), laurylsulfate, malate, ascorbate, mandelate, saccharinate, xinafoate, pamoate, cinnamate, adipate, cysteine salt, N-acetyl cysteine salt, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, acrylic acid polymer salt, and carboxyvinyl polymer; inorganic base addition salts such as lithium salt, sodium salt, potassium salt, and calcium salt; organic base addition salts such as morpholine and piperidine; amino acid addition salts such as aspartic acid and glutamic acid; and the like.


In one embodiment, the compound of the present disclosure can be administered directly, or as a formulation, medicament, or a pharmaceutical composition using a suitable dosage form, by oral or parenteral administration. Specific examples of such dosage forms include, but are not limited to, tablets, capsules, powdered agents, granules, liquid agents, suspension, injection agents, patch-on agents, poultice, and the like. These formulations can be manufactured by a known method using an additive that is commonly used as a pharmaceutical additive.


As these additives, an excipient, disintegrant, binding agent, fluidizer, lubricant, coating agent, solubilizing agent, solubilizing promotor, thickener, dispersant, stabilizer, sweetener, flavoring agent, or the like can be used depending on the objective. Specific examples of these additives include, but are not limited to, lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, talc, and the like.


The dosage of the compound of the present disclosure is appropriately selected depending on the subject targeted for administration, route of administration, disease, age of subject, body weight, and symptom. For example, the dosage is 0.01 mg as the lower limit (preferably 100 mg) and 10000 mg as the upper limit (preferably 6000 mg) per day for adults for oral administration. This amount can be administered once daily, or divided into several doses.


In one embodiment, the compound of the present disclosure is a compound with an antiviral activity for a virus in the Lyssavirus genus. The virus in the Lyssavirus genus comprises a rabies virus, Lagos bat virus, mokola virus, Duvenhage virus, European bat 1 lyssavirus, European bat 2 lyssavirus, Australian bat lyssavirus, and the like. The virus in the Lyssavirus genus preferably comprises a rabies virus.


In one embodiment, the compound of the present disclosure is a compound with the ability to suppress or kill tumor or cancer. The tumor or cancer can be any tumor or cancer such as carcinoma, lymphoma, blastoma, sarcoma, or leukemia. Tumor and cancer can be squamous cell carcinoma, lung cancer such as small cell lung cancer, non-small cell lung cancer, or pulmonary adenocarcinoma, squamous cell carcinoma of the lung, peritoneal cancer, hepatoma, esophageal cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, uterine cancer such as cervical cancer, ovarian cancer, liver cancer, hepatocellular cancer, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, colorectal cancer, epithelial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma, various types of head and neck cancer, blood cancer (leukemia), prostate cancer, gastric cancer, fibrous cancer, glioma, melanoma, or the like.


The timing of dosing of the compound of the present disclosure and therapeutic agents thereof is not limited. The compound and therapeutic agent can be administered concurrently or sequentially to a subject being administered therewith. The compound of the present disclosure and therapeutic agent thereof can be formulated as a combined agent. The dosage of the therapeutic agent can be appropriately selected based on the clinically used dose. The ratio of the compound of the present disclosure and therapeutic agent thereof can be appropriately selected depending on the subject of administration, route of administration, target disease, symptom, combination, or the like.


In one embodiment of the present disclosure, the compound of the present disclosure can be combined and administered concurrently or at different times upon use of a pharmaceutical composition. Such a pharmaceutical composition is also within the scope of the present disclosure.


Such a medicament, formulation, or pharmaceutical composition can be manufactured by mixing the compound of the present disclosure and/or an addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like) with any suitable component, together or separately, as a combined agent, or as separate agents using any technology that is known in the art. An appropriate formulation such as a tablet, capsule, powder, granule, liquid agent, suspension, injection, patch, or poultice can be formulated by using any technology that is known in the art. If the compound of the present disclosure and/or an addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like) are prepared as separate agents, they can be provided as a kit of two agents. The kit can provide one of the components as a single agent, with instructions (package insert or the like) instructing to combine and administer the other component (for the compound of the present disclosure, the additional agent; for the addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like), the compound of the present disclosure) concurrently or at different times.


If the compound of the present disclosure is used as an active ingredient of a medicament, the compound is intended for use in not just humans, but also other animals other than humans (cat, dog, cow, horse, bat, fox, mangoose, raccoon, and the like).


(Method of Manufacturing the Compound of the Present Disclosure)


Hereinafter, the method of manufacturing the compound of the present disclosure is described with examples, but the present disclosure is not limited thereto.


The compound of the present disclosure can be manufactured by, for example, the following manufacturing methods, but are not limited to such methods. These manufacturing methods can be appropriately improved upon based on the expertise of those skilled in the art of organic synthetic chemistry. Salts of the compounds used as a raw material can be used in the following manufacturing method, as long as the reaction is not affected.


In the following manufacturing methods, even if use of a protecting group is not specifically described, a functional group other than those at the reaction point can be protected as needed and deprotected after the completion of a reaction or after a series of reations to obtain a compound of interest if one of the functional groups other than those at the reaction point is altered under the reaction condition or if it is unsuitable for post-reaction processing. Common protecting groups described in the document (Peter G. M. Wuts, “Greene's Protective Groups in Organic Synthesis”, 5th Ed., John Wiley & Sons, Inc., Hoboken, N.J. (2014)) or the like can be used as the protecting groups used in these processes. A protecting group can be introduced or removed by a method that is commonly used in organic synthetic chemistry (e.g., method described in the aforementioned document or the like) or a method in accordance thereto.


The starting material and intermediate in the following manufacturing methods can be purchased as a commercially available product or are available by synthesis in accordance with a method described in a known document or a known method from a known compound. Salts of the starting material and intermediate can also be used, as long as the reaction is not affected.


The intermediate and compound of interest in the following manufacturing methods can also be converted into another compound encompassed by the present disclosure by appropriately converting their functional groups. A functional group can be converted in doing so by a method that is commonly used in organic synthetic chemistry (e.g., method described in R. C. Larock, “Comprehensive Organic Transformations”, 2nd Ed., John Wiley and Sons, Inc., New York (1999) or the like) or a method in accordance therewith.


An inert solvent in the following manufacturing methods refers to a solvent that does not react with a raw material, reagent, base, acid, catalyst, ligand, or the like used in the reaction (hereinafter, also referred to as “raw material or the like used in the reaction”). A solvent used in each step can be used as an inert solvent even if the solvent reacts with the raw material or the like used in the reaction, as long as the reaction of interest proceeds to result in a compound of interest.


The overview of compound synthesis related to the present disclosure is shown below. “B” and “F” following the Roman numeral compound number indicate that a 5-membered ring comprising nitrogen is located in the “back” and “front”, respectively. In other words, a —C(═O)NH—R2 group attached to a 5-membered ring comprising nitrogen referred to as “back”, and a —C(═O)NH—R2 that is not attached to a 5-membered ring comprising nitrogen is referred to as “front”.


Synthesis Scheme 1

Synthesis of compound III


Compound III can be manufactured by, for example, the following manufacturing method.


(1) Route 1-1 Synthesis from Compound VII and Compound VIII




embedded image


(2) Route 1-2 Synthesis from Compound VII and Compound VIII Through Protection of Amine




embedded image


(3) Route 1-3 Synthesis from Compound XI and Compound XII




embedded image


wherein XL represents a leaving group in a nucleophilic substitution reaction. Examples thereof include halogen (e.g., chlorine, bromine, or iodine), sulfate esters (—OSO3H and the like), and sulfonyl-O— groups (e.g., methanesulfonyl-O—, toluenesulfonyl-O—, and the like).


(4) Route 1-4 Synthesis from Compound XI and Compound XIII




embedded image


(5) Route 1-5 Synthesis from Compound VII and Compound XIV




embedded image


wherein if R1 in compound III can be expressed as —CH2—R1′, R1 in compound III can be replaced with —CH2—R1′ to express compound III as compound III′.


In the formula, R1 is as defined in item 1 or A1 herein, and “Protect” is a protecting group of amino group. Examples of protecting groups of an amino group include an ethoxycarbonyl group, tert-butoxycarbonyl group, acetyl group, benzoyl group, trifluoroacetyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, triphenylmethyl group, methanesulfonyl group, p-toluenesulfonyl group, trimethylsilyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, benzylsulfonyl group, benzyl group, 4-nitrobenzyl group, 4-methoxybenzyl group, methyl group, ethyl group, and the like.


A compound that is commercially available or a compound manufactured by a known method can be used as a starting raw material compound.


Synthesis Scheme 2


Synthesis of Compound V

A compound of formula V can be manufactured by, for example, the following manufacturing method.


(1) Route 2-1 Synthesis from Compound XVI and Compound XVII




embedded image


wherein R8 indicates alkoxy, aryloxy, hydroxy, or halogen. Examples thereof include an ethoxy group. This synthesis is achieved by various reactions known to those skilled in the art. If R2 is aryl, compound V can be synthesized in accordance with the method described in C. W. Cheung, M. L. Ploeger, and X. Hu, Nature Communications 2017, 8, 14878.


(2) Route 2-2 Synthesis from Compound XVIII




embedded image


wherein R2 is as defined in item 1 or A1 herein. A compound that is commercially available or a compound that is manufactured by a known method can be used as the starting compound.


Synthesis Scheme 3


Synthesis of Compound VI

A compound of formula VI can be manufactured from compound III and compound IV by, for example, the following manufacturing method.




embedded image


wherein R1 and R3 are as defined in item 1 or A1 herein.


Synthesis Scheme 4


Compound of Formula IIF and Compound of Formula IIB-Route 1


A compound of formula IIF and compound of formula IIB can be manufactured, for example, from three components through one-pot synthesis in accordance with a known method (e.g., method described in Bioorg. Med. Chem. 23 (2015) 2629-2635, Tetrahedron 63 (2007) 6004-6014, Eur. J. Org. Chem. 2009, 2185-2189, Eur. J. Org. Chem. 2011, 2354-2359 or the like).




embedded image


wherein R1, R2, and R3 are as defined in item 1 or A1 herein.


Synthesis Scheme 5


Compound of formula IIF and compound of formula IIB-Route 2


A compound of formula IIF and compound of formula IIB can be manufactured, for example, from two components as described below.




embedded image


wherein R1, R2, and R3 are as defined in item 1 or A1 herein.


Synthesis Scheme 6


Synthesis of Compound IF and Compound IB


Step 6-1


Reduction of Imine


Compound IF (i.e., compound of formula IF) or compound


IB (i.e., compound of formula IB) can be manufactured, for example, from compound IIF (i.e., compound of formula IIF) or compound IIB (i.e., compound of formula IIB) by reduction as described below. However, R4 therein is H.




embedded image


Step 6-2


Modification of Amine of Piperidine Ring


Amine of a piperidine ring of compound IF or compound IB can be modified, for example by alkylation, amidation, or the like as follows.




embedded image


Synthesis Scheme 7


Synthesis of Compound V′

A compound of formula V′ can be manufactured by, for example, the following manufacturing method.


(1) Route 7-1 Synthesis from Compound XVI and Compound XVII′




embedded image


A compound of formula V′ can be manufactured under the same condition as Route 2-1 of Synthesis Scheme 2. R8 indicates alkoxy, aryloxy, hydroxy, or halogen.


(2) Route 7-2 Synthesis from Compound XVIII′




embedded image


wherein R2A and R2B are as defined in item 1 herein. A compound that is commercially available or a compound manufactured by a known method can be used as a starting raw material compound.


Synthesis Scheme 8


Synthesis of Compound of Formula XXIIF and Compound of Formula XXIIB-Route 1

A compound of formula XXIIF and a compound of formula XXIIB can be synthesized under the same condition as Synthesis Scheme 4.




embedded image


wherein R1, R2A, R2B, and R3 are as defined in item 1 herein.


Synthesis Scheme 9


Synthesis of Compound of Formula XXIIF and Compound of Formula XXIIB-Route 2

A compound of formula XXIIF and compound of formula XXIIB can be manufactured, for example, from two components as described below.




embedded image


wherein R1, R2A, R2B, and R3 are as defined in item 1 herein.


Synthesis Scheme 10


Synthesis of Compound XXIF and Compound XXIB

Step 10-1


Reduction of Imine


Under the same condition as step 6-1 of Synthesis Scheme 6, compound XXIF (i.e., compound of formula XXIF) or compound XXIB (i.e., compound of formula XXIB) can be manufactured, for example, from compound XXIIF (i.e., compound of formula XXIIF) or compound XXIIB (i.e., compound of formula XXIIB) by reduction as described below. However, R4 therein is H.




embedded image


Step 10-2


Modification of Amine of Piperidine Ring


Amine of a piperidine ring in compound XXIF or compound XXIB can be modified by, for example, alkylation, amidation, or the like as follows.




embedded image


R4 in the product of this step is a group defined herein other than H.


The intermediate and compound of interest in the manufacturing methods described above can be isolated and purified by subjecting them to a purification method that is commonly used in organic synthesis chemistry (e.g., neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography, or the like). Each intermediate can also be subjected to the subsequent reaction without any particular purification.


Optically active forms of the compound of the present disclosure can be manufactured by using an optically active starting material or intermediate, or by optically resolving a racemate of the final product or intermediate. Examples of optional resolution methods include, but are not limited to, separation method using an optically active column or a separation method such as fractional crystallization method. A diastereomer of the compound of the present disclosure can be manufactured by, for example, but not limited to, a separation method such as column chromatography or fractional crystallization.


A pharmaceutically acceptable salt of a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula can be manufactured by, for example, but not limited to, mixing a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula with a pharmaceutically acceptable acid or base in a solvent such as water, methanol, ethanol, 2-propanol, ethyl acetate, or acetone.


As used herein, “or” is used when “at least one or more” of the listed matters in the sentence can be employed. When explicitly described herein as “within the range of two values”, the range also includes the two values themselves.


Reference literatures such as scientific literatures, patents, and patent applications cited herein are incorporated herein by reference to the same extent that the entirety of each document is specifically described.


The present disclosure has been described while showing preferred embodiments to facilitate understanding. While the present disclosure is described hereinafter based on the Examples, the above descriptions and the following Examples are provided for the sole purpose of exemplification, not limitation of the present disclosure. Thus, the scope of the present disclosure is not limited to the embodiments and Examples that are specifically described herein and is limited only by the scope of claims.


EXAMPLES

The present disclosure is specifically described based on the Examples. The scope of the present disclosure is not limited to the Examples described below.


For Thin Layer Chromatography (TLC), Merck's TLC Silica gel 60 F254 (25 glass plate, 20×20 cm) and Fuji Silysia Chemical's CHROMATOREX NH-TLC Plates (20×20 cm) were used. As the developing solvent, chloroform-methanol mixed solvent system, ethyl acetate-methanol mixed solvent system, or ethyl acetate-hexane mixed solvent system was used. Spots were checked using coloring with UV irradiation, ninhydrin, iodine, or phosphomolybdic acid (ethanol solution). An organic solvent was dried using anhydrous sodium sulfate and anhydrous magnesium sulfate. For column chromatography, Fuji Silysia Chemical's cartridge column CHROMATOREX Q-PACKS 130 (SIZE 10, 20, or 60) and DNH (SIZE 20) or Shoko Science's Purif-Pack®-EX SI50 (SIZE 20 or 60) were used in accordance with the amount of raw product to be purified. Silica gel thin layer chromatography for separation (PTLC: Preparative Thin Layer Chromatography) used Merck's PLC Silica gel 60 F254 (20×20 cm; thickness: 0.5 mm; product number: 1.05744.0001; thickness: 1 mm; product number: 1.13895.0001) and Fuji Silysia Chemical's CHROMATOREX NH-PLCO5 (20×20 cm; thickness: 0.5 mm). Synthesized compounds were identified by LC/MS (Liquid Chromatography/Mass Spectrometry). Tables 1 to 4 show the retention (tR) and m/z value [M+1]+. For measurement, Shimadzu's LCMS-2020 system was used, and Chemicals Evaluation and Research Institute's L-column2 ODS, 3 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 40° C., and compounds were detected by using both UV absorption (220 nm, 254 nm) and mass spectrometry. Elution condition A or B shown below was used.


Elution Condition A:


Flow rate 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile; 0-0.9 minutes, linear gradient, A:B (95:5)-A:B (10:90), 0.9-2 minutes


Elution Condition B:


Flow rate 1.0 mL/min, mobile phase a=aqueous 0.05% (v/v) formic acid solution, mobile phase b=0.05% (v/v) formic acid containing acetonitril; 0-0.9 minutes, linear gradient, A:B (95:5)-A:B (10:90), 0.9-2 minutes


Elution Condition B1:


Flow rate 1.0 mL/min, mobile phase a=aqueous 0.05% (v/v) formic acid solution, mobile phase b=0.05% (v/v) formic acid containing acetonitrile; 0.1-2.0 minutes, linear gradient, A:B (95:5)-A:B (60:40), 2.0-3.0 minutes, linear gradient, A:B (60:40)-A:B (10:90), 3.0-4.0 minutes


Furthermore, LC/MS measurement used the following instrument and measurement conditions.


Measurement Condition C:


Shimadzu's LCMS-2020 system was used, and Chemicals Evaluation and Research Institute's L-column2 ODS, 3 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 40° C., and the compound was detected by using both UV absorption (220 nm, 254 nm) and mass spectrometry.


Elution condition: flow rate of 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A1








Ratio of mobile



Time (min)
phase b (%)









0.0 
 5



0.01-0..89
5-90 linear gradient



0.9 
90



2.00
90










Measurement Condition D:


The same apparatus as measurement condition C was used.


Elution condition: flow rate of 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A2








Ratio of mobile



Time (min)
phase b (%)









0.0 
 0



0.5 
 0



0.51-1.39
0-70 linear gradient



1.4 
70



1.5 
90



2.00
90










Measurement Condition E:


The same apparatus as measurement condition C was used.


Elution condition: flow rate of 1.5 mL/min, mobile phase a=5 mM NH4HCO3 containing water/acetonitrile=900/100 (v/v), mobile phase b=5 mM NH4HCO3 containing water/acetonitrile=100/900 (v/v)












TABLE A3








Ratio of mobile



Time (min)
phase b (%)









0.0 
 0



0.5 
 0



0.51-1.39
0-70 linear gradient



1.4 
70



1.5 
90



2.00
90










Measurement Condition F:


Waters' Alliance 2695 Separation Module system was used, and YMC's YMC-Triart C18, 5 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 30° C., and the compound was detected using both UV absorption (220 nm) and mass spectrometry.


Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A4








Ratio of mobile



Time (min)
phase b (%)









0.0
10



1.0
10



1.0-1.5
10-30 gradient



1.5-4.5
30-70 gradient



4.5-5.0
70-90 gradient



6.0
90










Measurement Condition G:


The same apparatus as measurement condition F was used.


Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A5








Ratio of mobile



Time (min)
phase b (%)









0.0
 1



1.0
 1



1.0-4.0
1-40 gradient



4.0-5.0
40-90 gradient



6.0
90










Measurement Condition H:


Waters' 2767 system was used, and YMC's YMC-Triart C18, 5 μm, 4.6×50 mm was used as the analysis column. The column oven was set to 25° C., and compound was detected using UV absorption (220 nm), mass spectrometry, and ELS (Evaporative Light Scattering).


Elution condition: flow rate of 2 mL/min, mobile phase a=aqueous 0.1% (v/v) trifluoroacetic acid solution, mobile phase b=0.1% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A6








Ratio of mobile



Time (min)
phase b (%)









0.0
 5



0.5
 5



0.5-3.0
5-95 gradient



5.0
95










Measurement Condition I:


Waters' H-class/SQD2 system was used, and Waters' ACQUITY UPLC BEH C18 1.7 μm, 2.1×50 mm was used as the analysis column. A compound was detected using both UV absorption (220 nm) and mass spectrometry.


Elution condition: flow rate of 0.6 mL/min, mobile phase a=aqueous 0.1% (v/v) formic acid solution, mobile phase b=0.1% (v/v) formic acid containing acetonitrile












TABLE A7








Ratio of mobile



Time (min)
phase b (%)









0.0
 2



2.0-2.6
2-100



2.6-3.0
100










Measurement Condition J:


The same apparatus as measurement condition F was used.


Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile












TABLE A8








Ratio of mobile



Time (min)
phase b (%)









0.0
10



1.0
10



1.0-2.0
10-60 gradient



2.0-5.0
60-99 gradient



5.0-6.0
99










Nuclear Magnetic Resonance (NMR) was measured using Bruker AVANCE III 400 MHz Spectrometer (resonant frequency: 1H: 400 MHz, 13C: 100 MHz) and Bruker AVANCE III 300 MHz Spectrometer (resonant frequency: 1H: 300 MHz, 13C: 75 MHz). For the measurement of X-ray crystal structure, Rigaku Corporation's single crystal X-ray diffractometer XtaLAB P200 was used. Cu—Kα rays monochromed with a multilayer mirror were used as the source. The structure was determined by a direct method using SIR2008. The structure was refined by the full-matrix least-squares method with respect to F2 using SHELEX-2014/7. Non-hydrogen atoms were refined with anisotropic atomic displacement parameters.


The abbreviations described above and the following abbreviations are also used in the Examples to simplify the description.


s: singlet


d: doublet


t: triplet


m: multiplet


dd: double doublet


J: coupling constant


Hz: Hertz

δ: chemical shift


min: minute


RT and tR: retention


CDCl3: deuterated chloroform


Me: methyl


Et: ethyl


Pr: propyl


i-Pr: isopropyl


i-Bu: isobutyl


s-Bu and sec-Bu: secondary butyl

tBu, tBu and tert-Bu: tertiary butyl


i-Pnt: isopentyl


Hxy: n-hexyl


Ac: acetyl


Bz: benzoyl


Bnzl: benzyl


3-Me-Bnzl: 3-methylbenzyl


4-Me-Bnzl: 4-methylbenzyl


3-MeO-Bnzl: 3-methoxybenzyl


4-MeO-Bnzl: 4-methoxybenzyl


4-OH-Bnzl: 4-hydroxybenzyl


3-F-Bnzl: 3-fluorobenzyl


4-F-Bnzl: 4-fluorobenzyl


3-Cl-Bnzl: 3-chlorobenzyl


4-Cl-Bnzl: 4-chlorobenzyl


3,4-Cl2-Bnzl: 3,4-dichlorobenzyl


4-tBuO-Bnzl: 4-(tert-butoxy)benzyl


4-Nt-Bnzl: 4-nitrobenzyl


Cbx-E and 2-Cbx-Et: 2-carboxyethyl


Cbm-M: 2-amino-2-oxoethyl or carbamoylmethyl


Cbm-E: 3-amino-3-oxopropyl or 2-carbamoylethyl


tBOC-E: 2-(tert-butoxycarbonyl)ethyl or 3-(tert-butoxy)-3-oxopropyl


Gun-Pr and 3-Gun-Pr: 3-guanidinopropyl


Hdr-M: hydroxymethyl


Hdr-E and 2-OH-Et: 2-hydroxyethyl


tBuO-E and 2-OtBu-Et: 2-(tert-butoxy)ethyl


Ph-Et: 2-phenylethyl


Ph-Pr: 3-phenylpropyl


Ph-Bu: 4-phenylbutyl


Np-M and 1-Npm: naphthalen-1-ylmethyl


2-Npm: naphthalen-2-ylmethyl


Np-E: 2-(naphthalen-1-yl)ethyl


Cpm: cyclopentylmethyl


Chm: cyclohexylmethyl


Boc and tBOC and tBOC: tert-butoxycarbonyl


TBSO-E and 2-0TBS-Et: 2-(tert-butyldimethylsilyloxy)ethyl




embedded image


Example 1: Synthesis of Compound
Synthesis Example for Compound V
Synthesis of N-benzyl-1,2,4-triazine-3-carboxamide

Ethyl 1,2,4-triazine-3-carboxylate (1.53 g, 10.0 mmol) was dissolved in methanol (10.0 mL), and phenylmethaneamine (1.18 g, 11.0 mmol) was added. The mixture was then stirred for 3 hours at 50° C. Methanol was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 60, eluent: ethyl acetate-methanol (gradient from 0% to 15%)). A fraction of a compound of interest was concentrated. The eluted crystal was filtered out to obtain the aforementioned compound (1.25 g, yield: 58%).


Under the same conditions as this reaction, the following compounds were synthesized. N-(naphthalen-1-ylmethyl)-1,2,4-triazine-3-carboxamide tert-butyl (4-(1,2,4-triazine-3-carboxamide)butyl)carbamate N-(4-(tert-butoxy)benzyl)-1,2,4-triazine-3-carboxamide N-isobutyl-1,2,4-triazine-3-carboxamide N-(4-methylbenzyl)-1,2,4-triazine-3-carboxamide N-phenethyl-1,2,4-triazine-3-carboxamide N-(3-methylbenzyl)-1,2,4-triazine-3-carboxamide N-(3-chlorobenzyl)-1,2,4-triazine-3-carboxamide N-(4-chlorobenzyl)-1,2,4-triazine-3-carboxamide N-(2-(naphthalen-1-yl)ethyl)-1,2,4-triazine-3-carboxamide tert-butyl 3-(2-(1,2,4-triazine-3-carboxamide)ethyl)-1H-indol-1-carboxylate N-(3,4-dichlorobenzyl)-1,2,4-triazine-3-carboxamide


Synthesis Example for Compound V
Synthesis of N-(2-hydroxyethyl)-1,2,4-triazine-3-carboxamide

Ethyl 1,2,4-triazine-3-carboxylate (76.5 mg, 0.500 mmol) was dissolved in ethanol (1.00 mL), and 2-aminoethanol (24.2 mg, 0.525 mmol) was added. The mixture was then stirred for 3 hours at room temperature. Methanol was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 20, eluent: ethyl acetate-methanol (gradient from 0% to 30%)). A fraction of a compound of interest was concentrated to obtain the aforementioned compound (44.8 mg, yield: 53%).


Under the same conditions as this reaction, the following compound was synthesized. N-(cyclohexylmethyl)-1,2,4-triazine-3-carboxamide


Synthesis Example for Compound V
Synthesis of Tert-Butyl 3-(1,2,4-triazine-3-carboxamide)propanoate

Triethylamine (0.245 mL, 1.75 mmol) was added to an ethanol (2.00 mL) solution of tert-butyl 3-aminopropanoate.HCl (272 mg, 1.50 mmol). A methanol (1.00 mL) suspension of ethyl 1,2,4-triazine-3-carboxylate (76.0 mg, 0.500 mmol) was added thereto. The mixture was stirred for 4 hours at room temperature. Ethanol was evaporated under reduced pressure. The residue was dissolved in ethyl acetate. The organic layer was washed with 10% citric acid water and 5% bicarbonate aqueous solution and dried with anhydrous sodium sulfate. The solvent was evaporated. The resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 20, eluent: hexane-ethyl acetate (gradient from 60% to 100%)) to obtain the aforementioned compound (65.7 mg, yield: 52%).


Synthesis Example for Compound XV
Synthesis of 4-methylpentanal

A methylene chloride (40.0 mL) solution of acetic acid (0.0994 mL, 1.30 mmol) and 4-methylpentan-1-ol (1.49 mL, 11.8 mmol) was slowly added dropwise into a methylene chloride (45.0 mL) solution of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess-Martin periodinane) (5.25 g, 12.4 mmol) at room temperature. After completion of the addition, the mixture was stirred for another hour, and then diethyl ether (280 mL) was added. An aqueous 1.30M sodium hydroxide solution (200 mL) was added to the organic layer and stirred for 10 minutes at room temperature. The organic layer was washed with an aqueous 1.30M sodium hydroxide solution (90.0 mL) and (50.0 mL). After drying with anhydrous sodium magnesium sulfate, the solvent was carefully evaporated to obtain the aforementioned compound (1.01 g, 86%).


Under the same conditions as this reaction, the following compound was synthesized. 5-methylhexanal


Synthesis Example for Compound III
Synthesis of N-benzylprop-2-en-1-amine

(Bromomethyl)benzene (0.992 mL, 8.35 mmol) was gradually added dropwise to a suspension of anhydrous potassium carbonate (1.39 g, 10.0 mmol) and prop-2-en-1-amine (7.53 mL, 100 mmol) and then stirred for 3 hours at room temperature. The solids were filtered and washed with methylene chloride. The combined organic layer was evaporated under reduced pressure. The resulting residue was purified with CHROMATOREX Q-PACK SI30 SIZE 20 (hexane: ethyl acetate=50%:50% to 0%:100%) to obtain the aforementioned compound (934 mg, yield: 76%).


Under the same conditions as this reaction, the following compound was synthesized. N-(3,4-dichlorobenzyl)prop-2-en-1-amine


Synthesis Example for Compound III
Synthesis of N-(cyclohexylmethyl)prop-2-en-1-amine

Prop-2-en-1-amine (3.42 g, 60.0 mmol) was added dropwise to a methanol (40.0 mL) solution of cyclohexanecarbaldehyde (7.06 g, 63.0 mmol) while cooling with ice. After the completion of the addition, sodium tetrahydroborate (0.850 g, 22.0 mmol) was resolved and added while cooling with ice, and the mixture was stirred for another hour. Methanol was evaporated under reduced pressure. Ethyl ether was added to the residue. The organic layer was washed with saturated saline and dried with anhydrous sodium sulfate and then concentrated under reduce pressure. The residue was evaporated under reduced pressure to obtain the aforementioned compound (7.35 g, 80%, boiling point, 79 to 84° C./9.1 mmHg).


Under the same conditions as this reaction, the following compounds were synthesized. N-isobutylprop-2-en-1-amine N-allyl-3-methylbutan-1-amine


Synthesis Example for Compound III
Synthesis of N-(4-tert-butoxybenzyl)prop-2-en-1-amine

A methanol (2.00 mL) solution of 4-tert-butoxybenzaldehyde (468 mg, 2.63 mmol) was added dropwise to a methanol (3.00 mL) solution of prop-2-en-1-amine (143 mg, 2.50 mmol) while cooling with ice. After the completion of the addition, sodium tetrahydroborate (35.0 mg, 0.920 mmol) was resolved and added while cooling with ice, and the mixture was stirred for another hour. Methanol was evaporated under reduced pressure. Ethyl acetate was added to the residue. The organic layer was washed with saturated saline and dried with anhydrous sodium sulfate and then concentrated under reduce pressure. The resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 60, eluent: hexane-ethyl acetate (gradient from 20% to 100%) and then ethyl acetate-methanol (gradient from 0% to 15%)) to obtain the aforementioned compound (370 mg, yield: 68%).


Under the same conditions as this reaction, the following compounds were synthesized. N-(naphthalen-1-ylmethyl)prop-2-en-1-amine N-(3,4-dichlorobenzyl)prop-2-en-1-amine


Synthesis Example: IIB-1 and IIF-1
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-1) and (3S*, 3aR*, 6S*, 7R*, 7aR*)—N, 7-dibenzyl-1-isobutyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-1)

4A molecular sieves (850 mg), 3-phenylpropanal (0.157 mL, 1.19 mmol), and N-isobutylprop-2-en-1-amine (purity: 90%, 150 mg, 1.19 mmol) were added to a chloroform (8.50 mL) solution of N-benzyl-1,2,4-triazine-3-carboxamide (III) (170 mg, 0.794 mmol), and heated and refluxed for 10 hours. The molecular sieves were filtered and washed twice with chloroform (5.00 mL). The combined organic layer was evaporated under reduced pressure. The resulting residue was purified with CHROMATOREX Q-PACK SI30 SIZE 60 (ethyl acetate:methanol=100%: 0% to 960:40) to obtain the aforementioned compounds (IIF-1) (86.9 mg, yield: 26%, RT=1.14 minutes (B method), [M+1]+=416) and (IIB-1) (149 mg, yield: 45%, RT=1.19 minutes (B method), [M+1]+=416).


Synthesis Example: IIB-29
Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N-(4-aminobutyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-29)

Formic acid (300 μL) was added to (3S*, 3aS*, 6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-30) (9.30 mg, 0.0187 mmol) and incubated overnight at room temperature. Formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (7.70 mg, yield: 84%, RT=0.71 minutes (A method), [M+1]+=397).


Synthesis Example: IIF-26
Synthesis of 3-((3S*, 3aR*, 6S*, 7R*, 7aR*)-7-benzyl-1-isobutyl-1,2,3,3a, 7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide) propanoic acid (11-26)

Formic acid (1.00 mL) was added to (3S*, 3aR*, 6S*, 7R*, 7aR*)-7-benzyl-1-isobutyl-N— (2-(tert-butoxy)-2-oxoethyl)-1,2,3,3a, 7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-27) (30.4 mg, 0.0660 mmol), and heated overnight at 50° C. Formic acid was evaporated under reduced pressure to obtain a monoformic acid salt of the aforementioned compound (29.7 mg, yield: 100%, RT=0.75 minutes (A method), [M+1]+=398).


Synthesis Example: IIB-28
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N-(3-amino-3-oxopropyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-28)

3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide)propanoic acid (IIB-26) (15.0 mg, 0.0380 mmol) was dissolved in methanol (2.00 mL), and ammonium water (25.0 μL) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (110 mg, 0.397 mmol) were resolved and added 4 times each at room temperature. The solvent was evaporated under reduced pressure. The resulting residue was purified by preparative PLC (Fuji Silysia Chemical's CHROMATOREX NH-PLCO5 (layer thickness 0.500 mm) (ethyl acetate:methanol=9:1) to obtain the aforementioned compound (7.10 mg, yield: 47%, RT=0.79 minutes (A method), [M+1]+=397).


Tables 1 to 4 summarize the synthesized compounds of formula IIB and compounds of IIF. The following abbreviations are used in the following tables.


INT-iBu: N-isobutyl-1,2,4-triazine-3-carboxamide


INT-Bnzl: N-benzyl-1,2,4-triazine-3-carboxamide


SM1-iBu: N-isobutylprop-2-en-1-amine


SM1-Bnzl: N-benzylprop-2-en-1-amine


SM2-Ph: 3-phenylpropanal


SM2-Pnt: 4-methylpentanal


Since samples with a blank entry under Mass in the following tables are prepared based on Mass Number in HPLC, it can be understood that the molecular weight is inferred and confirmed based on the time of retension (UV) of HPLC to identify the structure.









TABLE 1-1









embedded image



















Compound



Synthesis





number
R1
R2
R3
method
Intermediate
Raw material 1
Raw material 2





IIB-1
i-Bu
Bnzl
Bnzl
EX
INT-Bnzl
SM1-iBu
SM2-Ph























TABLE 1-2







IIB-
i-Bu
i-Bu
i-Bu
IIB-1,
INT-iBu
SM1-iBu
SM2-Pnt


2



IIF-1





IIB-
i-Bu
i-Bu
Bnzl
IIB-1,
INT-iBu
SM1-iBu
SM2-Ph


3



IIF-1





IIB-
Bnzl
i-Bu
i-Bu
IIB-1,
INT-iBu
SM1-Bnzl
SM2-Pnt


4



IIF-1





IIB-
i-Bu
Bnzl
i-Bu
IIB-1,
INT-Bnzl
SM1-iBu
SM2-Pnt


5



IIF-1





IIB-
Bnzl
i-Bu
Bnzl
IIB-1,
INT-iBu
SM1-Bnzl
SM2-Ph


6



IIF-1





IIB-
Bnzl
Bnzl
i-Bu
IIB-1,
INT-Bnzl
SM1-Bnzl
SM2-Pnt


7



IIF-1





IIB-
Bnzl
Bnzl
Bnzl
IIB-1,
INT-Bnzl
SM1-Bnzl
SM2-Ph


8



IIF-1





IIB-
i-Pnt
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-allyl-
SM2-Ph


9



IIF-1

3-









methylbutan-









1-amine



IIB-
Bnzl
Bnzl
i-Pnt
IIB-1,
INT-Bnzl
SM1-Bnzl
5-


10



IIF-1


methylhexanal


IIB-
i-Bu
Bnzl
Ph-Et
IIB-1,
INT-Bnzl
SM1-iBu
4-


11



IIF-1


phenylbutanal


IIB-
i-Bu
Ph-Et
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph


12



IIF-1
phenethyl-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
Bnzl
3-Me-
IIB-1,
INT-Bnzl
SM1-iBu
3-(m-tolyl)


13


Bnzl
IIF-1


propanal


IIB-
i-Bu
Bnzl
4-Me-
IIB-1,
INT-Bnzl
SM1-iBu
3-(p-tolyl)


14


Bnzl
IIF-1


propanal


IIB-
i-Bu
3-Me-
Bnzl
IIB-1,
N-(3-
SM1-iBu
SM2-Ph


15

Bnzl

IIF-1
methylbenzyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
4-Me-
Bnzl
IIB-1,
N-(4-
SM1-iBu
SM2-Ph


16

Bnzl

IIF-1
methylbenzyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
3-Cl-
Bnzl
IIB-1,
N-(3-
SM1-iBu
SM2-Ph


17

Bnzl

IIF-1
chlorobenzyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
4-Cl-
Bnzl
IIB-1,
N-(4-
SM1-iBu
SM2-Ph


18

Bnzl

IIF-1
chlorobenzyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
3,4-
Bnzl
i-Bu
IIB-1,
INT-Bnzl
N-(3,4-
SM2-Pnt


19
Cl2-


IIF-1

dichlorobenzyl)




Bnzl




prop-2-en-1-









amine



IIB-
Bnzl
3,4-Cl2-
i-Bu
IIB-1,
N-(3,4-
SM1-Bnzl
SM2-Pnt


20

Bnzl

IIF-1
dichlorobenzyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
Me
Np-E
Bnzl
IIB-1,
N-(2-
N-
SM2-Ph


21



IIF-1
(naphthalen-1-
methylprop-








yl)ethyl)-
2-en-1-amine








1,2,4-









triazine-3-









carboxamide























TABLE 1-3







IIB-
i-Bu
4-(tert-
Bnzl
IIB-1,
N-(4-tert-
SM1-iBu
SM2-Ph


23

butoxy)

IIF-1
butoxybenzyl)-






benzyl


1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
Np-M
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph


24



IIF-1
((naphthalen-









1-yl)methyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
Hdr-E
Bnzl
IIB-1,
N-(2-
SM1-iBu
SM2-Ph


25



IIF-1
hydroxyethyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
Cbx-E
Bnzl
IB-40

IIB-27



26









IIB-
i-Bu
2-(tert-
Bnzl
IIB-1,
tert-butyl
SM1-iBu
SM2-Ph


27

butoxy)-

IIF-1
3-(1,2,4-






2-


triazine-3-






oxoethyl


carboxamide)









propanoate




IIB-
i-Bu
Cbm-E
Bnzl
EX

IIB-26



28









IIB-
i-Bu
4-
Bnzl
EX

IIB-30



29

aminobutyl







IIB-
i-Bu
4-
Bnzl
IIB-1,
tert-butyl
SM1-iBu
SM2-Ph


30

((tert-

IIF-1
4-(1,2,4-






butoxycarbonyl)


triazine-3-






amino)butyl


carboxamide)









butylcarbamate




IIB-
i-Bu
Chm
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph


31



IIF-1
(cyclohexyl-









methyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
(tetrahydro-
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph


32

2H-

IIF-1
((tetrahydro-






pyran-2-


2H-pyran-






yl)methyl


2-yl)methyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
i-Bu
Bnzl
4-
IIB-1,
INT-Bnzl
SM1-iBu
tert-


34


((tert-
IIF-1


butyl





butoxy-



5-





carbonyl)



formyl-





amino)



pentyl-





butyl



carbamate


IIB-
i-Bu
Bnzl
3-
IIB-1,
INT-Bnzl
SM1-iBu
methyl


36


methoxy-
IIF-1


4-formyl-





3-



butanoate





oxopropyl






IIB-
i-Bu
Bnzl
Chm
IIB-1,
INT-Bnzl
SM1-iBu
3-


38



IIF-1


cyclo-









hexylpropanal


IIB-
Chm
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-
SM2-Ph


39



IIF-1

(cyclohexylmethyl)









prop-









2-en-1-









amine



IIB-
4-OH-
Bnzl
Bnzl
IB-40

IIB-41



40
Bnzl








IIB-
4-
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-(4-
SM2-Ph


41
(tert-


IIF-1

tert-




butoxy)




butoxybenzyl)




benzyl




prop-2-en-









1-amine



IIB-
Np-M
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-
SM2-Ph


42



IIF-1

((naphthalen-









1-yl)methyl)









prop-









2-en-1-









amine























TABLE 1-4







IIB-
3-
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-(3-
SM2-Ph


76
(tert-


IIF-1

(tert-




butoxy)-




butoxy)-




3-




3-




oxopropyl




oxopropyl)-









prop-2-en-1-









amine



IIB-
Bnzl
Bnzl
4-OH-
IIB-1,
INT-Bnzl
SM1-Bnzl
3-(4-


77


Bnzl
IIF-1


hydroxy-









phenyl)









propanal


IIB-
Me
2-(1-
Bnzl
IIB-1,
N-(2-(1-
N-
SM2-Ph


78

(tert-

IIF-1
(tert-
methyl-





butoxycarbonyl)-


butoxycarbonyl)-
prop-2-





1H-


1H-
en-1-





indol-3-


indol-3-
amine





yl)ethyl


yl)ethyl)-









1,2,4-









triazine-3-









carboxamide




IIB-
Np-M
Bnzl
Pr
IIB-1,
INT-Bnzl
N-
pentanal


80



IF-1

((naphthalen-









1-









yl)methyl)









prop-









2-en-1-









amine



IIB-
benzyl
naphthalen-
isobutyl
IIB-1,





81

1-ylmethyl

IF-1





EX: described in the Examples



















TABLE 1-5









LCMS
Mass



Compound



tR
(M +
Measurement


number
R1
R2
R3
(min)
H)+
condition







IIB-81
benzyl
naphthalen-
isobutyl
1.29
467
B




1-ylmethyl






IIB-82
benzyl
4-(trifluoromethyl)
isobutyl
1.29
484
B




benzyl






IIB-83
4-chlorobenzyl
benzyl
isobutyl
1.29
450
B


IIB-84
3-chlorobenzyl
benzyl
isobutyl
1.30
450
B


IIB-85
4-methoxybenzyl
benzyl
isobutyl
1.23
446
B


IIB-86
4-methylbenzyl
benzyl
isobutyl
1.27
430
B


IIB-88
isobutyl
isobutyl
4-chlorobenzyl
1.26
416
B


IIB-89
isobutyl
4-chlorobenzyl
isobutyl
1.27
416
B


IIB-90
isobutyl
benzyl
isopentyl
1.26
396
B


IIB-91
isopentyl
benzyl
isobutyl
1.26
396
B


IIB-92
isobutyl
isopentyl
benzyl
1.27
396
B


IIB-93
4-hydroxybenzyl
benzyl
isobutyl
1.19
432
B


IIB-94
4-(dimethylamino)
benzyl
isobutyl
1.27
459
B



benzyl






















TABLE 1-6







IIB-95
4-(tert-butyl)
benzyl
isobutyl
1.31
472
B



benzyl







IIB-96
4-(trifluoro-
benzyl
isobutyl
1.32
500
B



methoxy)benzyl







IIB-97
4-ethoxybenzyl
benzyl
isobutyl
1.25
460
B


IIB-98
isopentyl
isobutyl
benzyl
1.26
396
B


IIB-99
benzyl
4-hydroxy-
isobutyl
1.17
432
B




benzyl






IIB-100
4-methoxybenzyl
4-hydroxy-
isobutyl
1.17
462
B




benzyl






IIB-101
4-hydroxybenzyl
benzyl
isopentyl
1.20
446
B


IIB-102
benzyl
naphthalen-2-
isobutyl
1.27
466
B




ylmethyl






IIB-103
isopentyl
4-chlorobenzyl
isobutyl
1.28
431
B


IIB-104
isopentyl
4-fluorobenzyl
isobutyl
1.26
414
B


IIB-105
benzyl
pyridin-4-yl
isobutyl
1.06
417
B




methyl






IIB-106
4-methoxybenzyl
benzyl
benzyl
0.99
480
C


IIB-107
phenethyl
benzyl
2-(tert-
1.12
532
C





butyl-








dimethyl-








silyloxy)








ethyl





IIB-108
cyclopentyl-
4-hydroxy-
2-carboxy-
0.78
440
C



methyl
benzyl
ethyl





IIB-109
4-nitrobenzyl
4-(tert-butoxy)
2-(tert-
1.03
605
C




benzyl
butoxy-








carbonyl)








ethyl





IIB-110
i-Bu
i-Pr
Bnzl
3.09
368
F


IIB-111
i-Bu
i-Bu
4-tBuO-
3.95
454
F





Bnzl





IIB-112
i-Bu
Bnzl
4-tBuO-
4.05
488
F





Bnzl





IIB-113
i-Bu
tBOC-E
4-tBuO-
4.12
526
F





Bnzl





IIB-114
i-Bu
s-Bu
4-tBuO-
3.93
454
F





Bnzl





IIB-115
i-Bu
1-Npm
4-tBuO-
4.48
538
F





Bnzl






















TABLE 1-7







IIB-116
i-Bu
i-Pr
4-tBuO-
3.64
440
F





Bnzl





IIB-117
i-Bu
1-Npm
tBOC-E
4.11
504
F


IIB-118
i-Bu
i-Pr
tBOC-E
3.18
406
F


IIB-119
i-Bu
1-Npm
1-Npm
4.39
516
F


IIB-120
i-Bu
i-Pr
1-Npm
3.52
418
F


IIB-121
Bnzl
4-tBuO-Bnzl
Bnzl
4.23
522
F


IIB-122
Bnzl
i-Bu
4-tBuO-
4.11
488
F





Bnzl





IIB-123
Bnzl
Bnzl
4-tBuO-
4.20
522
F





Bnzl





IIB-124
Bnzl
tBOC-E
4-tBuO-
4.27
560
F





Bnzl





IIB-125
Bnzl
Bnzl
tBOC-E
3.72
488
F


IIB-126
Bnzl
4-tBuO-Bnzl
tBOC-E
4.22
560
F


IIB-127
Bnzl
1-Npm
tBOC-E
4.18
538
F


IIB-128
Bnzl
i-Bu
1-Npm
3.98
466
F


IIB-129
Bnzl
Bnzl
1-Npm
4.09
500
F


IIB-130
Bnzl
4-tBuO-Bnzl
1-Npm
4.55
572
F


IIB-131
Bnzl
tBOC-E
1-Npm
4.17
538
F


IIB-132
Bnzl
s-Bu
1-Npm
3.96
466
F


IIB-133
Bnzl
1-Npm
1-Npm
4.49
550
F


IIB-134
Bnzl
i-Pr
1-Npm
3.71
452
F


IIB-135
4-tBuO-Bnzl
i-Bu
Bnzl
3.92
488
F


IIB-136
4-tBuO-Bnzl
Bnzl
Bnzl
4.57
522
F


IIB-137
4-tBuO-Bnzl
1-Npm
Bnzl
5.10
572
F


IIB-138
4-tBuO-Bnzl
Bnzl
tBOC-E
3.95
560
F


IIB-139
4-tBuO-Bnzl
1-Npm
tBOC-E
4.35
610
F


IIB-140
4-tBuO-Bnzl
i-Bu
1-Npm
4.07
538
F


IIB-141
4-tBuO-Bnzl
Bnzl
1-Npm
5.00
572
F


IIB-142
4-tBuO-Bnzl
tBOC-E
1-Npm
4.14
610
F


IIB-143
4-tBuO-Bnzl
s-Bu
1-Npm
4.27
538
F


IIB-144
4-tBuO-Bnzl
1-Npm
1-Npm
5.40
622
F


IIB-145
i-Bu
4-tBuO-Bnzl
Bnzl
4.13
488
F


IIB-146
i-Bu
tBOC-E
Bnzl
3.66
454
F


IIB-147
i-Bu
s-Bu
Bnzl
3.38
382
F


IIB-148
i-Bu
i-Bu
tBOC-E
3.44
420
F


IIB-149
i-Bu
Bnzl
tBOC-E
3.63
454
F






















TABLE 1-8







IIB-150
i-Bu
4-tBuO-Bnzl
tBOC-E
4.18
526
F


IIB-151
i-Bu
s-Bu
tBOC-E
3.46
420
F


IIB-152
i-Bu
i-Bu
1-Npm
3.87
432
F


IIB-153
i-Bu
Bnzl
1-Npm
3.98
466
F


IIB-154
i-Bu
4-tBuO-Bnzl
1-Npm
4.44
538
F


IIB-155
i-Bu
tBOC-E
1-Npm
4.04
504
F


IIB-156
Bnzl
tBOC-E
Bnzl
3.82
488
F


IIB-157
Bnzl
s-Bu
Bnzl
3.55
416
F


IIB-158
Bnzl
1-Npm
Bnzl
4.21
500
F


IIB-159
Bnzl
i-Pr
Bnzl
3.31
402
F


IIB-160
Bnzl
s-Bu
4-tBuO-
4.08
488
F





Bnzl





IIB-161
Bnzl
1-Npm
4-tBuO-
4.61
572
F





Bnzl





IIB-162
Bnzl
i-Pr
4-tBuO-
3.83
474
F





Bnzl





IIB-163
Bnzl
s-Bu
tBOC-E
3.60
454
F


IIB-164
Bnzl
i-Pr
tBOC-E
3.28
440
F


IIB-165
4-tBuO-Bnzl
i-Pr
Bnzl
3.70
474
F


IIB-166
4-tBuO-Bnzl
i-Pr
tBOC-E
3.75
512
F


IIB-167
4-tBuO-Bnzl
i-Pr
1-Npm
4.07
524
F


IIB-168
tBOC-E
i-Bu
Bnzl
3.77
454
F


IIB-169
tBOC-E
Bnzl
Bnzl
3.86
488
F


IIB-170
tBOC-E
4-tBuO-Bnzl
Bnzl
4.34
560
F


IIB-171
tBOC-E
s-Bu
Bnzl
3.76
454
F


IIB-172
tBOC-E
1-Npm
Bnzl
4.34
538
F


IIB-173
tBOC-E
i-Bu
4-tBuO-
4.30
526
F





Bnzl





IIB-174
tBOC-E
Bnzl
4-tBuO-
4.40
560
F





Bnzl





IIB-175
tBOC-E
s-Bu
4-tBuO-
4.31
526
F





Bnzl





IIB-176
tBOC-E
1-Npm
4-tBuO-
4.80
610
F





Bnzl





IIB-177
tBOC-E
i-Pr
4-tBuO-
4.05
512
F





Bnzl





IIB-178
tBOC-E
i-Bu
1-Npm
4.13
504
F


IIB-179
tBOC-E
4-tBuO-Bnzl
1-Npm
4.66
610
F


IIB-180
tBOC-E
s-Bu
1-Npm
4.09
504
F


IIB-181
tBOC-E
1-Npm
1-Npm
4.63
588
F


IIB-182
1-Npm
4-tBuO-Bnzl
Bnzl
4.18
572
F


IIB-183
1-Npm
s-Bu
Bnzl
3.82
466
F






















TABLE 1-9







IIB-184
1-Npm
Bnzl
4-tBuO-
4.68
572
F





Bnzl





IIB-185
1-Npm
tBOC-E
4-tBuO-
4.24
610
F





Bnzl





IIB-186
1-Npm
s-Bu
4-tBuO-
4.84
538
F





Bnzl





IIB-187
1-Npm
1-Npm
4-tBuO-
4.85
622
F





Bnzl





IIB-188
1-Npm
i-Pr
4-tBuO-
4.20
524
F





Bnzl





IIB-189
1-Npm
i-Bu
tBOC-E
3.80
504
F


IIB-190
1-Npm
Bnzl
tBOC-E
4.45
538
F


IIB-191
1-Npm
4-tBuO-Bnzl
tBOC-E
4.84
610
F


IIB-192
1-Npm
s-Bu
tBOC-E
4.29
504
F


IIB-193
1-Npm
1-Npm
tBOC-E
4.49
588
F


IIB-194
1-Npm
Bnzl
1-Npm
4.75
550
F


IIB-195
1-Npm
4-tBuO-Bnzl
1-Npm
4.74
622
F


IIB-196
1-Npm
tBOC-E
1-Npm
4.59
588
F


IIB-197
1-Npm
s-Bu
1-Npm
4.57
516
F


IIB-198
i-Bu
4-tBuO-Bnzl
i-Bu
4.04
454
F


IIB-199
i-Bu
tBOC-E
i-Bu
3.35
420
F


IIB-200
i-Bu
s-Bu
i-Bu
3.25
348
F


IIB-201
i-Bu
1-Npm
i-Bu
4.00
432
F


IIB-202
i-Bu
i-Pr
i-Bu
2.97
334
F


IIB-203
i-Bu
(tBOC)Gun-Pr
4-tBuO-
2.81
641
J





Bnzl





IIB-204
i-Bu
1-Npm
(tBOC)Gun-
3.27
675
J





Pr





IIB-205
i-Bu
s-Bu
1-Npm
3.85
432
F


IIB-206
Bnzl
4-tBuO-Bnzl
i-Bu
4.13
488
F


IIB-207
Bnzl
s-Bu
i-Bu
3.45
382
F


IIB-208
Bnzl
i-Pr
i-Bu
3.14
368
F


IIB-209
Bnzl
i-Bu
(tBOC)Gun-
3.22
625
J





Pr





IIB-210
Bnzl
4-tBuO-Bnzl
(tBOC)Gun-
2.96
675
J





Pr





IIB-211
tBOC-E
i-Bu
i-Bu
3.63
420
F


IIB-212
tBOC-E
Bnzl
i-Bu
3.83
454
F


IIB-213
tBOC-E
4-tBuO-Bnzl
i-Bu
4.35
526
F


IIB-214
tBOC-E
s-Bu
i-Bu
3.68
420
F


IIB-215
tBOC-E
1-Npm
i-Bu
4.32
504
F


IIB-216
tBOC-E
i-Pr
i-Bu
3.41
406
F


IIB-217
tBOC-E
Bnzl
1-Npm
4.19
538
F






















TABLE 1-10







IIB-218
tBOC-E
i-Pr
1-Npm
3.87
490
F


IIB-219
1-Npm
Bnzl
i-Bu
3.62
466
F


IIB-220
1-Npm
i-Bu
Bnzl
3.67
466
F


IIB-221
1-Npm
(tBOC)Gun-Pr
Bnzl
3.97
709
F


IIB-222
1-Npm
i-Bu
4-tBuO-
4.18
538
F





Bnzl





IIB-223
1-Npm
i-Pr
tBOC-E
3.62
490
F


IIB-224
1-Npm
1-Npm
(tBOC)Gun-
5.14
759
F





Pr





IIB-225
1-Npm
i-Pr
(tBOC)Gun-
3.15
661
F





Pr





IIB-226
1-Npm
i-Bu
1-Npm
4.07
516
F


IIB-227
1-Npm
(tBOC)Gun-Pr
1-Npm
2.99
459
F


IIB-228
1-Npm
i-Pr
1-Npm
3.90
502
F


IIB-229
i-Bu
(tBOC)Gun-Pr
i-Bu
3.10
591
J


IIB-230
i-Bu
(tBOC)Gun-Pr
Bnzl
3.03
625
J


IIB-231
i-Bu
i-Bu
(tBOC)Gun-
3.01
591
J





Pr





IIB-232
i-Bu
Bnzl
(tBOC)Gun-
3.02
625
J





Pr





IIB-233
i-Bu
4-tBuO-Bnzl
(tBOC)Gun-
2.84
641
J





Pr





IIB-234
i-Bu
s-Bu
(tBOC)Gun-
2.99
591
J





Pr





IIB-235
i-Bu
i-Pr
(tBOC)Gun-
2.90
577
J





Pr





IIB-236
i-Bu
(tBOC)Gun-Pr
1-Npm
3.17
675
J


IIB-237
Bnzl
(tBOC)Gun-Pr
i-Bu
3.19
625
J


IIB-238
Bnzl
(tBOC)Gun-Pr
Bnzl
3.26
659
J


IIB-239
Bnzl
(tBOC)Gun-Pr
4-tBuO-
2.84
675
J





Bnzl





IIB-240
Bnzl
i-Bu
tBOC-E
3.56
454
F


IIB-241
Bnzl
Bnzl
(tBOC)Gun-
3.28
659
J





Pr





IIB-242
Bnzl
s-Bu
(tBOC)Gun-
3.04
625
J





Pr





IIB-243
Bnzl
i-Pr
(tBOC)Gun-
2.99
611
J





Pr





IIB-244
Bnzl
(tBOC)Gun-Pr
1-Npm
3.36
709
J


IIB-245
tBOC-E
i-Pr
Bnzl
3.45
440
F


IIB-246
(tBOC)Gun-Pr
1-Npm
i-Bu
3.65
657
J


IIB-247
(tBOC)Gun-Pr
i-Pr
i-Bu
3.21
577
J


IIB-248
(tBOC)Gun-Pr
1-Npm
Bnzl
3.75
709
J


IIB-249
(tBOC)Gun-Pr
i-Pr
Bnzl
3.24
611
J


IIB-250
(tBOC)Gun-Pr
1-Npm
4-tBuO-
3.30
725
J





Bnzl





IIB-251
(tBOC)Gun-Pr
i-Pr
4-tBuO-
2.92
627
J





Bnzl






















TABLE 1-11







IIB-252
(tBOC)Gun-Pr
1-Npm
1-Npm
3.86
759
J


IIB-253
(tBOC)Gun-Pr
i-Pr
1-Npm
3.38
661
J


IIB-254
1-Npm
(tBOC)Gun-Pr
i-Bu
4.29
675
F


IIB-255
1-Npm
1-Npm
i-Bu
4.05
516
F


IIB-256
1-Npm
1-Npm
Bnzl
4.92
550
F


IIB-257
Bnzl
tBOC-E
i-Bu
3.73
454
F


IIB-258
Bnzl
1-Npm
(tBOC)Gun-
3.80
709
J





Pr





IIB-259
4-tBuO-Bnzl
i-Bu
i-Bu
3.67
454
F


IIB-260
4-tBuO-Bnzl
Bnzl
i-Bu
3.67
488
F


IIB-261
4-tBuO-Bnzl
tBOC-E
i-Bu
3.82
526
F


IIB-262
4-tBuO-Bnzl
(tBOC)Gun-Pr
i-Bu
3.38
641
F


IIB-263
4-tBuO-Bnzl
s-Bu
i-Bu
3.75
454
F


IIB-264
4-tBuO-Bnzl
1-Npm
i-Bu
4.22
538
F


IIB-265
4-tBuO-Bnzl
i-Pr
i-Bu
3.47
440
F


IIB-266
4-tBuO-Bnzl
tBOC-E
Bnzl
3.88
560
F


IIB-267
4-tBuO-Bnzl
(tBOC)Gun-Pr
Bnzl
3.24
675
F


IIB-268
4-tBuO-Bnzl
s-Bu
Bnzl
3.85
488
F


IIB-269
4-tBuO-Bnzl
i-Bu
tBOC-E
3.88
526
F


IIB-270
4-tBuO-Bnzl
s-Bu
tBOC-E
3.79
526
F


IIB-271
4-tBuO-Bnzl
i-Bu
(tBOC)Gun-
3.45
641
F





Pr





IIB-272
4-tBuO-Bnzl
Bnzl
(tBOC)Gun-
3.82
675
F





Pr





IIB-273
4-tBuO-Bnzl
s-Bu
(tBOC)Gun-
3.38
641
F





Pr





IIB-274
4-tBuO-Bnzl
1-Npm
(tBOC)Gun-
3.88
725
F





Pr





IIB-275
4-tBuO-Bnzl
i-Pr
(tBOC)Gun-
3.27
627
F





Pr





IIB-276
4-tBuO-Bnzl
(tBOC)Gun-Pr
1-Npm
3.74
725
F


IIB-277
(tBOC)Gun-Pr
i-Bu
i-Bu
4.52
591
F


IIB-278
(tBOC)Gun-Pr
Bnzl
i-Bu
4.25
625
F


IIB-279
(tBOC)Gun-Pr
4-tBuO-Bnzl
i-Bu
3.79
641
F


IIB-280
(tBOC)Gun-Pr
s-Bu
i-Bu
4.04
591
F


IIB-281
(tBOC)Gun-Pr
i-Bu
Bnzl
4.39
625
F


IIB-282
(tBOC)Gun-Pr
Bnzl
Bnzl
4.30
659
F


IIB-283
(tBOC)Gun-Pr
4-tBuO-Bnzl
Bnzl
3.82
675
F


IIB-284
(tBOC)Gun-Pr
s-Bu
Bnzl
4.09
625
F


IIB-285
(tBOC)Gun-Pr
i-Bu
4-tBuO-
3.80
641
F





Bnzl






















TABLE 1-12







IIB-286
(tBOC)Gun-Pr
Bnzl
1-Npm
4.57
709
F


IIB-287
(tBOC)Gun-Pr
s-Bu
1-Npm
4.49
675
F


IIB-288
1-Npm
i-Bu
i-Bu
3.65
432
F


IIB-289
1-Npm
4-tBuO-Bnzl
i-Bu
4.09
538
F


IIB-290
1-Npm
tBOC-E
i-Bu
3.77
504
F


IIB-291
1-Npm
s-Bu
i-Bu
3.71
432
F


IIB-292
1-Npm
i-Pr
i-Bu
3.54
418
F


IIB-293
1-Npm
tBOC-E
Bnzl
3.99
538
F


IIB-294
1-Npm
i-Pr
Bnzl
3.69
452
F


IIB-295
1-Npm
(tBOC)Gun-Pr
4-tBuO-
3.59
725
F





Bnzl





IIB-296
1-Npm
i-Bu
(tBOC)Gun-
4.00
675
F





Pr





IIB-297
1-Npm
Bnzl
(tBOC)Gun-
4.17
709
F





Pr





IIB-298
1-Npm
4-tBuO-Bnzl
(tBOC)Gun-
3.65
725
F





Pr





IIB-299
Bnzl
1-Npm
3-Gun-Pr
2.70
509
F


IIB-300
4-OH-Bnzl
3-Gun-Pr
i-Bu
2.47
441
F


IIB-301
4-OH-Bnzl
1-Npm
3-Gun-Pr
2.90
525
F


IIB-302
1-Npm
3-Gun-Pr
4-OH-Bnzl
2.70
525
F


IIB-303
1-Npm
i-Bu
3-Gun-Pr
2.82
475
F


IIB-304
1-Npm
Bnzl
3-Gun-Pr
2.97
509
F


IIB-305
1-Npm
4-OH-Bnzl
3-Gun-Pr
2.77
525
F


IIB-306
1-Npm
s-Bu
3-Gun-Pr
2.82
475
F


IIB-307
Bnzl
Ph-Et
i-Bu
0.97
430
C


IIB-308
Ph-Et
i-Bu
Bnzl
1.00
430
C


IIB-309
Chm
i-Bu
Bnzl
1.05
422
C


IIB-310
Bnzl
4-F-Bnzl
i-Bu
0.98
434
C


IIB-311
Chm
Bnzl
i-Bu
1.04
422
C


IIB-312
Bnzl
Hxy
i-Bu
1.08
410
C


IIB-313
Ph-Et
i-Bu
i-Bu
0.99
396
C


IIB-314
Ph-Et
i-Bu
1-Npm
1.04
480
C


IIB-315
Bnzl
i-Bu
Ph-Et
1.00
430
C


IIB-316
4-F-Bnzl
i-Bu
Bnzl
1.00
434
C


IIB-317
i-Bu
4-F-Bnzl
Bnzl
0.99
434
C


IIB-318
Ph-Et
Bnzl
i-Bu
0.98
430
C


IIB-319
Bnzl
i-Pnt
i-Bu
1.00
396
C
























TABLE 1-13









IIB-320
i-Bu
Hxy
Bnzl
1.05
410
C



IIB-321
4-F-Bnzl
Bnzl
Bnzl
0.99
468
C



IIB-322
Ph-Et
Bnzl
Bnzl
1.00
464
C



IIB-323
Bnzl
i-Bu
i-Pnt
1.03
396
C



IIB-324
4-F-Bnzl
Bnzl
i-Bu
0.98
434
C

















TABLE 1-14







Formula XXII3




embedded image



















Compound




LCMS
Mass
Measurement


number
R1
R2A
R2B
R3
RT (min)
(M + H)+
condition

















IIB-325
2-Npm
H
Bnzl
i-Bu
2.89
466
 B1


IIB-326
i-Pnt
H
3-Cl-Bnzl
Bnzl
2.85
464
 B1


IIB-327
i-Pnt
H
4-Me-Bnzl
Bnzl
2.83
444
 B1


IIB-328
i-Pnt
H
4-MeO-Bnzl
Bnzl
2.71
460
 B1


IIB-329
Me
H
quinolin-8-ylethyl
Bnzl
2.09
439
 B1


IIB-330
Me
H
quinolin-5-ylethyl
Bnzl
1.62
439
 B1


IIB-331
i-Bu
H
4-Cl-Bnzl
Ph-Et
2.84
464
 B1


IIB-332
i-Bu
H
3-Cl-Bnzl
Ph-Et
2.68
464
 B1


IIB-333
i-Bu
H
4-MeO-Bnzl
Ph-Et
2.70
460
 B1


IIB-334
i-Bu
H
4-Me-Bnzl
Ph-Et
2.83
445
 B1


IIB-335
i-Bu
H
2-Npm
Ph-Et
2.92
480
 B1


IIB-336
i-Bu
H
Bnzl
Ph-Pr
2.82
444
 B1


IIB-337
i-Bu
H
3-Cl-Bnzl
Ph-Pr
1.29
478
B


IIB-338
i-Bu
H
3-F-Bnzl
Ph-Pr
1.33
462
B


IIB-339
Cpm
H
4-OH-Bnzl
Cbx-E
1.10
440
B


IIB-340
i-Bu
H
3-Me-Bnzl
Ph-Pr
1.33
458
B


IIB-341
i-Bu
H
3-MeO-Bnzl
Ph-Pr
1.29
474
B


IIB-342
i-Bu
H
3-Cl-Bnzl
Ph-Bu
1.33
492
B


IIB-343
i-Bu
H
3-F-Bnzl
Ph-Bu
1.29
476
B


IIB-344
i-Bu
H
3-Me-Bnzl
Ph-Bu
1.31
473
B


IIB-345
i-Bu
H
3-MeO-Bnzl
Ph-Bu
1.36
488
B


IIB-346
i-Bu
H
Bnzl
Ph-Bu
1.29
458
B


IIB-347
i-Pnt
H
3-F-Bnzl
Ph-Pr
1.25
476
B


IIB-348
1-Npm
H
pentyl
Ph-Et
1.08
494
C













IIB-349
1-Npm
pyrrolidine
Ph-Et
0.96
478
C























TABLE 1-15







IIB-
1-Npm
H
cyclo-
Ph-Et
1.07
506
C


350


hexyl






IIB-
1-Npm
H
cyclo-
Ph-Et
1.05
492
C


351


pentyl

















IIB-
1-Npm
piperidine
Ph-Et
1.01
492
C














352









IIB-
1-Npm
H
heptyl
Ph-Et
1.14
522
C


353









IIB-
Hdr-E
H
4-
1-Npm
0.93
486
C


354


fluoro-









phenethyl






IIB-
tBuO-E
H
4-
1-Npm
1.07
542
C


355


fluoro-









phenethyl






IIB-
Pr
H
Chm
Bnzl
1.00
408
C


356









IIB-
1-Npm
H
Hxy
4-methyl-
1.13
522
C


357



phenethyl





IIB-
1-Npm
H
Hxy
4-
1.18
550
C


358



Isopropyl









phenethyl





IIB-
1-Npm
H
Hxy
2-
1.15
558
C


359



(naphthalen-









2-yl)ethyl





IIB-
1-Npm
H
Hxy
cyclohexyl-
1.19
514
C


360



ethyl





IIB-
tBuO-E
H
4-
1-Npm
1.07
545
C


361


Cl-Bnzl






IIB-
tBuO-E
H
4-
1-Npm
1.07
524
C


362


Me-Bnzl






IIB-
Pr
H
Bnzl
Chm
1.00
408
C


363









IIB-
Pr
H
2-
Bnzl
0.95
416
C


364


methyl-









benzyl






IIB-
Pr
H
(1,2,3,4-
Bnzl
1.01
456
C


365


tetra-









hydro-









naphthalen-









1-yl)methyl






IIB-
Pr
H
Cpm
Bnzl
0.96
394
C


366









IIB-
Pr
H
Bnzl
Cpm
0.95
394
C


367









IIB-
1-Npm
H
Hxy
3-
1.13
522
C


368



methyl-









phenethyl





IIB-
4-Nt-Bnzl
H
Bnzl
Bnzl
0.96
495
C


369









IIB-
4-Nt-Bnzl
H
Hxy
Ph-Et
1.04
503
C


370









IIB-
i-Pnt
H
4-F-
Bnzl
2.73
448
B1


371


Bnzl






IIB-
i-Pnt
H
Ph-
Bnzl
2.76
444
B1


372


Et






IIB-
i-Pnt
H
1-
Bnzl
2.93
480
B1


373


Npm






IIB-
i-Bu
H
4-F-
Ph-Et
2.73
448
B1


374


Bnzl






IIB-
i-Bu
H
Ph-
Ph-Et
2.76
444
B1


375


Et






IIB-
i-Bu
H
1-
Ph-Et
2.93
480
B1


376


Npm






IIB-
4-F-Bnzl
H
1-
Bnzl
2.98
518
B1


377


Npm






IIB-
4-F-Bnzl
H
1-
i-Bu
1.30
484
B


378


Npm






IIB-
tBuO-E
H
4-F-
1-Npm
1.06
528
C


379


Bnzl






IIB-
tBOC-E
H
Bnzl
Ph-Et
1.02
502
C


380









IIB-
4-tBuO-
H
Bnzl
Ph-Et
1.06
536
C


381
Bnzl








IIB-
tBuO-E
H
Bnzl
1-Npm
1.05
510
C


382









IIB-
Chm
H
tBuO-E
1-Npm
1.07
516
C


383









IIB-
1-Npm
H
4-F-
TBSO-E
1.16
586
C


384


Bnzl






IIB-
i-Pnt
H
Bnzl
Ph-Et
1.01
444
C


385









IIB-
1-Npm
H
4-F-
Hdr-E
0.91
472
C


386


Bnzl






IIB-
Hdr-E
H
4-F-
1-Npm
0.91
472
C


387


Bnzl






IIB-
Cbx-E
H
Bnzl
Ph-Et
0.88
446
C


388









IIB-
TBSO-E
H
Ph-
1-Npm
1.07
524
C


389


Et






IIB-
Ph-Et
H
Hxy
1-Npm
1.08
508
C


390









IIB-
Ph-Et
H
i-Bu
4-tBuO-
1.06
502
C


391



Bnzl





IIB-
Ph-Et
H
i-Bu
4-OH-Bnzl
0.89
446
C


392























TABLE 1-16







IIB-393
Ph-Et
H
i-Bu
TBSO-E
1.13
498
C


IIB-394
Ph-Et
H
i-Bu
Hdr-E
0.82
384
C


IIB-395
Ph-Et
H
i-Bu
i-Pnt
1.02
410
C


IIB-396
i-Bu
H
i-Bu
4-OH-Bnzl
0.85
398
C


IIB-397
i-Bu
H
Bnzl
4-OH-Bnzl
0.87
432
C


IIB-398
i-Bu
H
2-
4-OH-Bnzl
0.69
414
C





Cbx-Et






IIB-399
i-Bu
H
s-Bu
4-OH-Bnzl
0.85
398
C


IIB-400
i-Bu
H
1-Npm
4-OH-Bnzl
0.95
482
C


IIB-401
i-Bu
H
i-Pr
4-OH-Bnzl
0.80
384
C


IIB-402
i-Bu
H
1-Npm
2-Cbx-Et
0.89
448
C


IIB-403
i-Bu
H
i-Pr
2-Cbx-Et
0.72
350
C


IIB-404
Bnzl
H
4-
Bnzl
0.90
466
C





OH-Bnzl






IIB-405
Bnzl
H
i-Bu
4-OH-Bnzl
0.89
432
C


IIB-406
Bnzl
H
2-Cbx-Et
4-OH-Bnzl
0.74
448
C


IIB-407
Bnzl
H
Bnzl
2-Cbx-Et
0.82
432
C


IIB-408
Bnzl
H
4-
2-Cbx-Et
0.73
448
C





OH-Bnzl






IIB-409
Bnzl
H
1-Npm
2-Cbx-Et
0.90
482
C


IIB-410
Bnzl
H
4-
1-Npm
0.93,
516
C


*


OH-Bnzl

0.95




IIB-411
Bnzl
H
2-Cbx-Et
1-Npm
0.88
482
C


IIB-412
4-OH-Bnzl
H
i-Bu
Bnzl
0.89
432
C


IIB-413
4-OH-Bnzl
H
1-Npm
Bnzl
0.97
516
C


IIB-414
4-OH-Bnzl
H
Bnzl
2-Cbx-Et
0.76
448
C


IIB-415
4-OH-Bnzl
H
1-Npm
2-Cbx-Et
0.84
498
C


IIB-416
4-OH-Bnzl
H
i-Bu
1-Npm
0.93,
482
C







0.94




IIB-417
4-OH-Bnzl
H
Bnzl
1-Npm
0.95
516
C


IIB-418
4-OH-Bnzl
H
2-Cbx-Et
1-Npm
0.82
498
C


IIB-419
4-OH-Bnzl
H
s-Bu
1-Npm
0.94
482
C


IIB-420
4-OH-Bnzl
H
1-Npm
1-Npm
0.98,
566
C







1.00




IIB-421
i-Bu
H
4-
Bnzl
0.88
432
C





OH-Bnzl






IIB-422
i-Bu
H
i-Bu
2-Cbx-Et
0.78
364
C


IIB-423
i-Bu
H
Bnzl
2-Cbx-Et
0.81
398
C


IIB-424
i-Bu
H
4-
2-Cbx-Et
0.71
414
C





OH-Bnzl






IIB-425
i-Bu
H
s-Bu
2-Cbx-Et
0.77
364
C


IIB-426
i-Bu
H
4-
1-Npm
0.94
482
C





OH-Bnzl






IIB-427
i-Bu
H
2-Cbx-Et
1-Npm
0.87
448
C


IIB-428
Bnzl
H
2-
Bnzl
0.83
432
C





Cbx-Et






IIB-429
Bnzl
H
s-Bu
4-OH-Bnzl
0.88
432
C


IIB-430
Bnzl
H
1-Npm
4-OH-Bnzl
0.97
516
C


IIB-431
Bnzl
H
i-Pr
4-OH-Bnzl
0.84
418
C


IIB-432
Bnzl
H
s-Bu
2-Cbx-Et
0.79
398
C


IIB-433
Bnzl
H
i-Pr
2-Cbx-Et
0.74
384
C


IIB-434
4-OH-Bnzl
H
i-Pr
Bnzl
0.85
418
C


IIB-435
4-OH-Bnzl
H
i-Pr
2-Cbx-Et
0.68
400
C


IIB-436
4-OH-Bnzl
H
i-Pr
1-Npm
0.90
468
C


IIB-437
2-Cbx-Et
H
i-Bu
Bnzl
0.82
398
C


IIB-438
2-Cbx-Et
H
Bnzl
Bnzl
0.84
432
C


IIB-439
2-Cbx-Et
H
4-
Bnzl
0.76
448
C





OH-Bnzl






IIB-440
2-Cbx-Et
H
s-Bu
Bnzl
0.81
398
C


IIB-441
2-Cbx-Et
H
1-Npm
Bnzl
0.91
482
C


IIB-442
2-Cbx-Et
H
i-Bu
4-OH-Bnzl
0.76
414
C























TABLE 1-17







IIB-443
2-Cbx-Et
H
Bnzl
4-OH-Bnzl
0.78
448
C


IIB-444
2-Cbx-Et
H
s-Bu
4-OH-Bnzl
0.75
414
C


IIB-445
2-Cbx-Et
H
1-Npm
4-OH-Bnzl
0.86
498
C


IIB-446
2-Cbx-Et
H
i-Pr
4-OH-Bnzl
0.71
400
C


IIB-447
2-Cbx-Et
H
i-Bu
1-Npm
0.88
448
C


IIB-448
2-Cbx-Et
H
4-OH-Bnzl
1-Npm
0.83
498
C


IIB-449
2-Cbx-Et
H
s-Bu
1-Npm
0.87
448
C


IIB-450
2-Cbx-Et
H
1-Npm
1-Npm
0.96
532
C


IIB-451
1-Npm
H
4-OH-Bnzl
Bnzl
0.95
516
C


IIB-452
1-Npm
H
Bnzl
4-OH-Bnzl
0.95
516
C


IIB-453
1-Npm
H
2-Cbx-Et
4-OH-Bnzl
0.80
498
C


IIB-454
1-Npm
H
s-Bu
4-OH-Bnzl
0.94
482
C


IIB-455
1-Npm
H
1-Npm
4-OH-Bnzl
1.01
566
C


IIB-456
1-Npm
H
i-Pr
4-OH-Bnzl
0.90
468
C


IIB-457
1-Npm
H
i-Bu
2-Cbx-Et
0.88
448
C


IIB-458
1-Npm
H
Bnzl
2-Cbx-Et
0.89
482
C


IIB-459
1-Npm
H
4-OH-Bnzl
2-Cbx-Et
0.81
498
C


IIB-460
1-Npm
H
s-Bu
2-Cbx-Et
0.88
448
C


IIB-461
1-Npm
H
1-Npm
2-Cbx-Et
0.96
532
C


IIB-462
1-Npm
H
4-OH-Bnzl
1-Npm
0.97, 1.00
566
C


*









IIB-463
1-Npm
H
2-Cbx-Et
1-Npm
0.93, 0.95
532
C


*









IIB-464
i-Bu
H
4-OH-Bnzl
i-Bu
0.86
398
C


IIB-465
i-Bu
H
2-Cbx-Et
i-Bu
0.78
364
C


IIB-466
i-Bu
H
1-Npm
3-Gun-Pr
0.78
475
C


IIB-467
Bnzl
H
i-Bu
3-Gun-Pr
0.69
425
C


IIB-468
2-Cbx-Et
H
i-Bu
i-Bu
0.81
364
C


IIB-469
2-Cbx-Et
H
Bnzl
i-Bu
0.83
398
C


IIB-470
2-Cbx-Et
H
4-OH-Bnzl
i-Bu
0.75
414
C


IIB-471
2-Cbx-Et
H
s-Bu
i-Bu
0.81
364
C


IIB-472
2-Cbx-Et
H
1-Npm
i-Bu
0.91
448
C


IIB-473
2-Cbx-Et
H
i-Pr
i-Bu
0.76
350
C


IIB-474
2-Cbx-Et
H
Bnzl
1-Npm
0.89
482
C


IIB-475
2-Cbx-Et
H
i-Pr
1-Npm
0.84
434
C


IIB-476
1-Npm
H
3-Gun-Pr
Bnzl
0.78
509
C


IIB-477
1-Npm
H
i-Bu
4-OH-Bnzl
0.94
482
C


IIB-478
1-Npm
H
i-Pr
2-Cbx-Et
0.83
434
C


IIB-479
1-Npm
H
1-Npm
3-Gun-Pr
0.84
559
C


IIB-480
1-Npm
H
i-Pr
3-Gun-Pr
0.72
461
C


IIB-481
1-Npm
H
3-Gun-Pr
1-Npm
0.83
559
C


IIB-482
i-Bu
H
3-Gun-Pr
i-Bu
0.69
391
C


IIB-483
i-Bu
H
3-Gun-Pr
Bnzl
0.70
425
C


IIB-484
i-Bu
H
i-Bu
3-Gun-Pr
0.68
391
C


IIB-485
i-Bu
H
Bnzl
3-Gun-Pr
0.71
425
C


IIB-486
i-Bu
H
s-Bu
3-Gun-Pr
0.67
391
C


IIB-487
i-Bu
H
i-Pr
3-Gun-Pr
0.63
377
C


IIB-488
i-Bu
H
3-Gun-Pr
1-Npm
0.76
475
C


IIB-489
Bnzl
H
3-Gun-Pr
i-Bu
0.71
425
C


IIB-490
Bnzl
H
3-Gun-Pr
Bnzl
0.73
459
C


IIB-491
Bnzl
H
Bnzl
3-Gun-Pr
0.71
459
C


IIB-492
Bnzl
H
s-Bu
3-Gun-Pr
0.68
425
C























TABLE 1-18







IIB-493
Bnzl
H
i-Pr
3-Gun-Pr
0.64
411
C


IIB-494
Bnzl
H
3-Gun-Pr
1-Npm
0.78
509
C


IIB-495
2-Cbx-Et
H
i-Pr
Bnzl
0.77
384
C


IIB-496
3-Gun-Pr
H
1-Npm
i-Bu
0.79
475
C


IIB-497
3-Gun-Pr
H
i-Pr
i-Bu
0.66
377
C


IIB-498
3-Gun-Pr
H
1-Npm
Bnzl
0.79
509
C


IIB-499
3-Gun-Pr
H
i-Pr
Bnzl
0.66, 0.67
411
C


IIB-500
3-Gun-Pr
H
1-Npm
1-Npm
0.82
559
C


IIB-501
3-Gun-Pr
H
i-Pr
1-Npm
0.71, 0.74
461
C


*









IIB-502
1-Npm
H
3-Gun-Pr
i-Bu
0.77
475
C


IIB-503
3-
H
4-F-
1-Npm
1.05
542
C



tertbutoxy-

Bnzl







propyl








IIB-504
3-
H
4-F-
1-Npm
0.9
486
C



hydroxy-

Bnzl







propyl








IIB-505
Hdr-E
H
4-Cl-
1-Npm
0.93
488
C





Bnzl






IIB-506
3-
H
3-
3-
1.06
751
C



aminopropyl

amino-
amino-








propy
propyl





IIB-507
1-Npm
H
β-
Ph-Et
0.98
544
C





hydroxy-









phenethy






IIB-508
1-Npm
H
α-
Ph-Et
0.97
558
C





(hydroxy-









methyl)-









phenethyl






IIB-509
1-Npm
H
α-
Ph-Et
1.00
558
C





(hydroxy-









methyl)-









phenethyl






IIB-510
4-Nt-Bnzl
H
Bnzl
tBOC-E
0.96
533
C


IIB-511
2-OH-Et
H
Ph-Et
1-Npm
0.89
468.3
C


IIB-512
Chm
H
2-OH-
1-Npm
0.86
460.3
C





Et






IIB-513
i-Bu
H
i-Pr
3-Gun-Pr
0.58
377.3
C


IIB-514
Bnzl
H
4-OH-
i-Bu
0.81
432.2
C





Bnzl






IIB-515
Bnzl
H
i-Bu
4-OH-Bnzl
0.81
432.2
C


IIB-516
i-Bu
H
Bnzl
4-OH-Bnzl
0.81
432.3
C


IIB-517
i-Bu
H
4-OH-
Bnzl
0.81
432.3
C





Bnzl






IIB-518
2-OH-Et
H
Bnzl
1-Npm
0.87
454.3
C


IIB-519
Ph-Et
H
1-Npm
Hxy
1.10
508.4
C


IIB-520
1-Npm
H
Ph-Et
Hxy
1.10
508.4
C


IIB-521
Hxy
H
Ph-Et
1-Npm
1.08
508.4
C


IIB-522
Hxy
H
1-Npm
Ph-Et
1.09
508.4
C


IIB-523
i-Pnt
H
i-Pr
i-Bu
3.52
348
F


IIB-524
Chm
H
i-Pr
i-Bu
3.94
374
F


IIB-525
Chm
H
i-Pr
i-Pnt
4.35
388
F


IIB-526
i-Bu
H
s-Bu
i-Pnt
3.95
362
F


IIB-527
i-Pnt
H
s-Bu
i-Bu
3.75
362
F


IIB-528
i-Pnt
H
s-Bu
Ph-Et
4.29
410
F


IIB-529
Chm
H
s-Bu
i-Bu
4.22
388
F


IIB-530
Chm
H
s-Bu
Ph-Et
4.32
436
F


IIB-531
Chm
H
s-Bu
i-Pnt
4.52
402
F


IIB-532
Chm
H
i-Pnt
i-Bu
4.7
402
F


IIB-533
i-Pnt
H
Hxy
i-Bu
4.55
390
F


IIB-534
2-Cbx-Et
H
Bnzl
2-OH-Et
2.27
386
F


IIB-535
2-Cbx-Et
H
Bnzl
i-Pnt
3.49
412
F


IIB-536
Ph-Et
H
Bnzl
2-Cbx-Et
3.02
446
F


IIB-537
4-F-Bnzl
H
Bnzl
2-Cbx-Et
3.13
450
F























TABLE 1-19







IIB-538
2-OH-Et
H
Bnzl
2-Cbx-Et
2.52
386
F


IIB-539
i-Pnt
H
Bnzl
2-Cbx-Et
3.15
412
F


IIB-540
i-Pnt
H
Bnzl
2-OH-Et
3.07
384
F


IIB-541
Chm
H
Bnzl
2-Cbx-Et
3.42
438
F


IIB-542
2-Cbx-Et
H
i-Bu
Ph-Et
3.3
412
F


IIB-543
2-Cbx-Et
H
i-Bu
i-Pnt
3.29
378
F


IIB-544
Ph-Et
H
i-Bu
2-Cbx-Et
3.13
412
F


IIB-545
4-F-Bnzl
H
i-Bu
2-Cbx-Et
2.98
416
F


IIB-546
2-OH-Et
H
i-Bu
2-Cbx-Et
3.57
352
G


IIB-547
i-Pnt
H
i-Bu
4-OH-Bnzl
3.38
412
F


IIB-548
i-Pnt
H
i-Bu
2-Cbx-Et
2.99
378
F


IIB-549
Chm
H
i-Bu
4-OH-Bnzl
3.63
438
F


IIB-550
Chm
H
i-Bu
2-Cbx-Et
3.29
404
F


IIB-551
2-Cbx-Et
H
1-Npm
Ph-Et
3.84
496
F


IIB-552
2-Cbx-Et
H
1-Npm
2-OH-Et
2.82
436
F


IIB-553
2-Cbx-Et
H
1-Npm
i-Pnt
3.92
462
F


IIB-554
Ph-Et
H
1-Npm
2-Cbx-Et
3.72
496
F


IIB-555
4-F-Bnzl
H
1-Npm
2-Cbx-Et
3.62
500
F


IIB-556
2-OH-Et
H
1-Npm
2-Cbx-Et
2.95
436
F


IIB-557
i-Pnt
H
1-Npm
2-Cbx-Et
3.65
462
F


IIB-558
Chm
H
1-Npm
2-Cbx-Et
3.94
488
F


IIB-559
4-OH-Bnzl
H
i-Pr
Ph-Et
3.3
432
F


IIB-560
4-OH-Bnzl
H
i-Pr
i-Pnt
3.1
398
F


IIB-561
2-Cbx-Et
H
i-Pr
Ph-Et
3.04
398
F


IIB-562
2-Cbx-Et
H
i-Pr
2-OH-Et
2.82
338
G


IIB-563
2-Cbx-Et
H
i-Pr
i-Pnt
3
364
F


IIB-564
Ph-Et
H
i-Pr
2-Cbx-Et
2.87
398
F


IIB-565
Ph-Et
H
i-Pr
2-OH-Et
2.82
370
F


IIB-566
4-F-Bnzl
H
i-Pr
2-OH-Et
2.77
374
F


IIB-567
2-OH-Et
H
i-Pr
Bnzl
2.77
356
F


IIB-568
2-OH-Et
H
i-Pr
1-Npm
3.24
406
F


IIB-569
2-OH-Et
H
i-Pr
4-OH-Bnzl
2.52
372
F


IIB-570
2-OH-Et
H
i-Pr
2-Cbx-Et
3.09
338
G


IIB-571
2-OH-Et
H
i-Pr
Ph-Et
3.02
370
F


IIB-572
i-Pnt
H
i-Pr
4-OH-Bnzl
3.04
398
F


IIB-573
i-Pnt
H
i-Pr
2-Cbx-Et
2.69
364
F


IIB-574
i-Pnt
H
i-Pr
2-OH-Et
2.65
336
F


IIB-575
Chm
H
i-Pr
4-OH-Bnzl
3.34
424
F


IIB-576
Chm
H
i-Pr
2-Cbx-Et
2.94
390
F


IIB-577
i-Bu
H
s-Bu
2-OH-Et
2.62
336
F


IIB-578
4-OH-Bnzl
H
s-Bu
Ph-Et
3.50
446
F


IIB-579
4-OH-Bnzl
H
s-Bu
i-Pnt
3.38
412
F


IIB-580
2-Cbx-Et
H
s-Bu
Ph-Et
3.22
412
F


IIB-581
2-Cbx-Et
H
s-Bu
i-Pnt
3.27
378
F


IIB-582
Ph-Et
H
s-Bu
2-Cbx-Et
3.10
412
F


IIB-583
4-F-Bnzl
H
s-Bu
2-Cbx-Et
2.88
416
F


IIB-584
2-OH-Et
H
s-Bu
4-OH-Bnzl
2.69
386
F


IIB-585
2-OH-Et
H
s-Bu
2-Cbx-Et
3.47
352
G


IIB-586
2-OH-Et
H
s-Bu
i-Pnt
3.24
350
F


IIB-587
i-Pnt
H
s-Bu
4-OH-Bnzl
3.34
412
F























TABLE 1-20







IIB-588
i-Pnt
H
s-Bu
2-Cbx-Et
2.90
378
F


IIB-589
i-Pnt
H
s-Bu
2-OH-Et
2.90
350
F


IIB-590
Chm
H
s-Bu
4-OH-Bnzl
3.62
438
F


IIB-591
Chm
H
s-Bu
2-Cbx-Et
3.24
404
F


IIB-592
i-Bu
H
4-OH-
i-Pnt
3.52
412
F





Bnzl






IIB-593
2-Cbx-Et
H
4-OH-
Ph-Et
3.04
462
F





Bnzl






IIB-594
2-Cbx-Et
H
4-OH-
i-Pnt
2.92
428
F





Bnzl






IIB-595
Ph-Et
H
4-OH-
2-Cbx-Et
2.85
462
F





Bnzl






IIB-596
4-F-Bnzl
H
4-OH-
2-Cbx-Et
2.77
466
F





Bnzl






IIB-597
2-OH-Et
H
4-OH-
2-Cbx-Et
3.24
402
G





Bnzl






IIB-598
i-Pnt
H
4-OH-
2-Cbx-Et
2.72
428
F





Bnzl






IIB-599
Chm
H
4-OH-
2-Cbx-Et
2.97
454
F





Bnzl






IIB-600
i-Bu
H
2-
Ph-Et
3.12
412
F





Cbx-Et






IIB-601
i-Bu
H
2-
i-Pnt
3.12
378
F





Cbx-Et






IIB-602
2-OH-Et
H
2-
i-Bu
3.5
352
G





Cbx-Et






IIB-603
i-Pnt
H
2-
i-Bu
3.04
378
F





Cbx-Et






IIB-604
i-Pnt
H
2-
4-OH-Bnzl
2.63
428
F





Cbx-Et






IIB-605
Chm
H
2-
i-Bu
3.34
404
F





Cbx-Et






IIB-606
Chm
H
2-
4-OH-Bnzl
2.85
454
F





Cbx-Et






IIB-607
Chm
H
2-
i-Pnt
3.59
418
F





Cbx-Et






IIB-608
Bnzl
H
4-F-
4-OH-Bnzl
3.63
484
F





Bnzl






IIB-609
Bnzl
H
4-F-
2-Cbx-Et
3.12
450
F





Bnzl






IIB-610
i-Bu
H
4-F-
4-OH-Bnzl
3.44
450
F





Bnzl






IIB-611
i-Bu
H
4-F-
2-Cbx-Et
3.02
416
F





Bnzl






IIB-612
1-Npm
H
4-F-
4-OH-Bnzl
3.99
534
F





Bnzl






IIB-613
1-Npm
H
4-F-
2-Cbx-Et
3.57
500
F





Bnzl






IIB-614
4-OH-Bnzl
H
4-F-
2-Cbx-Et
2.85
466
F





Bnzl






IIB-615
4-OH-Bnzl
H
4-F-
Ph-Et
3.63
498
F





Bnzl






IIB-616
4-OH-Bnzl
H
4-F-
i-Pnt
3.57
464
F





Bnzl






IIB-617
2-Cbx-Et
H
4-F-
4-OH-Bnzl
2.95
466
F





Bnzl






IIB-618
2-Cbx-Et
H
4-F-
Ph-Et
3.48
464
F





Bnzl






IIB-619
2-Cbx-Et
H
4-F-
i-Pnt
3.42
430
F





Bnzl






IIB-620
Ph-Et
H
4-F-
4-OH-Bnzl
3.67
498
F





Bnzl






IIB-621
Ph-Et
H
4-F-
2-Cbx-Et
3.32
464
F





Bnzl






IIB-622
2-OH-Et
H
4-F-
4-OH-Bnzl
2.95
438
F





Bnzl






IIB-623
2-OH-Et
H
4-F-
2-Cbx-Et
2.57
404
F





Bnzl






IIB-624
i-Pnt
H
4-F-
4-OH-Bnzl
3.54
464
F





Bnzl






IIB-625
i-Pnt
H
4-F-
2-Cbx-Et
3.19
430
F





Bnzl






IIB-626
Chm
H
4-F-
4-OH-Bnzl
3.80
490
F





Bnzl






IIB-627
Chm
H
4-F-
2-Cbx-Et
3.45
456
F





Bnzl






IIB-628
i-Bu
H
i-Pnt
2-Cbx-Et
3.05
378
F


IIB-629
4-OH-Bnzl
H
i-Pnt
2-Cbx-Et
2.80
428
F


IIB-630
2-Cbx-Et
H
i-Pnt
i-Bu
3.25
378
F


IIB-631
2-Cbx-Et
H
i-Pnt
4-OH-Bnzl
2.90
428
F


IIB-632
2-OH-Et
H
i-Pnt
i-Bu
3.20
350
F


IIB-633
2-OH-Et
H
i-Pnt
2-Cbx-Et
2.59
366
F


IIB-634
Chm
H
i-Pnt
2-Cbx-Et
3.54
418
F


IIB-635
i-Bu
H
2-OH-
i-Bu
2.69
336
F





Et






IIB-636
i-Bu
H
2-OH-
4-OH-Bnzl
2.35
386
F





Et






IIB-637
1-Npm
H
2-OH-
4-OH-Bnzl
2.94
470
F





Et























TABLE 1-21







IIB-638
1-Npm
H
2-OH—Et
2-Cbx-Et
2.63
436
F


IIB-639
4-OH-Bnzl
H
2-OH—Et
Bnzl
2.67
420
F


IIB-640
4-OH-Bnzl
H
2-OH—Et
1-Npm
3.04
470
F


IIB-641
4-OH-Bnzl
H
2-OH—Et
Ph—Et
2.75
434
F


IIB-642
4-OH-Bnzl
H
2-OH—Et
i-Pnt
2.60
400
F


IIB-643
2-Cbx-Et
H
2-OH—Et
Bnzl
3.60
386
F


IIB-644
2-Cbx-Et
H
2-OH—Et
i-Bu
3.40
352
F


IIB-645
2-Cbx-Et
H
2-OH—Et
1-Npm
2.84
436
F


IIB-646
2-Cbx-Et
H
2-OH—Et
Ph—Et
2.57
400
F


IIB-647
2-Cbx-Et
H
2-OH—Et
i-Pnt
2.52
366
F


IIB-648
Ph—Et
H
2-OH—Et
2-Cbx-Et
2.37
400
F


IIB-649
4-F-Bnzl
H
2-OH—Et
2-Cbx-Et
2.12
404
F


IIB-650
i-Pnt
H
2-OH—Et
i-Bu
2.94
350
F


IIB-651
i-Pnt
H
2-OH—Et
2-Cbx-Et
3.34
366
F


IIB-652
Chm
H
2-OH—Et
1-Bu
3.17
376
F


IIB-653
Chm
H
2-OH—Et
2-Cbx-Et
2.47
392
F


IIB-654
Bnzl
H
Ph—Et
4-OH-Bnzl
3.69
480
F


IIB-655
Bnzl
H
Ph—Et
2-Cbx-Et
3.15
446
F


IIB-656
i-Bu
H
Ph—Et
4-OH-Bnzl
3.47
446
F


IIB-657
i-Bu
H
Ph—Et
2-Cbx-Et
3.05
412
F


IIB-658
1-Npm
H
Ph—Et
4-OH-Bnzl
4.02
530
F


IIB-659
1-Npm
H
Ph—Et
2-Cbx-Et
3.62
496
F


IIB-660
4-OH-Bnzl
H
Ph—Et
2-Cbx-Et
2.85
462
F


IIB-661
4-OH-Bnzl
H
Ph—Et
i-Pnt
3.74
460
F


IIB-662
2-Cbx-Et
H
Ph—Et
4-OH-Bnzl
3.02
462
F


IIB-663
2-Cbx-Et
H
Ph—Et
i-Pnt
3.55
426
F


IIB-664
4-F-Bnzl
H
Ph—Et
4-OH-Bnzl
3.69
498
F


IIB-665
4-F-Bnzl
H
Ph—Et
2-Cbx-Et
3.22
464
F


IIB-666
2-OH—Et
H
Ph—Et
4-OH-Bnzl
2.99
434
F


IIB-667
2-OH—Et
H
Ph—Et
2-Cbx-Et
2.62
400
F


IIB-668
i-Pnt
H
Ph—Et
4-OH-Bnzl
3.63
460
F


IIB-669
i-Pnt
H
Ph—Et
2-Cbx-Et
3.27
426
F


IIB-670
Chm
H
Ph—Et
4-OH-Bnzl
3.92
486
F


IIB-671
Chm
H
Ph—Et
2-Cbx-Et
3.55
452
F


IIB-672
Bnzl
H
Hxy
2-Cbx-Et
3.54
426
F


IIB-673
i-Bu
H
Hxy
2-Cbx-Et
3.42
392
F


IIB-674
1-Npm
H
Hxy
2-Cbx-Et
4
476
F


IIB-675
4-OH-Bnzl
H
Hxy
2-Cbx-Et
3.17
442
F


IIB-676
2-Cbx-Et
H
Hxy
i-Bu
3.54
392
F


IIB-677
2-Cbx-Et
H
Hxy
4-OH-Bnzl
3.25
442
F


IIB-678
2-Cbx-Et
H
Hxy
i-Pnt
3.84
406
F


IIB-679
Ph—Et
H
Hxy
2-Cbx-Et
3.75
440
F


IIB-680
4-F-Bnzl
H
Hxy
2-Cbx-Et
3.6
444
F


IIB-681
2-OH—Et
H
Hxy
i-Bu
3.6
364
F


IIB-682
2-OH—Et
H
Hxy
4-OH-Bnzl
3.29
414
F


IIB-683
2-OH—Et
H
Hxy
2-Cbx-Et
2.88
380
F


IIB-684
2-OH—Et
H
Hxy
i-Pnt
3.87
378
F


IIB-685
i-Pnt
H
Hxy
4-OH-Bnzl
3.98
440
F


IIB-686
i-Pnt
H
Hxy
2-Cbx-Et
3.59
406
F


IIB-687
i-Pnt
H
Hxy
2-OH—Et
3.52
378
F























TABLE 1-22







IIB-688
Chm
H
Hxy
4-OH-Bnzl
4.24
466
F


IIB-689
Chm
H
Hxy
2-Cbx-Et
3.88
432
F


IIB-690
tBOC-E
H
Bnzl
i-Pnt
4.47
468
F


IIB-691
Ph—Et
H
Bnzl
tBOC-E
4.34
502
F


IIB-692
4-F-Bnzl
H
Bnzl
tBOC-E
4.09
506
F


IIB-693
2-OtBu—Et
H
Bnzl
tBOC-E
4.27
498
F


IIB-694
i-Pnt
H
Bnzl
tBOC-E
4.25
468
F


IIB-695
Chm
H
Bnzl
tBOC-E
4.5
494
F


IIB-696
tBOC-E
H
i-Bu
Ph—Et
4.25
468
F


IIB-697
tBOC-E
H
i-Bu
i-Pnt
4.3
434
F


IIB-698
Ph—Et
H
i-Bu
tBOC-E
4.18
468
F


IIB-699
2-OtBu—Et
H
i-Bu
tBOC-E
4.09
464
F


IIB-700
i-Pnt
H
i-Bu
4-tBuO-
4.43
468
F






Bnzl





IIB-701
i-Pnt
H
i-Bu
tBOC-E
3.97
434
F


IIB-702
Chm
H
i-Bu
4-tBuO-
4.67
494
F






Bnzl





IIB-703
Chm
H
i-Bu
tBOC-E
4.43
460
F


IIB-704
tBOC-E
H
1-Npm
Ph—Et
4.78
552
F


IIB-705
tBOC-E
H
1-Npm
i-Pnt
4.89
518
F


IIB-706
Ph—Et
H
1-Npm
tBOC-E
4.72
552
F


IIB-707
4-F-Bnzl
H
1-Npm
tBOC-E
4.52
556
F


IIB-708
2-OtBu—Et
H
1-Npm
tBOC-E
5.37
548
F


IIB-709
i-Pnt
H
1-Npm
tBOC-E
4.68
518
F


IIB-710
Chm
H
1-Npm
tBOC-E
4.9
544
F


IIB-711
4-tBuO-Bnzl
H
i-Pr
Ph—Et
4.29
488
F


IIB-712
tBOC-E
H
i-Pr
Ph—Et
3.92
454
F


IIB-713
tBOC-E
H
i-Pr
i-Pnt
4
420
F


IIB-714
Ph—Et
H
i-Pr
tBOC-E
3.92
454
F


IIB-715
2-OtBu—Et
H
i-Pr
Bnzl
3.77
412
F


IIB-716
2-OtBu—Et
H
i-Pr
1-Npm
4.24
462
F


IIB-717
2-OtBu—Et
H
i-Pr
4-tBuO-
4.37
484
F






Bnzl





IIB-718
2-OtBu—Et
H
i-Pr
tBOC-E
3.94
450
F


IIB-719
2-OtBu—Et
H
i-Pr
i-Pnt
4.04
392
F


IIB-720
i-Pnt
H
i-Pr
4-tBuO-
4.22
454
F






Bnzl





IIB-721
i-Pnt
H
i-Pr
tBOC-E
4.82
420
F


IIB-722
Chm
H
i-Pr
4-tBuO-
4.57
480
F






Bnzl





IIB-723
4-tBuO-Bnzl
H
s-Bu
Ph—Et
4.5
502
F


IIB-724
4-tBuO-Bnzl
H
s-Bu
i-Pnt
4.62
468
F


IIB-725
tBOC-E
H
s-Bu
Ph—Et
4.29
468
F


IIB-726
tBOC-E
H
s-Bu
i-Pnt
4.3
434
F


IIB-727
Ph—Et
H
s-Bu
tBOC-E
4.14
468
F


IIB-728
4-F-Bnzl
H
s-Bu
tBOC-E
4.52
472
F


IIB-729
2-OtBu—Et
H
s-Bu
4-tBuO-
4.68
498
F






Bnzl





IIB-730
2-OtBu—Et
H
s-Bu
tBOC-E
4.17
464
F


IIB-731
i-Pnt
H
s-Bu
4-tBuO-
4.74
468
F






Bnzl





IIB-732
i-Pnt
H
s-Bu
tBOC-E
4.27
434
F


IIB-733
Chm
H
s-Bu
4-tBuO-
4.74
494
F






Bnzl





IIB-734
i-Bu
H
4-tBuO-
i-Pnt
4.57
468
F





Bnzl






IIB-735
tBOC-E
H
4-tBuO-
Ph—Et
5.2
574
F





Bnzl






IIB-736
tBOC-E
H
4-tBuO-
i-Pnt
4.6
540
F





Bnzl






IIB-737
Ph—Et
H
4-tBuO-
tBOC-E
4.59
574
F





Bnzl























TABLE 1-23







IIB-738
4-F-Bnzl
H
4-tBuO-
tBOC-E
4.5
578
F





Bnzl






IIB-739
2-OtBu—Et
H
4-tBuO-
tBOC-E
4.79
570
F





Bnzl






IIB-740
i-Pnt
H
4-tBuO-
tBOC-E
4.8
540
F





Bnzl






IIB-741
Chm
H
4-tBuO-
tBOC-E
4.99
566
F





Bnzl






IIB-742
i-Bu
H
tBOC-
Ph—Et
4.12
468
F





E






IIB-743
i-Bu
H
tBOC-
i-Pnt
4.18
434
F





E






IIB-744
2-OtBu—Et
H
tBOC-
i-Bu
4.1
464
F





E






IIB-745
i-Pnt
H
tBOC-
i-Bu
4.17
434
F





E






IIB-746
Chm
H
tBOC-
4-tBuO-
4.95
566
F





E
Bnzl





IIB-747
Chm
H
tBOC-
i-Pnt
4.55
474
F





E






IIB-748
Bnzl
H
4-F-
4-tBuO-
4.54
540
F





Bnzl
Bnzl





IIB-749
Bnzl
H
4-F-
tBOC-E
4.05
506
F





Bnzl






IIB-750
i-Bu
H
4-F-
4-tBuO-
4.39
506
F





Bnzl
Bnzl





IIB-751
i-Bu
H
4-F-
tBOC-E
3.97
472
F





Bnzl






IIB-752
1-Npm
H
4-F-
4-tBuO-
4.92
590
F





Bnzl
Bnzl





IIB-753
1-Npm
H
4-F-
tBOC-E
4.57
556
F





Bnzl






IIB-754
4-tBuO-Bnzl
H
4-F-
tBOC-E
4.62
578
F





Bnzl






IIB-755
4-tBuO-Bnzl
H
4-F-
Ph—Et
4.6
554
F





Bnzl






IIB-756
4-tBuO-Bnzl
H
4-F-
i-Pnt
4.47
520
F





Bnzl






IIB-757
tBOC-E
H
4-F-
4-tBuO-
4.74
578
F





Bnzl
Bnzl





IIB-758
tBOC-E
H
4-F-
Ph—Et
4.24
520
F





Bnzl






IIB-759
tBOC-E
H
4-F-
i-Pnt
4.4
486
F





Bnzl






IIB-760
Ph—Et
H
4-F-
4-tBuO-
4.59
554
F





Bnzl
Bnzl





IIB-761
Ph—Et
H
4-F-
tBOC-E
4.4
520
F





Bnzl






IIB-762
2-OtBu—Et
H
4-F-
4-tBuO-
4.72
550
F





Bnzl
Bnzl





IIB-763
2-OtBu—Et
H
4-F-
tBOC-E
4.3
516
F





Bnzl






IIB-764
i-Pnt
H
4-F-
4-tBuO-
4.57
520
F





Bnzl
Bnzl





IIB-765
i-Pnt
H
4-F-
tBOC-E
4.22
486
F





Bnzl






IIB-766
Chm
H
4-F-
4-tBuO-
4.89
546
F





Bnzl
Bnzl





IIB-767
Chm
H
4-F-
tBOC-E
4.39
512
F





Bnzl






IIB-768
i-Bu
H
i-Pnt
tBOC-E
4
434
F


IIB-769
4-tBuO-Bnzl
H
i-Pnt
tBOC-E
4.77
540
F


IIB-770
tBOC-E
H
i-Pnt
i-Bu
4.37
434
F


IIB-771
tBOC-E
H
i-Pnt
4-tBuO-
4.79
540
F






Bnzl





IIB-772
2-OtBu—Et
H
i-Pnt
i-Bu
4.5
406
F


IIB-773
2-OtBu—Et
H
i-Pnt
tBOC-E
4.67
478
F


IIB-774
i-Bu
H
2-
i-Bu
3.49
392
F





OtBu—Et






IIB-775
i-Bu
H
2-
4-tBuO-
4.34
498
F





OtBu—Et
Bnzl





IIB-776
i-Bu
H
2-
tBOC-E
3.74
464
F





OtBu—Et






IIB-777
1-Npm
H
2-
4-tBuO-
4.75
582
F





OtBu—Et
Bnzl





IIB-778
1-Npm
H
2-
tBOC-E
4.42
548
F





OtBu—Et






IIB-779
4-tBuO-Bnzl
H
2-
Bnzl
4.42
532
F





OtBu—Et






IIB-780
4-tBuO-Bnzl
H
2-
1-Npm
4.82
582
F





OtBu—Et






IIB-781
4-tBuO-Bnzl
H
2-
tBOC-E
4.4
570
F





OtBu—Et






IIB-782
4-tBuO-Bnzl
H
2-
i-Pnt
4.64
512
F





OtBu—Et






IIB-783
tBOC-E
H
2-
Bnzl
3.99
498
F





OtBu—Et






IIB-784
tBOC-E
H
2-
i-Bu
4.15
464
F





OtBu—Et






IIB-785
tBOC-E
H
2-
4-tBuO-
4.54
570
F





OtBu—Et
Bnzl





IIB-786
tBOC-E
H
2-
i-Pnt
4.22
478
F





OtBu—Et






IIB-787
Ph—Et
H
2-
tBOC-E
4.04
512
F





OtBu—Et























TABLE 1-24







IIB-788
Chm
H
2-
i-Bu
4.12
432
F





OtBu—Et






IIB-789
Chm
H
2-
tBOC-E
4.32
504
F





OtBu—Et






IIB-790
Bnzl
H
Ph—Et
4-tBuO-
4.62
536
F






Bnzl





IIB-791
Bnzl
H
Ph—Et
tBOC-E
4.15
502
F


IIB-792
i-Bu
H
Ph—Et
4-tBuO-
4.47
502
F






Bnzl





IIB-793
i-Bu
H
Ph—Et
tBOC-E
4.09
468
F


IIB-794
1-Npm
H
Ph—Et
4-tBuO-
4.95
586
F






Bnzl





IIB-795
1-Npm
H
Ph—Et
tBOC-E
4.62
552
F


IIB-796
4-tBuO-Bnzl
H
Ph—Et
tBOC-E
4.72
574
F


IIB-797
4-tBuO-Bnzl
H
Ph—Et
i-Pnt
4.74
516
F


IIB-798
tBOC-E
H
Ph—Et
i-Pnt
4.65
482
F


IIB-799
4-F-Bnzl
H
Ph—Et
4-tBuO-
4.67
554
F






Bnzl





IIB-800
4-F-Bnzl
H
Ph—Et
tBOC-E
4.24
520
F


IIB-801
2-OtBu—Et
H
Ph—Et
4-tBuO-
4.8
546
F






Bnzl





IIB-802
2-OtBu—Et
H
Ph—Et
tBOC-E
4.3
512
F


IIB-803
i-Pnt
H
Ph—Et
4-tBuO-
4.67
516
F






Bnzl





IIB-804
i-Pnt
H
Ph—Et
tBOC-E
4.34
482
F


IIB-805
Chm
H
Ph—Et
4-tBuO-
4.93
542
F






Bnzl





IIB-806
Chm
H
Ph—Et
tBOC-E
4.6
508
F


IIB-807
Bnzl
H
Hxy
tBOC-E
4.49
482
F


IIB-808
1-Npm
H
Hxy
tBOC-E
5
532
F


IIB-809
4-tBuO-Bnzl
H
Hxy
1-Npm
5.37
566
F


IIB-810
4-tBuO-Bnzl
H
Hxy
tBOC-E
5.05
554
F


IIB-811
tBOC-E
H
Hxy
i-Bu
4.75
448
F


IIB-812
tBOC-E
H
Hxy
1-Npm
4.92
532
F


IIB-813
tBOC-E
H
Hxy
4-tBuO-
5.04
554
F






Bnzl





IIB-814
tBOC-E
H
Hxy
i-Pnt
5
462
F


IIB-815
Ph—Et
H
Hxy
tBOC-E
4.72
496
F


IIB-816
4-F-Bnzl
H
Hxy
tBOC-E
4.6
500
F


IIB-817
2-
H
Hxy
4-tBuO-
5.17
526
F



OtBu—Et


Bnzl





IIB-818
2-
H
Hxy
tBOC-E
4.87
492
F



OtBu—Et








IIB-819
2-
H
Hxy
i-Pnt
4.95
434
F



OtBu—Et








IIB-820
i-Pnt
H
Hxy
4-tBuO-
5.05
496
F






Bnzl





IIB-821
i-Pnt
H
Hxy
tBOC-E
4.7
462
F


IIB-822
Chm
H
Hxy
4-tBuO-
5.29
522
F






Bnzl





IIB-823
i-Bu
H
i-Bu
Ph—Et
3.33
396
H


IIB-824
i-Bu
H
i-Bu
i-Pnt
3.17
362
H


IIB-825
1-Npm
H
i-Bu
i-Pnt
3.45
446
H


IIB-826
4-F-Bnzl
H
i-Bu
i-Bu
3.03
400
H


IIB-827
4-F-Bnzl
H
i-Bu
1-Npm
3.26
484
H


IIB-828
4-F-Bnzl
H
i-Bu
Ph—Et
3.15
448
H


IIB-829
4-F-Bnzl
H
i-Bu
i-Pnt
3.15
414
H


IIB-830
i-Pnt
H
i-Bu
i-Bu
3.13
362
H


IIB-831
i-Pnt
H
i-Bu
1-Npm
3.3
446
H


IIB-832
i-Pnt
H
i-Bu
Ph—Et
3.17
410
H


IIB-833
Chm
H
i-Bu
i-Bu
3.26
388
H


IIB-834
Chm
H
i-Bu
1-Npm
3.48
472
H


IIB-835
Chm
H
i-Bu
Ph—Et
3.32
436
H


IIB-836
Bnzl
H
Bnzl
Ph—Et
3.39
464
H


IIB-837
1-Npm
H
Bnzl
i-Pnt
3.37
480
H























TABLE 1-25







IIB-
Ph—Et
H
Bnzl
1-Npm
3.4
514
H


838









IIB-
Ph—Et
H
Bnzl
i-Pnt
3.26
444
H


839









IIB-
4-F-Bnzl
H
Bnzl
1-Npm
3.34
518
H


840









IIB-
4-F-Bnzl
H
Bnzl
Ph—Et
3.17
482
H


841









IIB-
4-F-Bnzl
H
Bnzl
i-Pnt
3.21
448
H


842









IIB-
i-Pnt
H
Bnzl
1-Npm
3.36
480
H


843









IIB-
Chm
H
Bnzl
1-Npm
3.47
506
H


844









IIB-
Chm
H
Bnzl
Ph—Et
3.33
470
H


845









IIB-
Chm
H
Bnzl
i-Pnt
3.37
436
H


846









IIB-
Bnzl
H
1-Npm
Ph—Et
3.39
514
H


847









IIB-
Bnzl
H
1-Npm
i-Pnt
3.44
480
H


848









IIB-
i-Bu
H
1-Npm
i-Pnt
3.3
446
H


849









IIB-
1-Npm
H
1-Npm
Ph—Et
3.56
564
H


850









IIB-
1-Npm
H
1-Npm
i-Pnt
3.59
530
H


851









IIB-
Ph—Et
H
1-Npm
Bnzl
3.41
514
H


852









IIB-
Ph—Et
H
1-Npm
i-Bu
3.38
480
H


853









IIB-
Ph—Et
H
1-Npm
1-Npm
3.53
564
H


854









IIB-
Ph—Et
H
1-Npm
i-Pnt
3.46
494
H


855









IIB-
4-F-Bnzl
H
1-Npm
1-Npm
3.48
568
H


856









IIB-
4-F-Bnzl
H
1-Npm
Ph—Et
3.39
532
H


857









IIB-
4-F-Bnzl
H
1-Npm
i-Pnt
3.4
498
H


858









IIB-
i-Pnt
H
1-Npm
i-Bu
3.42
446
H


859









IIB-
i-Pnt
H
1-Npm
1-Npm
3.51
530
H


860









IIB-
i-Pnt
H
1-Npm
Ph—Et
3.42
494
H


861









IIB-
Chm
H
1-Npm
Bnzl
3.58
506
H


862









IIB-
Chm
H
1-Npm
i-Bu
3.54
472
H


863









IIB-
Chm
H
1-Npm
1-Npm
3.67
556
H


864









IIB-
Chm
H
1-Npm
Ph—Et
3.57
520
H


865









IIB-
Chm
H
1-Npm
i-Pnt
3.59
486
H


866









IIB-
Bnzl
H
i-Pr
Ph—Et
3.16
416
H


867









IIB-
Bnzl
H
i-Pr
i-Pnt
3.17
382
H


868









IIB-
i-Bu
H
i-Pr
Ph—Et
3.12
382
H


869









IIB-
1-Npm
H
i-Pr
Ph—Et
3.34
466
H


870









IIB-
1-Npm
H
i-Pr
i-Pnt
3.38
432
H


871









IIB-
Ph—Et
H
i-Pr
Bnzl
3.15
416
H


872









IIB-
Ph—Et
H
i-Pr
i-Bu
3.12
382
H


873









IIB-
Ph—Et
H
i-Pr
1-Npm
3.34
466
H


874









IIB-
Ph—Et
H
i-Pr
i-Pnt
3.22
396
H


875









IIB-
4-F-Bnzl
H
i-Pr
Bnzl
3.11
420
H


876









IIB-
4-F-Bnzl
H
i-Pr
i-Bu
3.04
386
H


877









IIB-
4-F-Bnzl
H
i-Pr
1-Npm
3.28
470
H


878









IIB-
4-F-Bnzl
H
i-Pr
Ph—Et
3.13
434
H


879









IIB-
4-F-Bnzl
H
i-Pr
i-Pnt
3.11
400
H


880









IIB-
i-Pnt
H
i-Pr
Bnzl
3.08
382
H


881









IIB-
i-Pnt
H
i-Pr
1-Npm
3.31
432
H


882









IIB-
i-Pnt
H
i-Pr
Ph—Et
3.19
396
H


883









IIB-
Chm
H
i-Pr
Bnzl
3.27
408
H


884









IIB-
Chm
H
i-Pr
1-Npm
3.45
458
H


885









IIB-
Chm
H
i-Pr
Ph—Et
3.32
422
H


886









IIB-
Bnzl
H
s-Bu
Ph—Et
3.22
430
H


887























TABLE 1-26







IIB-
Bnzl
H
s-Bu
i-Pnt
3.25
396
H


888









IIB-
i-Bu
H
s-Bu
Ph—Et
3.19
396
H


889









IIB-
1-Npm
H
s-Bu
Ph—Et
3.41
480
H


890









IIB-
1-Npm
H
s-Bu
i-Pnt
3.42
446
H


891









IIB-
Ph—Et
H
s-Bu
Bnzl
3.24
430
H


892









IIB-
Ph—Et
H
s-Bu
i-Bu
3.22
396
H


893









IIB-
Ph—Et
H
s-Bu
1-Npm
3.39
480
H


894









IIB-
Ph—Et
H
s-Bu
i-Pnt
3.32
410
H


895









IIB-
4-F-Bnzl
H
s-Bu
Bnzl
3.25
434
H


896









IIB-
4-F-Bnzl
H
s-Bu
i-Bu
3.13
400
H


897









IIB-
4-F-Bnzl
H
s-Bu
1-Npm
3.35
484
H


898









IIB-
4-F-Bnzl
H
s-Bu
Ph—Et
3.23
448
H


899









IIB-
4-F-Bnzl
H
s-Bu
i-Pnt
3.25
414
H


900









IIB-
i-Pnt
H
s-Bu
Bnzl
3.23
396
H


901









IIB-
i-Pnt
H
s-Bu
1-Npm
3.39
446
H


902









IIB-
Chm
H
s-Bu
Bnzl
3.38
422
H


903









IIB-
Chm
H
s-Bu
1-Npm
3.51
472
H


904









IIB-
Bnzl
H
Ph—Et
Bnzl
3.24
464
H


905









IIB-
Bnzl
H
Ph—Et
1-Npm
3.43
514
H


906









IIB-
Bnzl
H
Ph—Et
i-Pnt
3.28
444
H


907









IIB-
i-Bu
H
Ph—Et
i-Bu
3.15
396
H


908









IIB-
i-Bu
H
Ph—Et
1-Npm
3.38
480
H


909









IIB-
i-Bu
H
Ph—Et
i-Pnt
4.41
410
H


910









IIB-
1-Npm
H
Ph—Et
Bnzl
3.47
514
H


911









IIB-
1-Npm
H
Ph—Et
i-Bu
3.43
480
H


912









IIB-
1-Npm
H
Ph—Et
1-Npm
3.58
564
H


913









IIB-
4-F-Bnzl
H
Ph—Et
Bnzl
3.23
482
H


914









IIB-
4-F-Bnzl
H
Ph—Et
i-Bu
3.17
448
H


915









IIB-
4-F-Bnzl
H
Ph—Et
1-Npm
3.38
532
H


916









IIB-
4-F-Bnzl
H
Ph—Et
i-Pnt
3.26
462
H


917









IIB-
i-Pnt
H
Ph—Et
i-Bu
3.24
410
H


918









IIB-
i-Pnt
H
Ph—Et
1-Npm
3.42
494
H


919









IIB-
Chm
H
Ph—Et
Bnzl
3.38
470
H


920









IIB-
Chm
H
Ph—Et
i-Bu
3.33
436
H


921









IIB-
Chm
H
Ph—Et
1-Npm
3.49
520
H


922









IIB-
Chm
H
Ph—Et
i-Pnt
3.45
450
H


923









IIB-
Bnzl
H
4-F-
Bnzl
3.2
468
H


924


Bnzl






IIB-
Bnzl
H
4-F-
1-Npm
3.34
518
H


925


Bnzl






IIB-
Bnzl
H
4-F-
Ph—Et
3.2
482
H


926


Bnzl






IIB-
Bnzl
H
4-F-
i-Pnt
3.23
448
H


927


Bnzl






IIB-
i-Bu
H
4-F-
i-Bu
3.13
400
H


928


Bnzl






IIB-
i-Bu
H
4-F-
1-Npm
3.32
484
H


929


Bnzl






IIB-
i-Bu
H
4-F-
i-Pnt
3.21
414
H


930


Bnzl






IIB-
1-Npm
H
4-F-
Bnzl
3.47
518
H


931


Bnzl






IIB-
1-Npm
H
4-F-
i-Bu
3.43
484
H


932


Bnzl






IIB-
1-Npm
H
4-F-
1-Npm
3.63
568
H


933


Bnzl






IIB-
1-Npm
H
4-F-
Ph—Et
3.48
532
H


934


Bnzl






IIB-
1-Npm
H
4-F-
i-Pnt
3.5
498
H


935


Bnzl






IIB-
Ph—Et
H
4-F-
Bnzl
3.28
482
H


936


Bnzl






IIB-
Ph—Et
H
4-F-
i-Bu
3.27
448
H


937


Bnzl























TABLE 1-27







IIB-
Ph—Et
H
4-F-
1-Npm
3.42
532
H


938


Bnzl






IIB-
Ph—Et
H
4-F-
i-Pnt
3.33
462
H


939


Bnzl






IIB-
i-Pnt
H
4-F-
1-Npm
3.33
498
H


940


Bnzl






IIB-
i-Pnt
H
4-F-
Ph—Et
3.28
462
H


941


Bnzl






IIB-
Chm
H
4-F-
Bnzl
3.31
474
H


942


Bnzl






IIB-
Chm
H
4-F-
i-Bu
3.29
440
H


943


Bnzl






IIB-
Chm
H
4-F-
1-Npm
3.47
524
H


944


Bnzl






IIB-
Chm
H
4-F-
Ph—Et
3.42
488
H


945


Bnzl






IIB-
Chm
H
4-F-
i-Pnt
3.38
454
H


946


Bnzl






IIB-
Bnzl
H
i-Pnt
Bnzl
3.27
430
H


947









IIB-
Bnzl
H
i-Pnt
1-Npm
3.42
480
H


948









IIB-
Bnzl
H
i-Pnt
Ph—Et
3.29
444
H


949









IIB-
i-Bu
H
i-Pnt
1-Npm
3.38
446
H


950









IIB-
i-Bu
H
i-Pnt
Ph—Et
3.3
410
H


951









IIB-
1-Npm
H
i-Pnt
Bnzl
3.45
480
H


952









IIB-
1-Npm
H
i-Pnt
i-Bu
3.42
446
H


953









IIB-
1-Npm
H
i-Pnt
1-Npm
3.56
530
H


954









IIB-
Ph—Et
H
i-Pnt
Bnzl
3.29
444
H


955









IIB-
Ph—Et
H
i-Pnt
i-Bu
3.28
410
H


956









IIB-
Ph—Et
H
i-Pnt
1-Npm
3.43
494
H


957









IIB-
4-F-Bnzl
H
i-Pnt
Bnzl
3.27
448
H


958









IIB-
4-F-Bnzl
H
i-Pnt
i-Bu
3.2
414
H


959









IIB-
4-F-Bnzl
H
i-Pnt
1-Npm
3.42
498
H


960









IIB-
4-F-Bnzl
H
i-Pnt
Ph—Et
3.28
462
H


961









IIB-
Chm
H
i-Pnt
Bnzl
3.44
436
H


962









IIB-
Chm
H
i-Pnt
1-Npm
3.58
486
H


963









IIB-
Chm
H
i-Pnt
Ph—Et
3.45
450
H


964









IIB-
Bnzl
H
Hxy
Bnzl
3.42
444
H


965









IIB-
Bnzl
H
Hxy
1-Npm
3.53
494
H


966









IIB-
Bnzl
H
Hxy
i-Pnt
3.43
424
H


967









IIB-
i-Bu
H
Hxy
1-Npm
3.49
460
H


968









IIB-
1-Npm
H
Hxy
1-Npm
3.67
544
H


969









IIB-
1-Npm
H
Hxy
i-Pnt
3.63
474
H


970









IIB-
Ph—Et
H
Hxy
Bnzl
3.43
458
H


971









IIB-
Ph—Et
H
Hxy
i-Bu
3.39
424
H


972









IIB-
Ph—Et
H
Hxy
i-Pnt
3.49
438
H


973









IIB-
4-F-Bnzl
H
Hxy
Bnzl
3.41
462
H


974









IIB-
4-F-Bnzl
H
Hxy
i-Bu
3.33
428
H


975









IIB-
4-F-Bnzl
H
Hxy
1-Npm
3.52
512
H


976









IIB-
4-F-Bnzl
H
Hxy
Ph—Et
3.4
476
H


977









IIB-
4-F-Bnzl
H
Hxy
i-Pnt
3.42
442
H


978









IIB-
i-Pnt
H
Hxy
Bnzl
3.41
424
H


979









IIB-
i-Pnt
H
Hxy
1-Npm
3.58
474
H


980









IIB-
Chm
H
Hxy
Bnzl
3.54
450
H


981









IIB-
Chm
H
Hxy
1-Npm
3.64
500
H


982









IIB-
2-
H
i-Bu
Bnzl
4.35
426
H


983
OtBu—Et








IIB-
2-
H
i-Bu
1-Npm
4.49
476
H


984
OtBu—Et








IIB-
2-
H
Bnzl
i-Pnt
4.48
440
H


985
OtBu—Et








IIB-
i-Pnt
H
Bnzl
4-tBuO-
3.42
502
H


986



Bnzl





IIB-
Chm
H
Bnzl
4-tBuO-
3.53
528
H


987



Bnzl























TABLE 1-28







IIB-
4-tBuO-Bnzl
H
1-Npm
Ph—Et
3.58
586
H


988









IIB-
4-tBuO-Bnzl
H
1-Npm
i-Pnt
3.58
552
H


989









IIB-
Ph—Et
H
1-Npm
4-tBuO-
3.53
586
H


990



Bnzl





IIB-
4-F-Bnzl
H
1-Npm
4-tBuO-
3.54
590
H


991



Bnzl





IIB-
2-OtBu—Et
H
1-Npm
Bnzl
4.52
510
H


992









IIB-
2-OtBu—Et
H
1-Npm
i-Bu
4.52
476
H


993









IIB-
2-OtBu—Et
H
1-Npm
1-Npm
4.6
560
H


994









IIB-
i-Pnt
H
1-Npm
4-tBuO-
3.58
552
H


995



Bnzl





IIB-
Chm
H
1-Npm
4-tBuO-
3.69
578
H


996



Bnzl





IIB-
Bnzl
H
4-tBuO-
Ph—Et
3.46
536
H


997


Bnzl






IIB-
Bnzl
H
4-tBuO-
i-Pnt
3.46
502
H


998


Bnzl






IIB-
i-Bu
H
4-tBuO-
Ph—Et
3.42
502
H


999


Bnzl






IIB-
1-Npm
H
4-tBuO-
Ph—Et
3.6
586
H


1000


Bnzl






IIB-
1-Npm
H
4-tBuO-
i-Pnt
3.61
552
H


1001


Bnzl






IIB-
Ph—Et
H
4-tBuO-
Bnzl
3.47
536
H


1002


Bnzl






IIB-
Ph—Et
H
4-tBuO-
1-Npm
3.53
586
H


1003


Bnzl






IIB-
Ph—Et
H
4-tBuO-
i-Pnt
3.53
516
H


1004


Bnzl






IIB-
4-F-Bnzl
H
4-tBuO-
Bnzl
3.39
540
H


1005


Bnzl






IIB-
4-F-Bnzl
H
4-tBuO-
1-Npm
3.53
590
H


1006


Bnzl






IIB-
4-F-Bnzl
H
4-tBuO-
Ph—Et
3.43
554
H


1007


Bnzl






IIB-
4-F-Bnzl
H
4-tBuO-
i-Pnt
3.44
520
H


1008


Bnzl






IIB-
2-OtBu—Et
H
4-tBuO-
1-Npm
3.63
582
H


1009


Bnzl






IIB-
i-Pnt
H
4-tBuO-
i-Bu
3.38
468
H


1010


Bnzl






IIB-
i-Pnt
H
4-tBuO-
1-Npm
3.58
552
H


1011


Bnzl






IIB-
i-Pnt
H
4-tBuO-
Ph—Et
3.48
516
H


1012


Bnzl






IIB-
Chm
H
4-tBuO-
Bnzl
3.54
528
H


1013


Bnzl






IIB-
Chm
H
4-tBuO-
i-Bu
3.43
494
H


1014


Bnzl






IIB-
Chm
H
4-tBuO-
1-Npm
3.66
578
H


1015


Bnzl






IIB-
Chm
H
4-tBuO-
Ph—Et
3.63
542
H


1016


Bnzl






IIB-
Chm
H
4-tBuO-
i-Pnt
3.63
508
H


1017


Bnzl






IIB-
Bnzl
H
tBOC-
Ph—Et
3.27
502
H


1018


E






IIB-
Bnzl
H
tBOC-
i-Pnt
3.25
468
H


1019


E






IIB-
1-Npm
H
tBOC-
Ph—Et
3.45
552
H


1020


E






IIB-
1-Npm
H
tBOC-
i-Pnt
3.47
518
H


1021


E






IIB-
4-tBuO-Bnzl
H
tBOC-
Ph—Et
3.48
574
H


1022


E






IIB-
4-tBuO-Bnzl
H
tBOC-
i-Pnt
3.53
540
H


1023


E






IIB-
Ph—Et
H
tBOC-
Bnzl
3.23
502
H


1024


E






IIB-
Ph—Et
H
tBOC-
i-Bu
3.29
468
H


1025


E






IIB-
Ph—Et
H
tBOC-
1-Npm
3.41
552
H


1026


E






IIB-
Ph—Et
H
tBOC-
4-tBuO-
3.47
574
H


1027


E
Bnzl





IIB-
Ph—Et
H
tBOC-
i-Pnt
3.32
482
H


1028


E






IIB-
4-F-Bnzl
H
tBOC-
Bnzl
3.26
506
H


1029


E






IIB-
4-F-Bnzl
H
tBOC-
i-Bu
3.21
472
H


1030


E






IIB-
4-F-Bnzl
H
tBOC-
1-Npm
3.42
556
H


1031


E






IIB-
4-F-Bnzl
H
tBOC-
4-tBuO-
3.44
578
H


1032


E
Bnzl





IIB-
4-F-Bnzl
H
tBOC-
Ph—Et
3.27
520
H


1033


E






IIB-
4-F-Bnzl
H
tBOC-
i-Pnt
3.29
486
H


1034


E






IIB-
2-OtBu—Et
H
tBOC-
Bnzl
3.34
498
H


1035


E






IIB-
2-OtBu—Et
H
tBOC-
1-Npm
3.46
548
H


1036


E






IIB-
2-OtBu—Et
H
tBOC-
4-tBuO-
3.52
570
H


1037


E
Bnzl























TABLE 1-29







IIB-
2-OtBu—Et
H
tBOC-
Ph—Et
3.36
512
H


1038


E






IIB-
1-Pnt
H
tBOC-
Bnzl
3.25
468
H


1039


E






IIB-
i-Pnt
H
tBOC-
1-Npm
3.38
518
H


1040


E






IIB-
1-Pnt
H
tBOC-
Ph—Et
3.27
482
H


1041


E






IIB-
Chm
H
tBOC-
Bnzl
3.39
494
H


1042


E






IIB-
Chm
H
tBOC-
1-Npm
3.54
544
H


1043


E






IIB-
Chm
H
tBOC-
Ph—Et
3.5
508
H


1044


E






IIB-
Ph—Et
H
i-Pr
4-tBuO-
3.36
488
H


1045



Bnzl





IIB-
4-F-Bnzl
H
i-Pr
4-tBuO-
3.33
492
H


1046



Bnzl





IIB-
Ph—Et
H
s-Bu
4-tBuO-
3.43
502
H


1047



Bnzl





IIB-
4-F-Bnzl
H
s-Bu
4-tBuO-
3.46
506
H


1048



Bnzl





IIB-
2-OtBu—Et
H
s-Bu
Bnzl
3.28
426
H


1049









IIB-
2-OtBu—Et
H
s-Bu
i-Bu
3.26
392
H


1050









IIB-
2-OtBu—Et
H
s-Bu
1-Npm
3.48
476
H


1051









IIB-
2-OtBu—Et
H
s-Bu
Ph—Et
3.39
440
H


1052









IIB-
4-tBuO-Bnzl
H
Ph—Et
Bnzl
3.48
536
H


1053









IIB-
4-tBuO-Bnzl
H
Ph—Et
i-Bu
3.38
502
H


1054









IIB-
4-tBuO-Bnzl
H
Ph—Et
1-Npm
3.58
586
H


1055









IIB-
tBOC-E
H
Ph—Et
Bnzl
3.3
502
H


1056









IIB-
tBOC-E
H
Ph—Et
i-Bu
3.28
468
H


1057









IIB-
tBOC-E
H
Ph—Et
1-Npm
3.47
552
H


1058









IIB-
2-OtBu—Et
H
Ph—Et
Bnzl
3.29
474
H


1059









IIB-
2-OtBu—Et
H
Ph—Et
i-Bu
3.27
440
H


1060









IIB-
2-OtBu—Et
H
Ph—Et
i-Pnt
3.36
454
H


1061









IIB-
4-tBuO-Bnzl
H
4-F-
Bnzl
3.52
540
H


1062


Bnzl






IIB-
4-tBuO-Bnzl
H
4-F-
i-Bu
3.42
506
H


1063


Bnzl






IIB-
4-tBuO-Bnzl
H
4-F-
1-Npm
3.6
590
H


1064


Bnzl






IIB-
tBOC-E
H
4-F-
Bnzl
3.27
506
H


1065


Bnzl






IIB-
tBOC-E
H
4-F-
1-Bu
3.28
472
H


1066


Bnzl






IIB-
tBOC-E
H
4-F-
1-Npm
3.45
556
H


1067


Bnzl






IIB-
2-OtBu—Et
H
4-F-
i-Bu
3.22
444
H


1068


Bnzl






IIB-
2-OtBu—Et
H
4-F-
Ph—Et
3.33
492
H


1069


Bnzl






IIB-
2-OtBu—Et
H
4-F-
i-Pnt
3.33
458
H


1070


Bnzl






IIB-
Bnzl
H
2-
Bnzl
4.32
460
H


1071


OtBu—Et






IIB-
Bnzl
H
2-
i-Bu
4.25
426
H


1072


OtBu—Et






IIB-
Bnzl
H
2-
1-Npm
4.42
510
H


1073


OtBu—Et






IIB-
Bnzl
H
2-
Ph—Et
4.31
474
H


1074


OtBu—Et






IIB-
Bnzl
H
2-
i-Pnt
4.34
440
H


1075


OtBu—Et






IIB-
i-Bu
H
2-
Bnzl
4.33
426
H


1076


OtBu—Et






IIB-
i-Bu
H
2-
1-Npm
4.42
476
H


1077


OtBu—Et






IIB-
i-Bu
H
2-
Ph—Et
4.35
440
H


1078


OtBu—Et






IIB-
1-Npm
H
2-
Bnzl
4.45
510
H


1079


OtBu—Et






IIB-
1-Npm
H
2-
i-Bu
4.48
476
H


1080


OtBu—Et






IIB-
1-Npm
H
2-
Ph—Et
4.48
524
H


1081


OtBu—Et






IIB-
1-Npm
H
2-
i-Pnt
4.53
490
H


1082


OtBu—Et






IIB-
4-tBuO-
H
2-
i-Bu
4.43
498
H


1083
Bnzl

OtBu—Et






IIB-
Ph—Et
H
2-
Bnzl
4.33
474
H


1084


OtBu—Et






IIB-
Ph—Et
H
2-
i-Bu
4.33
440
H


1085


OtBu—Et






IIB-
Ph—Et
H
2-
1-Npm
4.47
524
H


1086


OtBu—Et






IIB-
Ph—Et
H
2-
4-tBuO-
4.49
546
H


1087


OtBu—Et
Bnzl























TABLE 1-30







IIB-
Ph—Et
H
2-
i-Pnt
4.41
454
H


1088


OtBu—Et






IIB-
4-F-Bnzl
H
2-
Bnzl
4.33
478
H


1089


OtBu—Et






IIB-
4-F-Bnzl
H
2-
i-Bu
4.26
444
H


1090


OtBu—Et






IIB-
4-F-Bnzl
H
2-
1-Npm
4.43
528
H


1091


OtBu—Et






IIB-
4-F-Bnzl
H
2-
4-tBuO-
4.47
550
H


1092


OtBu—Et
Bnzl





IIB-
4-F-Bnzl
H
2-
Ph—Et
4.32
492
H


1093


OtBu—Et






IIB-
4-F-Bnzl
H
2-
i-Pnt
4.37
458
H


1094


OtBu—Et






IIB-
i-Pnt
H
2-
Bnzl
4.29
440
H


1095


OtBu—Et






IIB-
i-Pnt
H
2-
1-Npm
4.43
490
H


1096


OtBu—Et






IIB-
i-Pnt
H
2-
4-tBuO-
4.47
512
H


1097


OtBu—Et
Bnzl





IIB-
Chm
H
2-
Bnzl
4.43
466
H


1098


OtBu—Et






IIB-
Chm
H
2-
4-tBuO-
4.56
538
H


1099


OtBu—Et
Bnzl





IIB-
Chm
H
2-
Ph—Et
4.46
480
H


1100


OtBu—Et






IIB-
Bnzl
H
i-Pnt
4-tBuO-
3.43
502
H


1101



Bnzl





IIB-
Bnzl
H
i-Pnt
tBOC-E
3.23
468
H


1102









IIB-
1-Npm
H
i-Pnt
4-tBuO-
3.6
552
H


1103



Bnzl





IIB-
1-Npm
H
i-Pnt
tBOC-E
3.45
518
H


1104









IIB-
4-tBuO-Bnzl
H
i-Pnt
Bnzl
3.48
502
H


1105









IIB-
4-tBuO-Bnzl
H
i-Pnt
i-Bu
3.47
468
H


1106









IIB-
4-tBuO-Bnzl
H
i-Pnt
1-Npm
3.64
552
H


1107









IIB-
4-tBuO-Bnzl
H
i-Pnt
Ph—Et
3.53
516
H


1108









IIB-
tBOC-E
H
i-Pnt
Bnzl
3.33
468
H


1109









IIB-
tBOC-E
H
i-Pnt
1-Npm
3.49
518
H


1110









IIB-
tBOC-E
H
i-Pnt
Ph—Et
3.38
482
H


1111









IIB-
Ph—Et
H
i-Pnt
4-tBuO-
3.53
516
H


1112



Bnzl





IIB-
Ph—Et
H
i-Pnt
tBOC-E
3.34
482
H


1113









IIB-
4-F-Bnzl
H
i-Pnt
4-tBuO-
3.44
520
H


1114



Bnzl





IIB-
4-F-Bnzl
H
i-Pnt
tBOC-E
2.47
486
H


1115









IIB-
Chm
H
i-Pnt
4-tBuO-
2.82
508
H


1116



Bnzl





IIB-
Bnzl
H
Hxy
4-tBuO-
2.73
516
H


1117



Bnzl





IIB-
i-Bu
H
Hxy
4-tBuO-
2.7
482
H


1118



Bnzl





IIB-
1-Npm
H
Hxy
4-tBuO-
2.88
566
H


1119



Bnzl





IIB-
4-tBuO-Bnzl
H
Hxy
Bnzl
2.78
516
H


1120









IIB-
4-tBuO-Bnzl
H
Hxy
Ph—Et
2.83
530
H


1121









IIB-
4-tBuO-Bnzl
H
Hxy
i-Pnt
2.85
496
H


1122









IIB-
tBOC-E
H
Hxy
Bnzl
2.62
482
H


1123









IIB-
tBOC-E
H
Hxy
Ph—Et
2.68
496
H


1124









IIB-
Ph—Et
H
Hxy
4-tBuO-
2.77
530
H


1125



Bnzl





IIB-
4-F-Bnzl
H
Hxy
4-tBuO-
2.75
534
H


1126



Bnzl





IIB-
2-OtBu—Et
H
Hxy
Bnzl
2.48
454
H


1127









IIB-
2-OtBu—Et
H
Hxy
1-Npm
2.75
504
H


1128









IIB-
2-OtBu—Et
H
Hxy
Ph—Et
2.68
468
H


1129






Ring formed together by R2A and R2B



*IIB-410, 416, 420, 462, 463, 499, and 501 are mixtures of conformational isomers.


















TABLE 1-31







LCMS





Compound

tR
Mass
Measurement
Yield


number
Name of compound
(min)
(M + H)+
condition
(%)







IIB-1
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
1.19
416
B
18



dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-2
(3S*,3aS*,6R*,7R*,7aS*)-N,1,7-
1.17
348
B
33



triisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-3
(3S*,3aS*,6R*,7R*,7aS*)-7-
1.18
382
B
26



benzyl-N,1-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-4
(3S*,3aS*,6R*,7R*,7aS*)-1-
1.17
382
B
40



benzyl-N,7-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-5
(3S*,3aS*,6R*,7R*,7aS*)-N-
1.18
382
B
36



benzyl-1,7-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-6
(3S*,3aS*,6R*,7R*,7aS*)-1,7-
1.19
416
B
47



dibenzyl-N-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-7
(3S*,3aS*,6R*,7R*,7aS*)-N,1-
1.19
416
B
35



dibenzyl-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-8
(3S*,3aS*,6R*,7R*,7aS*)-N,1,7-
1.21
450
B
36



tribenzyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-9
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
1.22
430
B
35



dibenzyl-1-isopentyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-10
(3S*,3aS*,6R*,7R*,7aS*)-N,1-
1.22
430
B
27



dibenzyl-7-isopentyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-11
(3S*,3aS*,6R*,7R*,7aS*)-N-
1.21
430
B
35



benzyl-1-isobutyl-7-phenethyl-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-12
(3S*,3aS*,6R*,7R*,7aS*)-1-
1.21
430
B
19



benzyl-7-isobutyl-N-phenethyl-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide





















TABLE 1-32







IIB-13
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.22
430
B
39



isobutyl-7-(3-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-14
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.21
430
B
37



isobutyl-7-(4-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-15
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.22
430
B
20



isobutyl-N-(3-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-16
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.23
430
B
30



isobutyl-N-(4-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-17
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-
1.22
450
B
34



(3-chlorobenzyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-18
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-
1.22
450
B
24



(4-chlorobenzyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-19
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.28
484
B
27



(3,4-dichlorobenzyl)-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-20
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N-
1.25
484
B
31



(3,4-dichlorobenzyl)-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-21
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.18
438
B
54



isobutyl-N-(2-(naphthalen-1-yl)ethyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-23
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.05
488
A
28



isobutyl-N-(4-(tert-butoxy)benzyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-24
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.03
466
A
30



isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-25
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-
0.79
370
A
20



(2-hydroxyethyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-26
3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-
0.80
398
A
95



1-isobutyl-1,2,3,6,7,7a-hexahydro-1H-3,6-methanopyrrolo







[3,2-b]pyridine-3a-carboxamide)propanoic acid






IIB-27
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.98
454
A
11



isobutyl-N-(2-(tert-butoxy)-2-oxoethyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-28
(3S*,3aS*,6R*,7R*,7aS*)-N-(3-amino-
0.79
397
A
80



3-oxopropyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-29
(3S*,3aS*,6R*,7R*,7aS*)-N-(4-
0.71
397
A
93



aminobutyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-30
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.97
497
A
18



isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl)-1,2,3,6,7,7a-







hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide






IIB-31
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-
1.04
422
A
5



cyclohexylmethyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-carboxamide





















TABLE 1-33







IIB-32
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-
0.93
424
A
38



1-isobutyl-N-((tetrahydro-2H-pyran-







2-yl)methyl)-1,2,3,6,7,7a-







hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-34
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-
0.99
497
A
36



1-isobutyl-7-(4-((tert-







butoxycarbonyl)amino)butyl)-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-36
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-
0.89
412
A
22



1-isobutyl-7-(3-methoxy-3-







oxopropyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-







b]pyridine-3a-carboxamide






IIB-38
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-
1.05
422
A
59



7-(cyclohexylmethyl)-1-isobutyl-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-39
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
1.04
456
A
12



dibenzyl-1-cyclohexylmethyl-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-40
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
0.91
466
A
92



dibenzyl-1-(4-hydroxybenzyl)-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-41
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
1.05
522
A
10



dibenzyl-1-(4-(tert-







butoxy)benzyl)-1,2,3,6,7,7a-







hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-42
(3S*,3aS*,6R*,7R*,7aS*)-N,7-
1.04
500
A
 4



dibenzyl-1-(naphthalen-1-







ylmethyl)-1,2,3,6,7,7a-hexahydro-







3aH-3,6-methanopyrrolo[3,2-







b]pyridine-3a-carboxamide






IIB-76
tert-butyl 3-
0.83
488
B
34



((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-







3a-(benzylcarbamoyl)-







2,3,3a,6,7,7a-hexahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridin-







1-yl)propanoate






IIB-77
(3S*,3aS*,6R*,7R*,7aS*)-N,1-
0.85
466
B
34



dibenzyl-7-(4-hydroxybenzyl)-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IIB-78
tert-butyl 3-
1.00
527
B
49



((3S*,3aS*,6R*,7R*,7aS*)-2-(7-







benzyl-1-methyl-2,3,3a,6,7,7a-







hexahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide)ethyl)-1H-indole-1-







carboxylate






IIB-80
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-
0.95
452
A
 9



1-(naphthalen-1-ylmethyl)-7-propyl-







1,2,3,6,7,7a-hexahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide
















TABLE 2-1









embedded image



















Compound



Synthesis

Raw
Raw


number
R1
R2
R3
method
Intermediate
material
material








1
2























TABLE 2-2







IIF-1
i-Bu
Bnzl
Bnzl
EX
INT-Bnzl
SM1-iBu
SM2-Ph


IIF-2
i-Bu
i-Bu
i-Bu
IIB-1,
INT-iBu
SM1-iBu
SM2-Pnt






IIF-1





IIF-3
i-Bu
i-Bu
Bnzl
IIB-1,
INT-iBu
SM1-iBu
SM2-Ph






IIF-1





IIF-4
Bnzl
i-Bu
i-Bu
IIB-1,
INT-iBu
SM1-Bnzl
SM2-Pnt






IIF-1





IIF-5
i-Bu
Bnzl
i-Bu
IIB-1,
INT-Bnzl
SM1-iBu
SM2-Pnt






IIF-1





IIF-6
Bnzl
i-Bu
Bnzl
IIB-1,
INT-iBu
SM1-Bnzl
SM2-Ph






IIF-1





IIF-7
Bnzl
Bnzl
i-Bu
IIB-1,
N-(benzyl-
SM1-Bnzl
SM2-Pnt






IIF-1
1,2,4-triazine-









3-carboxamide




IIF-8
Bnzl
Bnzl
Bnzl
IIB-1,
INT-Bnzl
SM1-Bnzl
SM2-Ph






IIF-1





IIF-9
i-Pnt
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-allyl-3-
SM2-Ph






IIF-1

methylbutan-









1-amine



IIF-10
Bnzl
Bnzl
i-Pnt
IIB-1,
INT-Bnzl
SM1-Bnzl
5-






IIF-1


methylhexanal


IIF-11
i-Bu
Bnzl
Ph-Et
IIB-1,
INT-Bnzl
SM1-iBu
4-






IIF-1


phenylbutanal


IIF-12
i-Bu
Ph-Et
Bnzl
IIB-1,
N-phenethyl-
SM1-iBu
SM2-Ph






IIF-1
1,2,4-triazine-3-









carboxamide




IIF-13
i-Bu
Bnzl
3-Me-
IIB-1,
INT-Bnzl
SM1-iBu
3-(m-tolyl)propanal





Bnzl
IIF-1





IIF-14
i-Bu
Bnzl
4-Me-
IIB-1,
INT-Bnzl
SM1-iBu
3-(p-tolyl)propanal





Bnzl
IIF-1





IIF-15
i-Bu
3-Me-
Bnzl
IIB-1,
N-(3-methylbenzyl)-
SM1-iBu
SM2-Ph




Bnzl

IIF-1
1,2,4-triazine-3-









carboxamide




IIF-16
i-Bu
4-Me-
Bnzl
IIB-1,
N-(4-methylbenzyl)-
SM1-iBu
SM2-Ph




Bnzl

IIF-1
1,2,4-triazine-3-









carboxamide




IIF-17
i-Bu
3-Cl-
Bnzl
IIB-1,
N-(3-chlorobenzyl)-
SM1-iBu
SM2-Ph




Bnzl

IIF-1
1,2,4-triazine-3-









carboxamide




IIF-18
i-Bu
4-Cl-
Bnzl
IIB-1,
N-(4-chlorobenzyl)-
SM1-iBu
SM2-Ph




Bnzl

IIF-1
1,2,4-triazine-3-









carboxamide




IIF-19
3,4-
Bnzl
i-Bu
IIB-1,
INT-Bnzl
N-(3,4-
SM2-Pnt



Cl2-


IIF-1

dichlorobenzyl)




Bnzl




prop-2-en-1-amine



IIF-20
Bnzl
3,4-
i-Bu
IIB-1,
N-(3,4-
SM1-Bnzl
SM2-Pnt




Cl2-

IIF-1
dichlorobenzyl)-






Bnzl


1,2,4-triazine-3-









carboxamide




IIF-23
i-Bu
4-
Bnzl
IIB-1,
N-(4-tert-
SM1-iBu
SM2-Ph




(tert-

IIF-1
butoxybenzyl)-






butoxy)


1,2,4-triazine-3-






benzyl


carboxamide























TABLE 2-3







IIF-24
i-Bu
Np-M
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph






IIF-1
((naphthalen-1-yl)









methyl)-1,2,4-triazine-









3-carboxamide




IIF-25
i-Bu
Hdr-E
Bnzl
IIB-1,
N-(2-
SM1-iBu
SM2-Ph






IIF-1
hydroxyethyl)-









1,2,4-triazine-









3-carboxamide




IIF-26
i-Bu
Cbx-E
Bnzl
EX

IIB-27



IIF-27
i-Bu
2-(tert-
Bnzl
IIB-1,
tert-butyl
SM1-iBu
SM2-Ph




butoxy)-

IIF-1
3-(1,2,4-






2-oxoethyl


triazine-3-









carboxamide)









propanoate




IIF-28
i-Bu
Cbm-E
Bnzl
IIB-28

IIF-26



IIF-29
i-Bu
4-aminobutyl
Bnzl
IIB-29

IIF-30



IIF-30
i-Bu
4-((tert-
Bnzl
IIB-1,
tert-butyl
SM1-iBu
SM2-Ph




butoxycarbonyl)

IIF-1
4-(1,2,4-






amino)butyl


triazine-3-









carboxamide)









butylcarbamate




IIF-31
i-Bu
Chm
Bnzl
IIB-1,
N-
SM1-iBu
SM2-Ph






IIF-1
(cyclohexyl









methyl)-









1,2,4-triazine-









3-carboxamide




IIF-32
i-Bu
(tetrahydro-
Bnzl
IIB-1,
N-((tetrahydro-2H-
SM1-iBu
SM2-Ph




2H-pyran-2-yl)

IIF-1
pyran-2-yl)methyl)-






methyl


1,2,4-triazine-









3-carboxamide




IIF-34
i-Bu
Bnzl
4-
IIB-1,
INT-Bnzl
SM1-iBu
tert-butyl





((tert-
IIF-1


5-





butoxycarbonyl)



formylpentylcarbamate





amino)butyl






IIF-36
i-Bu
Bnzl
3-methoxy-
IIB-1,
INT-Bnzl
SM1-iBu
methyl





3-oxopropyl
IIF-1


4-formylbutanoate


IIF-38
i-Bu
Bnzl
Chm
IIB-1,
INT-Bnzl
SM1-iBu
3-cyclohexylpropanal






IIF-1





IIF-39
Chm
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-
SM2-Ph






IIF-1

(cyclohexylmethyl)









prop-2-en-1-amine



IIF-40
4-OH-Bnzl
Bnzl
Bnzl
IF-40

IIF-41



IIF-41
4-(tert-
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-(4-tert-
SM2-Ph



butoxy)


IIF-1

butoxybenzyl)




benzyl




prop-2-en-1-amine



IIF-42
Np-M
Bnzl
Bnzl
IIB-1,
INT-Bnzl
N-
SM2-Ph






IIF-1

((naphthalen-1-yl)









methyl)prop-2-en-









1-amine























TABLE 2-4







IIF-76
3-(tert-
Bnzl
Bnzl
IIB-1,
N-benzyl-
N-(3-(tert-
SM2-Ph



butoxy)-


IIF-1
1,2,4-
butoxy)-




3-



triazine-3-
3-oxopropyl)-




oxopropyl



carboxamide
prop-2-en-1-









amine



IIF-77
Bnzl
Bnzl
4-
IIB-1,
N-benzyl-
SM1-Bnzl
3-(4-





OH-
IIF-1
1,2,4-

hydroxyphenyl)





Bnzl

triazine-3-

propanal







carboxamide




IIF-80
Np-M
Bnzl
Pr
IIB-1,
N-benzyl
N-
pentanal






IIF-1
1,2,4-
((naphthalen-1-yl)








triazine-3-
methyl)prop-2-en-








carboxamide
1-amine






















TABLE 2-5









LCMS




Compound



t R
Mass
Measurement


number
R1
R2
R3
(min)
(M + H) +
condition







IIF-81
benzyl
naphthalen-1-
isobutyl
1.29
467
B




ylmethyl






IIF-82
benzyl
4-(trifluoromethyl)
isobutyl
1.29
484
B




benzyl






IIF-83
4-chlorobenzyl
benzyl
isobutyl
1.29
450
B


IIF-84
3-chlorobenzyl
benzyl
isobutyl
1.30
450
B


IIF-85
4-methoxybenzyl
benzyl
isobutyl
1.23
446
B


IIF-86
4-methylbenzyl
benzyl
isobutyl
1.24
430
B


IIF-88
isobutylbenzyl
isobutyl
4-chloro
1.26
416
B


IIF-89
isobutyl
4-chlorobenzyl
isobutyl
1.22
416
B


IIF-90
isobutyl
benzyl
isopentyl
1.23
396
B


IIF-91
isopentyl
benzyl
isobutyl
1.26
396
B


IIF-92
isobutyl
isopentyl
benzyl
1.23
396
B


IIF-93
4-hydroxybenzyl
benzyl
isobutyl
1.19
432
B


IIF-94
4-(dimethylamino)
benzyl
isobutyl
1.27
459
B



benzyl







IIF-95
4-(tert-butyl)
benzyl
isobutyl
1.29
472
B



benzyl







IIF-96
4-(trifluoromethoxy)
benzyl
isobutyl
1.32
500
B



benzyl







IIF-97
4-ethoxybenzyl
benzyl
isobutyl
1.25
460
B


IIF-98
isopentyl
isobutyl
benzyl
1.22
396
B


IIF-99
benzyl
4-hydroxybenzyl
isobutyl
1.17
432
B






















TABLE 2-6







IIF-100
4-methoxybenzyl
4-hydroxybenzyl
isobutyl
1.17
462
B


IIF-101
4-hydroxybenzyl
benzyl
isopentyl
1.20
446
B


IIF-102
benzyl
naphthalen-2-
isobutyl
1.27
466
B




ylmethyl






IIF-103
isopentyl
4-chlorobenzyl
isobutyl
1.28
431
B


IIF-104
isopentyl
4-fluorobenzyl
isobutyl
1.26
414
B


IIF-105
benzyl
pyridin-4-
isobutyl
1.06
417
B




ylmethyl






IIF-106
4-methoxybenzyl
benzyl
benzyl
0.93
480
c


IIF-107
phenethyl
benzyl
2-(tert-
1.08
532
C





butyldimethylsilyloxy)








ethyl





IIF-109
4-nitrobenzyl
4-(tert-butoxy)
2-(tert-
1.00
605
C




benzyl
butoxycarbonyl)








ethyl





IIF-110
i-Bu
i-Pr
Bnzl
2.92
368
F


IIF-111
i-Bu
i-Bu
4-tBuO-Bnzl
3.64
454
F


IIF-112
i-Bu
Bnzl
4-tBuO-Bnzl
3.75
488
F


IIF-113
i-Bu
tBOC-E
4-tBuO-Bnzl
3.73
526
F


IIF-114
i-Bu
s-Bu
4-tBuO-Bnzl
3.64
454
F


IIF-115
i-Bu
1-Npm
4-tBuO-Bnzl
4.18
538
F


IIF-116
i-Bu
i-Pr
4-tBuO-Bnzl
3.4
440
F


IIF-117
i-Bu
1-Npm
tBOC-E
3.92
504
F


IIF-118
i-Bu
1-Npm
1-Npm
4.25
516
F


IIF-119
i-Bu
i-Pr
1-Npm
3.4
418
F


IIF-120
Bnzl
4-tBuO-Bnzl
Bnzl
3.95
522
F


IIF-121
Bnzl
i-Bu
4-tBuO-Bnzl
3.79
488
F


IIF-122
Bnzl
Bnzl
4-tBuO-Bnzl
3.91
522
F


IIF-123
Bnzl
tBOC-E
4-tBuO-Bnzl
3.94
560
F


IIF-124
Bnzl
Bnzl
tBOC-E
3.47
488
F


IIF-125
Bnzl
4-tBuO-Bnzl
tBOC-E
3.98
560
F


IIF-126
Bnzl
1-Npm
tBOC-E
3.96
538
F


IIF-127
Bnzl
i-Bu
1-Npm
3.74
466
F






















TABLE 2-7







IIF-128
Bnzl
Bnzl
1-Npm
3.92
500
F


IIF-129
Bnzl
4-tBuO-Bnzl
1-Npm
4.27
572
F


IIF-130
Bnzl
tBOC-E
1-Npm
3.8
538
F


IIF-131
Bnzl
s-Bu
1-Npm
3.74
466
F


IIF-132
Bnzl
1-Npm
1-Npm
4.31
550
F


IIF-133
4-tBuO-Bnzl
Bnzl
Bnzl
4.1
522
F


IIF-134
4-tBuO-Bnzl
tBOC-E
Bnzl
3.6
560
F


IIF-135
4-tBuO-Bnzl
s-Bu
Bnzl
3.47
488
F


IIF-136
4-tBuO-Bnzl
1-Npm
Bnzl
4.75
572
F


IIF-137
4-tBuO-Bnzl
Bnzl
tBOC-E
3.69
560
F


IIF-138
4-tBuO-Bnzl
1-Npm
tBOC-E
4.04
610
F


IIF-139
4-tBuO-Bnzl
i-Bu
1-Npm
3.82
538
F


IIF-140
4-tBuO-Bnzl
Bnzl
1-Npm
4.68
572
F


IIF-141
4-tBuO-Bnzl
tBOC-E
1-Npm
3.8
610
F


IIF-142
4-tBuO-Bnzl
s-Bu
1-Npm
3.92
538
F


IIF-143
4-tBuO-Bnzl
1-Npm
1-Npm
4.65
622
F


IIF-144
i-Bu
4-tBuO-Bnzl
Bnzl
3.87
488
F


IIF-145
i-Bu
tBOC-E
Bnzl
3.25
454
F


IIF-146
i-Bu
s-Bu
Bnzl
3.12
382
F


IIF-147
i-Bu
i-Bu
tBOC-E
3.19
420
F


IIF-148
i-Bu
Bnzl
tBOC-E
3.37
454
F


IIF-149
i-Bu
4-tBuO-Bnzl
tBOC-E
3.93
526
F


IIF-150
i-Bu
i-Pr
tBOC-E
2.93
406
F


IIF-151
i-Bu
i-Bu
1-Npm
3.68
432
F


IIF-152
i-Bu
Bnzl
1-Npm
3.72
466
F


IIF-153
i-Bu
4-tBuO-Bnzl
1-Npm
4.24
538
F


IIF-154
i-Bu
tBOC-E
1-Npm
3.74
504
F


IIF-155
Bnzl
tBOC-E
Bnzl
3.44
488
F


IIF-156
Bnzl
s-Bu
Bnzl
3.24
416
F


IIF-157
Bnzl
1-Npm
Bnzl
3.87
500
F


IIF-158
Bnzl
i-Pr
Bnzl
3.01
402
F


IIF-159
Bnzl
s-Bu
4-tBuO-Bnzl
3.82
488
F


IIF-160
Bnzl
1-Npm
4-tBuO-Bnzl
4.43
572
F


IIF-161
Bnzl
i-Pr
4-tBuO-Bnzl
3.51
474
F






















TABLE 2-8







IIF-162
Bnzl
s-Bu
tBOC-E
3.34
454
F


IIF-163
Bnzl
i-Pr
tBOC-E
3.15
440
F


IIF-164
Bnzl
i-Pr
1-Npm
3.5
452
F


IIF-165
4-tBuO-Bnzl
i-Pr
Bnzl
3.49
474
F


IIF-166
4-tBuO-Bnzl
i-Pr
tBOC-E
3.38
512
F


IIF-167
4-tBuO-Bnzl
i-Pr
1-Npm
3.82
524
F


IIF-168
tBOC-E
i-Bu
Bnzl
3.5
454
F


IIF-169
1-Npm
i-Bu
Bnzl
3.54
466
F


IIF-170
1-Npm
4-tBuO-Bnzl
Bnzl
3.95
572
F


IIF-171
1-Npm
s-Bu
Bnzl
3.52
466
F


IIF-172
1-Npm
i-Pr
Bnzl
3.19
452
F


IIF-173
1-Npm
Bnzl
4-tBuO-Bnzl
4.3
572
F


IIF-174
1-Npm
tBOC-E
4-tBuO-Bnzl
3.95
610
F


IIF-175
1-Npm
s-Bu
4-tBuO-Bnzl
3.87
538
F


IIF-176
1-Npm
1-Npm
4-tBuO-Bnzl
4.62
622
F


IIF-177
1-Npm
i-Pr
4-tBuO-Bnzl
3.84
524
F


IIF-178
1-Npm
Bnzl
tBOC-E
3.8
538
F


IIF-179
1-Npm
4-tBuO-Bnzl
tBOC-E
4.5
610
F


IIF-180
1-Npm
s-Bu
tBOC-E
3.62
504
F


IIF-181
1-Npm
1-Npm
tBOC-E
4.15
588
F


IIF-182
1-Npm
Bnzl
1-Npm
4.3
550
F


IIF-183
1-Npm
4-tBuO-Bnzl
1-Npm
4.75
622
F


IIF-184
1-Npm
tBOC-E
1-Npm
4.02
588
F


IIF-185
1-Npm
s-Bu
1-Npm
4.25
516
F


IIF-186
i-Bu
4-tBuO-Bnzl
i-Bu
3.68
454
F


IIF-187
i-Bu
tBOC-E
i-Bu
3.05
420
F


IIF-188
i-Bu
s-Bu
i-Bu
2.84
348
F


IIF-189
i-Bu
1-Npm
i-Bu
3.71
432
F


IIF-190
i-Bu
i-Pr
i-Bu
2.66
334
F


IIF-191
i-Bu
(tBOC)Gun-Pr
4-tBuO-Bnzl
2.71
641
J


IIF-192
i-Bu
1-Npm
(tBOC)Gun-Pr
3.47
675
J


IIF-193
i-Bu
s-Bu
1-Npm
3.64
432
F


IIF-194
Bnzl
4-tBuO-Bnzl
i-Bu
3.93
488
F


IIF-195
Bnzl
i-Pr
i-Bu
3.01
368
F






















TABLE 2-9







IIF-196
Bnzl
i-Bu
tBOC-E
3.32
454
F


IIF-197
tBOC-E
Bnzl
i-Bu
3.52
454
F


IIF-198
tBOC-E
4-tBuO-Bnzl
i-Bu
4.01
526
F


IIF-199
tBOC-E
s-Bu
i-Bu
3.26
420
F


IIF-200
tBOC-E
1-Npm
i-Bu
4.09
504
F


IIF-201
tBOC-E
i-Pr
i-Bu
3.03
406
F


IIF-202
tBOC-E
1-Npm
Bnzl
4.06
538
F


IIF-203
tBOC-E
Bnzl
4-tBuO-Bnzl
4.19
560
F


IIF-204
tBOC-E
1-Npm
4-tBuO-Bnzl
4.62
610
F


IIF-205
tBOC-E
i-Bu
1-Npm
3.96
504
F


IIF-206
tBOC-E
4-tBuO-Bnzl
1-Npm
4.41
610
F


IIF-207
tBOC-E
1-Npm
1-Npm
4.48
588
F


IIF-208
tBOC-E
i-Pr
1-Npm
3.71
490
F


IIF-209
1-Npm
i-Bu
i-Bu
3.32
432
F


IIF-210
1-Npm
Bnzl
i-Bu
3.38
466
F


IIF-211
1-Npm
4-tBuO-Bnzl
i-Bu
3.67
538
F


IIF-212
1-Npm
s-Bu
i-Bu
3.35
432
F


IIF-213
1-Npm
1-Npm
i-Bu
3.8
516
F


IIF-214
1-Npm
i-Pr
i-Bu
3.17
418
F


IIF-215
1-Npm
i-Bu
4-tBuO-Bnzl
3.92
538
F


IIF-216
1-Npm
i-Bu
tBOC-E
3.5
504
F


IIF-217
1-Npm
i-Pr
tBOC-E
3.34
490
F


IIF-218
1-Npm
i-Bu
1-Npm
3.79
516
F


IIF-219
1-Npm
(tBOC)Gun-Pr
1-Npm
3.82
759
F


IIF-220
1-Npm
i-Pr
1-Npm
3.65
502
F


IIF-221
i-Bu
(tBOC)Gun-Pr
i-Bu
2.89
591
J


IIF-222
i-Bu
(tBOC)Gun-Pr
Bnzl
2.96
625
J


IIF-223
i-Bu
s-Bu
tBOC-E
3.13
420
F


IIF-224
i-Bu
i-Bu
(tBOC)Gun-Pr
2.96
591
J


IIF-225
i-Bu
Bnzl
(tBOC)Gun-Pr
3
625
J


IIF-226
i-Bu
4-tBuO-Bnzl
(tBOC)Gun-Pr
2.78
641
J


IIF-227
i-Bu
s-Bu
(tBOC)Gun-Pr
2.95
591
J


IIF-228
i-Bu
i-Pr
(tBOC)Gun-Pr
2.81
577
J


IIF-229
i-Bu
(tBOC)Gun-Pr
1-Npm
3.08
675
J






















TABLE 2-10







IIF-230
Bnzl
(tBOC)Gun-Pr
i-Bu
2.93
625
J


IIF-231
Bnzl
s-Bu
i-Bu
3.23
382
F


IIF-232
Bnzl
(tBOC)Gun-Pr
Bnzl
2.94
659
J


IIF-233
Bnzl
(tBOC)Gun-Pr
4-tBuO-Bnzl
2.74
675
J


IIF-234
Bnzl
i-Bu
(tBOC)Gun-Pr
3.49
698?
J


IIF-235
Bnzl
Bnzl
(tBOC)Gun-Pr
3.18
659
J


IIF-236
Bnzl
4-tBuO-Bnzl
(tBOC)Gun-Pr
2.95
675
J


IIF-237
Bnzl
s-Bu
(tBOC)Gun-Pr
3.04
625
J


IIF-238
Bnzl
1-Npm
(tBOC)Gun-Pr
4.09
709
J


IIF-239
Bnzl
(tBOC)Gun-Pr
1-Npm
3.36
709
J


IIF-240
tBOC-E
i-Bu
i-Bu
3.25
420
F


IIF-241
tBOC-E
Bnzl
Bnzl
3.62
488
F


IIF-242
tBOC-E
4-tBuO-Bnzl
Bnzl
4.1
560
F


IIF-243
tBOC-E
s-Bu
Bnzl
4.48
454
F


IIF-244
tBOC-E
i-Pr
Bnzl
3.24
440
F


IIF-245
tBOC-E
i-Bu
4-tBuO-Bnzl
4.15
526
F


IIF-246
tBOC-E
i-Pr
4-tBuO-Bnzl
3.89
512
F


IIF-247
tBOC-E
Bnzl
1-Npm
4.03
538
F


IIF-248
tBOC-E
s-Bu
1-Npm
3.96
504
F


IIF-249
(tBOC)
1-Npm
i-Bu
3.77
657
J



Gun-Pr







IIF-250
(tBOC)
i-Pr
i-Bu
3.16
577
J



Gun-Pr







IIF-251
(tBOC)
1-Npm
Bnzl
3.71
709
J



Gun-Pr







IIF-252
(tBOC)
i-Pr
Bnzl
3.18
611
J



Gun-Pr







IIF-253
(tBOC)
1-Npm
4-tBuO-Bnzl
3.39
725
J



Gun-Pr







IIF-254
(tBOC)
i-Pr
4-tBuO-Bnzl
2.96
627
J



Gun-Pr







IIF-255
(tBOC)
1-Npm
1-Npm
3.97
759
J



Gun-Pr







IIF-256
(tBOC)
i-Pr
1-Npm
3.47
661
J



Gun-Pr







IIF-257
1-Npm
1-Npm
Bnzl
4.5
550
F


IIF-258
Bnzl
tBOC-E
i-Bu
3.51
454
F


IIF-259
Bnzl
i-Pr
(tBOC)Gun-Pr
2.99
611
J


IIF-260
4-tBuO-
i-Bu
i-Bu
3.42
454
F



Bnzl







IIF-261
4-tBuO-
Bnzl
i-Bu
3.44
488
F



Bnzl







IIF-262
4-tBuO-
tBOC-E
i-Bu
3.5
526
F



Bnzl







IIF-263
4-tBuO-
(tBOC)Gun-Pr
i-Bu
3.29
641
F



Bnzl






















TABLE 2-11







IIF-264
4-tBuO-Bnzl
s-Bu
i-Bu
3.45
454
F


IIF-265
4-tBuO-Bnzl
1-Npm
i-Bu
3.9
538
F


IIF-266
4-tBuO-Bnzl
i-Pr
i-Bu
3.24
440
F


IIF-267
4-tBuO-Bnzl
i-Bu
Bnzl
3.57
488
F


IIF-268
4-tBuO-Bnzl
(tBOC)Gun-Pr
Bnzl
3.1
675
F


IIF-269
4-tBuO-Bnzl
i-Bu
tBOC-E
3.6
526
F


IIF-270
4-tBuO-Bnzl
s-Bu
tBOC-E
3.59
526
F


IIF-271
4-tBuO-Bnzl
i-Bu
(tBOC)Gun-Pr
3.38
641
F


IIF-272
4-tBuO-Bnzl
Bnzl
(tBOC)Gun-Pr
3.72
675
F


IIF-273
4-tBuO-Bnzl
s-Bu
(tBOC)Gun-Pr
3.38
641
F


IIF-274
4-tBuO-Bnzl
1-Npm
(tBOC)Gun-Pr
3.79
725
F


IIF-275
4-tBuO-Bnzl
i-Pr
(tBOC)Gun-Pr
3.27
627
F


IIF-276
4-tBuO-Bnzl
(tBOC)Gun-Pr
1-Npm
3.54
725
F


IIF-277
tBOC-E
s-Bu
4-tBuO-Bnzl
4.09
526
F


IIF-278
(tBOC)Gun-Pr
i-Bu
i-Bu
4.24
591
F


IIF-279
(tBOC)Gun-Pr
Bnzl
i-Bu
3.99
625
F


IIF-280
(tBOC)Gun-Pr
4-tBuO-Bnzl
i-Bu
3.51
641
F


IIF-281
(tBOC)Gun-Pr
s-Bu
i-Bu
3.82
591
F


IIF-282
(tBOC)Gun-Pr
i-Bu
Bnzl
4.27
625
F


IIF-283
(tBOC)Gun-Pr
Bnzl
Bnzl
4.14
659
F


IIF-284
(tBOC)Gun-Pr
4-tBuO-Bnzl
Bnzl
3.72
675
F


IIF-285
(tBOC)Gun-Pr
s-Bu
Bnzl
3.99
625
F


IIF-286
(tBOC)Gun-Pr
i-Bu
4-tBuO-Bnzl
3.59
641
F


IIF-287
(tBOC)Gun-Pr
Bnzl
4-tBuO-Bnzl
4.32
675
F


IIF-288
(tBOC)Gun-Pr
Bnzl
1-Npm
4.57
709
F


IIF-289
(tBOC)Gun-Pr
s-Bu
1-Npm
4.49
675
F


IIF-290
1-Npm
tBOC-E
i-Bu
3.35
504
F


IIF-291
1-Npm
(tBOC)Gun-Pr
i-Bu
3.95
675
F


IIF-292
1-Npm
(tBOC)Gun-Pr
Bnzl
3.7
709
F


IIF-293
1-Npm
(tBOC)Gun-Pr
4-tBuO-Bnzl
3.3
725
F


IIF-294
1-Npm
i-Bu
(tBOC)Gun-Pr
3.77
675
F


IIF-295
1-Npm
Bnzl
(tBOC)Gun-Pr
3.82
709
F


IIF-296
1-Npm
4-tBuO-Bnzl
(tBOC)Gun-Pr
3.6
725
F


IIF-297
1-Npm
s-Bu
(tBOC)Gun-Pr
4.15
675
F






















TABLE 2-12







IIF-298
1-Npm
1-Npm
(tBOC)Gun-Pr
4.91
759
F


IIF-299
1-Npm
i-Pr
(tBOC)Gun-Pr
3.5
661
F


IIF-300
1-Npm
tBOC-E
Bnzl
3.47
538
F


IIF-301
Bnzl
i-Pr
3-Gun-Pr
1.47
411
F


IIF-302
4-OH-Bnzl
i-Pr
3-Gun-Pr
1.37
427
F


IIF-303
1-Npm
3-Gun-Pr
i-Bu
2.75
475
F


IIF-304
1-Npm
i-Bu
3-Gun-Pr
2.6
475
F


IIF-305
1-Npm
Bnzl
3-Gun-Pr
2.69
509
F


IIF-306
1-Npm
i-Pr
3-Gun-Pr
2.49
461
F


IIF-307
Bnzl
Ph-Et
i-Bu
0.93
430
C


IIF-308
Chm
i-Bu
Bnzl
0.97
422
C


IIF-309
Bnzl
4-F-Bnzl
i-Bu
0.93
434
C


IIF-310
Chm
Bnzl
i-Bu
0.97
422
C


IIF-311
Bnzl
Hxy
i-Bu
1.02
410
C


IIF-312
Ph-Et
i-Bu
i-Bu
0.94
396
C


IIF-313
Ph-Et
i-Bu
1-Npm
1.01
480
C


IIF-314
Bnzl
i-Bu
Ph-Et
0.97
430
C


IIF-315
4-F-Bnzl
i-Bu
Bnzl
0.94
434
C


IIF-316
i-Bu
4-F-Bnzl
Bnzl
0.93
434
C


IIF-317
Ph-Et
Bnzl
i-Bu
0.94
430
C


IIF-318
Bnzl
i-Pnt
i-Bu
0.96
396
C


IIF-319
i-Bu
Hxy
Bnzl
0.98
410
C


IIF-320
4-F-Bnzl
Bnzl
Bnzl
0.94
468
C


IIF-321
Ph-Et
Bnzl
Bnzl
0.96
464
C


IIF-322
Bnzl
i-Bu
i-Pnt
0.97
396
C


IIF-323
4-F-Bnzl
Bnzl
i-Bu
0.94
434
C
















TABLE 2-13







Formula XXIIF




embedded image



















Compound




LCMS
Mass
Measurement


number
R1
R2A
R2B
R3
RT (min)
(M + H)+
condition

















IIF-324
2-Npm
H
Bnzl
i-Bu
2.89
466
 B1


IIF-325
i-Pnt
H
3-Cl-Bnzl
Bnzl
2.85
464
 B1


IIF-326
i-Pnt
H
4-Cl-Bnzl
Bnzl
2.85
464
 B1


IIF-327
i-Pnt
H
4-F-Bnzl
Bnzl
2.73
448
 B1


IIF-328
i-Pnt
H
4-Me-Bnzl
Bnzl
2.83
444
 B1


IIF-329
i-Pnt
H
4-MeO-Bnzl
Bnzl
2.71
460
 B1


IIF-330
i-Bu
H
4-Cl-Bnzl
Ph-Et
2.68
464
 B1


IIF-331
i-Bu
H
3-Cl-Bnzl
Ph-Et
2.85
464
 B1


IIF-332
i-Bu
H
4-MeO-Bnzl
Ph-Et
2.50
460
 B1


IIF-333
i-Bu
H
4-Me-Bnzl
Ph-Et
2.65
444
 B1


IIF-334
i-Bu
H
2-Npm
Ph-Et
2.77
480
 B1


IIF-335
i-Bu
H
Bnzl
Ph-Pr
2.65
444
 B1


IIF-336
i-Bu
H
3-Cl-Bnzl
Ph-Pr
1.27
478
B


IIF-337
i-Bu
H
3-F-Bnzl
Ph-Pr
1.25
462
B


IIF-338
Cpm
H
4-OH-Bnzl
Cbx-E
0.96
440
B


IIF-339
i-Bu
H
3-Me-Bnzl
Ph-Pr
1.26
458
B


IIF-340
i-Bu
H
3-MeO-Bnzl
Ph-Pr
1.25
474
B


IIF-341
i-Bu
H
3-Cl-Bnzl
Ph-Bu
1.30
492
B


IIF-342
i-Bu
H
3-F-Bnzl
Ph-Bu
1.26
476
B


IIF-343
i-Bu
H
3-Me-Bnzl
Ph-Bu
1.29
472
B


IIF-344
i-Bu
H
3-MeO-Bnzl
Ph-Bu
1.26
488
B


IIF-345
i-Bu
H
Bnzl
Ph-Bu
1.25
458
B


IIF-346
i-Pnt
H
3-F-Bnzl
Ph-Pr
1.25
476
B


IIF-347
Hdr-E
H
4-fluorophenethyl
1-Npm
0.9
486
C


IIF-348
1-Npm
H
cyclohexyl
Ph-Et
1.02
506
C


IIF-349
1-Npm
H
cyclopentyl
Ph-Et
0.99
492
C


IIF-350
1-Npm
H
pentyl
Ph-Et
1.01
494
C


IIF-351
1-Npm
H
heptyl
Ph-Et
1.08
522
C


IIF-352
propyl
H
Chm
Bnzl
0.95
408
C


IIF-353
1-Npm
H
hexyl
4-methylphenethyl
1.07
522
C


IIF-354
1-Npm
H
hexyl
2-(naphthalen-2-yl)ethyl
1.10
558
C


IIF-355
1-Npm
H
hexyl
4-isopropylphenethyl
1.12
550
C


IIF-356
1-Npm
H
hexyl
cyclohexylethyl
1.13
514
C


IIF-357
tBuO-E
H
4-fluorophenethyl
1-Npm
1.01
542
C


IIF-358
tBuO-E
H
4-Cl-Bnzl
1-Npm
1.03
545
C


IIF-359
tBuO-E
H
4-Me-Bnzl
1-Npm
1.02
524
C













IIF-360
1-Npm
piperidine
Ph-Et
0.95
492
C






















TABLE 2-14







IIF-361
1-Npm
pyrrolidine
Ph-Et
0.93
478
C














IIF-362
propyl
H
Bnzl
Chm
0.94
408
C


IIF-363
propyl
H
2-methylbenzyl
Bnzl
0.91
416
C


IIF-364
propyl
H
(1,2,3,4-
Bnzl
0.97
456
C





tetrahydronaphthalen-









1-yl)methyl






IIF-365
propyl
H
Cpm
Bnzl
0.92
394
C


IIF-366
propyl
H
Bnzl
Cpm
0.91
394
C


IIF-367
1-Npm
H
Hxy
3-
1.07
522
C






methylphenethyl





IIF-368
4-
H
Bnzl
Bnzl
0.92
495
C



Nt-Bnzl








IIF-369
4-
H
Hxy
Ph-Et
1.01
503
C



Nt-Bnzl








IIF-370
i-Pnt
H
Ph-Et
Bnzl
2.76
444
B1


IIF-371
i-Pnt
H
1-Npm
Bnzl
2.93
480
B1


IIF-372
i-Bu
H
4-F-Bnzl
Ph-Et
2.56
448
B1


IIF-373
i-Bu
H
Ph-Et
Ph-Et
2.60
444
B1


IIF-374
i-Bu
H
1-Npm
Ph-Et
2.79
480
B1


IIF-375
4-F-
H
1-Npm
Bnzl
2.80
518
B1



Bnzl








IIF-376
4-F-
H
1-Npm
i-Bu
1.26
484
B



Bnzl








IIF-377
tBuO-E
H
4-F-Bnzl
1-Npm
1.01
528
C


IIF-378
4-tBuO-
H
Bnzl
Ph-Et
1.01
536
C



Bnzl








IIF-379
tBuO-E
H
Bnzl
1-Npm
1.00
510
C


IIF-380
Chm
H
tBuO-E
1-Npm
1.01
516
C


IIF-381
tBOC-E
H
Bnzl
Ph-Et
0.97
502
C


IIF-382
i-Pnt
H
Bnzl
Ph-Et
0.96
444
C


IIF-383
1-Npm
H
4-F-Bnzl
Hdr-E
0.83
472
C


IIF-384
Hdr-E
H
4-F-Bnzl
1-Npm
0.88
472
C


IIF-385
Cbx-E
H
Bnzl
Ph-Et
0.86
446
C


IIF-386
tBuO-E
H
Ph-Et
1-Npm
1.02
524
C


IIF-387
Ph-Et
H
Hxy
1-Npm
1.06
508
C


IIF-388
Ph-Et
H
i-Bu
TBSO-E
1.09
498
C


IIF-389
Ph-Et
H
i-Bu
Hdr-E
0.77
384
C


IIF-390
Ph-Et
H
i-Bu
i-Pnt
0.96
410
C


IIF-391
Ph-Et
H
i-Bu
4-tBuO-Bnzl
1.02
502
C


IIF-392
Ph-Et
H
i-Bu
4-OH-Bnzl
0.85
446
C


IIF-393
i-Bu
H
i-Bu
4-OH-Bnzl
0.80
398
C


IIF-394
i-Bu
H
Bnzl
4-OH-Bnzl
0.82
432
C


IIF-395
i-Bu
H
2-Cbx-Et
4-OH-Bnzl
0.63
414
C


IIF-396
i-Bu
H
s-Bu
4-OH-Bnzl
0.79
398
C


IIF-397
i-Bu
H
1-Npm
4-OH-Bnzl
0.89
482
C


IIF-398
i-Bu
H
i-Pr
4-OH-Bnzl
0.75
384
C


IIF-399
i-Bu
H
1-Npm
2-Cbx-Et
0.82
448
C


IIF-400
Bnzl
H
4-OH-Bnzl
Bnzl
0.83
466
C


IIF-401
Bnzl
H
i-Bu
4-OH-Bnzl
0.82
432
C


IIF-402
Bnzl
H
2-Cbx-Et
4-OH-Bnzl
0.67
448
C


IIF-403
Bnzl
H
Bnzl
2-Cbx-Et
0.76
432
C


IIF-404
Bnzl
H
4-OH-Bnzl
2-Cbx-Et
0.68
448
C


IIF-405
Bnzl
H
1-Npm
2-Cbx-Et
0.84
482
C


IIF-406
Bnzl
H
4-OH-Bnzl
1-Npm
0.89
516
C


IIF-407
Bnzl
H
2-Cbx-Et
1-Npm
0.83
482
C


IIF-408
4-
H
2-Cbx-Et
Bnzl
0.69
448
C



OH-Bnzl





























TABLE 2-15







IIF-409
4-OH-
H
s-Bu
Bnzl
0.84
432
C



Bnzl








IIF-410
4-OH-
H
1-Npm
Bnzl
0.93
516
C



Bnzl








IIF-411
4-OH-
H
Bnzl
2-Cbx-Et
0.73
448
C



Bnzl








IIF-412
4-OH-
H
1-Npm
2-Cbx-Et
0.81
498
C



Bnzl








IIF-413
4-OH-
H
i-Bu
1-Npm
0.91
482
C



Bnzl








IIF-414
4-OH-
H
Bnzl
1-Npm
0.92
516
C



Bnzl








IIF-415
4-OH-
H
2-Cbx-
1-Npm
0.76
498
C



Bnzl

Et






IIF-416
4-OH-
H
s-Bu
1-Npm
0.91
482
C



Bnzl








IIF-417
4-OH-
H
1-Npm
1-Npm
0.98
566
C



Bnzl








IIF-418
i-Bu
H
4-OH-
Bnzl
0.81
432
C





Bnzl






IIF-419
i-Bu
H
i-Bu
2-Cbx-Et
0.71
364
C


IIF-420
i-Bu
H
Bnzl
2-Cbx-Et
0.73
398
C


IIF-421
i-Bu
H
4-OH-
2-Cbx-Et
0.65
414
C





Bnzl






IIF-422
i-Bu
H
i-Pr
2-Cbx-Et
0.65
350
C


IIF-423
i-Bu
H
4-OH-
1-Npm
0.87
482
C





Bnzl






IIF-424
i-Bu
H
2-Cbx-
1-Npm
0.81
448
C





Et






IIF-425
Bnzl
H
2-Cbx-
Bnzl
0.76
432
C





Et






IIF-426
Bnzl
H
s-Bu
4-OH-Bnzl
0.81
432
C


IIF-427
Bnzl
H
1-Npm
4-OH-Bnzl
0.90
516
C


IIF-428
Bnzl
H
i-Pr
4-OH-Bnzl
0.77
418
C


IIF-429
Bnzl
H
s-Bu
2-Cbx-Et
0.73
398
C


IIF-430
Bnzl
H
i-Pr
2-Cbx-Et
0.69
384
C


IIF-431
4-OH-
H
i-Pr
Bnzl
0.8
418
C



Bnzl








IIF-432
4-OH-
H
i-Pr
2-Cbx-Et
0.65
400
C



Bnzl








IIF-433
4-OH-
H
i-Pr
1-Npm
0.87
468
C



Bnzl








IIF-434
2-Cbx-
H
i-Bu
Bnzl
0.80
398
C



Et








IIF-435
1-Npm
H
4-OH-
Bnzl
0.89
516
C





Bnzl






IIF-436
1-Npm
H
Bnzl
4-OH-Bnzl
0.87
516
C


IIF-437
1-Npm
H
2-Cbx-
4-OH-Bnzl
0.73
498
C





Et






IIF-438
1-Npm
H
s-Bu
4-OH-Bnzl
0.86
482
C


IIF-439
1-Npm
H
1-Npm
4-OH-Bnzl
0.94
566
C


IIF-440
1-Npm
H
i-Pr
4-OH-Bnzl
0.82
468
C


IIF-441
1-Npm
H
Bnzl
2-Cbx-Et
0.81
482
C


IIF-442
1-Npm
H
4-OH-
2-Cbx-Et
0.74
498
C





Bnzl






IIF-443
1-Npm
H
s-Bu
2-Cbx-Et
0.79
448
C


IIF-444
1-Npm
H
1-Npm
2-Cbx-Et
0.88
532
C


IIF-445
1-Npm
H
4-OH-
1-Npm
0.96
566
C





Bnzl






IIF-446
1-Npm
H
2-Cbx-
1-Npm
0.88
532
C





Et






IIF-447
i-Bu
H
4-OH-
i-Bu
0.78
398
C





Bnzl






IIF-448
i-Bu
H
2-Cbx-
i-Bu
0.70
364
C





Et






IIF-449
i-Bu
H
1-Npm
3-Gun-Pr
0.72
475
C


IIF-450
Bnzl
H
i-Bu
2-Cbx-Et
0.73
398
C


IIF-451
2-Cbx-
H
Bnzl
i-Bu
0.80
398
C



Et








IIF-452
2-Cbx-
H
4-OH-
i-Bu
0.70
414
C



Et

Bnzl






IIF-453
2-Cbx-
H
s-Bu
i-Bu
0.78
364
C



Et








IIF-454
2-Cbx-
H
1-Npm
i-Bu
0.88
448
C



Et








IIF-455
2-Cbx-
H
i-Pr
i-Bu
0.74
350
C



Et








IIF-456
2-Cbx-
H
1-Npm
Bnzl
0.88
482
C



Et








IIF-457
2-Cbx-
H
Bnzl
4-OH-Bnzl
0.77
448
C



Et








IIF-458
2-Cbx-
H
1-Npm
4-OH-Bnzl
0.84
498
C



Et























TABLE 2-16







IIF-459
2-Cbx-
H
i-Bu
1-Npm
0.86
448
C



Et








IIF-460
2-Cbx-
H
4-OH
1-Npm
0.77
498
C



Et

Bnzl






IIF-461
2-Cbx-
H
1-Npm
1-Npm
0.94
532
C



Et








IIF-462
2-Cbx-
H
i-Pr
1-Npm
0.82
434
C



Et








IIF-463
1-Npm
H
4-OH-
i-Bu
0.87
482
C





Bnzl






IIF-464
1-Npm
H
i-Bu
4-OH-
0.85
482
C






Bnzl





IIF-465
1-Npm
H
i-Bu
2-Cbx-
0.78
448
C






Et





IIF-466
1-Npm
H
i-Pr
2-Cbx-
0.75
434
C






Et





IIF-467
1-Npm
H
3-Gun-
1-Npm
0.78
559
C





Pr






IIF-468
i-Bu
H
3-Gun-
i-Bu
0.63
391
C





Pr






IIF-469
i-Bu
H
3-Gun-
Bnzl
0.66
425
C





Pr






IIF-470
i-Bu
H
s-Bu
2-Cbx-
0.70
364
C






Et





IIF-471
i-Bu
H
i-Bu
3-Gun-
0.62
391
C






Pr





IIF-472
i-Bu
H
Bnzl
3-Gun-
0.65
425
C






Pr





IIF-473
i-Bu
H
s-Bu
3-Gun-
0.62
391
C






Pr





IIF-474
i-Bu
H
i-Pr
3-Gun-
0.58
377
C






Pr





IIF-475
i-Bu
H
3-Gun-
1-Npm
0.72
475
C





Pr






IIF-476
Bnzl
H
3-Gun-
i-Bu
0.67
425
C





Pr






IIF-477
Bnzl
H
3-Gun-
Bnzl
0.69
459
C





Pr






IIF-478
Bnzl
H
i-Bu
3-Gun-
0.64
425
C






Pr





IIF-479
Bnzl
H
Bnzl
3-Gun-
0.66
459
C






Pr





IIF-480
Bnzl
H
s-Bu
3-Gun-
0.64
425
C






Pr





IIF-481
Bnzl
H
1-Npm
3-Gun-
0.73
509
C






Pr





IIF-482
Bnzl
H
3-Gun-
1-Npm
0.74
509
C





Pr






IIF-483
2-Cbx-
H
i-Bu
i-Bu
0.79
364
C



Et








IIF-484
2-Cbx-
H
Bnzl
Bnzl
0.81
432
C



Et








IIF-485
2-Cbx-
H
4-OH-
Bnzl
0.72
448
C



Et

Bnzl






IIF-486
2-Cbx-
H
s-Bu
Bnzl
0.79
398
C



Et








IIF-487
2-Cbx-
H
i-Pr
Bnzl
0.75
384
C



Et








IIF-488
2-Cbx-
H
i-Bu
4-OH-
0.75
414
C



Et


Bnzl





IIF-489
2-Cbx-
H
i-Pr
4-OH-
0.70
400
C



Et


Bnzl





IIF-490
2-Cbx-
H
Bnzl
1-Npm
0.87
482
C



Et








IIF-491
2-Cbx-
H
s-Bu
1-Npm
0.86
448
C



Et








IIF-492
3-Gun-
H
1-Npm
i-Bu
0.79
475
C



Pr








IIF-493
3-Gun-
H
i-Pr
i-Bu
0.67
377
C



Pr








IIF-494
3-Gun-
H
i-Pr
Bnzl
0.66
411
C



Pr








IIF-495
3-Gun-
H
1-Npm
1-Npm
0.83
559
C



Pr








IIF-496
3-Gun-
H
i-Pr
1-Npm
0.73
461
C



Pr








IIF-497
3-
H
4-F-
1-Npm
1.00
542
C



tert-

Bnzl







butoxy-









propyl








IIF-498
3-
H
4-F-
1-Npm
0.88
486
C



hydroxy-

Bnzl







propyl








IIF-499
3-amino-
H
3-
3-
1.02
751
C



propyl

amino-
amino-








propyl
propyl





IIF-500
1-Npm
H
β-
Ph—Et
0.93
544
C





hydroxy-









phenethyl






IIF-501
1-Npm
H
α-
Ph—Et
0.92
558
C





(hydroxy-









methyl)









phenethyl






IIF-502
1-Npm
H
α-
Ph—Et
0.95
558
C





(hydroxy-









methyl)









phenethyl























TABLE 2-17







IIF-503
4-Nt-
H
Bnzl
tBOC-E
0.93
533
C



Bnzl








IIF-504
2-OH-
H
Ph—Et
1-Npm
0.89
468.3
C



Et








IIF-505
Chm
H
2-
1-Npm
0.86
460.3
C





OH—Et






IIF-506
2-OH—Et
H
Benzl
1-Npm
0.87
454.3
C


IIF-507
Ph—Et
H
1-Npm
Hxy
1.06
508.4
C


IIF-508
1-Npm
H
Ph—Et
Hxy
1.04
508.4
C


IIF-509
Hxy
H
Ph—Et
1-Npm
1.04
508.4
C


IIF-510
Hxy
H
1-Npm
Ph—Et
1.03
508.4
C


IIF-511
i-Pnt
H
i-Pr
i-Bu
3.25
348
F


IIF-512
Chm
H
i-Pr
i-Bu
3.49
374
F


IIF-513
Chm
H
i-Pr
i-Pnt
3.74
388
F


IIF-514
i-Bu
H
s-Bu
i-Pnt
3.55
362
F


IIF-515
i-Pnt
H
s-Bu
i-Bu
3.45
362
F


IIF-516
Chm
H
s-Bu
i-Bu
3.72
388
F


IIF-517
Chm
H
s-Bu
Ph—Et
4
436
F


IIF-518
Chm
H
s-Bu
i-Pnt
4.02
402
F


IIF-519
i-Bu
H
i-Pnt
i-Bu
3.52
362
F


IIF-520
Chm
H
i-Pnt
i-Bu
3.99
402
F


IIF-521
i-Bu
H
Hxy
i-Bu
3.88
376
F


IIF-522
Chm
H
Hxy
i-Bu
4.34
416
F


IIF-523
2-Cbx-
H
Bnzl
i-Pnt
3.3
412
F



Et








IIF-524
Ph—Et
H
Bnzl
2-Cbx-
3.02
446
F






Et





IIF-525
4-F-
H
Bnzl
2-Cbx-
2.85
450
F



Bnzl


Et





IIF-526
2-
H
Bnzl
2-Cbx-
2.45
386
F



OH—Et


Et





IIF-527
i-Pnt
H
Bnzl
2-Cbx-
2.85
412
F






Et





IIF-528
i-Pnt
H
Bnzl
2-
2.84
384
F






OH—Et





IIF-529
Chm
H
Bnzl
2-Cbx-
3
438
F






Et





IIF-530
2-Cbx-
H
i-Bu
Ph—Et
3.17
412
F



Et








IIF-531
2-Cbx-
H
i-Bu
i-Pnt
3.12
378
F



Et








IIF-532
4-F-Bnzl
H
i-Bu
2-Cbx-
2.69
416
F






Et





IIF-533
2-
H
i-Bu
2-Cbx-
3.49
352
G



OH—Et


Et





IIF-534
i-Pnt
H
i-Bu
4-OH-
3.12
412
F






Bnzl





IIF-535
Chm
H
i-Bu
2-Cbx-
2.84
404
F






Et





IIF-536
2-
H
1-Npm
Ph—Et
3.72
496
F



Cbx-









Et








IIF-537
2-Cbx-
H
1-Npm
i-Pnt
3.65
462
F



Et








IIF-538
Ph—Et
H
1-Npm
2-Cbx-
3.47
496
F






Et





IIF-539
4-F-Bnzl
H
1-Npm
2-Cbx-
3.3
500
F






Et





IIF-540
2-
H
1-Npm
2-Cbx-
2.87
436
F



OH—Et


Et





IIF-541
i-Pnt
H
1-Npm
2-Cbx-
3.34
462
F






Et





IIF-542
Chm
H
1-Npm
2-Cbx-
3.4
488
F






Et





IIF-543
4-
H
i-Pr
Ph—Et
3.19
432
F



OH-Bnzl








IIF-544
4-
H
i-Pr
i-Pnt
3.09
398
F



OH-









Bnzl








IIF-545
2-Cbx-
H
i-Pr
Ph—Et
2.92
398
F



Et








IIF-546
2-
H
i-Pr
2-
3.02
338
G



Cbx-Et


OH—Et





IIF-547
Ph—Et
H
i-Pr
2-Cbx-
2.65
398
F






Et





IIF-548
Ph—Et
H
i-Pr
2-
2.62
370
F






OH—Et





IIF-549
4-F-
H
i-Pr
2-Cbx-
2.5
402
F



Bnzl


Et





IIF-550
4-F-
H
i-Pr
2-
2.47
374
F



Bnzl


OH—Et





IIF-551
2-
H
i-Pr
Bnzl
2.69
356
F



OH—Et








IIF-552
2-
H
i-Pr
i-Bu
2.57
322
F



OH—Et























TABLE 2-18







IIF-553
2-
H
I-Pr
1-Npm
3.07
406
F



OH—Et








IIF-554
2-
H
i-Pr
4-
2.45
372
F



OH—Et


OH-Bnzl





IIF-555
2-
H
i-Pr
2-Cbx-
3.12
338
G



OH—Et


Et





IIF-556
2-
H
i-Pr
Ph—Et
2.9
370
F



OH—Et








IIF-557
2-
H
i-Pr
i-Pnt
2.82
336
F



OH—Et








IIF-558
i-Pnt
H
i-Pr
4-
2.88
398
F






OH-









Bnzl





IIF-559
i-Pnt
H
i-Pr
2-Cbx-
2.49
364
F






Et





IIF-560
i-Pnt
H
i-Pr
2-
3.67
336
G






OH—Et





IIF-561
i-Bu
H
s-Bu
2-
3.69
336
G






OH—Et





IIF-562
4-
H
s-Bu
Ph—Et
3.35
446
F



OH-Bnzl








IIF-563
4-
H
s-Bu
i-Pnt
3.2
412
F



OH-Bnzl








IIF-564
2-
H
s-Bu
i-Pnt
3.09
378
F



Cbx-Et








IIF-565
Ph—Et
H
s-Bu
2-Cbx-
2.8
412
F






Et





IIF-566
4-F-
H
s-Bu
2-Cbx-
2.69
416
F



Bnzl


Et





IIF-567
2-
H
s-Bu
4-OH-
2.67
386
F



OH—Et


Bnzl





IIF-568
2-
H
s-Bu
2-Cbx-
3.47
352
G



OH—Et


Et





IIF-569
i-Pnt
H
s-Bu
4-OH-
3.07
412
F






Bnzl





IIF-570
i-Pnt
H
s-Bu
2-Cbx-
2.67
378
F






Et





IIF-571
Chm
H
s-Bu
4-
3.2
438
F






OH-Bnzl





IIF-572
Chm
H
s-Bu
2-Cbx-
2.8
404
F






Et





IIF-573
i-Bu
H
4-
i-Pnt
3.1
412
F





OH-









Bnzl






IIF-574
2-Cbx-
H
4-
Ph—Et
2.77
462
F



Et

OH-









Bnzl






IIF-575
2-Cbx-
H
4-
i-Pnt
2.72
428
F



Et

OH-









Bnzl






IIF-576
Ph—Et
H
4-
2-Cbx-
2.67
462
F





OH-
Et








Bnzl






IIF-577
4-F-Bnzl
H
4-
2-Cbx-
2.55
466
F





OH-
Et








Bnzl






IIF-578
2-OH-Et
H
4-
2-Cbx-
3.2
402
G





OH-
Et








Bnzl






IIF-579
i-Pnt
H
4-
2-Cbx-
2.52
428
F





OH-
Et








Bnzl






IIF-580
Chm
H
4-
2-Cbx-
2.67
454
F





OH-
Et








Bnzl






IIF-581
i-Bu
H
2-
Ph—Et
2.82
412
F





Cbx-









Et






IIF-582
i-Bu
H
2-
i-Pnt
2.72
378
F





Cbx-









Et






IIF-583
i-Pnt
H
2-
i-Bu
2.74
378
F





Cbx-









Et






IIF-584
i-Pnt
H
2-
4-OH-
2.45
428
F





Cbx-
Bnzl








Et






IIF-585
Chm
H
2-
i-Bu
2.94
404
F





Cbx-









Et






IIF-586
Chm
H
2-
i-Pnt
3.17
418
F





Cbx-









Et






IIF-587
Bnzl
H
4-F-
4-OH-
3.25
484
F





Bnzl
Bnzl





IIF-588
Bnzl
H
4-F-
2-Cbx-
2.88
450
F





Bnzl
Et





IIF-589
i-Bu
H
4-F-
4-OH-
3.12
450
F





Bnzl
Bnzl





IIF-590
i-Bu
H
4-F-
2-Cbx-
2.72
416
F





Bnzl
Et





IIF-591
1-Npm
H
4-F-
4-OH-
3.5
534
F





Bnzl
Bnzl





IIF-592
1-Npm
H
4-F-
2-Cbx-
3.13
500
F





Bnzl
Et





IIF-593
4-OH-
H
4-F-
2-Cbx-
2.7
466
F



Bnzl

Bnzl
Et





IIF-594
4-OH-
H
4-F-
Ph—Et
3.5
498
F



Bnzl

Bnzl






IIF-595
4-OH-
H
4-F-
i-Pnt
3.44
464
F



Bnzl

Bnzl






IIF-596
2-Cbx-
H
4-F-
4-OH-
2.9
466
F



Et

Bnzl
Bnzl





IIF-597
2-Cbx-
H
4-F-
Ph—Et
3.32
464
F



Et

Bnzl






IIF-598
2-Cbx-
H
4-F-
i-Pnt
3.25
430
F



Et

Bnzl






IIF-599
Ph—Et
H
4-F-
4-OH-
3.42
498
F





Bnzl
Bnzl





IIF-600
Ph—Et
H
4-F-
2-Cbx-
3.07
464
F





Bnzl
Et





IIF-601
2-OH-
H
4-F-
4-OH-
2.84
438
F



Et

Bnzl
Bnzl





IIF-602
2-OH-
H
4-F-
2-Cbx-
2.52
404
F



Et

Bnzl
Et























TABLE 2-19







IIF-603
i-
H
4-F-
4-OH-
3.27
464
F



Pnt

Bnzl
Bnzl





IIF-604
Chm
H
4-F-
4-OH-
3.37
490
F





Bnzl
Bnzl





IIF-605
Chm
H
4-F-
2-Cbx-
3
456
F





Bnzl
Et





IIF-606
i-Bu
H
i-Pnt
2-Cbx-
2.72
378
F






Et





IIF-607
4-
H
i-Pnt
2-Cbx-
2.72
428
F



OH-


Et






Bnzl








IIF-608
2-Cbx-
H
i-Pnt
i-Bu
3.1
378
F



Et








IIF-609
2-Cbx-
H
i-Pnt
4-OH-
2.94
428
F



Et


Bnzl





IIF-610
2-OH-
H
i-Pnt
i-Bu
3.04
350
F



Et








IIF-611
Chm
H
i-Pnt
2-Cbx-
3.05
418
F






Et





IIF-612
i-Bu
H
2-OH-
i-Bu
2.43
336
F





Et






IIF-613
i-Bu
H
2-OH-
4-OH-
1.34
386
F





Et
Bnzl





IIF-614
i-Bu
H
2-OH-
2-Cbx-
2.57
352
F





Et
Et





IIF-615
1-Npm
H
2-OH-
4-OH-
2.62
470
F





Et
Bnzl





IIF-616
1-Npm
H
2-OH-
2-Cbx-
2.45
436
F





Et
Et





IIF-617
4-OH-
H
2-OH-
Bnzl
2.43
420
F



Bnzl

Et






IIF-618
4-OH-
H
2-OH-
1-Npm
2.74
470
F



Bnzl

Et






IIF-619
4-OH-
H
2-OH-
i-Pnt
2.45
400
F



Bnzl

Et






IIF-620
2-Cbx-
H
2-OH-
Bnzl
3.32
386
F



Et

Et






IIF-621
2-Cbx-
H
2-OH-
4-OH-
2.94
402
G



Et

Et
Bnzl





IIF-622
2-Cbx-
H
2-OH-
i-Pnt
3.42
366
G



Et

Et






IIF-623
Bnzl
H
Ph—Et
4-OH-
3.29
480
F






Bnzl





IIF-624
Bnzl
H
Ph—Et
2-Cbx-
2.9
446
F






Et





IIF-625
i-Bu
H
Ph—Et
4-OH-
3.15
446
F






Bnzl





IIF-626
i-Bu
H
Ph—Et
2-Cbx-
2.77
412
F






Et





IIF-627
1-Npm
H
Ph—Et
4-OH-
3.55
530
F






Bnzl





IIF-628
4-OH-
H
Ph—Et
i-Pnt
3.57
460
F



Bnzl








IIF-629
2-Cbx-
H
Ph—Et
4-OH-
2.95
462
F



Et


Bnzl





IIF-630
4-F-
H
Ph—Et
4-OH-
3.3
498
F



Bnzl


Bnzl





IIF-631
2-OH-
H
Ph—Et
4-OH-
2.88
434
F



Et


Bnzl





IIF-632
i-Pnt
H
Ph—Et
4-OH-
3.37
460
F






Bnzl





IIF-633
i-Pnt
H
Ph—Et
2-Cbx-
2.99
426
F






Et





IIF-634
Chm
H
Ph—Et
4-OH-
3.47
486
F






Bnzl





IIF-635
Chm
H
Ph—Et
2-Cbx-
3.1
452
F






Et





IIF-636
Bnzl
H
Hxy
2-Cbx-
3.15
426
F






Et





IIF-637
4-OH-
H
Hxy
1-Npm
4.15
510
F



Bnzl








IIF-638
4-OH-
H
Hxy
2-Cbx-
3
442
F



Bnzl


Et





IIF-639
2-Cbx-
H
Hxy
i-Bu
3.4
392
F



Et








IIF-640
2-Cbx-
H
Hxy
1-Npm
3.85
476
F



Et








IIF-641
2-Cbx-
H
Hxy
4-OH-
3.22
442
F



Et


Bnzl





IIF-642
2-Cbx-
H
Hxy
i-Pnt
3.65
406
F



Et








IIF-643
Ph—Et
H
Hxy
2-Cbx-
3.37
440
F






Et





IIF-644
4-F-
H
Hxy
2-Cbx-
3.2
444
F



Bnzl


Et





IIF-645
2-
H
Hxy
i-Bu
3.35
364
F



OH—Et








IIF-646
2-
H
Hxy
4-OH-
3.15
414
F



OH—Et


Bnzl





IIF-647
2-
H
Hxy
2-Cbx-
2.79
380
F



OH—Et


Et





IIF-648
2-
H
Hxy
i-Pnt
3.55
378
F



OH—Et








IIF-649
i-Pnt
H
Hxy
4-OH-
3.69
440
F






Bnzl





IIF-650
i-Pnt
H
Hxy
2-Cbx-
3.24
406
F






Et





IIF-651
i-Pnt
H
Hxy
2-
3.24
378
F






OH—Et





IIF-652
Chm
H
Hxy
4-OH-
3.75
466
F






Bnzl























TABLE 2-20







IIF-653
Chm
H
Hxy
2-Cbx-
3.35
432
F






Et





IIF-654
tBOC-
H
Bnzl
i-Pnt
4.09
468
F



E








IIF-655
Ph—Et
H
Bnzl
tBOC-
4.04
502
F






E





IIF-656
4-F-
H
Bnzl
tBOC-
3.8
506
F



Bnzl


E





IIF-657
tBOC-
H
i-Bu
Ph—Et
3.92
468
F



E








IIF-658
4-F-
H
i-Bu
tBOC-
3.7
472
F



Bnzl


E





IIF-659
i-Pnt
H
i-Bu
4-tBuO-
4.39
468
F






Bnzl





IIF-660
Chm
H
i-Bu
4-tBuO-
4.35
494
F






Bnzl





IIF-661
Chm
H
i-Bu
tBOC-
3.94
460
E






E





IIF-662
tBOC-
H
1-Npm
Ph—Et
4.47
552
F



E








IIF-663
tBOC-
H
1-Npm
i-Pnt
4.52
518
F



E








IIF-664
Ph—Et
H
1-Npm
tBOC-
4.39
552
F






E





IIF-665
4-F-
H
1-Npm
tBOC-
4.25
556
F



Bnzl


E





IIF-666
2-
H
1-Npm
tBOC-
4.89
548
F



OtBu-


E






Et








IIF-667
i-Pnt
H
1-Npm
tBOC-
4.35
518
F






E





IIF-668
Chm
H
1-Npm
tBOC-
4.54
544
F






E





IIF-669
4-
H
i-Pr
i-Pnt
4.07
454
F



tBuO-









Bnzl








IIF-670
tBOC-
H
i-Pr
Ph—Et
3.72
454
F



E








IIF-671
2-
H
i-Pr
1-Npm
3.87
462
F



OtBu-









Et








IIF-672
2-
H
i-Pr
4-tBuO-
3.9
484
F



OtBu-


Bnzl






Et








IIF-673
Chm
H
i-Pr
4-tBuO-
4.07
480
F






Bnzl





IIF-674
4-
H
s-Bu
Ph—Et
4.22
502
F



tBuO-









Bnzl








IIF-675
4-
H
s-Bu
i-Pnt
4.07
468
F



tBuO-









Bnzl








IIF-676
tBOC-
H
s-Bu
i-Pnt
3.82
434
F



E








IFF-677
Ph—Et
H
s-Bu
tBOC-
3.84
468
F






E





IIF-678
4-F-
H
s-Bu
tBOC-
3.95
472
F



Bnzl


E





IIF-679
2-
H
s-Bu
tBOC-
3.7
464
F



OtBu-


E






Et








IIF-680
i-Pnt
H
s-Bu
4-tBuO-
4.12
468
F






Bnzl





IIF-681
i-Pnt
H
s-Bu
tBOC-
3.7
434
F






E





IIF-682
Chm
H
s-Bu
4-tBuO-
4.35
494
F






Bnzl





IIF-683
i-Bu
H
4-
i-Pnt
4.07
468
F





tBuO-









Bnzl






IIF-684
tBOC-
H
4-
Ph—Et
4.52
574
F



E

tBuO-









Bnzl






IIF-685
tBOC-
H
4-
i-Pnt
4.42
540
F



E

tBuO-









Bnzl






IIF-686
Ph—Et
H
4-
tBOC-
4.52
574
F





tBuO-
E








Bnzl






IIF-687
4-F-
H
4-
tBOC-
4.22
578
F



Bnzl

tBuO-
E








Bnzl






IIF-688
Chm
H
4-
tBOC-
4.54
566
F





tBuO-
E








Bnzl






IIF-689
i-Bu
H
tBOC-
i-Pnt
3.7
434
F





E






IIF-690
Bnzl
H
4-F-
4-tBuO-
4.17
540
F





Bnzl
Bnzl





IIF-691
i-Bu
H
4-F-
4-tBuO-
3.99
506
F





Bnzl
Bnzl





IIF-692
i-Bu
H
4-F-
tBOC-
3.67
472
F





Bnzl
E





IIF-693
1-Npm
H
4-F-
4-tBuO-
4.59
590
F





Bnzl
Bnzl





IIF-694
1-Npm
H
4-F-
tBOC-
4.17
556
F





Bnzl
E





IIF-695
4-
H
4-F-
tBOC-
4.34
578
F



tBuO-

Bnzl
E






Bnzl








IIF-696
4-
H
4-F-
Ph—Et
4.75
554
F



tBuO-

Bnzl







Bnzl








IIF-697
4-
H
4-F-
i-Pnt
4.42
520
F



tBuO-

Bnzl







Bnzl








IIF-698
tBOC-
H
4-F-
4-tBuO-
4.39
578
F



E

Bnzl
Bnzl





IIF-699
tBOC-
H
4-F-
i-Pnt
4.09
486
F



E

Bnzl






IIF-700
Ph—Et
H
4-F-
4-tBuO-
4.34
554
F





Bnzl
Bnzl





IIF-701
2-
H
4-F-
4-tBuO-
4.32
550
F



OtBu-

Bnzl
Bnzl






Et























TABLE 2-21







IIF-703
Chm
H
4-F-
4-tBuO-
4.39
546
F





Bnzl
Bnzl





IIF-704
Chm
H
4-F-
tBOC-
4.05
512
F





Bnzl
E





IIF-705
4-
H
i-Pnt
tBOC-
4.32
540
F



tBuO-


E






Bnzl








IIF-706
tBOC-
H
i-Pnt
4-tBuO-
4.54
540
F



E


Bnzl





IIF-707
i-Bu
H
2-
4-tBuO-
3.87
498
F





OtBu-
Bnzl








Et






IIF-708
1-Npm
H
2-
4-tBuO-
4.47
582
F





OtBu-
Bnzl








Et






IIF-709
1-Npm
H
2-
tBOC-
4
548
F





OtBu-
E








Et






IIF-710
4-
H
2-
Bnzl
4.02
532
F



tBuO-

OtBu-







Bnzl

Et






IIF-711
4-
H
2-
i-Pnt
4.25
512
F



tBuO-

OtBu-







Bnzl

Et






IIF-712
tBOC-
H
2-
Bnzl
3.67
498
F



E

OtBu-









Et






IIF-713
tBOC-
H
2-
4-tBuO-
4.17
570
F



E

OtBu-
Bnzl








Et






IIF-714
Bnzl
H
Ph—Et
4-tBuO-
4.25
536
F






Bnzl





IIF-715
i-Bu
H
Ph—Et
4-tBuO-
4.1
502
F






Bnzl





IIF-716
1-Npm
H
Ph—Et
4-tBuO-
4.59
586
F






Bnzl





IIF-717
1-Npm
H
Ph—Et
tBOC-
4.2
552
F






E





IIF-718
4-F-
H
Ph—Et
4-tBuO-
4.29
554
F



Bnzl


Bnzl





IIF-719
2-
H
Ph—Et
4-tBuO-
4.39
546
F



OtBu-


Bnzl






Et








IIF-720
i-Pnt
H
Ph—Et
4-tBuO-
4.37
516
F






Bnzl





IIF-721
Chm
H
Ph—Et
4-tBuO-
4.54
542
F


IIF-722
Chm
H
Ph—Et
tBOC-
4.05
508
F






E





IIF-723
4-
H
Hxy
1-Npm
5.09
566
F



tBuO-









Bnzl








IIF-724
4-
H
Hxy
tBOC-
4.74
554
F



tBuO-


E






Bnzl








IIF-725
tBOC-
H
Hxy
4-tBuO-
4.8
554
F



E


Bnzl





IIF-726
Ph—Et
H
Hxy
tBOC-
4.45
496
F






E





IIF-727
4-F-
H
Hxy
tBOC-
4.27
500
F



Bnzl


E





IIF-728
2-
H
Hxy
4-tBuO-
4.79
526
F



OtBu-


Bnzl






Et








IIF-729
2-
H
Hxy
i-Pnt
4.42
434
F



OtBu-









Et








IIF-730
i-Pnt
H
Hxy
4-tBuO-
4.74
496
F






Bnzl





IIF-731
Chm
H
Hxy
4-tBuO-
4.87
522
F






Bnzl





IIF-732
i-Bu
H
i-Bu
Ph—Et
3.11
396
H


IIF-733
i-Bu
H
i-Bu
i-Pnt
2.96
362
H


IIF-734
1-Npm
H
i-Bu
i-Pnt
3.25
446
H


IIF-735
4-F-
H
i-Bu
i-Bu
2.88
400
H



Bnzl








IIF-736
4-F-
H
i-Bu
1-Npm
3.12
484
H



Bnzl








IIF-737
4-F-
H
i-Bu
Ph—Et
2.98
448
H



Bnzl








IIF-738
4-F-
H
i-Bu
i-Pnt
2.98
414
H



Bnzl








IIF-739
i-Pnt
H
i-Bu
i-Bu
2.92
362
H


IIF-740
i-Pnt
H
i-Bu
1-Npm
3.17
446
H


IIF-741
i-Pnt
H
i-Bu
Ph—Et
2.99
410
H


IIF-742
Chm
H
i-Bu
i-Bu
2.99
388
H


IIF-743
Chm
H
i-Bu
1-Npm
3.31
472
H


IIF-744
Chm
H
i-Bu
Ph—Et
3.1
436
H


IIF-745
Chm
H
i-Bu
i-Pnt
3.13
402
H


IIF-746
Bnzl
H
Bnzl
Ph—Et
3.22
464
H


IIF-747
1-Npm
H
Bnzl
i-Pnt
3.17
480
H


IIF-748
Ph—Et
H
Bnzl
1-Npm
3.27
514
H


IIF-749
Ph—Et
H
Bnzl
i-Pnt
3.12
444
H


IIF-750
4-F-
H
Bnzl
1-Npm
3.19
518
H



Bnzl








IIF-751
4-F-
H
Bnzl
Ph—Et
3.02
482
H



Bnzl








IIF-752
4-F-
H
Bnzl
i-Pnt
3.05
448
H



Bnzl























TABLE 2-22







IIF-753
i-Pnt
H
Bnzl
1-Npm
3.2
480
H


IIF-754
Chm
H
Bnzl
1-Npm
3.3
506
H


IIF-755
Chm
H
Bnzl
Ph—Et
3.12
470
H


IIF-756
Chm
H
Bnzl
i-Pnt
3.15
436
H


IIF-757
Bnzl
H
1-Npm
Ph—Et
3.22
514
H


IIF-758
Bnzl
H
1-Npm
i-Pnt
3.27
480
H


IIF-759
i-Bu
H
1-Npm
i-Pnt
3.13
446
H


IIF-760
1-Npm
H
1-Npm
Ph—Et
3.34
564
H


IIF-761
1-Npm
H
1-Npm
i-Pnt
3.38
530
H


IIF-762
Ph—Et
H
1-Npm
Bnzl
3.27
514
H


IIF-763
Ph—Et
H
1-Npm
i-Bu
3.22
480
H


IIF-764
Ph—Et
H
1-Npm
1-Npm
3.42
564
H


IIF-765
Ph—Et
H
1-Npm
i-Pnt
3.32
494
H


IIF-766
4-F-
H
1-Npm
1-Npm
3.36
568
H



Bnzl








IIF-767
4-F-
H
1-Npm
Ph—Et
3.22
532
H



Bnzl








IIF-768
4-F-
H
1-Npm
i-Pnt
3.24
498
H



Bnzl








IIF-769
i-Pnt
H
1-Npm
i-Bu
3.22
446
H


IIF-770
i-Pnt
H
1-Npm
1-Npm
3.39
530
H


IIF-771
i-Pnt
H
1-Npm
Ph—Et
3.27
494
H


IIF-772
Chm
H
1-Npm
Bnzl
3.38
506
H


IIF-773
Chm
H
1-Npm
i-Bu
3.3
472
H


IIF-774
Chm
H
1-Npm
1-Npm
3.49
556
H


IIF-775
Chm
H
1-Npm
Ph—Et
3.36
520
H


IIF-776
Chm
H
1-Npm
i-Pnt
3.38
486
H


IIF-777
Bnzl
H
i-Pr
Ph—Et
3
416
H


IIF-778
Bnzl
H
i-Pr
i-Pnt
3.01
382
H


IIF-779
i-Bu
H
i-Pr
Ph—Et
2.93
382
H


IIF-780
1-Npm
H
i-Pr
Ph—Et
3.14
466
H


IIF-781
1-Npm
H
i-Pr
i-Pnt
3.17
432
H


IIF-782
Ph—Et
H
i-Pr
Bnzl
2.99
416
H


IIF-783
Ph—Et
H
i-Pr
i-Bu
2.95
382
H


IIF-784
Ph—Et
H
i-Pr
1-Npm
3.22
466
H


IIF-785
Ph—Et
H
i-Pr
i-Pnt
3.08
396
H


IIF-786
4-F-
H
i-Pr
Bnzl
2.92
420
H



Bnzl








IIF-787
4-F-
H
i-Pr
i-Bu
2.92
386
H



Bnzl








IIF-788
4-F-
H
i-Pr
1-Npm
3.14
470
H



Bnzl








IIF-789
4-F-
H
i-Pr
Ph—Et
2.98
434
H



Bnzl








IIF-790
4-F-
H
i-Pr
i-Pnt
2.97
400
H



Bnzl








IIF-791
i-Pnt
H
i-Pr
Bnzl
2.91
382
H


IIF-792
i-Pnt
H
i-Pr
1-Npm
3.16
432
H


IIF-793
i-Pnt
H
i-Pr
Ph—Et
3.02
396
H


IIF-794
Chm
H
i-Pr
Bnzl
3.05
408
H


IIF-795
Chm
H
i-Pr
1-Npm
3.28
458
H


IIF-796
Chm
H
i-Pr
Ph—Et
3.09
422
H


IIF-797
Bnzl
H
s-Bu
Ph—Et
3.07
430
H


IIF-798
Bnzl
H
s-Bu
i-Pnt
3.07
396
H


IIF-799
i-Bu
H
s-Bu
Ph—Et
3
396
H


IIF-800
1-Npm
H
s-Bu
Ph—Et
3.21
480
H


IIF-801
1-Npm
H
s-Bu
i-Pnt
3.22
446
H


IIF-802
Ph—Et
H
s-Bu
Bnzl
3.09
430
H























TABLE 2-23







IIF-803
Ph—Et
H
s-Bu
i-Bu
3.05
396
H


IIF-804
Ph—Et
H
s-Bu
1-Npm
3.28
480
H


IIF-805
Ph—Et
H
s-Bu
i-Pnt
3.17
410
H


IIF-806
4-F-
H
s-Bu
Bnzl
3.07
434
H



Bnzl








IIF-807
4-F-
H
s-Bu
i-Bu
2.97
400
H



Bnzl








IIF-808
4-F-
H
s-Bu
1-Npm
3.22
484
H



Bnzl








IIF-809
4-F-
H
s-Bu
Ph—Et
3.06
448
H



Bnzl








IIF-810
4-F-
H
s-Bu
i-Pnt
3.1
414
H



Bnzl








IIF-811
i-Pnt
H
s-Bu
Bnzl
3.05
396
H


IIF-812
i-Pnt
H
s-Bu
1-Npm
3.25
446
H


IIF-813
Chm
H
s-Bu
Bnzl
3.15
422
H


IIF-814
Chm
H
s-Bu
1-Npm
3.34
472
H


IIF-815
Bnzl
H
Ph—Et
Bnzl
3.07
464
H


IIF-816
Bnzl
H
Ph—Et
1-Npm
3.31
514
H


IIF-817
Bnzl
H
Ph—Et
i-Pnt
3.15
444
H


IIF-818
i-Bu
H
Ph—Et
i-Bu
2.96
396
H


IIF-819
i-Bu
H
Ph—Et
1-Npm
3.22
480
H


IIF-820
i-Bu
H
Ph—Et
i-Pnt
4.26
410
H


IIF-821
1-Npm
H
Ph—Et
Bnzl
3.29
514
H


IIF-822
1-Npm
H
Ph—Et
i-Bu
3.26
480
H


IIF-823
1-Npm
H
Ph—Et
1-Npm
3.42
564
H


IIF-824
4-F-
H
Ph—Et
Bnzl
3.08
482
H



Bnzol








IIF-825
4-F-
H
Ph—Et
i-Bu
3.04
448
H



Bnzl








IIF-826
4-F-
H
Ph—Et
1-Npm
3.24
532
H



Bnzl








IIF-827
4-F-
H
Ph—Et
i-Pnt
3.13
462
H



Bnzl








IIF-828
i-Pnt
H
Ph—Et
i-Bu
3.07
410
H


IIF-829
i-Pnt
H
Ph—Et
1-Npm
3.28
494
H


IIF-830
Chm
H
Ph—Et
Bnzl
3.19
470
H


IIF-831
Chm
H
Ph—Et
i-Bu
3.12
436
H


IIF-832
Chm
H
Ph—Et
1-Npm
3.34
520
H


IIF-833
Chm
H
Ph—Et
i-Pnt
3.24
450
H


IIF-834
Bnzl
H
4-F-
Bnzl
3.03
468
H





Bnzl






IIF-835
Bnzl
H
4-F-
1-Npm
3.19
518
H





Bnzl






IIF-836
Bnzl
H
4-F-
Ph—Et
3.06
482
H





Bnzl






IIF-837
Bnzl
H
4-F-
i-Pnt
3.08
448
H





Bnzl






IIF-838
i-Bu
H
4-F-
i-Bu
2.92
400
H





Bnzl






IIF-839
i-Bu
H
4-F-
1-Npm
3.16
484
H





Bnzl






IIF-840
i-Bu
H
4-F-
i-Pnt
3.03
414
H





Bnzl






IIF-841
1-Npm
H
4-F-
Bnzl
3.31
518
H





Bnzl






IIF-842
1-Npm
H
4-F-
i-Bu
3.23
484
H





Bnzl






IIF-843
1-Npm
H
4-F-
1-Npm
3.47
568
H





Bnzl






IIF-844
1-Npm
H
4-F-
Ph—Et
3.29
532
H





Bnzl






IIF-845
1-Npm
H
4-F-
i-Pnt
3.31
498
H





Bnzl






IIF-846
Ph—Et
H
4-F-
Bnzl
3.16
482
H





Bnzl






IIF-847
Ph—Et
H
4-F-
i-Bu
3.11
448
H





Bnzl






IIF-848
Ph—Et
H
4-F-
1-Npm
3.31
532
H





Bnzl






IIF-849
Ph—Et
H
4-F-
i-Pnt
3.2
462
H





Bnzl






IIF-850
i-Pnt
H
4-F-
Bnzl
3.05
448
H





Bnzl






IIF-851
i-Pnt
H
4-F-
1-Npm
3.21
498
H





Bnzl






IIF-852
i-Pnt
H
4-F-
Ph—Et
3.13
462
H





Bnzl























TABLE 2-24







IIF-853
Chm
H
4-F-
Bnzl
3.12
474
H





Bnzl






IIF-854
Chm
H
4-F-
i-Bu
3.09
440
H





Bnzl






IIF-855
Chm
H
4-F-
1-Npm
3.3
524
H





Bnzl






IIF-856
Chm
H
4-F-
Ph—Et
3.21
488
H





Bnzl






IIF-857
Chm
H
4-F-
i-Pnt
3.17
454
H





Bnzl






IIF-858
Bnzl
H
i-Pnt
Bnzl
3.08
430
H


IIF-859
Bnzl
H
i-Pnt
1-Npm
3.28
480
H


IIF-860
Bnzl
H
i-Pnt
Ph—Et
3.12
444
H


IIF-861
i-Bu
H
i-Pnt
1-Npm
3.23
446
H


IIF-862
i-Bu
H
i-Pnt
Ph—Et
3.11
410
H


IIF-863
1-Npm
H
i-Pnt
Bnzl
3.25
480
H


IIF-864
1-Npm
H
i-Pnt
i-Bu
3.22
446
H


IIF-865
1-Npm
H
i-Pnt
1-Npm
3.42
530
H


IIF-866
Ph—Et
H
i-Pnt
Bnzl
3.16
444
H


IIF-867
Ph—Et
H
i-Pnt
i-Bu
3.13
410
H


IIF-868
Ph—Et
H
i-Pnt
1-Npm
3.33
494
H


IIF-869
4-F-
H
i-Pnt
Bnzl
3.09
448
H



Bnzl








IIF-870
4-F-
H
i-Pnt
i-Bu
3.05
414
H



Bnzl








IIF-871
4-F-
H
i-Pnt
1-Npm
3.29
498
H



Bnzl








IIF-872
4-F-
H
i-Pnt
Ph—Et
3.13
462
H



Bnzl








IIF-873
Chm
H
i-Pnt
Bnzl
3.23
436
H


IIF-874
Chm
H
i-Pnt
1-Npm
3.42
486
H


IIF-875
Chm
H
i-Pnt
Ph—Et
3.25
450
H


IIF-876
Bnzl
H
Hxy
Bnzl
3.24
444
H


IIF-877
Bnzl
H
Hxy
1-Npm
3.39
494
H


IIF-878
Bnzl
H
Hxy
i-Pnt
3.27
424
H


IIF-879
i-Bu
H
Hxy
1-Npm
3.36
460
H


IIF-880
1-Npm
H
Hxy
1-Npm
3.54
544
H


IIF-881
1-Npm
H
Hxy
i-Pnt
3.43
474
H


IIF-882
Ph—Et
H
Hxy
Bnzl
3.3
458
H


IIF-883
Ph—Et
H
Hxy
i-Bu
3.24
424
H


IIF-884
Ph—Et
H
Hxy
i-Pnt
3.35
438
H


IIF-885
4-F-
H
Hxy
Bnzl
3.23
462
H



Bnzl








IIF-886
4-F-
H
Hxy
i-Bu
3.17
428
H



Bnzl








IIF-887
4-F-
H
Hxy
1-Npm
3.4
512
H



Bnzl








IIF-888
4-F-
H
Hxy
Ph—Et
3.24
476
H



Bnzyl








IIF-889
4-F-
H
Hxy
i-Pnt
3.28
442
H



Bnzl








IIF-890
i-Pnt
H
Hxy
Bnzl
3.26
424
H


IIF-891
i-Pnt
H
Hxy
1-Npm
3.47
474
H


IIF-892
Chm
H
Hxy
Bnzl
3.34
450
H


IIF-893
Chm
H
Hxy
1-Npm
3.5
500
H


IIF-894
2-
H
i-Bu
Bnzl
4.15
426
H



OtBu-









Et








IIF-895
2-
H
i-Bu
i-Bu
4.18
392
H



OtBu-









Et








IIF-896
2-
H
i-Bu
1-Npm
4.31
476
H



OtBu-









Et








IIF-897
2-
H
i-Bu
4-
4.37
498
H



OtBu-


tBuO-






Et


Bnzl





IIF-898
2-
H
i-Bu
Ph—Et
4.18
440
H



OtBu-









Et








IIF-899
2-
H
i-Bu
i-Pnt
4.28
406
H



OtBu-









Et








IIF-900
2-
H
Bnzl
Bnzl
4.2
460
H



OtBu-









Et








IIF-901
2-
H
Bnzl
i-Bu
4.17
426
H



OtBu-









Et








IIF-902
2-
H
Bnzl
4-
4.32
532
H



OtBu-


tBuO-






Et


Bnzl























TABLE 2-25







IIF-903
2-
H
Bnzl
Ph—Et
4.29
474
H



OtBu-









Et








IIF-904
2-
H
Bnzl
i-Pnt
4.27
440
H



OtBu-









Et








IIF-905
i-Pnt
H
Bnzl
4-tBuO-Bnzl
3.26
502
H


IIF-906
Chm
H
Bnzl
4-tBuO-Bnzl
3.32
528
H


IIF-907
4-
H
1-Npm
Ph—Et
3.42
586
H



tBuO-









Bnzl








IIF-908
4-
H
1-Npm
i-Pnt
3.42
552
H



tBuO-









Bnzl








IIF-909
Ph—Et
H
1-Npm
4-tBuO-Bnzl
3.4
586
H


IIF-910
4-F-
H
1-Npm
4-tBuO-Bnzl
3.4
590
H



Bnzl








IIF-911
2-
H
1-Npm
Bnzl
4.38
510
H



OtBu-









Et








IIF-912
2-
H
1-Npm
i-Bu
4.35
476
H



OtBu-









Et








IIF-913
2-
H
1-Npm
1-Npm
4.5
560
H



OtBu-









Et








IIF-914
i-Pnt
H
1-Npm
4-tBuO-Bnzl
3.43
552
H


IIF-915
Chm
H
1-Npm
4-tBuO-Bnzl
3.5
578
H


IIF-916
Bnzl
H
4-tBuO-
Ph—Et
3.31
536
H





Bnzl






IIF-917
Bnzl
H
4-tBuO-
i-Pnt
3.29
502
H





Bnzl






IIF-918
i-Bu
H
4-tBuO-
Ph—Et
3.22
502
H





Bnzl






IIF-919
1-Npm
H
4-tBuO-
Ph—Et
3.41
586
H





Bnzl






IIF-920
1-Npm
H
4-tBuO-
i-Pnt
3.41
552
H





Bnzl






IIF-921
Ph—Et
H
4-tBuO-
Bnzl
3.32
536
H





Bnzl






IIF-922
Ph—Et
H
4-tBuO-
1-Npm
3.43
586
H





Bnzl






IIF-923
Ph—Et
H
4-tBuO-
i-Pnt
3.37
516
H





Bnzl






IIF-924
4-F-
H
4-tBuO-
Bnzl
3.22
540
H



Bnzl

Bnzl






IIF-925
4-F-
H
4-tBuO-
1-Npm
3.38
590
H



Bnzl

Bnzl






IIF-926
4-F-
H
4-tBuO-
Ph—Et
3.28
554
H



Bnzl

Bnzl






IIF-927
4-F-
H
4-tBuO-
i-Pnt
3.29
520
H



Bnzl

Bnzl






IIF-928
2-
H
4-tBuO-
1-Npm
3.46
582
H



OtBu-

Bnzl







Et








IIF-929
i-Pnt
H
4-tBuO-
i-Bu
3.2
468
H





Bnzl






IIF-930
i-Pnt
H
4-tBuO-
1-Npm
3.42
552
H





Bnzl






IIF-931
i-Pnt
H
4-tBuO-
Ph—Et
3.33
516
H





Bnzl






IIF-932
Chm
H
4-tBuO-
Bnzl
3.33
528
H





Bnzl






IIF-933
Chm
H
4-tBuO-
i-Bu
3.24
494
H





Bnzl






IIF-934
Chm
H
4-tBuO-
1-Npm
3.5
578
H





Bnzl






IIF-935
Chm
H
4-tBuO-
Ph—Et
3.41
542
H





Bnzl






IIF-936
Chm
H
4-tBuO-
i-Pnt
3.42
508
H





Bnzl






IIF-937
Bnzl
H
tBOC-E
Ph—Et
3.08
502
H


IIF-938
Bnzl
H
tBOC-E
i-Pnt
3.08
468
H


IIF-939
1-Npm
H
tBOC-E
Ph—Et
3.25
552
H


IIF-940
1-Npm
H
tBOC-E
i-Pnt
3.26
518
H


IIF-941
4-
H
tBOC-E
Ph—Et
3.32
574
H



tBuO-









Bnzl








IIF-942
4-
H
tBOC-E
i-Pnt
3.34
540
H



tBuO-









Bnzl








IIF-943
Ph—Et
H
tBOC-E
Bnzl
3.08
502
H


IIF-944
Ph—Et
H
tBOC-E
i-Bu
3.12
468
H


IIF-945
Ph—Et
H
tBOC-E
1-Npm
3.27
552
H


IIF-946
Ph—Et
H
tBOC-E
4-tBuO-Bnzl
3.33
574
H


IIF-947
Ph—Et
H
tBOC-E
i-Pnt
3.18
482
H


IIF-948
4-F-
H
tBOC-E
Bnzl
3.06
506
H



Bnzl








IIF-949
4-F-
H
tBOC-E
i-Bu
3.04
472
H



Bnzl








IIF-950
4-F-
H
tBOC-E
1-Npm
3.23
556
H



Bnzl








IIF-951
4-F-
H
tBOC-E
4-tBuO-Bnzl
3.27
578
H



Bnzl








IIF-952
4-F-
H
tBOC-E
Ph—Et
3.12
520
H



Bnzl























TABLE 2-26







IIF-953 
4-F-
H
tBOC-E
i-Pnt
3.13
486
H



Bnzl








IIF-954 
2-
H
tBOC-E
Bnzl
3.11
498
H



OtBu-









Et








IIF-955 
2-
H
tBOC-E
1-Npm
3.27
548
H



OtBu-









Et








IIF-956 
2-
H
tBOC-E
4-tBuO-Bnzl
3.37
570
H



OtBu-









Et








IIF-957 
2-
H
tBOC-E
Ph—Et
3.17
512
H



OtBu-









Et








IIF-958 
i-Pnt
H
tBOC-E
Bnzl
3.08
468
H


IIF-959 
i-Pnt
H
tBOC-E
1-Npm
3.22
518
H


IIF-960 
i-Pnt
H
tBOC-E
Ph—Et
3.13
482
H


IIF-961 
Chm
H
tBOC-E
Bnzl
3.17
494
H


IIF-962 
Chm
H
tBOC-E
1-Npm
3.34
544
H


IIF-963 
Ph—Et
H
i-Pr
4-tBuO-Bnzl
3.22
488
H


IIF-964 
4-F-
H
i-Pr
4-tBuO-Bnzl
3.16
492
H



Bnzl








IIF-965 
Ph—Et
H
s-Bu
4-tBuO-Bnzl
3.29
502
H


IIF-966 
4-F-
H
s-Bu
4-tBuO-Bnzl
3.29
506
H



Bnzl








IIF-967 
2-
H
s-Bu
Bnzl
3.04
426
H



OtBu-









Et








IIF-968 
2-
H
s-Bu
i-Bu
3.03
392
H



OtBu-









Et








IIF-969 
2-
H
s-Bu
1-Npm
3.3
476
H



OtBu-









Et








IIF-970 
2-
H
s-Bu
Ph—Et
3.15
440
H



OtBu-









Et








IIF-971 
4-
H
Ph—Et
Bnzl
3.33
536
H



tBuO-









Bnzl








IIF-972 
4-
H
Ph—Et
i-Bu
3.25
502
H



tBuO-









Bnzl








IIF-973 
4-
H
Ph—Et
1-Npm
3.47
586
H



tBuO-









Bnzl








IIF-974 
tBOC-
H
Ph—Et
Bnzl
3.16
502
H



E








IIF-975 
tBOC-
H
Ph—Et
i-Bu
3.13
468
H



E








IIF-976 
tBOC-
H
Ph—Et
1-Npm
3.35
552
H



E








IIF-977 
2-
H
Ph—Et
Bnzl
3.1
474
H



OtBu-









Et








IIF-978 
2-
H
Ph—Et
i-Bu
3.08
440
H



OtBu-









Et








IIF-979 
2-
H
Ph—Et
i-Pnt
3.17
454
H



OtBu-









Et








IIF-980 
4-
H
4-F-Bnzl
Bnzl
3.35
540
H



tBuO-









Bnzl








IIF-981 
4-
H
4-F-Bnzl
i-Bu
3.28
506
H



tBuO-









Bnzl








IIF-982 
4-
H
4-F-Bnzl
1-Npm
3.47
590
H



tBuO-









Bnzl








IIF-983 
tBOC-
H
4-F-Bnzl
Bnzl
3.14
506
H



E








IIF-984 
tBOC-
H
4-F-Bnzl
i-Bu
3.11
472
H



E








IIF-985 
tBOC-
H
4-F-Bnzl
1-Npm
3.32
556
H



E








IIF-986 
2-
H
4-F-Bnzl
i-Bu
3.03
444
H



OtBu-









Et








IIF-987 
2-
H
4-F-Bnzl
Ph—Et
3.13
492
H



OtBu-









Et








IIF-988 
2-
H
4-F-Bnzl
i-Pnt
3.13
458
H



OtBu-









Et








IIF-989 
Bnzl
H
2-OtBu-
Bnzl
4.08
460
H





Et






IIF-990 
Bnzl
H
2-OtBu-
i-Bu
4.07
426
H





Et






IIF-991 
Bnzl
H
2-OtBu-
1-Npm
4.26
510
H





Et






IIF-992 
Bnzl
H
2-OtBu-
Ph—Et
4.17
474
H





Et






IIF-993 
Bnzl
H
2-OtBu-
i-Pnt
4.15
440
H





Et






IIF-994 
i-Bu
H
2-OtBu-
Bnzl
4.12
426
H





Et






IIF-995 
i-Bu
H
2-OtBu-
1-Npm
4.29
476
H





Et






IIF-996 
i-Bu
H
2-OtBu-
Ph—Et
4.16
440
H





Et






IIF-997 
1-Npm
H
2-OtBu-
i-Bu
4.22
476
H





Et






IIF-998 
1-Npm
H
2-OtBu-
i-Pnt
4.33
490
H





Et






IIF-999 
4-
H
2-OtBu-
i-Bu
4.3
498
H



tBuO-

Et







Bnzl








IIF-1000
Ph—Et
H
2-OtBu-
Bnzl
4.2
474
H





Et






IIF-1001
Ph—Et
H
2-OtBu-
i-Bu
4.17
440
H





Et






IIF-1002
Ph—Et
H
2-OtBu-
1-Npm
4.35
524
H





Et























TABLE 2-27







IIF-1003
Ph—Et
H
2-OtBu-
4-tBuO-Bnzl
4.36
546
H





Et






IIF-1004
Ph—Et
H
2-OtBu-
i-Pnt
4.28
454
H





Et






IIF-1005
4-F-
H
2-OtBu-
Bnzl
4.17
478
H



Bnzl

Et






IIF-1006
4-F-
H
2-OtBu-
i-Bu
4.05
444
H



Bnzl

Et






IIF-1007
4-F-
H
2-OtBu-
1-Npm
4.3
528
H



Bnzl

Et






IIF-1008
4-F-
H
2-OtBu-
4-tBuO-Bnzl
4.35
550
H



Bnzl

Et






IIF-1009
4-F-
H
2-OtBu-
Ph—Et
4.18
492
H



Bnzl

Et






IIF-1010
4-F-
H
2-OtBu-
i-Pnt
4.18
458
H



Bnzl

Et






IIF-1011
i-Pnt
H
2-OtBu-
Bnzl
4.15
440
H





Et






IIF-1012
i-Pnt
H
2-OtBu-
1-Npm
4.32
490
H





Et






IIF-1013
i-Pnt
H
2-OtBu-
4-tBuO-Bnzl
4.36
512
H





Et






IIF-1014
i-Pnt
H
2-OtBu-
Ph—Et
4.26
454
H





Et






IIF-1015
Chm
H
2-OtBu-
Bnzl
4.25
466
H





Et






IIF-1016
Chm
H
2-OtBu-
4-tBuO-Bnzl
4.41
538
H





Et






IIF-1017
Chm
H
2-OtBu-
Ph—Et
4.28
480
H





Et






IIF-1018
Bnzl
H
i-Pnt
4-tBuO-Bnzl
3.27
502
H


IIF-1019
Bnzl
H
i-Pnt
tBOC-E
3.08
468
H


IIF-1020
1-Npm
H
i-Pnt
4-tBuO-Bnzl
3.46
552
H


IIF-1021
1-Npm
H
i-Pnt
tBOC-E
3.25
518
H


IIF-1022
4-
H
i-Pnt
Bnzl
3.32
502
H



tBuO-









Bnzl








IIF-1023
4-
H
i-Pnt
i-Bu
3.3
468
H



tBuO-









Bnzl








IIF-1024
4-
H
i-Pnt
1-Npm
3.53
552
H



tBuO-









Bnzl








IIF-1025
4-
H
i-Pnt
Ph—Et
3.37
516
H



tBuO-









Bnzl








IIF-1026
tBOC-
H
i-Pnt
Bnzl
3.18
468
H



E








IIF-1027
tBOC-
H
i-Pnt
1-Npm
3.38
518
H



E








IIF-1028
tBOC-
H
i-Pnt
Ph—Et
3.22
482
H



E








IIF-1029
Ph—Et
H
i-Pnt
4-tBuO-Bnzl
3.39
516
H


IIF-1030
Ph—Et
H
i-Pnt
tBOC-E
3.22
482
H


IIF-1031
4-F-
H
i-Pnt
4-tBuO-Bnzl
3.29
520
H



Bnzl








IIF-1032
4-F-
H
i-Pnt
tBOC-E
2.35
486
H



Bnzl








IIF-1033
Chm
H
i-Pnt
4-tBuO-Bnzl
2.62
508
H


IIF-1034
Bnzl
H
Hxy
4-tBuO-Bnzl
2.63
516
H


IIF-1035
i-Bu
H
Hxy
4-tBuO-Bnzl
2.55
482
H


IIF-1036
1-Npm
H
Hxy
4-tBuO-Bnzl
2.88
566
H


IIF-1037
4-
H
Hxy
Bnzl
2.63
516
H



tBuO-









Bnzl








IIF-1038
4-
H
Hxy
i-Bu
2.6
482
H



tBuO-









Bnzl








IIF-1039
4-
H
Hxy
Ph—Et
2.67
530
H



tBuO-









Bnzl








IIF-1040
4-
H
Hxy
i-Pnt
2.7
496
H



tBuO-









Bnzl








IIF-1041
tBOC-
H
Hxy
Ph—Et
2.55
496
H



E








IIF-1042
Ph—Et
H
Hxy
4-tBuO-Bnzl
2.68
530
H


IIF-1043
4-F-
H
Hxy
4-tBuO-Bnzl
2.63
534
H



Bnzl








IIF-1044
2-
H
Hxy
Bnzl
2.47
454
H



OtBu—Et








IIF-1045
2-
H
Hxy
1-Npm
2.63
504
H



OtBu—Et








IIF-1046
2-
H
Hxy
Ph—Et
2.5
468
H



OtBu—Et








IIF-1047
1-Npm
H
4-F-Bnzl
2-OTBS—Et
1.11
586.4
C






Ring formed together by R2A and R2B



















TABLE 2-28





Compound

LCMS tR
Mass
Measurement
Yield


number
Name of compound
(min)
(M + H)+
condition
(%)




















IIF-1 
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
1.14
416
B
10



dibenzyl-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-2 
(3S*,3aR*,6S*,7R*,7aR*)-N,1,7-
1.11
348
B
16



triisobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-3 
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
1.14
382
B
14



N,1-diisobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-4 
(3S*,3aR*,6S*,7R*,7aR*)-1-benzyl-
1.14
382
B
8



N,7-diisobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-5 
(3S*,3aR*,6S*,7R*,7aR*)-N-benzyl-
1.13
382
B
13



1,7-diisobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-6 
(3S*,3aR*,6S*,7R*,7aR*)-1,7-
1.15
416
B
19



dibenzyl-N-isobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-7 
(3S*,3aR*,6S*,7R*,7aR*)-N,1-
1.00
416
B
22



dibenzyl-7-isobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-8 
(3S*,3aR*,6S*,7R*,7aR*)-N,1,7-
1.16
450
B
21



tribenzyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-9 
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
1.18
430
B
20



dibenzyl-1-isopentyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-10
(3S*,3aR*,6S*,7R*,7aR*)-N,1-
1.18
430
B
11



dibenzyl-7-isopentyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide





















TABLE 2-29







IIF-11
(3S*,3aR*,6S*,7R*,7aR*)-N-benzyl-
1.16
430
B
12



1-isobutyl-7-phenethyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-12
(3S*,3aR*,6S*,7R*,7aR*)-1-benzyl-
1.16
430
B
12



7-isobutyl-N-phenethyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-13
(3S*,3aR*,6S*,7R*,7aR*)-N-benzyl-
1.17
430
B
17



1-isobutyl-7-(3-methylbenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-14
(3S*,3aR*,6S*,7R*,7aR*)-N-benzyl-
1.16
430
B
15



1-isobutyl-7-(4-methylbenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-15
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
1.18
430
B
16



1-isobutyl-N-(3-methylbenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-16
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
1.18
430
B
15



1-isobutyl-N-(4-methylbenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-17
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
1.18
450
B
14



N-(3-chlorobenzyl)-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-18
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
1.17
450
B
13



N-(4-chlorobenzyl)-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-19
(3S*,3aR*,6S*,7R*,7aR*)-N-benzyl-
1.28
484
B
22



1-(3,4-dichlorobenzyl)-7-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-20
(3S*,3aR*,6S*,7R*,7aR*)-1-benzyl-
1.25
484
B
21



N-(3,4-dichlorobenzyl)-7-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-23
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
0.99
488
A
33



1-isobutyl-N-(4-(tert-butoxy)benzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-24
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
0.98
466
A
14



1-isobutyl-N-(naphthalen-1-ylmethyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-25
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
0.74
370
A
5



N-(2-hydroxyethyl)-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-26
3-(3S*,3aR*,6S*,7R*,7aR*)-7-
0.75
398
A
100



benzyl-1-isobutyl-1,2,3,3a,7,7a-







hexahydro-1H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide)propanoic acid






IIF-27
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
0.92
454
A
20



1-isobutyl-N-(2-(tert-butoxy)-2-







oxoethyl)-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-28
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-
0.72
397
A
88



N-(3-amino-3-oxopropyl)-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-29
(3S*,3aR*,6S*,7R*,7aR*)-N-(4-
0.67
397
A
100



aminobutyl)-7-benzyl-1-isobutyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide





















TABLE 2-30







IIF-30
(3S*,3aR*,6S*,7R*,7aR*)-7-
0.91
497
A
10



benzyl-1-isobutyl-N-(4-((tert-







butoxycarbonyl)amino)butyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-31
(3S*,3aR*,6S*,7R*,7aR*)-7-
0.98
422
A
12



benzyl-N-cyclohexylmethyl-1-







isobutyl-1,2,3,3a,7,7a-hexahydro-







6H-3,6-methanopyrrolo[3,2-







c]pyridine-6-carboxamide






IIF-32
(3S*,3aR*,6S*,7R*,7aR*)-7-
0.87
424
A
24



benzyl-1-isobutyl-N-((tetrahydro-







2H-pyran-2-yl)methyl)-







1,2,3,3a,7,7a-hexahydro-6H-







3,6-methanopyrrolo[3,2-







c]pyridine-6-carboxamide






IIF-34
(3S*,3aR*,6S*,7R*,7aR*)-
0.93
497
A
17



N-benzyl-1-isobutyl-7-(4-((tert-







butoxycarbonyl)amino)butyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-36
(3S*,3aR*,6S*,7R*,7aR*)-
0.82
412
A
5



N-benzyl-1-isobutyl-7-(3-







methoxy-3-oxopropyl)-







1,2,3,3a,7,7a-hexahydro-6H-







3,6-methanopyrrolo[3,2-







c]pyridine-6-carboxamide






IIF-38
(3S*,3aR*,6S*,7R*,7aR*)-
0.99
422
A
23



N-benzyl-7-(cyclohexylmethyl)-







1-isobutyl-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-39
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
0.96
456
A
22



dibenzyl-1-cyclohexylmethyl-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-40
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
0.86
466
A
76



dibenzyl-1-(4-hydroxybenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-41
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
1.00
522
A
14



dibenzyl-1-(4-(tert-







butoxy)benzyl)-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-42
(3S*,3aR*,6S*,7R*,7aR*)-N,7-
0.97
500
A
4



dibenzyl-1-(naphthalen-1-







ylmethyl)-1,2,3,3a,7,7a-







hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IIF-76
tert-butyl 3-
0.70
488
B
22



(3S*,3aR*,6S*,7R*,7aR*)-7-







benzyl-6-(benzylcarbamoyl)-







2,3,3a,6,7,7a-hexahydro-1H-3,6-







methanopyrrolo[3,2-c]pyridin-1-







yl)propanoate






IIF-77
(3S*,3aR*,6S*,7R*,7aR*)-N,1-
0.80
466
B
19



dibenzyl-7-(4-hydroxybenzyl)-







1,2,3,3a,7,7a-hexahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IIF-80
(3S*,3aR*,6S*,7R*,7aR*)-N-
1.01
452
A
6



benzyl-1-(naphthalen-1-ylmethyl)-







7-propyl-1,2,3,3a,7,7a-hexahydro-







6H-3,6-methanopyrrolo[3,2-







c]pyridine-6-carboxamide









Synthesis Example: IF-1
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide(IF-1)

Sodium tetrahydroborate (1.86 mg, 0.0490 mmol) was added to a methanol (0.500 mL) solution of (3S*,3aR*,6S*,7R*,7aR*)—N,7-dibenzyl-1-isobutyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-1) (10.2 mg, 0.0245 mmol) and stirred for 1 hour. After evaporating the solvent under reduced pressure, 5% sodium bicarbonate solution (1.00 mL) was added to the residue, which was extracted with ethyl acetate (3.00 mL). The organic layer was washed with water (1.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (6.37 mg, yield: 62%, RT=0.99 minutes (B method), [M+1]+=418).



1H-NMR spectrum (400 MHz, CDCl3) δ (ppm): 0.52 (3H, d), 0.58 (3H, d), 0.89-0.97 (1H, m), 1.57-1.62 (1H, m), 1.83-1.94 (3H, m), 2.01-2.07 (1H, m), 2.18-2.24 (2H, m), 2.29 (1H, d), 2.40-2.44 (1H, m), 2.71-2.75 (2H, m), 2.86-2.89 (1H, m), 3.10-3.19 (2H, m), 4.39-4.48 (2H, m), 7.24-7.38 (11H, m). 13C-NMR spectrum (100 MHz, CDCl3) δ (ppm): 20.20, 26.99, 33.45, 35.79, 36.41, 39.83, 42.13, 42.79, 46.40, 56.95, 61.37, 61.78, 61.97, 125.50, 126.96, 127.39, 127.73, 128.25, 129.41, 138.20, 139.59, 175.20.


The three-dimensional structure of the molecules was studied by X-ray crystallography. FIG. 1 shows an ORTEP diagram thereof. Daicel Corporation's chiral column, CHIRALPAK IG (5 μm, 4.6×150 mm), mobile phase: methanol: diethylamine (100:0.1) was used to confirm that the molecule was a racemate through analysis. FIG. 2 shows the chromatogram thereof.


Synthesis Example: IB-1
Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1)

Sodium tetrahydroborate (3.83 mg, 0.101 mmol) was added to a methanol (1.00 mL) solution of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-1) (21.0 mg, 0.0506 mmol) and stirred for 1 hour. After evaporating the solvent under reduced pressure, 5% sodium bicarbonate solution (1.00 mL) was added to the residue, which was extracted with ethyl acetate (4.00 mL). The organic layer was washed with water (1.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=90:10) to obtain the aforementioned compound (17.0 mg, yield: 81%, RT=1.21 minutes (B method), [M+1]+=418).



1H-NMR spectrum (400 MHz, CDCl3) δ (ppm): 0.48 (3H, d), 0.57 (3H, d), 1.18-1.28 (1H, m), 1.35-1.39 (1H, m), 1.55 (1H, s), 1.83-1.88 (1H, m), 2.09-2.14 (3H, m), 2.24-2.28 (1H, m), 2.45 (1H, s), 2.70-2.75 (1H, m), 2.78-2.88 (1H, m), 2.97 (1H, s), 3.20-3.27 (1H, m), 3.28-3.31 (1H, m), 4.28-4.33 (1H, m), 4.48-4.53 (1H, m), 7.21-7.27 (1H, m), 9.56 (1H, t).



13C-NMR spectrum (400 MHz, CDCl3) δ (ppm): 20.20, 20.37, 25.84, 26.43, 38.09, 38.60, 39.25, 42.99, 58.19, 61.48, 62.33, 66.49, 125.58, 126.77, 127.49, 127.93, 128.07, 128.70, 138.22, 140.32, 173.83.


Synthesis Example: IB-29
Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N-(4-aminobutyl)-7-benzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-29)

Formic acid (500 μL) was added to (3S*, 3aS*, 6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl) octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-30) (7.70 mg, 0.0154 mmol) and incubated overnight at room temperature. The formic acid was evaporated under reduced pressure to obtain a triformic acid salt of the aforementioned compound (7.60 mg, yield: 92%, RT=0.75 minutes (A method), [M+1]+=399).


Synthesis Example: IB-40
Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-(4-hydroxybenzyl)octahydro-3aH-3,6-methanopyrrolo[ 3,2-b]pyridine-3a-carboxamide (IB-40)

Formic acid (250 μL) was added to (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-(4-(tert-butoxy)benzyl) octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-41) (7.80 mg, 0.0149 mmol) and incubated for 3 hours at room temperature. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (6.30 mg, yield: 99%, RT=0.89 minutes (A method), [M+1]+=468).


Synthesis Example: IB-74
Synthesis of tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*k)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-methoxy-3-oxopropyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-74)

(3S*, 3aS*, 6R*, 7R*, 7aS*)—N-benzyl-1-isobutyl-7-(3-methoxy-3-oxopropyl)octahydro-3aH-3,6-methanopyrrolo[ 3,2-b]pyridine-3a-carboxamide (IB-36) (23.5 mg, 0.0570 mmol) was dissolved in tetrahydrofuran (0.400 mL), and a 30% tetrahydrofuran solution (140 μL, 0.140 mmol) of di-tert-butyl dicarbonate was added and heated for 2 hours at 50° C. The solvent was evaporated under reduced pressure. The resulting residue was purified by preparative PLC (Merck 1.05744.0001 (layer thickness 0.500 mm) (ethyl acetate:methanol=9:1)) to obtain the aforementioned compound (22.0 mg, yield: 75%, RT=0.97 minutes (A method), [M+1]+=514).


Synthesis Example: IB-73
Synthesis of tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl) octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73)

tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-methoxy-3-oxopropyl) octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-74) (22.0 mg, 0.0430 mmol) was dissolved in methanol (1.00 mL), and lithium hydroxide monohydrate (18.0 mg, 0.430 mmol) was added and stirred overnight at room temperature. Methanol was evaporated under reduced pressure. 10% citric acid solvent (450 μL) and ethyl acetate were added thereto. The organic layer was dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the aforementioned compound (21.40 mg, yield: 100%, RT=0.91 minutes (A method), [M+1]+=500).


Synthesis Example: IB-75
Synthesis of tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-amino-3-oxopropyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-75)

tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73) (6.9 mg, 0.0130 mmol) was dissolved in tetrahydrofuran (0.200 mL), and carbonyldiimidazole (4.2 mg, 0.0260 mmol) was added and stirred overnight at room temperature. Ammonium water (13 M) (20.0 μL, 0.260 mmol) was added thereto and stirred for 1 hour. The solvent was evaporated. The resulting residue was purified by preparative PLC (Fuji Silysia Chemical's CHROMATOREX NH-TLC (layer thickness 0.200 mm) (ethyl acetate)) to obtain the aforementioned compound (1.70 mg, yield: 26%, RT=0.86 minutes (A method), [M+1]+=499).


Synthesis Example: IB-79
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N3a,7-dibenzyl-1-(cyclohexylmethyl)-N4-propylhexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridine-3a,4-dicarboxamide (IB-79)

(3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-cyclohexylmethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-39) (4.6 mg, 0.0100 mmol) was dissolved in tetrahydrofuran (0.180 mL), then triethylamine (1.6 μL, 0.0120 mmol) and propylisocyanate (1.13 μL, 0.120 mmol) were added and incubated for 1 hour at room temperature. The reaction mixture was purified with preparative PLC silica gel 60F254 (layer thickness 0.250 mm) (ethyl acetate:methanol=5:1) to obtain the aforementioned compound (3.50 mg, yield: 65%, RT=1.05 minutes (A method), [M+1]+=543).


Synthesis of 3-((3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyloctahydro-1H-3,6-methanopyrrolo[3,2-b]pyridin-7-yl)propanoic Acid (IB-35)

Trifluoroacetic acid (200 μL) was added to tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73) (5.50 mg, 0.0110 mmol) and incubated overnight at room temperature. Trifluoroacetic acid was evaporated under reduced pressure to obtain a ditrifluoroacetic acid salt of the aforementioned compound (6.80 mg, yield: 100%, RT=0.83 minutes (A method), [M+1]+=400).


Synthesis Example: IF-26
Synthesis of ((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyloctahydro-1H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide)propanoic Acid (IF-26)

Formic acid (0.500 mL) was added to (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(2-(tert-butoxy)-2-oxoethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-27) (15.0 mg, 0.0330 mmol) and heated overnight at 45° C. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (16.2 mg, yield: 100%, RT=0.66 minutes (A method), [M+1]+=400).


Synthesis Example: IF-33
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-7-(4-aminobutyl)-N-benzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-33)

Trifluoroacetic acid (200 μL) was added to (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(4-((tert-butoxycarbonyl)amino)butyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-34) (7.80 mg, 0.0156 mmol) and incubated overnight at room temperature. The trifluoroacetic acid was evaporated under reduced pressure to obtain a tritrifluoroacetic acid salt of the aforementioned compound (7.80 mg, yield: 100%, RT=0.62 minutes (A method), [M+1]+=399).


Synthesis Example: IF-41
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-(tert-butoxy)benzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-41)

9.50 mg of 10% palladium-carbon was added to a methanol (0.500 mL) solution of (3S*, 3aR*, 6S*, 7R*, 7aR*)—N, 7-dibenzyl-1-(4-(tert-butoxy)benzyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-41) (11 mg, 0.0210 mmol) and stirred for a week under a hydrogen gas atmosphere. After filtering out the palladium-carbon, the solution was concentrated. The residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=5:1) to obtain the aforementioned compound (5.70 mg, yield: 52%, RT=0.90 minutes (A method), [M+1]+=524).


Synthesis Example: IF-40
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-hydroxybenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-40)

Formic acid (250 μL) was added to (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-(tert-butoxy)benzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-41) (5.70 mg, 10.9 mmol) and incubated for 3 hours at room temperature. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (3.20 mg, yield: 52%, RT=0.75 minutes (A method), [M+1]+=468).


Synthesis Example: IF-71
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-4-methyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-71)

A 37% formalin solution (0.06 mL, 0.736 mmol) was added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-1) (30.8 mg, 0.0736 mmol) and stirred for 15 minutes at room temperature. Sodium triacetoxyborohydride (46.8 mg, 0.221 mmol) was added to the reaction mixture, and stirred for 1 hour at room temperature. An aqueous 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (12.1 mg, yield: 38%, RT=1.02 minutes (B method), [M+1]+=432).


Synthesis Example: IF-43
Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-43)

Triethylamine (0.0156 mL, 1.13 mmol) and acetyl chloride (0.00804 mL, 1.13 mmol) were added to a tetrahydrofuran (1.80 mL) solution of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-1) (31.4 mg, 0.0751 mmol), and stirred for 30 minutes while cooling with ice. A 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (17.6 mg, yield: 51%, RT=1.08 minutes (B method),[M+1]+=460).


Synthesis Example: IB-68
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-4-benzoyl-N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-68)

Triethylamine (0.0152 mL, 0.110 mmol) and benzoyl chloride (0.0127 mL, 1.10 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (30.6 mg, 0.0733 mmol) and stirred for 30 minutes while cooling with ice. An aqueous 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and an organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (14.8 mg, yield: 39%, RT=1.23 minutes (B method), [M+1]+=522).


Synthesis Example: IB-69
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-4-ethyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-69)

An acetaldehyde 2% N,N-dimethylformamide solution (0.870 mL, 0.395 mmol) was added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (33.0 mg, 0.790 mmol) and stirred for 15 minutes at room temperature. Sodium triacetoxyborohydride (50.2 mg, 0.273 mmol) was added to the reaction mixture, and further stirred for 2 hours at room temperature. An aqueous 5% sodium bicarbonate solution (10.0 mL) was added to the reaction mixture, and an organic phase was extracted with ethyl acetate (30.0 mL). The organic layer was washed twice with water (10.0 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (9.85 mg, yield: 28%, RT=1.24 minutes (B method), [M+1]+=446).


Synthesis Example: IB-70
Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-4-(methoxycarbonyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-70)

Triethylamine (0.0157 mL, 0.113 mmol) and chloroformic acid methyl (0.00870 mL, 0.113 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (31.5 mg, 0.0754 mmol), and stirred for 30 minutes while cooling with ice. After stirring for 30 minutes at room temperature, a 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (31.0 mg, yield: 87%, RT=1.18 minutes (B method), [M+1]+=476).


The following compounds were synthesized by the same method as the Synthesis Examples.


Compounds with a guanidinopropyl group in one of the substituents R1, R2, and R3 were synthesized by the following method. Representative examples are provided below.


Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-164) and (3S*,3aS*,6S*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-162)

1. Synthesis of tert-butyl (3S*,3aR*,6S*,7R*,7aS*)-(3-(7-isobutyl-3a-((naphthalen-1-ylmethyl)carbamoyl)-2,3,3a, 6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridin-yl)propyl) carbamate and tert-butyl (3S*, 3aR*, 6S*, 7R*, 7aR*)-(3-(7-isobutyl-6-(naphthalen-1-ylmethyl) carbamoyl)-2,3,3a, 6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-c]pyridin-1-yl)propyl)carbamate


N, N-dimethylformamide (1 mL) was added to 4-methylpentanal (60.1 mg, 0.6 mmol), tert-butyl (3-(allylamino)propyl)carbamate (128.6 mg, 0.6 mmol), and molecular sieve 4A (100 mg), and then N-(naphthalen-1-ylmethyl)-1,2,4-triazine-3-carboxamide (79.3 mg, 0.3 mmol) was added. The reaction mixture was heated for 16 hours at 85° C., and then filtered. The filtrate was purified by preparative HPLC (High Performance Liquid Chromatography). A fraction of the substance of interest was concentrated to obtain a mixture of the aforementioned compound.


2. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-aminopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*, 3aR*, 6S*, 7R*, 7aR*)-1-(3-aminopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,3a, 7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide


Trifluoroacetic acid (0.3 mL) was added to the compound (mixture) obtained in 1. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound (mixture).


3. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*, 3aR*, 6S*, 7R*, 7aR*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide


1,3-di(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine (234.8 mg, 0.6 mmol), triethylamine (60.7 mg, 0.6 mmol), and tetrahydrofuran (0.5 mL) were added to the compound (mixture) obtained in 2. and stirred for 3 hours at room temperature. The solvent was evaporated to obtain a mixture comprising the aforementioned compound. The mixture obtained in this step was used in synthesis of the next step without purification.


4. Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aS*,6S*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide


The reaction mixture obtained in 3. was dissolved in methanol (1 mL), then sodium borohydride (22.7 mg, 0.6 mmol) was added and stirred for 2 hours at room temperature. The reaction mixture was purified by preparative HPLC. Fractions of substances of interest were concentrated to obtain each of the aforementioned compounds separately.


5. Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide


Trifluoroacetic acid (0.3 mL) was added to (3S*,3aS*,6S*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide obtained in 4. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound.


6. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide


A trifluoroacetic acid salt of the aforementioned compound was obtained by the same method as 5. by using (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide obtained in 4.


Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aR*,6S*,7R*,7aR*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6H-carboxamide

Chloroform (1 mL) was added to N-phenethyl prop-2-en-1-amine (58.4 mg, 0.4 mmol), 4-((tert-butyldimethylsilyl)oxy)butanal (80.0 mg, 0.4 mmol), and molecular sieve 4A (400 mg), and then N-benzyl-1,2,4-triazine-3-carboxamide (43.8 mg, 0.2 mmol) and chloroform (1 mL) were further added. The reaction mixture was heated for 48 hours at 55° C. and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative TLC (Merck 1.13895.001, layer thickness 1 mm) (ethyl acetate:methanol=9:1) to obtain a mixture of the aforementioned compound (73.3 mg, yield 69%, RT=1.08 minutes, 1.12 minutes (C method), [M+1]+=532).


Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

The mixture obtained in the above reaction (73.3 mg) was dissolved in methanol (1.5 mL), and sodium borohydride (9 mg, 0.24 mmol) was added and stirred for 12 hours at room temperature. Ethyl acetate was added to the reaction mixture, which was washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate. The anhydrous sodium sulfate was filtered out. The filtrate was concentrated under reduced pressure and purified by preparative TLC (Merck 1.13895.001, layer thickness 1 mm) (ethyl acetate:methanol=4:1) to obtain (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (47.6 mg, two-step yield of 43%, RT=1.13 minutes (C method), [M+1]+=534) and (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (20.6 mg, two-step yield of 19%, RT=0.95 minutes (C method), [M+1]+=534).


Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-hydroxyethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3aH-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-a-carboxamide (46.7 mg, 0.087 mmol) was dissolved in tetrahydrofuran (1 mL), and tetrabutylammonium fluoride (approximately 1 mol/L tetrahydrofuran solution, 0.1 mL) was added and stirred overnight at room temperature. The reaction mixture was concentrated and ethyl acetate was added, and then transferred to a separatory funnel and washed with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by preparative TLC (Merck 1.05744.001, layer thickness 0.5 mm) (ethyl acetate:methanol=4:1) to obtain the aforementioned compound (35 mg, yield of 96%, RT=0.85 minutes (C method), [M+1]+=420).


Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-hydroxyethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6H-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (20.6 mg, 0.039 mmol) was dissolved in tetrahydrofuran (0.5 mL), and tetrabutylammonium fluoride (approximately 1 mol/L tetrahydrofuran solution, 0.05 mL) was added and stirred overnight at room temperature. The reaction mixture was concentrated, ethyl acetate was added and transferred to a separatory funnel, and washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by preparative TLC (Merck 105744.001, layer thickness 0.5 mm) (ethyl acetate:methanol=4:1) to obtain the aforementioned compound (16 mg, yield of 91%, RT=0.72 minutes (C method), [M+1]+=420).


Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,4,7-tribenzyl-1-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (compound IB-42, 5 mg, 0.01 mmol) was dissolved in tetrahydrofuran (0.2 mL), then benzaldehyde (2.1 mg, 0.02 mmol), trifluoroacetic acid (3.4 mg, 0.03 mmol), and molecular sieve 4A (40 mg) were added and heated for 18 hours at 50° C. Sodium triacetoxyborohydride (5 mg, 0.024 mmol) was added to the reaction mixture and stirred for 5 hours at room temperature. To the reaction mixture, ethyl acetate and saturated sodium bicarbonate water are added. The organic phase was washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by TLC (Merck 105715.001, layer thickness 0.25 mm) (hexane:ethyl acetate=2:1) to obtain the aforementioned compound (1.2 mg, yield of 20%, RT=1.14 minutes (C method), [M+1]+=592).


Tables 3 and 4 summarize the synthesized compounds of formula IB and compounds of IF. In the following tables, “EX” means that the synthesis method is described in the Examples.









TABLE 3-1









embedded image


















Compound




Synthesis



number
R1
R2
R3
R4
method
Intermediate





IB-1
i-Bu
Bnzl
Bnzl
H
EX
IIB-1


IB-2
i-Bu
i-Bu
i-Bu
H
IB-1
IIB-2


IB-3
i-Bu
i-Bu
Bnzl
H
IB-1
IIB-3


IB-4
Bnzl
i-Bu
i-Bu
H
IB-1
IIB-4


IB-5
i-Bu
Bnzl
i-Bu
H
IB-1
IIB-5


IB-6
Bnzl
i-Bu
Bnzl
H
IB-1
IIB-6


IB-7
Bnzl
Bnzl
i-Bu
H
IB-1
IIB-7


IB-8
Bnzl
Bnzl
Bnzl
H
IB-1
IIB-8


IB-9
i-Pnt
Bnzl
Bnzl
H
IB-1
IIB-9


IB-10
Bnzl
Bnzl
i-Pnt
H
IB-1
IIB-10


IB-11
i-Bu
Bnzl
Ph-Et
H
IB-1
IIB-11


IB-12
i-Bu
Ph-Et
Bnzl
H
IB-1
IIB-12


IB-13
i-Bu
Bnzl
3-Me-Bnzl
H
IB-1
IIB-13


IB-14
i-Bu
Bnzl
4-Me-Bnzl
H
IB-1
IIB-14


IB-15
i-Bu
3-Me-Bnzl
Bnzl
H
IB-1
IIB-15


IB-16
i-Bu
4-Me-Bnzl
Bnzl
H
IB-1
IIB-16


IB-17
i-Bu
3-Cl-Bnzl
Bnzl
H
IB-1
IIB-17


IB-18
i-Bu
4-Cl-Bnzl
Bnzl
H
IB-1
IIB-18


IB-19
3,4-Cl2-Bnzl
Bnzl
i-Bu
H
IB-1
IIB-19


IB-20
Bnzl
3,4-Cl2-Bnzl
i-Bu
H
IB-1
IIB-20


IB-21
Me
Np-E
Bnzl
H
IB-1
IIB-21


IB-22
i-Bu
4-OH-Bnzl
Bnzl
H
IB-40
IB-23


IB-23
i-Bu
4-(tert-butoxy)benzyl
Bnzl
H
IB-1
IIB-23


IB-24
i-Bu
Np-M
Bnzl
H
IB-1
IIB-24


IB-25
i-Bu
Hdr-E
Bnzl
H
IB-1
IIB-25


IB-26
i-Bu
Cbx-E
Bnzl
H
IF-26
IB-27


IB-27
i-Bu
2-(tert-butoxy)-2-oxoethyl
Bnzl
H
IB-1
IIB-27


IB-28
i-Bu
Cbm-E
Bnzl
H
IB-1
IIB-28


IB-29
i-Bu
4-aminobutyl
Bnzl
H
EX
IB-30


IB-30
i-Bu
4-((tert-butoxycarbonyl)amino)butyl
Bnzl
H
IB-1
IIB-30


IB-31
i-Bu
Chm
Bnzl
H
IB-1
IIB-31






















TABLE 3-2







IB-32
i-Bu
(tetrahydro-
Bnzl
H
IB-1 
IIB-32




2H-








pyran-








2-yl)








methyl






IB-33
i-Bu
Bnzl
4-
H
IF-33
IB-34





aminobutyl





IB-34
i-Bu
Bnzl
4-
H
IB-1 
IIB-34





((tert-








butoxy-








carbonyl)








amino)








butyl





IB-35
i-Bu
Bnzl
Cbx-E
H
EX
IB-73


IB-36
i-Bu
Bnzl
3-
H
IB-1 
IIB-36





methoxy-








3-








oxopropyl





IB-37
i-Bu
Bnzl
Cbm-E
H
IF-33
IB-75


IB-38
i-Bu
Bnzl
Chm
H
IB-1 
IIB-38


IB-39
Chm
Bnzl
Bnzl
H
IB-1 
IIB-39


IB-40
4-OH-
Bnzl
Bnzl
H
EX
IB-41



Bnzl







IB-41
4-
Bnzl
Bnzl
H
IB-1 
IIB-41



(tert-








butoxy)








benzyl







IB-42
Np-M
Bnzl
Bnzl
H
IB-1 
IIB-42


IB-43
i-Bu
Bnzl
Bnzl
Ac
IE-43
IB-1 


IB-44
i-Bu
i-Bu
i-Bu
Ac
IF-43
IB-2 


IB-45
i-Bu
i-Bu
Bnzl
Ac
IF-43
IB-3 


IB-46
Bnzl
i-Bu
i-Bu
Ac
IF-43
IB-4 


IB-47
i-Bu
Bnzl
i-Bu
Ac
IF-43
IB-5 


IB-49
Bnzl
Bnzl
i-Bu
Ac
IF-43
IB-7 


IB-50
Bnzl
Bnzl
Bnzl
Ac
IF-43
IB-8 


IB-54
i-Bu
Ph—Et
Bnzl
Ac
IF-43
IB-12


IB-57
i-Bu
3-Me-Bnzl
Bnzl
Ac
IF-43
IB-15


IB-58
i-Bu
4-Me-Bnzl
Bnzl
Ac
IF-43
IB-16


IB-64
Me
Np-E
Bnzl
Ac
IF-43
IB-21


IB-68
i-Bu
Bnzl
Bnzl
Bz
EX
IB-1 


IB-69
i-Bu
Bnzl
Bnzl
Et
EX
IB-1 


IB-70
i-Bu
Bnzl
Bnzl
methoxy-
EX
IB-1 






carbonyl




IB-71
i-Bu
Bnzl
Bnzl
Me
IF-71
IB-1 


IB-72
Me
Np-E
Bnzl
Et
IB-69
IB-21


IB-73
i-Bu
Bnzl
Cbx-E
tBOC
EX
IB-74


IB-74
i-Bu
Bnzl
3-
tBOC
EX
IB-36





methoxy-








3-








oxopropyl





IB-75
i-Bu
Bnzl
Cbm-E
tBOC
EX
IB-73


IB-76
3-
Bnzl
Bnzl
H
IB-1 
IIB-76



(tert-








butoxy)-








3-








oxopropyl







IB-77
Bnzl
Bnzl
4-OH-Bnzl
H
IB-1 
IIB-77


IB-78
Me
2-(1-
Bnzl
H
IB-1 
IIB-78




(tert-








butoxy-








carbonyl)-








1H-indol-








3-yl)








ethyl






IB-79
Chm
Bnzl
Bnzl
propyl-
EX
IB-39






carbamoyl




IB-80
Np-M
Bnzl
Pr
H
IB-1 
IIB-80





















TABLE 3-3





Compound

LCMS tR
Mass
Elution
Yield


number
Name of compound
(min)
(M + H)+
condition
(%)







IB-1 
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.21
418
B
81



1-isobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-2 
(3S*,3aS*,6R*,7R*,7aS*)-N,1,7-
1.20
350
B
77



triisobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-3 
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1-
1.19
384
B
75



diisobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-4 
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-
1.20
384
B
88



diisobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-5 
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1,7-
1.20
384
B
76



diisobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-6 
(3S*,3aS*,6R*,7R*,7aS*)-1,7-dibenzyl-
1.20
418
B
54



N-isobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-7 
(3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl-
1.21
418
B
81



7-isobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-8 
(3S*,3aS*,6R*,7R*,7aS*)-N,1,7-
1.21
452
B
76



tribenzyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-9 
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.23
432
B
81



1-isopentyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-10
(3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl-
1.23
432
B
37



7-isopentyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-11
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.22
432
B
63



isobutyl-7-phenethyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-12
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7-
1.23
432
B
65



isobutyl-N-phenethyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-13
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.24
432
B
64



isobutyl-7-(3-methylbenzyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-14
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.23
432
B
74



isobutyl-7-(4-methylbenzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide





















TABLE 3-4







IB-15
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.24
432
B
66



isobutyl-N-(3-methylbenzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-16
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.25
432
B
72



isobutyl-N-(4-methylbenzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-17
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(3-
1.03
452
B
85



chlorobenzyl)-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-18
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(4-
1.24
452
B
79



chlorobenzyl)-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-19
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
1.13
486
B
43



(3,4-dichlorobenzyl)-7-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-20
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N-
1.26
486
B
84



(3,4-dichlorobenzyl)-7-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-21
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.19
440
B
82



isobutyl-N-(2-(naphthalen-1-yl)ethyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-22
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(4-
0.89
434
A
95



hydroxybenzyl)-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-23
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.06
490
A
88



isobutyl-N-(4-(tert-butoxy)benzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-24
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
1.05
468
A
84



isobutyl-N-(naphthalen-1-ylmethyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-25
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(2-
0.80
372
A
77



hydroxyethyl)-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-26
3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.82
400
A
95



isobutyloctahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide)propanoic acid






IB-27
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.99
456
A
93



isobutyl-N-(2-(tert-butoxy)-2-







oxoethyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-28
(3S*,3aS*,6R*,7R*,7aS*)-N-(3-amino-3-
0.79
399
A
80



oxopropyl)-7-benzyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-29
(3S*,3aS*,6R*,7R*,7aS*)-N-(4-
0.75
399
A
100



aminobutyl)-7-benzyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-30
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.97
499
A
 62



isobutyl-N-(4-((tert-







butoxycarbonyl)amino)butyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-31
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-
1.05
424
A
 42



cyclohexylmethyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide





















TABLE 3-5







IB-32
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-
0.96
426
A
97



isobutyl-N-((tetrahydro-







2H-pyran-2-yl)methyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-33
(3S*,3aS*,6R*,7R*,7aS*)-7-(4-
0.74
399
A
100



aminobutyl)-N-benzyl-1-







isobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-34
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
0.99
499
A
77



isobutyl-7-(4-((tert-







butoxycarbonyl)amino)butyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-35
3-((3S*,3aS*,6R*,7R*,7aS*)-3a-
0.83
400
A
100



(benzylcarbamoyl)-1-







isobutyloctahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridin-7-







yl)propanoic acid






IB-36
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-
0.90
414
A
73



isobutyl-7-(3-methoxy-3-







oxopropyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-37
(3S*,3aS*,6R*,7R*,7aS*)-7-(3-amino-3-
0.78
399
A
100



oxopropyl)-N-benzyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-38
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-7-
1.07
424
A
82



(cyclohexylmethyl)-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-39
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.06
458
A
78



1-cyclohexylmethyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-40
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
0.89
468
A
99



1-(4-hydroxybenzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-41
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.05
524
A
65



1-(4-(tert-butoxy)benzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-42
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.05
502
A
63



1-(naphthalen-1-ylmethyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-43
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N,7-
1.14
460
B
86



dibenzyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-







b]pyridine-3a-carboxamide






IB-44
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-
1.10
392
B
86



N,1,7-triisobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-45
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7-
1.10
426
B
82



benzyl-N,1-diisobutyloctahydro-3aH-







3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-46
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-1-
1.10
426
B
91



benzyl-N,7-diisobutyloctahydro-3aH-







3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-47
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N-
1.11
426
B
85



benzyl-1,7-diisobutyloctahydro-3aH-







3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-49
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N,1-
1.13
460
B
86



dibenzyl-7-isobutyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide





















TABLE 3-6







IB-50
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-
1.16
494
B
81



N,1,7-tribenzyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-54
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-1-
1.15
474
B
82



benzyl-7-isobutyl-N-phenethyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-57
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7-
1.17
474
B
87



benzyl-1-isobutyl-N-(3-







methylbenzyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-58
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7-
1.17
474
B
80



benzyl-1-isobutyl-N-(4-







methylbenzyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-64
(3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7-
1.12
482
B
100 



benzyl-1-isobutyl-N-(2-(naphthalen-







1-yl)ethyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-68
(3S*,3aS*,6R*,7R*,7aS*)-4-benzoyl-
1.23
522
B
39



N,7-dibenzyl-1-isobutyloctahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-69
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.24
446
B
28



4-ethyl-1-isobutyloctahydro-3aH-







3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-70
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.18
476
B
85



1-isobutyl-4-(methoxycarbonyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-71
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-
1.22
432
B
35



1-isobutyl-4-methyloctahydro-3aH-







3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-72
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-4-
1.24
468
B
70



ethyl-1-isobutyl-N-(2-(naphthalen-







1-yl)ethyl)octahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide






IB-73
tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-
0.91
500
A
100 



3a-(benzylcarbamoyl)-1-isobutyl-7-







(2-carboxyethyl)octahydro-4H-3,6-







methanopyrrolo[3,2-b]pyridine-4-







carboxylate






IB-74
tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-
0.97
514
A
75



3a-(benzylcarbamoyl)-1-isobutyl-7-







(3-methoxy-3-oxopropyl)octahydro-







4H-3,6-methanopyrrolo[3,2-b]pyridine-







4-carboxylate






IB-75
tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-
0.86
499
A
26



3a-(benzylcarbamoyl)-1-isobutyl-7-







(3-amino-3-oxopropyl)octahydro-4H-







3,6-methanopyrrolo[3,2-b]pyridine-







4-carboxylate






IB-76
tert-butyl 3-
1.20
490
B
68



((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-







3a-(benzylcarbamoyl)octahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridin-1-







yl)propanoate






IB-77
(3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl-
1.13
468
B
60



7-(4-hydroxybenzyl)octahydro-







3aH-3,6-methanopyrrolo[3,2-b]pyridine-







3a-carboxamide






IB-78
tert-butyl 3-
1.25
529
B
71



((3S*,3aS*,6R*,7R*,7aS*)-2-







(7-benzyl-1-methyloctahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridine-







3a-carboxamide)ethyl)-1H-indole-







1-carboxylate





















TABLE 3-7







IB-79
(3S*,3aS*,6R*,7R*,7aS*)-N3a,7-
1.05
543
A
65



dibenzyl-1-(cyclohexylmethyl)-N4-







propylhexahydro-1H-3,6-







methanopyrrolo[3,2-b]pyridine-3a,4-







dicarboxamide






IB-80
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-
1.02
454
A
62



1-(naphthalen-1-ylmethyl)-7-







propyloctahydro-3aH-3,6-







methanopyrrolo[3,2-b]pyridine-3a-







carboxamide
















TABLE 3-8









embedded image






















Time of




Compound



retention
Mass
Measurement


number
R1
R2
R3
TR (min)
(M + H)+
condition
















IB-81
Cbm-M
Np-M
i-Bu
0.79
435
C


IB-82
Cbm-M
Np-M
Bnzl
0.80
469
C


IB-83
Cbm-M
Np-M
4-OH-Bnzl
0.75
485
C


IB-84
Cbm-M
Np-M
i-Pnt
0.83
449
C


IB-85
Cbm-M
Np-M
Ph-Et
0.83
483
C


IB-86
Cbm-M
Ph-Et
i-Bu
0.74
399
C


IB-87
Cbm-M
Ph-Et
Bnzl
0.75
433
C


IB-88
Cbm-M
Ph-Et
4-OH-Bnzl
0.69
449
C


IB-89
Cbm-M
Ph-Et
i-Pnt
0.78
413
C


IB-90
Cbm-M
Np-M
Np-M
0.84
519
C


IB-91
Cbm-M
4-F-Bnzl
i-Bu
0.74
403
C


IB-92
Cbm-M
4-F-Bnzl
Bnzl
0.75
437
C


IB-93
Cbm-M
4-F-Bnzl
4-OH-Bnzl
0.69
453
C


IB-94
Cbm-M
4-F-Bnzl
i-Pnt
0.78
417
C


IB-95
Cbm-M
4-F-Bnzl
Ph-Et
0.78
451
C


IB-96
Cbm-M
4-F-Bnzl
Np-M
0.80
487
C


IB-97
Cbm-M
Ph-Et
Np-M
0.82
483
C


IB-98
Cbm-M
i-Pnt
i-Bu
0.73
365
C


IB-99
Cbm-M
i-Pnt
Bnzl
0.74
399
C


IB-100
Cbm-M
i-Pnt
4-OH-Bnzl
0.70
415
C


IB-101
Cbm-M
i-Pnt
Cbx-E
0.64
381
C


IB-102
Cbm-M
i-Pnt
Ph-Et
0.78
413
C


IB-103
Cbm-M
i-Pnt
Np-M
0.80
449
C


IB-104
Cbm-M
Hxy
i-Bu
0.78
379
C


IB-105
Cbm-M
Hxy
Bnzl
0.79
413
C


IB-106
Cbm-M
Hxy
4-OH-Bnzl
0.74
429
C


IB-107
Cbm-M
Hxy
Cbx-E
0.70
395
C






















TABLE 3-9







IB-108
Cbm-M
Hxy
i-Pnt
0.82
393
C


IB-109
Cbm-M
Hxy
Ph—Et
0.82
427
C


IB-110
Cbm-M
Hxy
Np-M
0.84
463
C


IB-111
Cbm-M
i-Pr
i-Bu
0.65
337
C


IB-112
Cbm-M
i-Pr
Bnzl
0.66
371
C


IB-113
Cbm-M
i-Pr
4-OH-Bnzl
0.59
387
C


IB-114
Cbm-M
i-Pr
Cbx-E
0.98
353
D


IB-115
Cbm-M
i-Pr
i-Pnt
0.70
351
C


IB-116
Cbm-M
i-Pr
Ph—Et
0.72
385
C


IB-117
Cbm-M
i-Pr
Np-M
0.74
421
C


IB-118
Cbm-M
i-Bu
i-Bu
0.71
351
C


IB-119
Cbm-M
i-Bu
Bnzl
0.72
385
C


IB-120
Cbm-M
i-Bu
4-OH-Bnzl
0.65
401
C


IB-121
Cbm-M
i-Bu
Cbx-E
0.60
367
C


IB-122
Cbm-M
i-Bu
i-Pnt
0.76
365
C


IB-123
Cbm-M
i-Bu
Ph—Et
0.77
399
C


IB-124
Cbm-M
i-Bu
Np-M
0.79
435
C


IB-125
Cbm-M
Bnzl
i-Bu
0.74
385
C


IB-126
Cbm-M
Bnzl
Bnzl
0.75
419
C


IB-127
Cbm-M
Bnzl
4-OH-Bnzl
0.69
435
C


IB-128
Cbm-M
Bnzl
Cbx-E
0.63
401
C


IB-129
Cbm-M
Bnzl
i-Pnt
0.79
399
C


IB-130
Cbm-M
Bnzl
Ph—Et
0.80
433
C


IB-131
Cbm-M
Bnzl
Np-M
0.81
469
C


IB-132
Cbm-M
4-OH-Bnzl
i-Bu
0.67
401
C


IB-133
Cbm-M
4-OH-Bnzl
Bnzl
0.69
435
C


IB-134
Cbm-M
4-OH-Bnzl
Cbx-E
0.98
417
D


IB-135
Cbm-M
4-OH-Bnzl
i-Pnt
0.73
415
C


IB-136
Cbm-M
4-OH-Bnzl
Ph—Et
0.74
449
C


IB-137
Cbm-M
4-OH-Bnzl
Np-M
0.76
485
C


IB-138
Cbm-M
Cbx-E
i-Bu
0.61
367
C


IB-139
Cbm-M
Cbx-E
Bnzl
0.62
401
C


IB-140
Cbm-M
Cbx-E
4-OH-Bnzl
0.98
417
D


IB-141
Cbm-M
Cbx-E
i-Pnt
0.67
381
C


IB-142
Cbm-M
Cbx-E
Ph—Et
0.69
415
C


IB-143
Cbm-M
Cbx-E
Np-M
0.71
451
C


IB-144
Cbm-M
Cbm-E
i-Bu
0.59
366
C


IB-145
Cbm-M
Cbm-E
Bnzl
0.61
400
C


IB-146
Cbm-M
Cbm-E
4-OH-Bnzl
0.97
416
D


IB-147
Cbm-M
Cbm-E
Cbx-E
0.20
382
E


IB-148
Cbm-M
Cbm-E
i-Pnt
0.65
380
C


IB-149
Cbm-M
Cbm-E
Ph—Et
0.67
414
C


IB-150
Cbm-M
Cbm-E
Np-M
0.69
450
C


IB-151
Cbm-M
Gun-Pr
i-Bu
0.59
394
C


IB-152
Cbm-M
Gun-Pr
Bnzl
0.60
428
C


IB-153
Cbm-M
Gun-Pr
4-OH-Bnzl
0.91
444
D






















TABLE 3-10







IB-154
Cbm-M
Gun-Pr
i-Pnt
0.63
408
C


IB-155
Cbm-M
Gun-Pr
Ph—Et
0.65
442
C


IB-156
Cbm-M
Gun-Pr
Np-M
1.15
478
D


IB-157
Cbm-M
Hdr-E
i-Bu
0.60
339
C


IB-158
Cbm-M
Hdr-E
Bnzl
0.61
373
C


IB-159
Cbm-M
Hdr-E
4-OH-Bnz1
0.98
389
D


IB-160
Cbm-M
Hdr-E
Cbx-E
0.20
355
E


IB-161
Cbm-M
Hdr-E
i-Pnt
0.65
353
C


IB-162
Cbm-M
Hdr-E
Ph—Et
0.67
387
C


IB-163
Cbm-M
Hdr-E
Np-M
0.70
423
C


IB-164
Gun-Pr
Np-M
i-Bu
1.25
477
D


IB-165
Gun-Pr
Np-M
Bnzl
0.73
511
C


IB-166
Gun-Pr
Np-M
4-OH-Bnzl
0.71
527
C


IB-167
Gun-Pr
Np-M
i-Pnt
1.30
491
D


IB-168
Gun-Pr
Np-M
Ph—Et
1.31
525
D


IB-169
Gun-Pr
Np-M
Np-M
1.31
561
D


IB-170
Gun-Pr
Hxy
i-Bu
0.74
421
C


IB-171
Gun-Pr
Hxy
Bnzl
0.74
455
C


IB-172
Gun-Pr
Hxy
4-OH-Bnzl
1.23
471
D


IB-173
Gun-Pr
Hxy
i-Pnt
0.77
435
C


IB-174
Gun-Pr
Hxy
Ph—Et
1.33
469
D


IB-175
Gun-Pr
Hxy
Np-M
1.32
505
D


IB-176
Gun-Pr
i-Pr
i-Bu
1.08
379
D


IB-177
Gun-Pr
i-Pr
4-OH-Bnzl
1.04
429
D


IB-178
Gun-Pr
i-Pr
i-Pnt
1.15
393
D


IB-179
Gun-Pr
i-Pr
Ph—Et
1.17
427
D


IB-180
Gun-Pr
i-Pr
Np-M
1.18
463
D


IB-181
Gun-Pr
4-F-Bnzl
i-Bu
1.19
445
D


IB-182
Gun-Pr
4-F-Bnzl
Bnzl
0.70
479
C


IB-183
Gun-Pr
4-F-Bnzl
4-OH-Bnzl
1.14
495
D


IB-184
Gun-Pr
4-F-Bnzl
i-Pnt
1.26
459
D


IB-185
Gun-Pr
4-F-Bnzl
Ph—Et
0.74
493
C


IB-186
Gun-Pr
4-F-Bnzl
Np-M
0.74
529
C


IB-187
i-Bu
i-Bu
Gun-Pr
3.80
393
G


IB-188
i-Bu
Bnzl
Gun-Pr
4.09
427
G


IB-189
i-Bu
4-OH-Bnzl
Gun-Pr
3.67
443
G


IB-190
i-Bu
Cbm-E
Gun-Pr
3.04
408
G


IB-191
i-Bu
Hdr-E
Gun-Pr
3.00
381
G


IB-192
i-Bu
i-Pnt
Gun-Pr
4.15
407
G


IB-193
i-Bu
Ph—Et
Gun-Pr
4.30
441
G


IB-194
i-Bu
Np-M
Gun-Pr
4.70
477
G


IB-195
i-Bu
Hxy
Gun-Pr
4.54
421
G


IB-196
i-Bu
i-Pr
Gun-Pr
3.72
379
G


IB-197
i-Bu
4-F-Bnzl
Gun-Pr
4.29
445
G


IB-198
Bnzl
i-Bu
Gun-Pr
2.65
427
F


IB-199
Bnzl
4-OH-Bnzl
Gun-Pr
3.88
477
G






















TABLE 3-11







IB-200
Bnzl
Cbm-E
Gun-Pr
3.17
442
G


IB-201
Bnzl
Hdr-E
Gun-Pr
3.20
415
G


IB-202
Bnzl
i-Pr
Gun-Pr
3.82
413
F


IB-203
4-OH-Bnzl
i-Bu
Gun-Pr
3.65
443
G


IB-204
4-OH-Bnzl
i-Pnt
Gun-Pr
3.92
457
G


IB-205
4-OH-Bnzl
Ph—Et
Gun-Pr
3.95
491
G


IB-206
4-OH-Bnzl
Np-M
Gun-Pr
4.32
527
G


IB-207
4-OH-Bnzl
4-F-Bnzl
Gun-Pr
3.94
495
G


IB-208
i-Pnt
i-Bu
Gun-Pr
2.54
407
F


IB-209
i-Pnt
Bnzl
Gun-Pr
2.65
441
F


IB-210
i-Pnt
4-OH-Bnzl
Gun-Pr
2.43
457
F


IB-211
i-Pnt
Cbm-E
Gun-Pr
3.07
422
G


IB-212
i-Pnt
Hdr-E
Gun-Pr
3.07
395
G


IB-213
i-Pnt
Ph—Et
Gun-Pr
2.75
455
F


IB-214
i-Pnt
Np-M
Gun-Pr
3.07
491
F


IB-215
i-Pnt
Hxy
Gun-Pr
2.84
435
F


IB-216
i-Pnt
i-Pr
Gun-Pr
3.59
393
G


IB-217
i-Pnt
4-F-Bnzl
Gun-Pr
2.74
459
F


IB-218
Ph—Et
Hdr-E
Gun-Pr
3.63
429
G


IB-219
Np-M
i-Bu
Gun-Pr
3.02
477
F


IB-220
Np-M
Bnzl
Gun-Pr
4.80
511
G


IB-221
Np-M
4-OH-Bnzl
Gun-Pr
4.35
527
G


IB-222
Np-M
Cbm-E
Gun-Pr
3.85
492
G


IB-223
Np-M
Hdr-E
Gun-Pr
3.92
465
G


IB-224
Np-M
i-Pnt
Gun-Pr
3.22
491
F


IB-225
Np-M
Ph—Et
Gun-Pr
3.10
525
F


IB-226
Np-M
Np-M
Gun-Pr
3.24
561
F


IB-227
Np-M
Hxy
Gun-Pr
5.09
505
G


IB-228
Np-M
i-Pr
Gun-Pr
2.82
463
F


IB-229
Np-M
4-F-Bnzl
Gun-Pr
4.87
529
G


IB-230
Chm
i-Bu
Gun-Pr
2.82
433
F


IB-231
Chm
Bnzl
Gun-Pr
2.95
467
F


IB-232
Chm
4-OH-Bnzl
Gun-Pr
2.67
483
F


IB-233
Chm
Cbm-E
Gun-Pr
3.49
448
G


IB-234
Chm
Hdr-E
Gun-Pr
3.50
421
G


IB-235
Chm
i-Pnt
Gun-Pr
3.04
447
F


IB-236
Chm
Ph—Et
Gun-Pr
2.94
481
F


IB-237
Chm
Np-M
Gun-Pr
3.22
517
F


IB-238
Chm
Hxy
Gun-Pr
3.15
461
F


IB-239
Chm
i-Pr
Gun-Pr
2.69
419
F


IB-240
Chm
4-F-Bnzl
Gun-Pr
2.99
485
F


IB-241
4-F-Bnzl
4-OH-Bnzl
Gun-Pr
4.00
495
G


IB-242
4-F-Bnzl
Cbm-E
Gun-Pr
3.29
460
G


IB-243
4-F-Bnzl
Hdr-E
Gun-Pr
3.27
433
F


IB-244
4-F-Bnzl
i-Pr
Gun-Pr
3.84
431
G


IB-245
Bnzl
Bnzl
Gun-Pr
2.69
461
F






















TABLE 3-12







IB-246
Bnzl
i-Pnt
Gun-Pr
2.74
441
F


IB-247
Bnzl
Ph—Et
Gun-Pr
2.77
475
F


IB-248
Bnzl
Np-M
Gun-Pr
3.07
511
F


IB-249
Bnzl
Hxy
Gun-Pr
2.97
455
F


IB-250
Bnzl
4-F-Bnzl
Gun-Pr
2.77
479
F


IB-251
Ph—Et
i-Bu
Gun-Pr
2.75
441
F


IB-252
Ph—Et
Bnzl
Gun-Pr
2.85
475
F


IB-253
Ph—Et
4-OH-Bnzl
Gun-Pr
2.60
491
F


IB-254
Ph—Et
i-Pnt
Gun-Pr
2.85
455
F


IB-255
Ph—Et
Np-M
Gun-Pr
3.25
525
F


IB-256
Ph—Et
Hxy
Gun-Pr
3.15
469
F


IB-257
Ph—Et
i-Pr
Gun-Pr
2.52
427
F


IB-258
Ph—Et
4-F-Bnzl
Gun-Pr
2.97
493
F


IB-259
4-F-Bnzl
i-Bu
Gun-Pr
2.67
445
F


IB-260
4-F-Bnzl
Bnzl
Gun-Pr
2.80
479
F


IB-261
4-F-Bnzl
i-Pnt
Gun-Pr
2.84
459
F


IB-262
4-F-Bnzl
Ph—Et
Gun-Pr
2.88
493
F


IB-263
4-F-Bnzl
Np-M
Gun-Pr
3.20
529
F


IB-264
4-F-Bnzl
Hxy
Gun-Pr
3.04
473
F


IB-265
i-Bu
Cbm-E
Cbx-E
2.06
381
H


IB-266
i-Bu
Cbm-E
i-Pnt
2.48
379
H


IB-267
i-Bu
Gun-Pr
i-Bu
2.35
393
H


IB-268
i-Bu
Gun-Pr
Bnzl
2.39
427
H


IB-269
i-Bu
Gun-Pr
4-OH-Bnzl
1.98
443
H


IB-270
i-Bu
Gun-Pr
i-Pnt
2.24
407
H


IB-271
i-Bu
Gun-Pr
Ph—Et
2.25
441
H


IB-272
i-Bu
Gun-Pr
Np-M
2.28
477
H


IB-273
Bnzl
Cbm-E
Cbx-E
1.90
415
H


IB-274
Bnzl
Cbm-E
i-Pnt
2.28
413
H


IB-275
Bnzl
Gun-Pr
i-Bu
2.17
427
H


IB-276
Bnzl
Gun-Pr
Bnzl
2.25
461
H


IB-277
Bnzl
Gun-Pr
4-OH-Bnzl
2.07
477
H


IB-278
Bnzl
Gun-Pr
i-Pnt
2.36
441
H


IB-279
Bnzl
Gun-Pr
Ph—Et
2.28
475
H


IB-280
Bnzl
Gun-Pr
Np-M
2.33
511
H


IB-281
4-OH-Bnzl
Cbm-E
Cbx-E
1.71
431
H


IB-282
4-OH-Bnzl
Cbm-E
i-Pnt
2.03
429
H


IB-283
4-OH-Bnzl
Gun-Pr
i-Bu
1.96
443
H


IB-284
4-OH-Bnzl
Gun-Pr
Bnzl
2.12
477
H


IB-285
4-OH-Bnzl
Gun-Pr
i-Pnt
2.03
457
H


IB-286
4-OH-Bnzl
Gun-Pr
Ph—Et
2.13
491
H


IB-287
4-OH-Bnzl
Gun-Pr
Np-M
2.22
527
H


IB-288
Cbx-E
Cbm-E
i-Pnt
2.10
395
H


IB-289
Gun-Pr
i-Bu
i-Bu
2.02
393
H


IB-290
Gun-Pr
i-Bu
Bnzl
2.01
427
H


IB-291
Gun-Pr
i-Bu
4-OH-Bnzl
1.95
443
H






















TABLE 3-13







IB-292
Gun-Pr
i-Bu
i-Pnt
2.04
407
H


IB-293
Gun-Pr
i-Bu
Ph—Et
2.12
441
H


IB-294
Gun-Pr
i-Bu
Np-M
2.14
477
H


IB-295
Gun-Pr
Bnzl
i-Bu
2.03
427
H


IB-296
Gun-Pr
Bnzl
Bnzl
2.06
461
H


IB-297
Gun-Pr
Bnzl
4-OH-Bnzl
1.98
477
H


IB-298
Gun-Pr
Bnzl
i-Pnt
2.16
441
H


IB-299
Gun-Pr
Bnzl
Ph—Et
2.19
475
H


IB-300
Gun-Pr
Bnzl
Np-M
2.21
511
H


IB-301
Gun-Pr
4-OH-Bnzl
i-Bu
1.93
443
H


IB-302
Gun-Pr
4-OH-Bnzl
Bnzl
1.95
477
H


IB-303
Gun-Pr
4-OH-Bnzl
i-Pnt
2.05
457
H


IB-304
Gun-Pr
4-OH-Bnzl
Ph—Et
2.07
491
H


IB-305
Gun-Pr
4-OH-Bnzl
Np-M
2.11
527
H


IB-306
Gun-Pr
Cbm-E
i-Bu
1.83
408
H


IB-307
Gun-Pr
Cbm-E
Bnzl
1.85
442
H


IB-308
Gun-Pr
Cbm-E
4-OH-Bnzl
1.75
458
H


IB-309
Gun-Pr
Cbm-E
i-Pnt
1.91
422
H


IB-310
Gun-Pr
Cbm-E
Ph—Et
1.96
456
H


IB-311
Gun-Pr
Cbm-E
Np-M
1.98
492
H


IB-312
Gun-Pr
Hdr-E
i-Bu
1.81
381
H


IB-313
Gun-Pr
Hdr-E
Bnzl
1.85
415
H


IB-314
Gun-Pr
Hdr-E
4-OH-Bnzl
1.73
431
H


IB-315
Gun-Pr
Hdr-E
i-Pnt
1.92
395
H


IB-316
Gun-Pr
Hdr-E
Ph—Et
1.94
429
H


IB-317
Gun-Pr
Hdr-E
Np-M
1.98
465
H


IB-318
Gun-Pr
i-Pnt
i-Bu
2.10
407
H


IB-319
Gun-Pr
i-Pnt
Bnzl
2.11
441
H


IB-320
Gun-Pr
i-Pnt
4-OH-Bnzl
2.03
457
H


IB-321
Gun-Pr
i-Pnt
Ph—Et
2.12
455
H


IB-322
Gun-Pr
i-Pnt
Np-M
2.22
491
H


IB-323
Gun-Pr
Ph—Et
i-Bu
2.12
441
H


IB-324
Gun-Pr
Ph—Et
Bnzl
2.09
475
H


IB-325
Gun-Pr
Ph—Et
4-OH-Bnzl
2.02
491
H


IB-326
Gun-Pr
Ph—Et
i-Pnt
2.18
455
H


IB-327
Gun-Pr
Ph—Et
Np-M
2.25
525
H


IB-328
Hdr-E
Cbm-E
i-Pnt
1.98
367
H


IB-329
Hdr-E
Gun-Pr
i-Bu
1.89
381
H


IB-330
Hdr-E
Gun-Pr
Bnzl
1.96
415
H


IB-331
Hdr-E
Gun-Pr
4-OH-Bnzl
1.84
431
H


IB-332
Hdr-E
Gun-Pr
i-Pnt
2.00
395
H


IB-333
Hdr-E
Gun-Pr
Ph—Et
2.03
429
H


IB-334
Hdr-E
Gun-Pr
Np-M
1.83
465
H


IB-335
i-Pnt
Cbm-E
Cbx-E
1.85
395
H


IB-336
i-Pnt
Gun-Pr
i-Bu
2.14
408
H


IB-337
i-Pnt
Gun-Pr
Bnzl
2.17
441
H






















TABLE 3-14







IB-338
i-Pnt
Gun-Pr
4-OH-Bnzl
1.92
457
H


IB-339
i-Pnt
Gun-Pr
Ph—Et
2.26
455
H


IB-340
i-Pnt
Gun-Pr
Np-M
2.31
491
H


IB-341
Ph—Et
Cbm-E
Cbx-E
2.00
429
H


IB-342
Ph—Et
Cbm-E
i-Pnt
2.39
427
H


IB-343
Ph—Et
Gun-Pr
i-Bu
2.22
441
H


IB-344
Ph—Et
Gun-Pr
Bnzl
2.27
475
H


IB-345
Ph—Et
Gun-Pr
4-OH-Bnzl
2.10
491
H


IB-346
Ph—Et
Gun-Pr
i-Pnt
2.33
455
H


IB-347
Ph—Et
Gun-Pr
Np-M
2.38
525
H


IB-348
Np-M
Cbm-E
Cbx-E
2.14
465
H


IB-349
Np-M
Cbm-E
i-Pnt
2.57
463
H


IB-350
Np-M
Gun-Pr
i-Bu
2.33
477
H


IB-351
Np-M
Gun-Pr
Bnzl
2.31
511
H


IB-352
Np-M
Gun-Pr
4-OH-Bnzl
2.18
527
H


IB-353
Np-M
Gun-Pr
i-Pnt
2.42
491
H


IB-354
Np-M
Gun-Pr
Ph—Et
2.38
525
H


IB-355
Np-M
Gun-Pr
Np-M
2.41
561
H


IB-356
Chm
Cbm-E
Cbx-E
2.00
421
H


IB-357
Chm
Cbm-E
i-Pnt
2.41
419
H


IB-358
Chm
Gun-Pr
i-Bu
2.27
433
H


IB-359
Chm
Gun-Pr
Bnzl
2.31
467
H


IB-360
Chm
Gun-Pr
4-OH-Bnzl
2.13
483
H


IB-361
Chm
Gun-Pr
i-Pnt
2.33
447
H


IB-362
Chm
Gun-Pr
Ph—Et
2.34
481
H


IB-363
Chm
Gun-Pr
Np-M
2.42
517
H


IB-364
4-F-Bnzl
Cbm-E
Cbx-E
1.93
433
H


IB-365
4-F-Bnzl
Cbm-E
i-Pnt
2.29
431
H


IB-366
4-F-Bnzl
Gun-Pr
i-Bu
2.21
445
H


IB-367
4-F-Bnzl
Gun-Pr
Bnzl
2.26
478
H


IB-368
4-F-Bnzl
Gun-Pr
4-OH-Bnzl
2.09
495
H


IB-369
4-F-Bnzl
Gun-Pr
i-Pnt
2.27
459
H


IB-370
4-F-Bnzl
Gun-Pr
Ph—Et
2.28
493
H


IB-371
4-F-Bnzl
Gun-Pr
Np-M
2.36
529
H


IB-372
Hdr-E
i-Bu
i-Pnt
1.68
352
I


IB-373
Ph—Et
i-Bu
i-Pnt
2.16
412
I


IB-374
Np-M
i-Bu
i-Pnt
2.21
448
I


IB-375
Chm
i-Bu
i-Pnt
2.28
404
I


IB-376
4-F-Bnzl
i-Bu
i-Pnt
2.09
416
I


IB-377
Bnzl
i-Bu
i-Pnt
2.09
398
I


IB-378
i-Bu
i-Bu
i-Pnt
2.06
364
I


IB-379
Hdr-E
Cbx-E
i-Bu
1.33
354
I


IB-380
Hdr-E
4-OH-Bnzl
Cbx-E
1.11
404
I


IB-381
i-Pnt
Cbx-E
Np-M
1.87
464
I


IB-382
Chm
Cbx-E
i-Bu
1.87
406
I


IB-383
Chm
4-OH-Bnzl
Cbx-E
1.68
456
I






















TABLE 3-15







IB-384
4-F-Bnzl
Cbx-E
Np-M
1.90
502
I


IB-385
4-F-Bnzl
4-OH-Bnzl
Cbx-E
1.53
468
I


IB-386
i-Pnt
4-F-Bnzl
Cbx-E
1.85
432
I


IB-387
Ph—Et
Hdr-E
Cbx-E
1.37
402
I


IB-388
Np-M
Hdr-E
Cbx-E
1.54
438
I


IB-389
Chm
Np-M
Cbx-E
1.99
490
I


IB-390
4-F-Bnzl
Np-M
Cbx-E
1.86
502
I


IB-391
Cbx-E
Hdr-E
Bnzl
1.35
388
I


IB-392
Cbx-E
Np-M
i-Bu
1.80
450
I


IB-393
Cbx-E
Hxy
Bnzl
1.79
428
I


IB-394
Cbx-E
4-F-Bnzl
Bnzl
1.70
452
I


IB-395
Cbx-E
Hdr-E
i-Pnt
1.46
368
I


IB-396
Cbx-E
Hdr-E
Ph—Et
1.45
402
I


IB-397
Cbx-E
Hdr-E
Np-M
1.59
438
I


IB-398
Cbx-E
Np-M
i-Pnt
1.83
464
I


IB-399
Cbx-E
4-F-Bnzl
i-Pnt
1.82
432
I


IB-400
Cbx-E
i-Bu
Bnzl
1.53
400
I


IB-401
Cbx-E
Cbm-E
Ph—Et
1.49
429
I


IB-402
Cbx-E
4-OH-Bnzl
i-Pnt
1.60
430
I


IB-403
Bnzl
Hdr-E
Cbx-E
1.31
388
I


IB-404
Bnzl
Hxy
Cbx-E
1.88
428
I


IB-405
Bnzl
4-OH-Bnzl
Cbx-E
1.54
450
I


IB-406
i-Bu
Hxy
Cbx-E
1.88
394
I


IB-407
i-Bu
Cbx-E
i-Bu
1.62
366
I


IB-408
i-Bu
i-Bu
Cbx-E
1.71
366
I


IB-409
i-Bu
4-OH-Bnzl
Cbx-E
1.47
416
I


IB-410
4-OH-Bnzl
Cbx-E
Np-M
1.70
500
I


IB-411
Ph—Et
i-Bu
Np-M
2.32
482
I


IB-412
Ph—Et
4-OH-Bnzl
Np-M
2.02
532
I


IB-413
Np-M
i-Bu
Ph—Et
2.23
482
I


IB-414
Np-M
i-Bu
Np-M
2.25
518
I


IB-415
Np-M
i-Bu
Bnzl
2.15
468
I


IB-416
Np-M
4-OH-Bnzl
Ph—Et
2.08
532
I


IB-417
Np-M
4-OH-Bnzl
Np-M
2.11
568
I


IB-418
4-F-Bnzl
i-Bu
Np-M
2.15
486
I


IB-419
4-F-Bnzl
Ph—Et
Np-M
2.17
534
I


IB-420
Bnzl
i-Bu
Np-M
2.17
468
I


IB-421
Bnzl
4-OH-Bnzl
Ph—Et
1.92
482
I


IB-422
i-Bu
4-OH-Bnzl
Ph—Et
1.93
448
I


IB-423
4-OH-Bnzl
Ph—Et
Np-M
1.97
532
I


IB-424
4-OH-Bnzl
i-Bu
i-Pnt
1.82
414
I


IB-425
Hdr-E
Np-M
Cbx-E
1.55
438
I


IB-426
i-Pnt
Np-M
Hdr-M
1.91
422
I


IB-427
4-F-Bnzl
Np-M
Hdr-M
1.96
460
I


IB-428
Cbx-E
Ph—Et
4-OH-Bnzl
1.59
464
I


IB-429
Cbx-E
Np-M
Hdr-M
1.55
424
I






















TABLE 3-16







IB-430
Cbx-E
i-Bu
Ph—Et
1.66
414
I


IB-431
Cbx-E
i-Bu
Hdr-M
1.21
340
I


IB-432
Cbx-E
i-Bu
4-OH-Bnzl
1.40
416
I


IB-433
Cbx-E
Cbm-E
Np-M
1.56
465
I


IB-434
Cbx-E
Cbm-E
Bnzl
1.41
415
I


IB-435
Cbx-E
Cbm-E
i-Bu
1.37
381
I


IB-436
Cbx-E
Cbm-E
4-OH-Bnzl
1.19
431
I


IB-437
i-Bu
Np-M
Cbx-E
1.86
450
I


IB-438
4-OH-Bnzl
Ph—Et
Cbx-E
1.60
464
I


IB-439
4-OH-Bnzl
Np-M
Cbx-E
1.69
500
I


IB-440
4-OH-Bnzl
Np-M
Hdr-M
1.70
458
I


IB-441
Hdr-E
Cbm-E
4-OH-Bnzl
1.18
403
I


IB-442
Hdr-E
4-OH-Bnzl
i-Pnt
1.58
402
I


IB-443
Hdr-E
4-OH-Bnzl
Ph—Et
1.60
436
I


IB-444
Hdr-E
4-OH-Bnzl
Bnzl
1.52
422
I


IB-445
i-Pnt
4-OH-Bnzl
Np-M
2.02
498
I


IB-446
i-Pnt
4-OH-Bnzl
i-Bu
1.90
414
I


IB-447
Ph—Et
4-OH-Bnzl
i-Pnt
2.02
462
I


IB-448
Ph—Et
4-OH-Bnzl
Bnzl
1.93
482
I


IB-449
Ph—Et
4-OH-Bnzl
i-Bu
1.90
448
I


IB-450
Np-M
4-OH-Bnzl
i-Pnt
2.08
498
I


IB-451
Np-M
4-OH-Bnzl
Bnzl
1.99
518
I


IB-452
Np-M
4-OH-Bnzl
i-Bu
2.00
484
I


IB-453
Chm
4-OH-Bnzl
i-Pnt
2.11
454
I


IB-454
Chm
4-OH-Bnzl
Ph—Et
2.08
488
I


IB-455
Chm
4-OH-Bnzl
Np-M
2.13
524
I


IB-456
Chm
4-OH-Bnzl
Bnzl
2.02
474
I


IB-457
4-F-Bnzl
4-OH-Bnzl
Np-M
2.02
536
I


IB-458
4-F-Bnzl
4-OH-Bnzl
i-Bu
1.87
452
I


IB-459
Np-M
Hdr-E
4-OH-Bnzl
1.64
472
I


IB-460
Chm
Hdr-E
Bnzl
1.94
412
I


IB-461
Ph—Et
Hdr-E
i-Pnt
1.86
400
I


IB-462
Bnzl
4-OH-Bnzl
i-Pnt
1.94
448
I


IB-463
Bnzl
4-OH-Bnzl
Bnzl
1.86
468
I


IB-464
Bnzl
4-OH-Bnzl
i-Bu
1.84
434
I


IB-465
i-Bu
4-OH-Bnzl
i-Pnt
1.96
414
I


IB-466
i-Bu
4-OH-Bnzl
Np-M
2.00
484
I


IB-467
i-Bu
4-OH-Bnzl
i-Bu
1.85
400
I


IB-468
4-OH-Bnzl
Hdr-E
i-Bu
1.40
388
I


IB-469
4-OH-Bnzl
Hdr-E
i-Pnt
1.55
402
I


IB-470
Hdr-E
4-OH-Bnzl
Np-M
1.68
472
I


IB-471
Ph—Et
i-Pr
4-OH-Bnzl
1.24
434
I


IB-472
Np-M
Bnzl
4-OH-Bnzl
1.98
518
I


IB-473
Chm
i-Pr
4-OH-Bnzl
1.20
426
I


IB-474
4-F-Bnzl
Bnzl
Np-M
2.16
520
I


IB-475
4-F-Bnzl
i-Pr
4-OH-Bnzl
1.13
428
I






















TABLE 3-17







IB-476
Hdr-E
Hxy
Bnzl
1.92
400
I


IB-477
Hdr-E
Hxy
i-Bu
1.87
366
I


IB-478
Hdr-E
Hxy
4-OH-Bnzl
1.79
416
I


IB-479
Hdr-E
4-F-Bnzl
Bnzl
1.73
424
I


IB-480
i-Pnt
Hxy
4-OH-Bnzl
2.07
442
I


IB-481
i-Pnt
4-F-Bnzl
4-OH-Bnzl
1.93
466
I


IB-482
Np-M
Hxy
i-Bu
2.35

I


IB-483
Np-M
Hxy
4-OH-Bnzl
2.17
512
I


IB-484
Chm
Ph-Et
Bnzl
2.36

I


IB-485
Chm
Hxy
Bnzl
2.42

I


IB-486
Chm
Hxy
i-Bu
2.44

I


IB-487
Chm
Hxy
4-OH-Bnzl
2.18
468
I


IB-488
Chm
4-F-Bnzl
i-Bu
2.22
442
I


IB-489
4-F-Bnzl
Ph-Et
Bnzl
2.18
484
I


IB-490
Hdr-E
Hxy
i-Pnt
1.99
380
I


IB-491
Hdr-E
Hxy
Np-M
1.98
450
I


IB-492
Hdr-E
4-F-Bnzl
Ph-Et
1.80
438
I


IB-493
Np-M
Hdr-E
Np-M
1.99
506
I


IB-494
Chm
Hxy
i-Pnt
2.54

I


IB-495
i-Bu
Ph-Et
i-Bu
2.16
398
I


IB-496
i-Bu
Hxy
4-OH-Bnzl
2.04
428
I


IB-497
i-Bu
4-F-Bnzl
i-Bu
2.05
402
I


IB-498
i-Bu
4-F-Bnzl
4-OH-Bnzl
1.89
452
I


IB-499
4-OH-Bnzl
4-F-Bnzl
i-Bu
1.91
452
I


IB-500
4-OH-Bnzl
Bnzl
Np-M
1.92
518
I


IB-501
4-OH-Bnzl
i-Pr
i-Pnt
1.77
400
I


IB-502
4-OH-Bnzl
i-Pr
Np-M
1.83
470
I


IB-503
Hdr-E
Bnzl
Cbx-E
1.37
388
I


IB-504
Hdr-E
i-Bu
Cbx-E
1.28
354
I


IB-505
i-Pnt
Bnzl
Cbx-E
1.79
414
I


IB-506
i-Pnt
i-Bu
Cbx-E
1.75
380
I


IB-507
i-Pnt
4-OH-Bnzl
Cbx-E
1.49
430
I


IB-508
Ph-Et
i-Bu
Cbx-E
1.71
414
I


IB-509
Np-M
i-Bu
Cbx-E
1.93
450
I


IB-510
Chm
i-Bu
Cbx-E
1.91
406
I


IB-511
4-F-Bnzl
i-Pnt
Cbx-E
1.88
432
I


IB-512
Cbx-E
i-Pnt
4-OH-Bnzl
1.55
430
I


IB-513
Cbx-E
i-Pnt
Ph-Et
1.71
428
I


IB-514
Cbx-E
i-Pnt
Np-M
1.83
464
I


IB-515
Cbx-E
4-OH-Bnzl
Ph-Et
1.63
464
I


IB-516
Cbx-E
4-OH-Bnzl
Np-M
1.68
500
I


IB-517
i-Bu
Cbx-E
Np-M
1.81
450
I


IB-518
4-OH-Bnzl
i-Pnt
Cbx-E
1.61
430
I


IB-519
Hdr-E
Cbm-E
Np-M
1.54
437
I


IB-520
Np-M
Cbm-E
i-Bu
1.83
449
I


IB-521
Np-M
Cbm-E
4-OH-Bnzl
1.64
499
I






















TABLE 3-18







IB-522
Chm
Cbm-E
Np-M
1.95
489
I


IB-523
Chm
Cbm-E
4-OH-Bnzl
1.57
455
I


IB-524
4-F-Bnzl
Cbm-E
Ph-Et
1.78
465
I


IB-525
4-F-Bnzl
Cbm-E
Np-M
1.86
501
I


IB-526
Hdr-E
Ph-Et
4-OH-Bnzl
1.53
436
I


IB-527
Hdr-E
Np-M
4-OH-Bnzl
1.69

I


IB-528
Chm
Np-M
i-Bu
2.35
474
I


IB-529
Chm
4-F-Bnzl
4-OH-Bnzl
1.99
492
I


IB-530
4-F-Bnzl
Np-M
4-OH-Bnzl
1.98
536
I


IB-531
Hdr-E
Ph-Et
i-Pnt
1.80
400
I


IB-532
4-F-Bnzl
Np-M
i-Pnt
2.24
500
I


IB-533
Bnzl
4-F-Bnzl
i-Bu
2.07
436
I


IB-534
Bnzl
4-F-Bnzl
4-OH-Bnzl
1.88
486
I


IB-535
Bnzl
Cbm-E
Ph-Et
1.73
447
I


IB-536
i-Bu
Ph-Et
4-OH-Bnzl
1.85
448
I


IB-537
i-Bu
Np-M
4-OH-Bnzl
1.99
484
I


IB-538
i-Bu
Np-M
i-Pnt
2.28
448
I


IB-539
i-Bu
Cbm-E
Ph-Et
1.71
413
I


IB-540
4-OH-Bnzl
Ph-Et
i-Bu
1.80
448
I


IB-541
4-OH-Bnzl
Np-M
i-Bu
1.94
484
I


IB-542
4-OH-Bnzl
Hxy
Bnzl
1.98
462
I


IB-543
4-OH-Bnzl
4-F-Bnzl
Bnzl
1.83
486
I


IB-544
4-OH-Bnzl
Ph-Et
i-Pnt
1.92
462
I


IB-545
4-OH-Bnzl
Cbm-E
Bnzl
1.53
449
I


IB-546
Ph-Et
Bnzl
Np-M
2.22
516
I


IB-547
4-F-Bnzl
Bnzl
Ph-Et
2.15
484
I


IB-548
4-F-Bnzl
Cbm-E
4-OH-Bnzl
1.48
467
I


IB-549
Hdr-E
4-F-Bnzl
4-OH-Bnzl
1.51
440
I


IB-550
i-Pnt
Hxy
Bnzl
2.22
426
I


IB-551
i-Pnt
Hxy
i-Bu
2.24
392
I


IB-552
i-Pnt
4-F-Bnzl
Bnzl
2.11
450
I


IB-553
i-Pnt
4-F-Bnzl
i-Bu
2.10
416
I


IB-554
Ph-Et
Hxy
Bnzl
2.27
460
I


IB-555
Ph-Et
4-F-Bnzl
Bnzl
2.13
484
I


IB-556
Ph-Et
4-F-Bnzl
i-Bu
2.12
450
I


IB-557
i-Pnt
Hxy
Ph-Et
2.31
440
I


IB-558
i-Pnt
Hxy
Np-M
2.35
476
I


IB-559
Ph-Et
4-F-Bnzl
i-Pnt
2.20
464
I


IB-560
Chm
4-F-Bnzl
Np-M
2.29
526
I


IB-561
Bnzl
i-Pnt
i-Bu
2.13
398
I


IB-562
Bnzl
Hxy
Bnzl
2.20
446
I


IB-563
Bnzl
Hxy
i-Bu
2.22
412
I


IB-564
Bnzl
4-F-Bnzl
Bnzl
2.08
470
I


IB-565
Bnzl
Hxy
i-Pnt
2.27
426
I


IB-566
Bnzl
Hxy
Ph-Et
2.24
460
I


IB-567
Bnzl
4-F-Bnzl
i-Pnt
2.13
450
I






















TABLE 3-19







IB-568
Bnzl
4-F-Bnzl
Ph-Et
2.12
484
I


IB-569
Bnzl
Cbm-E
4-OH-Bnzl
1.47
449
I


IB-570
i-Bu
Hxy
i-Bu
2.22
378
I


IB-571
i-Bu
Hxy
i-Pnt
2.31
392
I


IB-572
i-Bu
Hxy
Ph-Et
2.25
426
I


IB-573
i-Bu
Hxy
Np-M
2.48
462
I


IB-574
4-OH-Bnzl
i-Pnt
Bnzl
1.90
448
I


IB-575
Cbx-E
i-Bu
Np-M
1.80
450
I


IB-576
i-Pnt
4-OH-Bnzl
Ph-Et
1.97
462
I


IB-577
i-Pnt
4-OH-Bnzl
Bnzl
1.87
448
I


IB-578
Np-M
Bnzl
Np-M
2.24
552
I


IB-579
Np-M
i-Pr
Ph-Et
2.15
468
I


IB-580
Np-M
i-Pr
Bnzl
2.05
454
I


IB-581
Chm
4-OH-Bnzl
i-Bu
2.02
440
I


IB-582
4-F-Bnzl
4-OH-Bnzl
i-Pnt
1.96
466
I


IB-583
4-F-Bnzl
4-OH-Bnzl
Bnzl
1.88
486
I


IB-584
Hdr-E
Ph-Et
Bnzl
1.75
420
I


IB-585
Hdr-E
Np-M
i-Bu
1.80
422
I


IB-586
Hdr-E
4-F-Bnzl
i-Bu
1.62
390
I


IB-587
i-Pnt
Hdr-E
4-OH-Bnzl
1.36
402
I


IB-588
Np-M
Hdr-E
Bnzl
1.89
456
I


IB-589
Np-M
Np-M
4-OH-Bnzl
2.06
568
I


IB-590
Np-M
4-F-Bnzl
i-Bu
2.16
486
I


IB-591
Chm
Hdr-E
4-OH-Bnzl
1.56
428
I


IB-592
Chm
4-F-Bnzl
Bnzl
2.23
476
I


IB-593
Ph-Et
Hdr-E
Np-M
1.88
470
I


IB-594
Ph-Et
i-Pnt
Np-M
2.24
496
I


IB-595
Ph-Et
Hxy
Np-M
2.33
510
I


IB-596
Np-M
Hdr-E
Ph-Et
1.94
470
I


IB-597
Np-M
Hxy
Ph-Et
2.34
510
I


IB-598
Np-M
Hxy
Np-M
2.36
546
I


IB-599
Np-M
4-F-Bnzl
i-Pnt
2.26
500
I


IB-600
Chm
4-F-Bnzl
i-Pnt
2.28
456
I


IB-601
Bnzl
Np-M
4-OH-Bnzl
1.98
518
I


IB-602
Bnzl
Hdr-E
Np-M
1.85
456
I


IB-603
Bnzl
i-Pnt
Np-M
2.29
482
I


IB-604
Bnzl
Hxy
Np-M
2.29
496
I


IB-605
Bnzl
i-Pr
Np-M
2.11
454
I


IB-606
Bnzl
4-OH-Bnzl
Np-M
1.96
518
I


IB-607
i-Bu
Hdr-E
4-OH-Bnzl
1.40
388
I


IB-608
i-Bu
4-F-Bnzl
Np-M
2.15
486
I


IB-609
i-Bu
Cbm-E
i-Bu
1.59
365
I


IB-610
Hdr-E
Cbx-E
Np-M
1.56
438
I


IB-611
i-Pnt
Cbx-E
i-Bu
1.68
380
I


IB-612
Np-M
Cbx-E
Bnzl
1.89
484
I


IB-613
Chm
Cbx-E
i-Pnt
1.95
420
I






















TABLE 3-20







IB-614
Chm
Cbx-E
Np-M
2.02
490
I


IB-615
4-F-Bnzl
Cbx-E
4-OH-Bnzl
1.53
468
I


IB-616
Bnzl
Cbx-E
Np-M
1.85
484
I


IB-617
Hdr-E
Bnzl
i-Pnt
1.79
286
I


IB-618
Hdr-E
Bnzl
Ph-Et
1.79
420
I


IB-619
Hdr-E
Bnzl
Bnzl
1.71
406
I


IB-620
Hdr-E
i-Bu
Ph-Et
1.74
386
I


IB-621
Hdr-E
i-Bu
Np-M
1.80
422
I


IB-622
Hdr-E
i-Bu
Bnzl
1.59
372
I


IB-623
Hdr-E
i-Bu
4-OH-Bnzl
1.48
388
I


IB-624
i-Pnt
Bnzl
Ph-Et
2.17
446
I


IB-625
Ph-Et
i-Bu
4-OH-Bnzl
1.88
448
I


IB-626
Chm
Bnzl
i-Pnt
2.35

I


IB-627
Chm
Bnzl
4-OH-Bnzl
2.01
474
I


IB-628
4-F-Bnzl
Bnzl
4-OH-Bnzl
1.94
486
I


IB-629
4-F-Bnzl
i-Bu
Bnzl
2.06
436
I


IB-630
4-F-Bnzl
i-Bu
i-Bu
2.03
402
I


IB-631
4-F-Bnzl
i-Bu
4-OH-Bnzl
1.90
452
I


IB-632
Bnzl
Bnzl
Ph-Et
2.12
466
I


IB-633
i-Bu
i-Bu
Ph-Et
2.11
398
I


IB-634
4-OH-Bnzl
Bnzl
Ph-Et
1.87
482
I


IB-635
4-OH-Bnzl
i-Bu
Np-M
1.97
484
I


IB-636
i-Pnt
Cbm-E
Ph-Et
1.80
427
I


IB-637
Chm
Cbm-E
Bnzl
1.83
439
I


IB-638
i-Pnt
Hdr-E
Bnzl
1.68
386
I


IB-639
i-Pnt
Hdr-E
i-Bu
1.62
352
I


IB-640
Ph-Et
Hdr-E
Bnzl
1.77
420
I


IB-641
Ph-Et
Hdr-E
i-Bu
1.77
386
I


IB-642
Ph-Et
4-F-Bnzl
4-OH-Bnzl
1.99
500
I


IB-643
Np-M
Hdr-E
i-Bu
1.87
422
I


IB-644
Np-M
i-Pnt
i-Bu
2.27
448
I


IB-645
Np-M
i-Pnt
4-OH-Bnzl
2.06
498
I


IB-646
Chm
Hdr-E
i-Bu
1.79
378
I


IB-647
Chm
i-Pnt
Bnzl
2.32
438
I


IB-648
Chm
i-Pnt
4-OH-Bnzl
2.07
454
I


IB-649
4-F-Bnzl
Hdr-E
Bnzl
1.76
424
I


IB-650
4-F-Bnzl
Hdr-E
i-Bu
1.70
390
I


IB-651
4-F-Bnzl
i-Pnt
Bnzl
2.17
450
I


IB-652
4-F-Bnzl
i-Pnt
i-Bu
2.14
416
I


IB-653
4-F-Bnzl
Np-M
i-Bu
2.19
486
I


IB-654
4-F-Bnzl
Hxy
Bnzl
2.24
464
I


IB-655
4-F-Bnzl
Hxy
i-Bu
2.24

I


IB-656
4-F-Bnzl
Hxy
4-OH-Bnzl
2.02
480
I


IB-657
Hdr-E
4-F-Bnzl
i-Pnt
1.83
404
I


IB-658
i-Pnt
Hdr-E
Ph-Et
1.79
400
I


IB-659
i-Pnt
Hdr-E
Np-M
1.94
436
I






















TABLE 3-21







IB-660
Ph-Et
Hxy
i-Pnt
2.39

I


IB-661
Np-M
Hdr-E
i-Pnt
1.98
436
I


IB-662
Np-M
Hxy
i-Pnt
2.44

I


IB-663
Chm
Hdr-E
Ph-Et
1.89
426
I


IB-664
Chm
Hdr-E
Np-M
1.98
462
I


IB-665
Chm
Hxy
Ph-Et
2.50

I


IB-666
Chm
Hxy
Np-M
2.54

I


IB-667
Chm
4-F-Bnzl
Ph-Et
2.31
490
I


IB-668
4-F-Bnzl
Hdr-E
i-Pnt
1.77
404
I


IB-669
4-F-Bnzl
Hdr-E
Ph-Et
1.78
438
I


IB-670
4-F-Bnzl
Hdr-E
Np-M
1.87
474
I


IB-671
4-F-Bnzl
i-Pnt
Ph-Et
2.21
464
I


IB-672
4-F-Bnzl
i-Pnt
Np-M
2.27
500
I


IB-673
4-F-Bnzl
Hxy
i-Pnt
2.30

I


IB-674
4-F-Bnzl
Hxy
Ph-Et
2.31

I


IB-675
4-F-Bnzl
Hxy
Np-M
2.37

I


IB-676
Bnzl
Hdr-E
Bnzl
1.70
406
I


IB-677
Bnzl
Hdr-E
i-Bu
1.66
372
I


IB-678
Bnzl
i-Pnt
4-OH-Bnzl
1.95
448
I


IB-679
Bnzl
Hxy
4-OH-Bnzl
2.02
462
I


IB-680
Bnzl
Hdr-E
i-Pnt
1.79
386
I


IB-681
Bnzl
Hdr-E
Ph-Et
1.76
420
I


IB-682
i-Bu
Hdr-E
i-Bu
1.62
338
I


IB-683
i-Bu
i-Pnt
i-Bu
2.11
364
I


IB-684
i-Bu
i-Pnt
4-OH-Bnzl
1.88
414
I


IB-685
i-Bu
Hdr-E
i-Pnt
1.71
352
I


IB-686
i-Bu
Hdr-E
Ph-Et
1.74
386
I


IB-687
i-Bu
Hdr-E
Np-M
1.82
422
I


IB-688
i-Bu
i-Pnt
Ph-Et
2.17
412
I


IB-689
i-Bu
4-F-Bnzl
i-Pnt
2.13
416
I


IB-690
i-Bu
4-F-Bnzl
Ph-Et
2.22

I


IB-691
Ph-Et
Bnzl
Cbx-E
1.84
448
I


IB-692
4-F-Bnzl
Bnzl
Cbx-E
1.79
452
I


IB-693
Np-M
i-Pnt
Cbx-E
1.99
464
I


IB-694
Cbx-E
Bnzl
i-Pnt
1.79
414
I


IB-695
Cbx-E
Bnzl
i-Bu
1.64
400
I


IB-696
Cbx-E
i-Bu
i-Pnt
1.77
380
I


IB-697
Bnzl
i-Pnt
Cbx-E
1.84
414
I


IB-698
Bnzl
Bnzl
Cbx-E
1.82
434
I


IB-699
Bnzl
i-Bu
Cbx-E
1.74
400
I


IB-700
i-Bu
i-Pnt
Cbx-E
1.81
380
I


IB-701
Hdr-E
Cbm-E
Ph-Et
1.46
401
I


IB-702
Hdr-E
Cbm-E
Bnzl
1.39
387
I


IB-703
i-Pnt
Cbm-E
Np-M
1.86
463
I


IB-704
i-Pnt
Cbm-E
Bnzl
1.71
413
I


IB-705
i-Pnt
Cbm-E
i-Bu
1.71
379
I






















TABLE 3-22







IB-706
i-Pnt
Cbm-E
4-OH-Bnzl
1.38
429
I


IB-707
Ph-Et
Cbm-E
Bnzl
1.77
447
I


IB-708
Ph-Et
Cbm-E
i-Bu
1.77
413
I


IB-709
Ph-Et
Cbm-E
4-OH-Bnzl
1.55
463
I


IB-710
Chm
Cbm-E
Ph-Et
1.91
453
I


IB-711
Chm
Cbm-E
i-Bu
1.84
405
I


IB-712
4-F-Bnzl
Cbm-E
Bnzl
1.76
451
I


IB-713
4-F-Bnzl
Cbm-E
i-Bu
1.71
417
I


IB-714
Hdr-E
i-Pnt
Bnzl
1.72
386
I


IB-715
Hdr-E
i-Pnt
i-Bu
1.71
352
I


IB-716
Hdr-E
i-Pnt
4-OH-Bnzl
1.61
402
I


IB-717
Hdr-E
Ph-Et
i-Bu
1.74
386
I


IB-718
i-Pnt
Np-M
i-Bu
2.29
448
I


IB-719
i-Pnt
Np-M
4-OH-Bnzl
2.02
498
I


IB-720
Ph-Et
i-Pnt
4-OH-Bnzl
1.99
462
I


IB-721
Np-M
Ph-Et
4-OH-Bnzl
2.09
532
I


IB-722
Chm
Ph-Et
i-Bu
2.32
438
I


IB-723
Chm
Np-M
4-OH-Bnzl
2.13
524
I


IB-724
4-F-Bnzl
i-Pnt
4-OH-Bnzl
2.00
466
I


IB-725
4-F-Bnzl
Ph-Et
i-Bu
2.16
450
I


IB-726
4-F-Bnzl
Ph-Et
4-OH-Bnzl
1.96
500
I


IB-727
Hdr-E
i-Pnt
Np-M
1.88
436
I


IB-728
Np-M
i-Pnt
Ph-Et
2.33
496
I


IB-729
Np-M
Ph-Et
Np-M
2.38

I


IB-730
Chm
i-Pnt
Ph-Et
2.36

I


IB-731
Chm
Np-M
i-Pnt
2.46

I


IB-732
4-F-Bnzl
Ph-Et
i-Pnt
2.22
464
I


IB-733
Bnzl
i-Pnt
Ph-Et
2.20
446
I


IB-734
Bnzl
Cbm-E
Bnzl
1.74
433
I


IB-735
i-Bu
Np-M
i-Bu
2.25
434
I


IB-736
i-Bu
i-Pnt
Np-M
2.27
448
I


IB-737
i-Bu
Cbm-E
Np-M
1.84
449
I


IB-738
i-Bu
Cbm-E
4-OH-Bnzl
1.40
415
I


IB-739
4-OH-Bnzl
i-Pnt
i-Bu
1.84
414
I


IB-740
4-OH-Bnzl
i-Pnt
Ph-Et
1.95
462
I


IB-741
4-OH-Bnzl
i-Pnt
Np-M
2.01
498
I


IB-742
4-OH-Bnzl
Cbm-E
Ph-Et
1.59
463
I


IB-743
4-OH-Bnzl
Cbm-E
Np-M
1.75
499
I


IB-744
Hdr-E
Bnzl
i-Bu
1.67
372
I


IB-745
Hdr-E
Bnzl
4-OH-Bnzl
1.51
422
I


IB-746
Hdr-E
i-Bu
i-Bu
1.57
338
I


IB-747
i-Pnt
Bnzl
Np-M
2.21
482
I


IB-748
i-Pnt
Bnzl
i-Bu
2.10
398
I


IB-749
i-Pnt
Bnzl
4-OH-Bnzl
1.82
448
I


IB-750
i-Pnt
i-Bu
Ph-Et
2.16
412
I


IB-751
i-Pnt
i-Bu
Np-M
2.18
448
I






















TABLE 3-23







IB-752
i-Pnt
i-Bu
Bnzl
2.06
398
I


IB-753
i-Pnt
i-Bu
i-Bu
2.04
364
I


IB-754
i-Pnt
i-Bu
4-OH-Bnzl
2.34

I


IB-755
Ph-Et
Bnzl
i-Pnt
2.22
446
I


IB-756
Ph-Et
Bnzl
Bnzl
2.10
466
I


IB-757
Ph-Et
Bnzl
i-Bu
2.13
432
I


IB-758
Ph-Et
Bnzl
4-OH-Bnzl
1.90
482
I


IB-759
Ph-Et
i-Bu
Bnzl
2.08
432
I


IB-760
Ph-Et
i-Bu
i-Bu
2.10
398
I


IB-761
Np-M
Bnzl
i-Bu
2.22
468
I


IB-762
Np-M
i-Bu
i-Bu
2.16
434
I


IB-763
Np-M
i-Bu
4-OH-Bnzl
1.97
484
I


IB-764
Chm
Bnzl
Ph-Et
2.31
472
I


IB-765
Chm
Bnzl
i-Bu
2.24
424
I


IB-766
Chm
i-Bu
Ph-Et
2.27
438
I


IB-767
Chm
i-Bu
Np-M
2.32
474
I


IB-768
Chm
i-Bu
Bnzl
2.19
424
I


IB-769
Chm
i-Bu
i-Bu
2.22
390
I


IB-770
Chm
i-Bu
4-OH-Bnzl
1.99
440
I


IB-771
4-F-Bnzl
Bnzl
i-Pnt
2.18
450
I


IB-772
4-F-Bnzl
Bnzl
Bnzl
2.10
470
I


IB-773
4-F-Bnzl
Bnzl
i-Bu
2.12
436
I


IB-774
4-F-Bnzl
i-Bu
Ph-Et
2.11
450
I


IB-775
Ph-Et
i-Pnt
Bnzl
2.18
446
I


IB-776
Bnzl
i-Pnt
Bnzl
2.13
432
I


IB-777
Bnzl
Bnzl
Np-M
2.20
502
I


IB-778
Bnzl
i-Bu
Ph-Et
2.14
432
I


IB-779
Bnzl
i-Bu
4-OH-Bnzl
1.85
434
I


IB-780
i-Bu
i-Pnt
Bnzl
2.15
398
I


IB-781
i-Bu
Bnzl
i-Pnt
2.19
398
I


IB-782
i-Bu
Bnzl
Np-M
2.16
468
I


IB-783
i-Bu
Bnzl
4-OH-Bnzl
1.85
434
I


IB-784
i-Bu
i-Bu
Np-M
2.19
434
I


IB-785
i-Bu
i-Bu
4-OH-Bnzl
1.81
400
I


IB-786
4-OH-Bnzl
Bnzl
i-Pnt
1.90
448
I


IB-787
4-OH-Bnzl
Bnzl
i-Bu
1.80
434
I


IB-788
Ph-Et
Cbm-E
Np-M
1.91
497
I


IB-789
Ph-Et
i-Pr
Np-M
2.19
468
I


IB-790
Np-M
Cbm-E
Bnzl
1.88
483
I


IB-791
i-Pnt
Np-M
Bnzl
2.27
483
I


IB-792
Ph-Et
Np-M
i-Bu
2.29
482
I


IB-793
Ph-Et
Np-M
4-OH-Bnzl
2.09
532
I


IB-794
Np-M
i-Pnt
Bnzl
2.29
482
I


IB-795
Np-M
Ph-Et
Bnzl
2.32
516
I


IB-796
Np-M
Np-M
i-Bu
2.37
518
I


IB-797
Np-M
4-F-Bnzl
Bnzl
2.24
520
I






















TABLE 3-24







IB-798
Chm
Np-M
Bnzl
2.41
508
I


IB-799
4-F-Bnzl
Np-M
Bnzl
2.25
520
I


IB-800
Ph-Et
Np-M
i-Pnt
2.36
497
I


IB-801
Ph-Et
4-F-Bnzl
Np-M
2.27
534
I


IB-802
Np-M
i-Pnt
Np-M
2.42
532
I


IB-803
Np-M
Np-M
i-Pnt
2.41
532
I


IB-804
Np-M
Np-M
Ph-Et
2.39
566
I


IB-805
Np-M
4-F-Bnzl
Ph-Et
2.28
534
I


IB-806
Np-M
4-F-Bnzl
Np-M
2.36
570
I


IB-807
Chm
Np-M
Ph-Et
2.47
522
I


IB-808
Chm
Np-M
Np-M
2.47
558
I


IB-809
4-F-Bnzl
Np-M
Ph-Et
2.28
534
I


IB-810
4-F-Bnzl
Np-M
Np-M
2.31
570
I


IB-811
Bnzl
Np-M
i-Pnt
2.30
482
I


IB-812
Bnzl
4-F-Bnzl
Np-M
2.21
520
I


IB-813
Bnzl
Cbm-E
Np-M
1.86
483
I


IB-814
i-Bu
Np-M
Np-M
2.39
518
I


IB-815
4-OH-Bnzl
Np-M
Bnzl
2.01
518
I


IB-816
4-OH-Bnzl
Np-M
Ph-Et
2.05
532
I


IB-817
Np-M
Bnzl
Ph-Et
2.32
516
I


IB-818
Np-M
Cbm-E
Np-M
2.00
533
I


IB-819
Chm
Bnzl
Np-M
2.40
508
I


IB-820
Hdr-E
Np-M
Bnzl
1.89
456
I


IB-821
i-Pnt
Ph-Et
4-OH-Bnzl
1.94
462
I


IB-822
Ph-Et
i-Pnt
i-Bu
2.13
412
I


IB-823
Ph-Et
Np-M
Bnzl
2.33
516
I


IB-824
Ph-Et
Hxy
i-Bu
2.35
426
I


IB-825
Np-M
Np-M
Bnzl
2.39
552
I


IB-826
Chm
Ph-Et
4-OH-Bnzl
2.02
488
I


IB-827
Hdr-E
i-Pnt
Ph-Et
1.82
400
I


IB-828
Hdr-E
Np-M
i-Pnt
1.98
436
I


IB-829
Hdr-E
Np-M
Ph-Et
1.99
470
I


IB-830
Hdr-E
Np-M
Np-M
2.02
506
I


IB-831
Hdr-E
4-F-Bnzl
Np-M
1.90
474
I


IB-832
i-Pnt
Np-M
Ph-Et
2.45
496
I


IB-833
i-Pnt
Np-M
Np-M
2.45
532
I


IB-834
i-Pnt
4-F-Bnzl
Np-M
2.24
500
I


IB-835
Chm
i-Pnt
Np-M
2.46
488
I


IB-836
Bnzl
Ph-Et
4-OH-Bnzl
1.98
482
I


IB-837
Bnzl
Np-M
Bnzl
2.30
502
I


IB-838
Bnzl
Ph-Et
Np-M
2.28
516
I


IB-839
i-Bu
Hxy
Bnzl
2.24
412
I


IB-840
i-Bu
4-F-Bnzl
Bnzl
2.11
436
I


IB-841
4-OH-Bnzl
Hdr-E
Np-M
1.72
472
I


IB-842
4-OH-Bnzl
Np-M
Np-M
2.08
568
I


IB-843
4-OH-Bnzl
i-Bu
Ph-Et
1.89
448
I






















TABLE 3-25







IB-844
Ph-Et
Cbx-E
i-Bu
0.85
414
C


IB-845
Ph-Et
Cbx-E
i-Pnt
0.89
428
C


IB-846
4-OH-Bnzl
Cbx-E
i-Pnt
0.73
430
C


IB-847
4-OH-Bnzl
Cbx-E
Bnzl
0.75
450
C


IB-848
4-OH-Bnzl
Cbx-E
Ph-Et
0.74

C


IB-849
Bnzl
Cbx-E
i-Bu
0.80
400
C


IB-850
Bnzl
Cbx-E
i-Pnt
0.84
414
C


IB-851
Bnzl
Cbx-E
Ph-Et
0.85
448
C


IB-852
i-Bu
Cbx-E
Ph-Et
0.84
414
C


IB-853
i-Bu
Cbx-E
4-OH-Bnzl
0.54
416
C


IB-854
i-Pnt
Cbx-E
Ph-Et
0.84
428
C


IB-855
i-Pnt
Cbx-E
4-OH-Bnzl
0.68
430
C


IB-856
Chm
Cbx-E
Ph-Et
0.91
454
C


IB-857
Chm
Cbx-E
4-OH-Bnzl
0.77
456
C


IB-858
i-Pnt
Cbx-E
Bnzl
0.80
414
C


IB-859
Chm
Cbx-E
Bnzl
0.90
440
C


IB-860
4-OH-Bnzl
Cbx-E
i-Bu
0.69
416
C
















TABLE 3-26









embedded image



















Compound




Retention
Mass
Measurement


number
R1
R2
R3
R4
RT (min)
(M + H)+
condition





IB-861
methyl
2-(1H-indol-3-yl)ethyl
benzyl
H
1.212
429
B


IB-862
benzyl
Np-M
i-Bu
H
1.29 
468
B


IB-863
benzyl
4-(trifluoromethyl)benzyl
i-Bu
H
1.298
486
B


IB-864
4-Cl-Bnzl
benzyl
i-Bu
H
1.288
452
B


IB-865
3-Cl-Bnzl
benzyl
i-Bu
H
1.293
452
B


IB-866
4-methoxybenzyl
benzyl
i-Bu
H
1.263
448
B


IB-867
4-methylbenzyl
benzyl
i-Bu
H
1.288
432
B


IB-868
i-Pnt
i-Bu
benzyl
H
1.277
398
B


IB-869
i-Bu
i-Bu
4-Cl-Bnzl
H
1.275
418
B


IB-870
i-Bu
i-Pnt
benzyl
H
1.287
398
B


IB-871
i-Bu
4-Cl-Bnzl
i-Bu
H
1.285
418
B


IB-872
4-hydroxybenzyl
benzyl
i-Bu
H
1.187
434
B























TABLE 3-27







IB-873
4-(dimethyl-
benzyl
i-Bu
H
1.255
461
B



amino)-









benzyl








IB-874
4-(tert-
benzyl
i-Bu
H
1.345
474
B



butyl)-









benzyl








IB-875
i-Bu
benzyl
i-Pnt
H
1.283
398
B


IB-876
i-Pnt
benzyl
i-Bu
H
1.067
398
B


IB-877
4-(trifluoro-
benzyl
i-Bu
H
1.29
502
B



methyl)-









benzyl








IB-878
4-ethoxy-
benzyl
i-Bu
H
1.275
462
B



benzyl








IB-879
benzyl
naphthalen-
i-Bu
H
1.282
468
B




2-ylmethyl







IB-880
4-methyl-
benzyl
i-Bu
ethyl
1.332
460
B



benzyl








IB-881
4-methyl-
benzyl
i-Bu
i-Bu
1.495
488
B



benzyl








IB-882
4-methyl-
benzyl
i-Bu
acetyl
1.223
474
B



benzyl








IB-883
4-methyl-
benzyl
i-Bu
3-methyl-
1.312
516
B



benzyl


butanoyl





IB-884
4-methyl-
benzyl
i-Bu
2-phenyl-
1.3
550
B



benzyl


acetyl





IB-885
4-methyl-
benzyl
i-Bu
methoxy-
1.267
490
B



benzyl


carbonyl





IB-886
4-methyl-
benzyl
i-Bu
2-methyl-
1.328
532
B



benzyl


propoxy-









carbonyl





IB-887
4-methyl-
benzyl
i-Bu
benzyloxy-
1.347
566
B



benzyl


carbonyl





IB-888
4-methyl-
benzyl
i-Bu
amino-
1.173
475
B



benzyl


carbonyl





IB-889
4-methyl-
benzyl
i-Bu
N-benzyl-
1.288
565
B



benzyl


amino-









carbonyl





IB-890
benzyl
pyridin-
i-Bu
H
1.11
419
B




4-ylmethyl







IB-891
4-(dimethyl-
3-hydroxy-
i-Bu
H
1.223
477
B



amino)-
benzyl








benzyl








IB-892
4-(dimethyl-
4-hydroxy-
i-Bu
H
1.208
477
B



amino)-
benzyl








benzyl








IB-893
4-methoxy-
benzyl
benzyl
H
0.98
482
C



benzyl








IB-894
4-methoxy-
benzyl
benzyl
tert-
1.06
582
C



benzyl


butoxy-









carbonyl























TABLE 3-28







IB-895
methyl
benzyl
benzyl
tert-
0.97
476
C






butoxy-









carbonyl





IB-896
methyl
benzyl
benzyl
H
0.84
376
C


IB-897
phenethyl
benzyl
2-(tert-
H
1.13
534
C





butyl-









dimethyl-









silyloxy)-









ethyl






IB-898
cyclo-
4-(tert-
2-(tert-
H
1.16
554
C



pentyl-
butoxy)-
butoxy-







methyl
benzyl
carbonyl)-









ethyl






IB-899
cyclo-
4-(tert-
2-(tert-
methoxy-
1.04
612
C



pentyl-
butoxy)-
butoxy-
carbonyl






methyl
benzyl
carbonyl)-









ethyl






IB-900
cyclo-
4-
2-carboxy-
H
0.77
442
C



pentyl-
hydroxy-
ethyl







methyl
benzyl







IB-901
cyclo-
4-
2-carboxy-
methoxy-
0.76
500
C



pentyl-
hydroxy-
ethyl
carbonyl






methyl
benzyl







IB-902
4-nitro-
4-(tert-
2-(tert-
H
1.06
607
C



benzyl
butoxy)-
butoxy-








benzyl
carbonyl)-









ethyl






IB-903
phenethyl
benzyl
2-hydroxy-
H
0.85
420
C





ethyl






IB-904
phenethyl
benzyl
2-hydroxy-
acetyl
0.81
462
C





ethyl






IB-905
phenethyl
benzyl
2-hydroxy-
methoxy-
0.86
478
C





ethyl
carbonyl





IB-906
phenethyl
benzyl
2-hydroxy-
ethyl
0.9
448
C





ethyl






IB-907
4-nitro-
4-(tert-
2-(tert-
methoxy-
1.04
665
C



benzyl
butoxy)-
butoxy-
carbonyl







benzyl
carbonyl)-









ethyl






IB-908
1-naphthyl-
benzyl
benzyl
benzyl
1.14
592
C



methyl








IB-909
4-amino-
4-(tert-
2-(tert-
methoxy-
0.94
635
C



benzyl
butoxy)-
butoxy-
carbonyl







benzyl
carbonyl)-









ethyl






IB-910
4-(cyclo-
4-(tert-
2-(tert-
methoxy-
1.05
731
C



pentyl-
butoxy)-
butoxy-
carbonyl






carbonyl-
benzyl
carbonyl)-







amino)-

ethyl







benzyl








IB-911
4-(2-car-
4-(tert-
2-(tert-
methoxy-
0.92
735
C



boxyethyl-
butoxy)-
butoxy-
carbonyl






carbonyl-
benzyl
carbonyl)-







amino)-

ethyl







benzyl








IB-912
4-(2-car-
4-(tert-
2-(tert-
methoxy-
0.9
734
C



boxyethyl-
butoxy)-
butoxy-
carbonyl






carbonyl-
benzyl
carbonyl)-







amino)-

ethyl







benzyl























TABLE 3-29







IB-913
4-nitro-
4-hydroxy-
2-carboxyl
H
0.76
495
C



benzyl
benzyl
ethyl






IB-914
4-(cyclo-
4-hydroxy-
2-carboxyl
methoxy-
0.79
619
C



pentyl-
benzyl
ethyl
carbonyl






carbonyl-









amino)-









benzyl








IB-915
4-nitro-
4-(tert-
2-(tert-
tert-butoxy-
1.12
707
C



benzyl
butoxy)-
butoxy-
carbonyl







benzyl
carbonyl)-









ethyl






IB-916
4-(cyclo-
4-(tert-
2-(tert-
methoxy-
1.14
717
C



pentyl-
butoxy)-
butoxy-
carbonyl






methyl-
benzyl
carbonyl)-







amino)-

ethyl







benzyl








IB-917
4-(cyclo-
4-(tert-
2-(tert-
tert-
1.14
774
C



pentyl-
butoxy)-
butoxy-
butoxy-






carbonyl-
benzyl
carbonyl)-
carbonyl






amino)-

ethyl







benzyl








IB-918
4-(cyclo-
4-(tert-
2-(tert-
tert-
1.24
760
C



pentyl-
butoxy)-
butoxy-
butoxy-






methyl-
benzyl
carbonyl)-
carbonyl






amino)-

ethyl







benzyl








IB-919
4-nitro-
4-(tert-
2-(tert-
formyl
0.98
635
C



benzyl
butoxy)-
butoxy-








benzyl
carbonyl)-









ethyl






IB-920
4-(2-car-
4-hydroxy-
2-carboxyl
methoxy-
0.61
622
C



bamoyl-
benzyl
ethyl
carbonyl






ethyl-









carbonyl-









amino)-









benzyl








IB-921
4-(cyclo-
4-hydroxy-
2-carboxyl
methoxy-
0.82
605
C



pentyl-
benzyl
ethyl
carbonyl






methyl-









amino)-









benzyl








IB-922
4-(cyclo-
4-hydroxy-
2-carboxyl
H
0.79
561
C



pentyl-
benzyl
ethyl







carbonyl-









amino)-









benzyl








IB-923
4-(cyclo-
4-hydroxy-
2-carboxyl
H
0.75
547
C



pentyl-
benzyl
ethyl







methyl-









amino)-









benzyl
















TABLE 3-30







Formula XXIB




embedded image




















Compound





Retention
Mass
Measurement


number
R1
R2A
R2B
R3
R4
RT (min)
(M + H)+
condition





IB-924
4-Me-Bnzl
H
Bnzl
i-Bu
N-isobutyl-
2.88
531
 B1







aminocarbonyl





IB-925
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
2.93
466
 B1


IB-926
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
2.94
466
 B1


IB-927
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
2.84
462
 B1


IB-928
i-Bu
H
4-Me-Bnzl
Ph-Et
H
2.93
446
 B1


IB-929
i-Bu
H
2-Npm
Ph-Et
H
2.97
482
 B1


IB-930
i-Bu
H
Bnzl
Ph-Pr
H
1.36
446
B


IB-931
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
1.31
480
B


IB-932
i-Bu
H
3-F-Bnzl
Ph-Pr
H
1.35
464
B


IB-933
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
1.38
460
B


IB-934
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
1.36
476
B


IB-935
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
1.33
494
B


IB-936
i-Bu
H
3-F-Bnzl
Ph-Bu
H
1.29
478
B


IB-937
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
1.38
474
B


IB-938
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
1.31
491
B


IB-939
i-Bu
H
Bnzl
Ph-Bu
H
1.32
461
B


IB-940
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
1.31
478
B


IB-941
1-Npm
H
pentyl
Ph-Et
H
1.08
496
C


IB-942
1-Npm
H
cyclohexyl
Ph-Et
H
1.08
508
C


IB-943
1-Npm
H
cyclopentyl
Ph-Et
H
1.06
494
C














IB-944
1-Npm
piperidine
Ph-Et
H
1.04
494
C


IB-945
1-Npm
piperidine
Ph-Et
H
1.00
480
C















IB-946
1-Npm
H
Hxy
4-methylphenethyl
H
1.14
524
C


IB-947
1-Npm
H
Hxy
2-(naphthalen-2-yl)ethyl
H
1.16
560
C


IB-948
1-Npm
H
heptyl
Ph-Et
H
1.14
524
C


IB-949
1-Npm
H
Hxy
4-isopropylphenethyl
H
1.19
552
C


IB-950
1-Npm
H
Hxy
cyclohexylethyl
H
1.19
516
C


IB-951
tBuO-E
H
4-fluorophenethyl
1-Npm
H
1.06
544
C


IB-952
H
H
4-tBuO-Bnzl
tBOC-E
methoxycarbonyl
0.93
530
C


IB-953 **
2-phenylacetyl
H
4-tBuO-Bnzl
tBOC-E
methoxycarbonyl
 1.17,
648
C








1.20
























TABLE 3-31







IB-
3-
H
4-tBuO-
tBOC-
methoxy-
1.16,
614
C


954
methyl-

Bnzl
E
carbonyl
1.21




**
buta-










noyl









IB-
2-
H
4-OH-
Cbx-E
methoxy-
0.78,
536
C


955
phenyl-

Bnzl

carbonyl
0.83




**
acetyl









IB-
3-
H
4-OH-
Cbx-E
methoxy-
0.75,
502
C


956
methyl-

Bnzl

carbonyl
0.81




**
buta-










noyl









IB-
i-Bu
H
Ph-Et
Ph-Et
H
2.89
446
B1


957










IB-
i-Bu
H
1-Npm
Ph-Et
H
2.97
482
B1


958










IB-
Chm
H
tBuO-E
1-Npm
H
1.10
518
C


959










IB-
tBuO-
H
Ph-Et
1-Npm
H
1.06
526
C


960
E









IB-
Hdr-E
H
4-
1-Npm
H
0.90
488.3
C


961


fluoro-










phenethyl







IB-
3-
H
4-F-Bnzl
1-Npm
H
1.04
544.4
C


962
tert-










butoxy-










propyl









IB-
tBuO-
H
4-Cl-Bnzl
1-Npm
H
1.07,
546.3
C


963
E




1.09




IB-
Hdr-E
H
4-Cl-Bnzl
1-Npm
H
0.92
490.3
C


964










IB-
Hdr-E
H
4-Cl-Bnzl
1-Npm
H
0.92
490.2
C


965










IB-
3-
H
4-F-Bnzl
1-Npm
H
0.87
488.3
C


966
hydroxy-










propyl









IB-
1-Npm
H
Hxy
3-
H
1.14
524.4
C


967



methyl-










phen-










ethyl






IB-
1-Npm
H
β-
Ph-Et
H
1.01
546.4
C


968


hydroxy-










phenethyl







IB-
1-Npm
H
α-
Ph-Et
H
1.01
560.4
C


969


hydroxy-










methyl-










phenethyl







IB-
1-Npm
H
α-
Ph-Et
H
1.03
560.4
C


970


hydroxy-










methyl-










phenethyl







IB-
4-Nt-
H
Bnzl
tBOC-
H
0.97
535
C


971
Bnzl


E






IB-
4-Nt-
H
Bnzl
tBOC-
ethoxy-
0.98
563
C


972
Bnzl


E
carbonyl





IB-
H
H
Bnzl
tBOC-
ethoxy-
0.87
472
C


973



E
carbonyl





IB-
phenyl-
H
Bnzl
tBOC-
ethoxy-
0.14,
590
C


974
acetyl



carbonyl
0.16




IB-
phenyl-
H
Bnzl
Cbx-E
ethoxy-
0.91,
534
C


975
acetyl



carbonyl
0.97




IB-
4-
H
Bnzl
tBOC-
ethoxy-
0.87
577
C


976
amino


E
carbonyl






benzyl









IB-
4-
H
Bnzl
tBOC-
ethoxy-
1.09
659
C


977
(cyclo-


E
carbonyl






pentyl-










methyl-










amino)-










benzyl









IB-
4-
H
Bnzl
Cbx-E
ethoxy-
0.93
603
C


978
(cyclo-



carbonyl






pentyl-










methyl-










amino)-










benzyl









IB-
4-
H
Bnzl
tBOC-
ethoxy-
1.00
673
C


979
(cyclo-


E
carbonyl






pentyl-










carbonyl-










amino)-










benzyl









IB-
3-
H
Bnzl
tBOC-
ethoxy-
1.13,
556
C


980
methyl-


E
carbonyl
1.16




**
butanoyl
























TABLE 3-32







IB-
H
H
Bnzl
Bnzl
tert-
0.93
462
C


981




butoxy-










carbonyl





IB-
3-
H
Bnzl
Cbx-E
ethoxy-
0.89,
500
C


982
methyl-



carbonyl
0.96




**
butanoyl









IB-
iso-
H
Bnzl
Cbx-E
ethoxy-
0.94
502
C


983
propoxy-



carbonyl






carbonyl









IB-
phenyl-
H
Bnzl
3-
ethoxy-
1.05,
562
C


984
acetyl


ethoxy-
carbonyl
1.08




**



3-oxo-










propyl






IB-
benzoyl
H
Bnzl
Bnzl
tert-
1.22
566
C


985




butoxy-










carbonyl





IB-
phenyl-
H
Bnzl
Bnzl
tert-
1.23
580
C


986
acetyl



butoxy-










carbonyl





IB-
4-
H
Bnzl
Cbx-E
ethoxy-
0.87
617
C


987
(cyclo



carbonyl






pentyl-










carbonyl-










amino)-










benzyl









IB-
1-Npm
H
4-F-Bnzl
2-OH-
H
0.89
474.3
C


988



Et






IB-
2-OH-
H
Ph-Et
1-Npm
H
0.89
470.3
C


989
Et









IB-
4-
H
Bnzl
i-Bu
H
1.02
490.3
C


990
tBuO-Bnzl









IB-
4-
H
i-Bu
Bnzl
H
1.03
490.4
C


991
tBuO-Bnzl









IB-
2-
H
Bnzl
1-Npm
H
1.04
512.4
C


992
OtBu-Et









IB-
2-OH-
H
Bnzl
1-Npm
H
0.87
456.3
C


993
Et









IB-
4-OH-
H
i-Bu
Bnzl
H
0.85
434.3
C


994
Bnzl









IB-
1-Npm
H
4-F-Bnzl
2-
H
1.17
588.4
C


995



OTBS-Et






Ring formed together by R2A and R2B



** IB-953, 954, 955, 956, 980, 982, and 984 are mixtures of cis-trans isomers. For this reason, two values are shown for the retention of LCMS.













TABLE 4-1









embedded image


















Compound




Synthesis



number
R1
R2
R3
R4
method
Intermediate





IF-1
i-Bu
Bnzl
Bnzl
H
EX
IIF-1


IF-2
i-Bu
i-Bu
i-Bu
H
IF-1
IIF-2


IF-3
i-Bu
i-Bu
Bnzl
H
IF-1
IIF-3


IF-4
Bnzl
i-Bu
i-Bu
H
IF-1
IIF-4


IF-5
i-Bu
Bnzl
i-Bu
H
IF-1
IIF-5


IF-6
Bnzl
i-Bu
Bnzl
H
IF-1
IIF-6


IF-7
Bnzl
Bnzl
i-Bu
H
IF-1
IIF-7


IF-8
Bnzl
Bnzl
Bnzl
H
IF-1
IIF-8


IF-9
i-Pnt
Bnzl
Bnzl
H
IF-1
IIF-9


IF-10
Bnzl
Bnzl
i-Pnt
H
IF-1
IIF-10


IF-11
i-Bu
Bnzl
Ph-Et
H
IF-1
IIF-11


IF-12
i-Bu
Ph-Et
Bnzl
H
IF-1
IIF-12


IF-13
i-Bu
Bnzl
3-Me-Bnzl
H
IF-1
IIF-13


IF-14
i-Bu
Bnzl
4-Me-Bnzl
H
IF-1
IIF-14


IF-15
i-Bu
3-Me-Bnzl
Bnzl
H
IF-1
IIF-15


IF-16
i-Bu
4-Me-Bnzl
Bnzl
H
IF-1
IIF-16


IF-17
i-Bu
3-Cl-Bnzl
Bnzl
H
IF-1
IIF-17


IF-18
i-Bu
4-Cl-Bnzl
Bnzl
H
IF-1
IIF-18


IF-19
3,4-Cl2-Bnzl
Bnzl
i-Bu
H
IF-1
IIF-19


IF-20
Bnzl
3,4-Cl2-Bnzl
i-Bu
H
IF-1
IIF-20


IF-22
i-Bu
4-OH-Bnzl
Bnzl
H
IF-40
IF-23


IF-23
i-Bu
4-(tert-butoxy)benzyl
Bnzl
H
IF-1
IIF-23


IF-24
i-Bu
Np-M
Bnzl
H
IF-1
IIF-24


IF-25
i-Bu
Hdr-E
Bnzl
H
IF-1
IIF-25


IF-26
i-Bu
Cbx-E
Bnzl
H
EX
IF-27


IF-27
i-Bu
2-(tert-butoxy)-2-oxoethyl
Bnzl
H
IF-1
IIF-27


IF-28
i-Bu
Cbm-E
Bnzl
H
IF-1
IIF-28


IF-29
i-Bu
4-aminobutyl
Bnzl
H
IB-29
IF-30


IF-30
i-Bu
4-((tert-butoxycarbonyl)amino)butyl
Bnzl
H
IF-1
IIF-30


IF-31
i-Bu
Chm
Bnzl
H
IF-1
IIF-31


IF-32
i-Bu
(tetrahydro-2H-pyran-2-yl)methyl
Bnzl
H
IF-1
IIF-32


IF-33
i-Bu
Bnzl
4-aminobutyl
H
EX
IF-34






















TABLE 4-2







IF-34
i-Bu
Bnzl
4-((tert-
H
IF-1
IIF-34





butoxy-








carbonyl) -








amino)butyl





IF-35
i-Bu
Bnzl
Cbx-E
H
IB-35
IF-73


IF-36
i-Bu
Bnzl
3-
H
IF-1
IIF-36





methoxy-








3-








oxopropyl





IF-38
i-Bu
Bnzl
Chm
H
IF-1
IIF-38


IF-39
Chm
Bnzl
Bnzl
H
IF-1
IIF-39


IF-40
4-OH-
Bnzl
Bnzl
H
EX
IF-41



Bnzl







IF-41
4-
Bnzl
Bnzl
H
EX
IIF-41



(tert-








butoxy)-








benzyl







IF-42
Np-M
Bnzl
Bnzl
H
IF-1
IIF-42


IF-43
i-Bu
Bnzl
Bnzl
Ac
EX
IF-1


IF-44
i-Bu
i-Bu
i-Bu
Ac
IF-43
IF-2


IF-45
i-Bu
i-Bu
Bnzl
Ac
IF-43
IF-3


IF-46
Bnzl
i-Bu
i-Bu
Ac
IF-43
IF-4


IF-47
i-Bu
Bnzl
i-Bu
Ac
IF-43
IF-5


IF-49
Bnzl
Bnzl
i-Bu
Ac
IF-43
IF-7


IF-50
Bnzl
Bnzl
Bnzl
Ac
IF-43
IF-8


IF-54
i-Bu
Ph-Et
Bnzl
Ac
IF-43
IF-12


IF-57
i-Bu
3-Me-Bnzl
Bnzl
Ac
IF-43
IF-15


IF-58
i-Bu
4-Me-Bnzl
Bnzl
Ac
IF-43
IF-16


IF-68
i-Bu
Bnzl
Bnzl
Bz
IB-68
IF-1


IF-69
i-Bu
Bnzl
Bnzl
Et
IB-69
IF-1


IF-70
i-Bu
Bnzl
Bnzl
meth-
IB-70
IF-1






oxy-








carbonyl




IF-71
i-Bu
Bnzl
Bnzl
Me
EX
IF-1


IF-72
Bnzl
Bnzl
i-Bu
Et
IB-69
IF-7


IF-73
i-Bu
Bnzl
Cbx-E
tBOC
IB-73
IF-74


IF-74
i-Bu
Bnzl
3-
tBOC
IB-74
IF-36





methoxy-








3-








oxopropyl





IF-76
3-
Bnzl
Bnzl
H
IF-1
IIF-76



(tert-








butoxy)-








3-








oxo-








propyl







IF-77
Bnzl
Bnzl
4-OH-Bnzl
H
IF-1
IIF-77


IF-80
Np-M
Bnzl
Pr
H
IB-1
IIF-80





















TABLE 4-3





Compound

LCMS tR
Mass
Elution
Yield


number
Name of compound
(min)
(M + H)+
condition
(%)







IF-1
(3S*,3aS*,6S*,7R*,7aS*)-N,7-
0.99
418
B
62



dibenzyl-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-







c]pyridine-6-carboxamide






IF-2
(3S*,3aS*,6S*,7R*,7aS*)-N,1,7-
0.93
350
B
73



triisobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide





















TABLE 4-4







IF-3 
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N,1-
0.96
384
B
67



diisobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-4 
(3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N,7-
0.97
384
B
82



diisobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-5 
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1,7-
0.95
384
B
73



diisobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-6 
(3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl-
1.00
418
B
68



N-isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-7 
(3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-
0.99
418
B
64



7-isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-8 
(3S*,3aS*,6S*,7R*,7aS*)-N,1,7-
1.02
452
B
69



tribenzyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-9 
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
1.01
432
B
47



1-isopentyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-10
(3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-
1.02
432
B
60



7-isopentyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-11
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
0.99
432
B
63



isobutyl-7-phenethyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-12
(3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-7-
1.01
432
B
60



isobutyl-N-phenethyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-13
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
1.01
432
B
55



isobutyl-7-(3-methylbenzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-14
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
1.01
432
B
57



isobutyl-7-(4-methylbenzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-15
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
1.02
432
B
62



isobutyl-N-(3-methylbenzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-16
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
1.02
432
B
63



isobutyl-N-(4-methylbenzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-17
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-
1.03
452
B
69



(3-chlorobenzyl)-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-18
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-
1.03
452
B
68



(4-chlorobenzyl)-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-19
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
1.13
486
B
38



(3,4-dichlorobenzyl)-7-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide





















TABLE 4-5







IF-20
(3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N-
1.06
486
B
37



(3,4-dichlorobenzyl)-7-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-22
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-(4-
0.71
434
A
95



hydroxybenzyl)-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-23
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
0.87
490
A
95



isobutyl-N-(4-(tert-butoxy)benzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-24
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
0.85
468
A
77



isobutyl-N-(naphthalen-1-







ylmethyl)octahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-25
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-(2-
0.65
372
A
95



hydroxyethyl)-1-isobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-26
3-((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
0.66
400
A
100



isobutyloctahydro-1H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide)propanoic acid






IF-27
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
0.81
456
A
100



isobutyl-N-(2-(tert-butoxy)-2-







oxoethyl)octahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-28
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-
0.67
399
A
53



N-(3-amino-3-oxopropyl)-1-







isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-29
(3S*,3aS*,6S*,7R*,7aS*)-N-(4-
0.83
399
A
100



aminobutyl)-7-benzyl-1-







isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-30
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
0.81
499
A
80



isobutyl-N-(4-((tert-







butoxycarbonyl)amino)butyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-31
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-
0.85
424
A
22



cyclohexylmethyl-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-32
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-
 0.76,
426
A
93



isobutyl-N-((tetrahydro-2H-pyran-2-
0.75






yl)methyl)octahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-33
(3S*,3aS*,6S*,7R*,7aS*)-7-(4-
0.62
399
A
100



aminobutyl)-N-benzyl-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-34
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
0.82
499
A
78



isobutyl-7-(4-((tert-







butoxycarbonyl)amino)butyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-35
3-((3S*,3aS*,6S*,7R*,7aS*)-3a-
0.65
400
A
100



(benzylcarbamoyl)-1-isobutyloctahydro-







1H-3,6-methanopyrrolo[3,2-c]pyridin-







7-yl)propanoic acid






IF-36
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
0.72
414
A




isobutyl-7-(3-methoxy-3-







oxopropyl)octahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-38
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-7-
0.86
424
A
83



(cyclohexylmethyl)-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide





















TABLE 4-6







IF-39
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
0.86
458
A
62



1-cyclohexylmethyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-40
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
0.75
468
A
63



1-(4-hydroxybenzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-41
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
0.90
524
A
52



1-(4-(tert-butoxy)benzyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-42
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
0.88
502
A
65



1-(naphthalen-1-ylmethyl)octahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-43
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,7-
1.08
460
B
51



dibenzyl-1-isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-44
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-
1.04
392
B
82



N,1,7-triisobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-45
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7-
1.05
426
B
83



benzyl-N,1-diisobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-46
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-1-
1.05
426
B
79



benzyl-N,7-diisobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-47
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N-
1.06
426
B
88



benzyl-1,7-diisobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-49
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,1-
1.08
460
B
84



dibenzyl-7-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-50
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-
1.10
494
B
75



N,1,7-tribenzyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-54
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-1-
1.10
474
B
58



benzyl-7-isobutyl-N-phenethyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-57
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7-
1.12
474
B
40



benzyl-1-isobutyl-N-







(3-methylbenzyl)octahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-58
(3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7-
1.12
474
B
55



benzyl-1-isobutyl-N-(4-







methylbenzyl)octahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-68
(3S*,3aS*,6S*,7R*,7aS*)-4-benzoyl-
1.17
522
B
51



N,7-dibenzyl-1-isobutyloctahydro-







6H-3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-69
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
1.06
446
B
57



4-ethyl-1-isobutyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-70
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
1.13
476
B
32



1-isobutyl-4-







(methoxycarbonyl)octahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide





















TABLE 4-7







IF-71
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-
1.02
432
B
38



1-isobutyl-4-methyloctahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-72
(3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-
1.06
446
B
45



4-ethyl-7-isobutyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide






IF-73
tert-butyl (3S*,3aS*,6S*,7R*,7aS*)-6-
0.84
500
A
9



(benzylcarbamoyl)-1-isobutyl-7-(2-







carboxyethyl)octahydro-5H-3,6-







methanopyrrolo[3,2-c]pyridine-5-







carboxylate






IF-74
tert-butyl (3S*,3aS*,6S*,7R*,7aS*)-
0.91
514
A
71



3a-(benzylcarbamoyl)-1-isobutyl-7-







(3-methoxy-3-oxopropyl)octahydro-







4H-3,6-methanopyrrolo[3,2-b]







pyridine-4-carboxylate






IF-76
tert-butyl 3-
1.04
490
B
53



((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-6-







(benzylcarbamoyl)octahydro-1H-3,6-







methanopyrrolo[3,2-c]pyridin-1-







yl)propanoate






IF-77
(3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-
0.93
468
B
60



7-(4-hydroxybenzyl)octahydro-6H-







3,6-methanopyrrolo[3,2-c]pyridine-







6-carboxamide






IF-80
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-
0.84
454
A
44



(naphthalen-1-ylmethyl)-7-







propyloctahydro-6H-3,6-







methanopyrrolo[3,2-c]pyridine-6-







carboxamide
















TABLE 4-8









embedded image


















Compound



Retention
Mass
Measurement


number
R1
R2
R3
RT (min)
(M + H)+
condition





IF-81
Cbm-M
Np-M
i-Bu
0.71
435
C


IF-82
Cbm-M
Np-M
Bnzl
0.72
469
C


IF-83
Cbm-M
Np-M
4-OH-Bnzl
0.67
485
C


IF-84
Cbm-M
Np-M
i-Pnt
0.73
449
C


IF-85
Cbm-M
Np-M
Ph-Et
0.75
483
C


IF-86
Cbm-M
Ph-Et
i-Bu
0.66
399
C


IF-87
Cbm-M
Ph-Et
Bnzl
0.68
433
C


IF-88
Cbm-M
Ph-Et
4-OH-Bnzl
0.63
449
C


IF-89
Cbm-M
Ph-Et
i-Pnt
0.70
413
C


IF-90
Cbm-M
Ph-Et
Np-M
0.74
483
C


IF-91
Cbm-M
Np-M
Np-M
0.76
519
C


IF-92
Cbm-M
4-F-Bnzl
i-Bu
0.65
403
C


IF-93
Cbm-M
4-F-Bnzl
Bnzl
0.67
437
C






















TABLE 4-9







IF-94
Cbm-M
4-F-Bnzl
4-OH-Bnzl
0.62
453
C


IF-95
Cbm-M
4-F-Bnzl
i-Pnt
0.69
417
C


IF-96
Cbm-M
4-F-Bnzl
Ph-Et
0.71
451
C


IF-97
Cbm-M
4-F-Bnzl
Np-M
0.73
487
C


IF-98
Cbm-M
i-Pnt
i-Bu
0.66
365
C


IF-99
Cbm-M
i-Pnt
Bnzl
0.67
399
C


IF-100
Cbm-M
i-Pnt
4-OH-Bnzl
0.62
415
C


IF-101
Cbm-M
i-Pnt
Cbx-E
0.58
381
C


IF-102
Cbm-M
i-Pnt
Ph-Et
0.71
413
C


IF-103
Cbm-M
i-Pnt
Np-M
0.73
449
C


IF-104
Cbm-M
Hxy
i-Bu
0.71
379
C


IF-105
Cbm-M
Hxy
Bnzl
0.72
413
C


IF-106
Cbm-M
Hxy
4-OH-Bnzl
0.67
429
C


IF-107
Cbm-M
Hxy
Cbx-E
0.63
395
C


IF-108
Cbm-M
Hxy
i-Pnt
0.73
393
C


IF-109
Cbm-M
Hxy
Ph-Et
0.75
427
C


IF-110
Cbm-M
Hxy
Np-M
0.77
463
C


IF-111
Cbm-M
i-Pr
i-Bu
1.03
337
D


IF-112
Cbm-M
i-Pr
Bnzl
0.58
371
C


IF-113
Cbm-M
i-Pr
4-OH-Bnzl
0.97
387
D


IF-114
Cbm-M
i-Pr
Cbx-E
0.22
353
E


IF-115
Cbm-M
i-Pr
i-Pnt
1.09
351
D


IF-116
Cbm-M
i-Pr
Ph-Et
0.63
385
C


IF-117
Cbm-M
i-Pr
Np-M
0.65
421
C


IF-118
Cbm-M
i-Bu
i-Bu
0.62
351
C


IF-119
Cbm-M
i-Bu
Bnzl
0.64
385
C


IF-120
Cbm-M
i-Bu
4-OH-Bnzl
0.59
401
C


IF-121
Cbm-M
i-Bu
Cbx-E
0.93
367
D


IF-122
Cbm-M
i-Bu
i-Pnt
0.66
365
C


IF-123
Cbm-M
i-Bu
Ph-Et
0.69
399
C


IF-124
Cbm-M
i-Bu
Np-M
0.71
435
C


IF-125
Cbm-M
Bnzl
i-Bu
0.65
385
C


IF-126
Cbm-M
Bnzl
Bnzl
0.67
419
C


IF-127
Cbm-M
Bnzl
4-OH-Bnzl
0.62
435
C


IF-128
Cbm-M
Bnzl
Cbx-E
0.99
401
D


IF-129
Cbm-M
Bnzl
i-Pnt
0.69
399
C


IF-130
Cbm-M
Bnzl
Ph-Et
0.71
433
C


IF-131
Cbm-M
Bnzl
Np-M
0.73
469
C


IF-132
Cbm-M
4-OH-Bnzl
i-Bu
0.57
401
C


IF-133
Cbm-M
4-OH-Bnzl
Bnzl
0.59
435
C


IF-134
Cbm-M
4-OH-Bnzl
Cbx-E
0.87
417
D


IF-135
Cbm-M
4-OH-Bnzl
i-Pnt
0.60
415
C


IF-136
Cbm-M
4-OH-Bnzl
Ph-Et
0.63
449
C


IF-137
Cbm-M
4-OH-Bnzl
Np-M
0.65
485
C


IF-138
Cbm-M
Cbx-E
Bnzl
0.94
401
D


IF-139
Cbm-M
Cbx-E
4-OH-Bnzl
0.47
417
D






















TABLE 4-10







IF-140
Cbm-M
Cbx-E
Ph-Et
1.01
415
D


IF-141
Cbm-M
Cbx-E
Np-M
0.60
451
C


IF-142
Cbm-M
Cbm-E
i-Bu
0.23
366
E


IF-143
Cbm-M
Cbm-E
Bnzl
0.88
400
D


IF-144
Cbm-M
Cbm-E
4-OH-Bnzl
0.23
416
E


IF-145
Cbm-M
Cbm-E
Cbx-E
0.20
382
E


IF-146
Cbm-M
Cbm-E
i-Pnt
0.91
380
D


IF-147
Cbm-M
Cbm-E
Ph-Et
0.89
414
D


IF-148
Cbm-M
Cbm-E
Np-M
0.57
450
C


IF-149
Cbm-M
Gun-Pr
i-Bu
0.83
394
D


IF-150
Cbm-M
Gun-Pr
Bnzl
0.92
428
D


IF-151
Cbm-M
Gun-Pr
4-OH-Bnzl
0.34
442 1)
E


IF-152
Cbm-M
Gun-Pr
i-Pnt
0.93
408
D


IF-153
Cbm-M
Gun-Pr
Ph-Et
0.96
442
D


IF-154
Cbm-M
Gun-Pr
Np-M
1.01
478
D


IF-155
Cbm-M
Hdr-E
i-Bu
0.46
339
E


IF-156
Cbm-M
Hdr-E
Bnzl
0.49
373
C


IF-157
Cbm-M
Hdr-E
4-OH-Bnzl
0.35
389
E


IF-158
Cbm-M
Hdr-E
Cbx-E
0.20
355
E


IF-159
Cbm-M
Hdr-E
i-Pnt
0.93
353
D


IF-160
Cbm-M
Hdr-E
Ph-Et
0.98
387
D


IF-161
Cbm-M
Hdr-E
Np-M
0.58
423
C


IF-162
Gun-Pr
Np-M
i-Bu
1.25
477
D


IF-163
Gun-Pr
Np-M
Bnzl
0.72
511
C


IF-164
Gun-Pr
Np-M
4-OH-Bnzl
0.69
527
C


IF-165
Gun-Pr
Np-M
i-Pnt
1.28
491
D


IF-166
Gun-Pr
Np-M
Ph-Et
0.75
525
C


IF-167
Gun-Pr
Np-M
Np-M
1.31
561
D


IF-168
Gun-Pr
Hxy
i-Pnt
0.74
435
C


IF-169
Gun-Pr
Hxy
Ph-Et
1.30
469
D


IF-170
Gun-Pr
Hxy
Np-M
1.33
505
D


IF-171
Gun-Pr
i-Pr
i-Bu
1.08
379
D


IF-172
Gun-Pr
i-Pr
4-OH-Bnzl
1.04
429
D


IF-173
Gun-Pr
i-Pr
i-Pnt
1.12
393
D


IF-174
Gun-Pr
i-Pr
Ph-Et
1.15
427
D


IF-175
Gun-Pr
i-Pr
Np-M
1.17
463
D


IF-176
Gun-Pr
4-F-Bnzl
i-Bu
1.17
445
D


IF-177
Gun-Pr
4-F-Bnzl
Bnzl
0.68
479
C


IF-178
Gun-Pr
4-F-Bnzl
4-OH-Bnzl
1.13
495
D


IF-179
Gun-Pr
4-F-Bnzl
i-Pnt
1.21
459
D


IF-180
Gun-Pr
4-F-Bnzl
Ph-Et
0.71
493
C


IF-181
Gun-Pr
4-F-Bnzl
Np-M
0.72
529
C


IF-182
i-Bu
Hdr-E
Cbm-M
0.63
339
G


IF-183
i-Bu
Ph-Et
Cbm-M
3.40
399
G


IF-184
i-Bu
Np-M
Cbm-M
3.87
435
G


IF-185
i-Bu
i-Bu
Gun-Pr
3.15
393
G






















TABLE 4-11







IF-186
i-Bu
Bnzl
Gun-Pr
3.42
427
G


IF-187
i-Bu
4-OH-Bnzl
Gun-Pr
3.09
443
G


IF-188
i-Bu
Hdr-E
Gun-Pr
1.17
381
G


IF-189
i-Bu
Ph-Et
Gun-Pr
3.57
441
G


IF-190
i-Bu
Np-M
Gun-Pr
3.87
477
G


IF-191
i-Bu
Hxy
Gun-Pr
3.79
421
G


IF-192
i-Bu
4-F-Bnzl
Gun-Pr
3.49
445
G


IF-193
Bnzl
Cbx-E
Cbm-M
1.82
401
G


IF-194
Bnzl
Hdr-E
Cbm-M
1.52
373
G


IF-195
Bnzl
i-Pnt
Cbm-M
3.59
399
G


IF-196
Bnzl
Ph-Et
Cbm-M
3.62
433
G


IF-197
Bnzl
i-Pr
Cbm-M
3.02
371
G


IF-198
Bnzl
4-OH-Bnzl
Gun-Pr
3.54
477
G


IF-199
Bnzl
Hdr-E
Gun-Pr
2.74
415
F


IF-200
4-OH-Bnzl
Ph-Et
Gun-Pr
3.59
491
G


IF-201
4-OH-Bnzl
Np-M
Gun-Pr
3.90
527
G


IF-202
Cbx-E
i-Pr
Cbm-M
0.95
353
G


IF-203
i-Pnt
i-Bu
Cbm-M
3.25
365
G


IF-204
i-Pnt
Bnzl
Cbm-M
3.47
399
F


IF-205
i-Pnt
4-OH-Bnzl
Cbm-M
3.13
415
G


IF-206
i-Pnt
Ph-Et
Cbm-M
2.43
413
F


IF-207
i-Pnt
Np-M
Cbm-M
2.62
449
F


IF-208
i-Pnt
Hxy
Cbm-M
3.97
393
G


IF-209
i-Pnt
i-Pr
Cbm-M
2.97
351
G


IF-210
i-Pnt
4-F-Bnzl
Cbm-M
3.60
417
G


IF-211
i-Pnt
Bnzl
Gun-Pr
3.60
441
G


IF-212
i-Pnt
Ph-Et
Gun-Pr
3.79
455
G


IF-213
i-Pnt
Np-M
Gun-Pr
2.63
491
G


IF-214
i-Pnt
i-Pr
Gun-Pr
3.25
393
G


IF-215
i-Pnt
4-F-Bnzl
Gun-Pr
3.72
459
G


IF-216
Ph-Et
Bnzl
Cbm-M
2.45
433
F


IF-217
Ph-Et
4-OH-Bnzl
Cbm-M
3.40
449
G


IF-218
Ph-Et
Cbx-E
Cbm-M
2.85
415
G


IF-219
Ph-Et
Cbm-E
Cbm-M
2.67
414
G


IF-220
Ph-Et
Gun-Pr
Cbm-M
2.94
442
G


IF-221
Ph-Et
Hdr-E
Cbm-M
2.75
387
G


IF-222
Ph-Et
i-Pnt
Cbm-M
3.87
413
G


IF-223
Ph-Et
Np-M
Cbm-M
2.75
483
F


IF-224
Ph-Et
4-F-Bnzl
Cbm-M
2.52
451
F


IF-225
Ph-Et
Hdr-E
Gun-Pr
3.05
429
G


IF-226
Np-M
i-Bu
Cbm-M
2.49
435
F


IF-227
Np-M
Bnzl
Cbm-M
2.62
469
F


IF-228
Np-M
Cbm-E
Cbm-M
3.27
450
G


IF-229
Np-M
Gun-Pr
Cbm-M
3.32
478
G


IF-230
Np-M
Hdr-E
Cbm-M
3.29
423
G


IF-231
Np-M
Ph-Et
Cbm-M
2.65
483
F






















TABLE 4-12







IF-232
Np-M
Np-M
Cbm-M
2.84
519
F


IF-233
Np-M
i-Pr
Cbm-M
3.62
421
G


IF-234
Np-M
4-F-Bnzl
Cbm-M
2.65
487
F


IF-235
Np-M
i-Bu
Gun-Pr
3.70
477
G


IF-236
Np-M
Bnzl
Gun-Pr
3.88
511
G


IF-237
Np-M
4-OH-Bnzl
Gun-Pr
3.62
527
G


IF-238
Np-M
Cbm-E
Gun-Pr
3.22
492
G


IF-239
Np-M
Hdr-E
Gun-Pr
3.20
465
G


IF-240
Np-M
i-Pnt
Gun-Pr
3.95
491
G


IF-241
Np-M
Ph-Et
Gun-Pr
4.07
525
G


IF-242
Np-M
Np-M
Gun-Pr
4.27
561
G


IF-243
Np-M
Hxy
Gun-Pr
4.25
505
G


IF-244
Np-M
i-Pr
Gun-Pr
2.38
463
F


IF-245
Np-M
4-F-Bnzl
Gun-Pr
3.95
529
G


IF-246
Chm
Bnzl
Cbm-M
3.75
425
G


IF-247
Chm
4-OH-Bnzl
Cbm-M
3.40
441
G


IF-248
Chm
Cbx-E
Cbm-M
2.90
407
G


IF-249
Chm
Cbm-E
Cbm-M
2.74
406
G


IF-250
Chm
i-Pnt
Cbm-M
2.50
405
F


IF-251
Chm
Ph-Et
Cbm-M
2.52
439
F


IF-252
Chm
Np-M
Cbm-M
2.69
475
F


IF-253
Chm
Hxy
Cbm-M
4.17
419
G


IF-254
Chm
i-Pr
Cbm-M
3.29
377
F


IF-255
Chm
4-F-Bnzl
Cbm-M
2.54
443
F


IF-256
Chm
Bnzl
Gun-Pr
3.79
467
G


IF-257
Chm
i-Pnt
Gun-Pr
3.90
447
G


IF-258
Chm
Ph-Et
Gun-Pr
3.95
481
G


IF-259
Chm
Np-M
Gun-Pr
4.27
517
G


IF-260
Chm
Hxy
Gun-Pr
4.12
461
G


IF-261
Chm
4-F-Bnzl
Gun-Pr
3.95
485
G


IF-262
4-F-Bnzl
i-Bu
Cbm-M
3.34
403
G


IF-263
4-F-Bnzl
Bnzl
Cbm-M
3.57
437
G


IF-264
4-F-Bnzl
4-OH-Bnzl
Cbm-M
3.22
453
G


IF-265
4-F-Bnzl
Cbx-E
Cbm-M
2.34
419
G


IF-266
4-F-Bnzl
Cbm-E
Cbm-M
1.63
418
G


IF-267
4-F-Bnzl
Hdr-E
Cbm-M
1.79
391
G


IF-268
4-F-Bnzl
i-Pnt
Cbm-M
3.70
417
G


IF-269
4-F-Bnzl
Ph-Et
Cbm-M
2.43
451
F


IF-270
4-F-Bnzl
Np-M
Cbm-M
2.62
487
F


IF-271
4-F-Bnzl
Hxy
Cbm-M
2.60
431
F


IF-272
4-F-Bnzl
i-Pr
Cbm-M
3.10
389
G


IF-273
4-F-Bnzl
Hdr-E
Gun-Pr
2.70
433
G


IF-274
4-F-Bnzl
i-Pr
Gun-Pr
3.37
431
G


IF-275
Cbx-E
i-Bu
Cbm-M
3.20
367
G


IF-276
Cbx-E
i-Pnt
Cbm-M
3.54
381
G


IF-277
Bnzl
Bnzl
Cbm-M
2.38
419
F






















TABLE 4-13







IF-278
Bnzl
Np-M
Cbm-M
4.09
469
G


IF-279
Bnzl
Hxy
Cbm-M
4.02
413
G


IF-280
Bnzl
4-F-Bnzl
Cbm-M
2.43
437
F


IF-281
Bnzl
Bnzl
Gun-Pr
2.40
461
F


IF-282
Bnzl
i-Pnt
Gun-Pr
2.47
441
F


IF-283
Bnzl
Ph-Et
Gun-Pr
2.50
475
F


IF-284
Bnzl
Np-M
Gun-Pr
2.62
511
F


IF-285
Bnzl
Hxy
Gun-Pr
2.62
455
F


IF-286
Bnzl
4-F-Bnzl
Gun-Pr
2.47
479
F


IF-287
Ph-Et
Bnzl
Gun-Pr
2.52
475
F


IF-288
Ph-Et
4-OH-Bnzl
Gun-Pr
2.38
491
F


IF-289
Ph-Et
i-Pnt
Gun-Pr
2.57
455
F


IF-290
Ph-Et
Np-M
Gun-Pr
2.72
525
F


IF-291
Ph-Et
Hxy
Gun-Pr
2.70
469
F


IF-292
Ph-Et
4-F-Bnzl
Gun-Pr
2.59
493
F


IF-293
4-F-Bnzl
i-Bu
Gun-Pr
2.34
445
F


IF-294
4-F-Bnzl
Bnzl
Gun-Pr
2.43
479
F


IF-295
4-F-Bnzl
i-Pnt
Gun-Pr
2.50
459
F


IF-296
4-F-Bnzl
Ph-Et
Gun-Pr
2.50
493
F


IF-297
4-F-Bnzl
Np-M
Gun-Pr
2.63
529
F


IF-298
4-F-Bnzl
Hxy
Gun-Pr
2.63
473
F


IF-299
i-Bu
Cbm-E
Cbx-E
1.03
381
H


IF-300
i-Bu
Cbm-E
i-Pnt
2.15
379
H


IF-301
i-Bu
Gun-Pr
i-Bu
2.13
393
H


IF-302
i-Bu
Gun-Pr
Bnzl
2.19
427
H


IF-303
i-Bu
Gun-Pr
4-OH-Bnzl
1.79
443
H


IF-304
i-Bu
Gun-Pr
i-Pnt
1.95
407
H


IF-305
i-Bu
Gun-Pr
Ph-Et
1.98
441
H


IF-306
i-Bu
Gun-Pr
Np-M
2.08
477
H


IF-307
Bnzl
Cbm-E
Cbx-E
1.76
415
H


IF-308
Bnzl
Cbm-E
i-Pnt
2.02
413
H


IF-309
Bnzl
Gun-Pr
i-Bu
1.82
427
H


IF-310
Bnzl
Gun-Pr
Bnzl
2.02
461
H


IF-311
Bnzl
Gun-Pr
4-OH-Bnzl
1.87
477
H


IF-312
Bnzl
Gun-Pr
i-Pnt
2.05
441
H


IF-313
Bnzl
Gun-Pr
Ph-Et
2.08
475
H


IF-314
Bnzl
Gun-Pr
Np-M
2.14
511
H


IF-315
4-OH-Bnzl
Cbm-E
Cbx-E
1.28
431
H


IF-316
4-OH-Bnzl
Cbm-E
i-Pnt
1.85
429
H


IF-317
4-OH-Bnzl
Gun-Pr
i-Bu
1.85
443
H


IF-318
4-OH-Bnzl
Gun-Pr
Bnzl
1.91
477
H


IF-319
4-OH-Bnzl
Gun-Pr
i-Pnt
1.89
457
H


IF-320
4-OH-Bnzl
Gun-Pr
Ph-Et
1.96
491
H


IF-321
4-OH-Bnzl
Gun-Pr
Np-M
2.00
527
H


IF-322
Cbx-E
Cbm-E
i-Pnt
1.73
395
H


IF-323
Gun-Pr
i-Bu
i-Bu
1.98
393
H






















TABLE 4-14







IF-324
Gun-Pr
i-Bu
Bnzl
1.99
427
H


IF-325
Gun-Pr
i-Bu
4-OH-Bnzl
1.92
443
H


IF-326
Gun-Pr
i-Bu
i-Pnt
2.10
407
H


IF-327
Gun-Pr
i-Bu
Ph-Et
2.15
441
H


IF-328
Gun-Pr
i-Bu
Np-M
2.14
477
H


IF-329
Gun-Pr
Bnzl
i-Bu
2.06
427
H


IF-330
Gun-Pr
Bnzl
Bnzl
2.08
461
H


IF-331
Gun-Pr
Bnzl
4-OH-Bnzl
1.98
 47
H


IF-332
Gun-Pr
Bnzl
i-Pnt
2.16
441
H


IF-333
Gun-Pr
Bnzl
Ph-Et
2.19
475
H


IF-334
Gun-Pr
Bnzl
Np-M
2.21
511
H


IF-335
Gun-Pr
4-OH-Bnzl
i-Bu
1.89
443
H


IF-336
Gun-Pr
4-OH-Bnzl
Bnzl
1.95
477
H


IF-337
Gun-Pr
4-OH-Bnzl
i-Pnt
1.92
457
H


IF-338
Gun-Pr
4-OH-Bnzl
Ph-Et
1.97
491
H


IF-339
Gun-Pr
4-OH-Bnzl
Np-M
2.01
527
H


IF-340
Gun-Pr
Cbm-E
i-Bu
1.64
408
H


IF-341
Gun-Pr
Cbm-E
Bnzl
1.72
442
H


IF-342
Gun-Pr
Cbm-E
4-OH-Bnzl
1.15
458
H


IF-343
Gun-Pr
Cbm-E
i-Pnt
1.73
422
H


IF-344
Gun-Pr
Cbm-E
Ph-Et
1.79
456
H


IF-345
Gun-Pr
Cbm-E
Np-M
1.84
492
H


IF-346
Gun-Pr
Hdr-E
i-Bu
1.70
381
H


IF-347
Gun-Pr
Hdr-E
Bnzl
1.73
415
H


IF-348
Gun-Pr
Hdr-E
4-OH-Bnzl
1.59
431
H


IF-349
Gun-Pr
Hdr-E
i-Pnt
1.78
395
H


IF-350
Gun-Pr
Hdr-E
Ph-Et
1.82
429
H


IF-351
Gun-Pr
Hdr-E
Np-M
1.84
465
H


IF-352
Gun-Pr
i-Pnt
i-Bu
2.07
407
H


IF-353
Gun-Pr
i-Pnt
Bnzl
2.10
441
H


IF-354
Gun-Pr
i-Pnt
4-OH-Bnzl
2.02
457
H


IF-355
Gun-Pr
i-Pnt
Ph-Et
2.12
455
H


IF-356
Gun-Pr
i-Pnt
Np-M
2.22
491
H


IF-357
Gun-Pr
Ph-Et
i-Bu
2.09
441
H


IF-358
Gun-Pr
Ph-Et
Bnzl
2.10
475
H


IF-359
Gun-Pr
Ph-Et
4-OH-Bnzl
2.02
491
H


IF-360
Gun-Pr
Ph-Et
i-Pnt
2.18
455
H


IF-361
Gun-Pr
Ph-Et
Np-M
2.19
525
H


IF-362
Hdr-E
Cbm-E
Cbx-E
0.41
369
H


IF-363
Hdr-E
Cbm-E
i-Pnt
1.71
367
H


IF-364
Hdr-E
Gun-Pr
i-Bu
1.64
381
H


IF-365
Hdr-E
Gun-Pr
Bnzl
1.76
415
H


IF-366
Hdr-E
Gun-Pr
4-OH-Bnzl
1.84
431
H


IF-367
Hdr-E
Gun-Pr
i-Pnt
1.75
395
H


IF-368
Hdr-E
Gun-Pr
Ph-Et
1.81
429
H


IF-369
Hdr-E
Gun-Pr
Np-M
1.83
465
H






















TABLE 4-15







IF-370
i-Pnt
Cbm-E
Cbx-E
1.75
395
H


IF-371
i-Pnt
Gun-Pr
i-Bu
2.01
407
H


IF-372
i-Pnt
Gun-Pr
Bnzl
2.05
441
H


IF-373
i-Pnt
Gun-Pr
4-OH-Bnzl
1.91

H


IF-374
i-Pnt
Gun-Pr
Ph-Et
2.09
455
H


IF-375
i-Pnt
Gun-Pr
Np-M
2.15
491
H


IF-376
Ph-Et
Cbm-E
Cbx-E
1.85
429
H


IF-377
Ph-Et
Cbm-E
i-Pnt
2.09
427
H


IF-378
Ph-Et
Gun-Pr
i-Bu
2.05
441
H


IF-379
Ph-Et
Gun-Pr
Bnzl
2.18

H


IF-380
Ph-Et
Gun-Pr
4-OH-Bnzl
1.94
491
H


IF-381
Ph-Et
Gun-Pr
i-Pnt
2.11
455
H


IF-382
Ph-Et
Gun-Pr
Np-M
2.20
525
H


IF-383
Np-M
Cbm-E
Cbx-E
1.91
465
H


IF-384
Np-M
Cbm-E
i-Pnt
2.17
463
H


IF-385
Np-M
Gun-Pr
i-Bu
1.82
477
H


IF-386
Np-M
Gun-Pr
Bnzl
2.15
511
H


IF-387
Np-M
Gun-Pr
4-OH-Bnzl
1.97
527
H


IF-388
Np-M
Gun-Pr
i-Pnt
2.17
491
H


IF-389
Np-M
Gun-Pr
Ph-Et
2.20
525
H


IF-390
Np-M
Gun-Pr
Np-M
2.22
561
H


IF-391
Chm
Cbm-E
Cbx-E
1.83
421
H


IF-392
Chm
Cbm-E
i-Pnt
2.10
419
H


IF-393
Chm
Gun-Pr
i-Bu
2.06
433
H


IF-394
Chm
Gun-Pr
Bnzl
2.13
467
H


IF-395
Chm
Gun-Pr
4-OH-Bnzl
1.91
483
H


IF-396
Chm
Gun-Pr
i-Pnt
2.13
447
H


IF-397
Chm
Gun-Pr
Ph-Et
2.15
481
H


IF-398
Chm
Gun-Pr
Np-M
2.22
517
H


IF-399
4-F-Bnzl
Cbm-E
Cbx-E
1.78
433
H


IF-400
4-F-Bnzl
Cbm-E
i-Pnt
2.06
431
H


IF-401
4-F-Bnzl
Gun-Pr
i-Bu
2.03
445
H


IF-402
4-F-Bnzl
Gun-Pr
Bnzl
2.10
479
H


IF-403
4-F-Bnzl
Gun-Pr
4-OH-Bnzl
1.90
495
H


IF-404
4-F-Bnzl
Gun-Pr
i-Pnt
2.10
459
H


IF-405
4-F-Bnzl
Gun-Pr
Ph-Et
2.13
493
H


IF-406
4-F-Bnzl
Gun-Pr
Np-M
2.19
529
H


IF-407
Ph-Et
i-Bu
i-Pnt
1.54
412
I


IF-408
Np-M
i-Bu
i-Pnt
1.68
448
I


IF-409
Chm
i-Bu
i-Pnt
1.55
404
I


IF-410
4-F-Bnzl
i-Bu
i-Pnt
1.51
416
I


IF-411
Bnzl
i-Bu
i-Pnt
1.46
398
I


IF-412
i-Bu
i-Bu
i-Pnt
1.40
364
I


IF-413
i-Pnt
Cbx-E
Np-M
1.41
464
I


IF-414
i-Pnt
Cbx-E
i-Bu
1.15
380
I


IF-415
Chm
Cbx-E
i-Pnt
1.15
420
I






















TABLE 4-16







IF-416
Chm
Cbx-E
Np-M
1.51
490
I


IF-417
4-F-Bnzl
Cbx-E
Np-M
1.46
502
I


IF-418
i-Pnt
4-F-Bnzl
Cbx-E
1.18
432
I


IF-419
Chm
Np-M
Cbx-E
1.40
490
I


IF-420
4-F-Bnzl
Np-M
Cbx-E
1.42
502
I


IF-421
Cbx-E
4-F-Bnzl
i-Bu
1.27
418
I


IF-422
Cbx-E
Np-M
i-Pnt
1.48
464
I


IF-423
Cbx-E
4-F-Bnzl
Np-M
1.47
502
I


IF-424
Cbx-E
i-Bu
Bnzl
1.20
400
I


IF-425
Cbx-E
4-OH-Bnzl
Np-M
1.28
500
I


IF-426
Bnzl
Hxy
Cbx-E
1.31
428
I


IF-427
i-Bu
Hxy
Cbx-E
1.24
394
I


IF-428
i-Bu
Cbx-E
Np-M
1.35
450
I


IF-429
i-Bu
Cbx-E
i-Bu
1.02
366
I


IF-430
Hdr-E
i-Bu
i-Pnt
1.23
352
I


IF-431
Ph-Et
i-Bu
Np-M
1.75
482
I


IF-432
Np-M
i-Bu
Ph-Et
1.75
482
I


IF-433
Np-M
i-Bu
Np-M
1.96
518
I


IF-434
Np-M
i-Bu
Bnzl
1.73
468
I


IF-435
Np-M
Cbm-E
4-OH-Bnzl
1.17
499
I


IF-436
4-F-Bnzl
i-Bu
Np-M
1.73
486
I


IF-437
i-Pnt
Ph-Et
i-Bu
1.55
412
I


IF-438
Ph-Et
Hxy
i-Bu
1.67
426
I


IF-439
Chm
Ph-Et
4-OH-Bnzl
1.43
488
I


IF-440
4-F-Bnzl
Ph-Et
Np-M
1.77
534
I


IF-441
Bnzl
i-Bu
Np-M
1.65
468
I


IF-442
4-OH-Bnzl
Hdr-E
Np-M
1.26
472
I


IF-443
4-OH-Bnzl
i-Bu
i-Pnt
1.25
414
I


IF-444
Hdr-E
Cbx-E
Np-M
1.15
438
I


IF-445
i-Pnt
4-OH-Bnzl
Cbx-E
0.97
430
I


IF-446
Chm
Cbx-E
i-Bu
1.25
406
I


IF-447
Chm
4-OH-Bnzl
Cbx-E
1.12
456
I


IF-448
Np-M
Hdr-E
Cbx-E
1.13
438
I


IF-449
Cbx-E
Np-M
i-Bu
1.43
450
I


IF-450
Cbx-E
Hxy
i-Bu
1.43
394
I


IF-451
Cbx-E
Hdr-E
Ph-Et
0.91
402
I


IF-452
Cbx-E
Hdr-E
Np-M
1.13
438
I


IF-453
Cbx-E
4-F-Bnzl
Ph-Et
1.41
466
I


IF-454
Cbx-E
i-Bu
Ph-Et
1.30
414
I


IF-455
Cbx-E
i-Bu
4-OH-Bnzl
1.11
416
I


IF-456
Cbx-E
Cbm-E
Ph-Et
0.95
429
I


IF-457
Cbx-E
Cbm-E
Np-M
1.16
465
I


IF-458
Cbx-E
4-OH-Bnzl
i-Pnt
1.13
430
I


IF-459
Bnzl
Cbx-E
Np-M
1.42
484
I


IF-460
i-Bu
Np-M
Cbx-E
1.32
450
I


IF-461
4-OH-Bnzl
Np-M
Cbx-E
1.26

I






















TABLE 4-17







IF-462
Hdr-E
4-OH-Bnzl
Ph-Et
1.20

I


IF-463
Hdr-E
4-OH-Bnzl
Np-M
1.27
472
I


IF-464
i-Pnt
4-OH-Bnzl
Ph-Et
1.40
462
I


IF-465
i-Pnt
4-OH-Bnzl
Np-M
1.53
498
I


IF-466
i-Pnt
4-OH-Bnzl
Bnzl
1.37
448
I


IF-467
i-Pnt
4-OH-Bnzl
i-Bu
1.32
414
I


IF-468
Ph-Et
4-OH-Bnzl
i-Pnt
1.48
462
I


IF-469
Ph-Et
4-OH-Bnzl
Bnzl
1.46
482
I


IF-470
Ph-Et
4-OH-Bnzl
i-Bu
1.38
448
I


IF-471
Np-M
4-OH-Bnzl
i-Pnt
1.63
498
I


IF-472
Np-M
4-OH-Bnzl
Bnzl
1.58
518
I


IF-473
Np-M
4-OH-Bnzl
i-Bu
1.51
484
I


IF-474
Chm
4-OH-Bnzl
i-Pnt
1.46
454
I


IF-475
Chm
4-OH-Bnzl
Ph-Et
1.49
488
I


IF-476
Chm
4-OH-Bnzl
Np-M
1.62
524
I


IF-477
Chm
4-OH-Bnzl
Bnzl
1.43
474
I


IF-478
Chm
4-OH-Bnzl
i-Bu
1.41
440
I


IF-479
4-F-Bnzl
4-OH-Bnzl
i-Pnt
1.41
466
I


IF-480
4-F-Bnzl
4-OH-Bnzl
Np-M
1.58
536
I


IF-481
4-F-Bnzl
4-OH-Bnzl
Bnzl
1.38
486
I


IF-482
4-F-Bnzl
4-OH-Bnzl
i-Bu
1.32
452
I


IF-483
i-Pnt
Hdr-E
Bnzl
1.23
386
I


IF-484
Ph-Et
Hdr-E
Bnzl
1.30
420
I


IF-485
Np-M
Hdr-E
4-OH-Bnzl
1.17
472
I


IF-486
Chm
Hdr-E
Bnzl
1.33
412
I


IF-487
4-F-Bnzl
Hdr-E
Bnzl
1.24
424
I


IF-488
4-F-Bnzl
Hdr-E
4-OH-Bnzl
0.75
440
I


IF-489
i-Pnt
Hdr-E
Ph-Et
1.29
400
I


IF-490
4-F-Bnzl
Hdr-E
i-Pnt
1.30
404
I


IF-491
4-F-Bnzl
Hdr-E
Ph-Et
1.34
438
I


IF-492
Bnzl
Hdr-E
i-Bu
1.17
372
I


IF-493
Bnzl
4-OH-Bnzl
i-Pnt
1.40
448
I


IF-494
Bnzl
4-OH-Bnzl
Bnzl
1.37
468
I


IF-495
Bnzl
4-OH-Bnzl
i-Bu
1.29
434
I


IF-497
i-Bu
Hdr-E
i-Pnt
1.12
352
I


IF-498
i-Bu
Hdr-E
Ph-Et
1.18
386
I


IF-499
i-Bu
4-OH-Bnzl
i-Pnt
1.29
414
I


IF-500
i-Bu
4-OH-Bnzl
Np-M
1.46
484
I


IF-501
i-Bu
4-OH-Bnzl
i-Bu
1.22
400
I


IF-502
4-OH-Bnzl
Hdr-E
i-Pnt
0.99
402
I


IF-503
4-OH-Bnzl
i-Pr
i-Pnt
1.20
400
I


IF-504
4-OH-Bnzl
i-Pr
Np-M
1.39
470
I


IF-505
Np-M
Bnzl
4-OH-Bnzl
1.46
518
I


IF-506
4-F-Bnzl
Bnzl
Np-M
1.73
520
I


IF-507
Hdr-E
Hxy
i-Bu
1.43
366
I


IF-508
Hdr-E
4-F-Bnzl
Bnzl
1.31
424
I






















TABLE 4-18







IF-509
i-Pnt
4-F-Bnzl
4-OH-Bnzl
1.40
466
I


IF-510
Ph-Et
Hxy
4-OH-Bnzl
1.59
476
I


IF-511
Np-M
Hxy
i-Bu
1.89
462
I


IF-512
Np-M
Hxy
4-OH-Bnzl
1.69
512
I


IF-513
Chm
Hxy
i-Bu
1.75
418
I


IF-514
Chm
Hxy
4-OH-Bnzl
1.49
468
I


IF-515
Hdr-E
4-F-Bnzl
i-Pnt
1.42
404
I


IF-516
Hdr-E
4-F-Bnzl
Ph-Et
1.41
438
I


IF-517
Ph-Et
Hxy
i-Pnt
1.83
440
I


IF-518
Np-M
Hdr-E
Ph-Et
1.46
470
I


IF-519
Np-M
Hxy
i-Pnt
1.98
476
I


IF-520
Chm
Hxy
i-Pnt
1.81
432
I


IF-521
Chm
4-F-Bnzl
Ph-Et
1.67
490
I


IF-522
4-F-Bnzl
Hxy
Ph-Et
1.85
478
I


IF-523
i-Bu
Hxy
4-OH-Bnzl
1.46
428
I


IF-524
i-Bu
4-F-Bnzl
4-OH-Bnzl
1.37
452
I


IF-525
i-Bu
4-F-Bnzl
Ph-Et
1.63
450
I


IF-526
Np-M
i-Bu
Cbx-E
1.39
450
I


IF-527
Ph-Et
i-Pnt
Cbx-E
1.35
428
I


IF-528
Cbx-E
i-Pnt
Bnzl
1.41
414
I


IF-529
Cbx-E
i-Pnt
Ph-Et
1.46
428
I


IF-530
Cbx-E
i-Bu
i-Pnt
1.30
380
I


IF-531
Hdr-E
Cbm-E
Np-M
1.10
437
I


IF-532
Hdr-E
Cbm-E
i-Bu
1.26
353
I


IF-533
Hdr-E
4-OH-Bnzl
i-Bu
1.47
388
I


IF-534
Ph-Et
4-OH-Bnzl
Np-M
1.55
532
I


IF-535
Np-M
Cbm-E
i-Bu
1.36
449
I


IF-536
Chm
Cbm-E
Np-M
1.51
489
I


IF-537
Chm
Cbm-E
4-OH-Bnzl
1.01
455
I


IF-538
4-F-Bnzl
Cbm-E
Ph-Et
1.31
465
I


IF-539
4-F-Bnzl
Cbm-E
Np-M
1.41
501
I


IF-540
Hdr-E
Ph-Et
Bnzl
1.32
420
I


IF-541
Hdr-E
Ph-Et
4-OH-Bnzl
1.25
436
I


IF-542
Hdr-E
Np-M
i-Bu
1.42
422
I


IF-543
Hdr-E
Np-M
4-OH-Bnzl
1.34

I


IF-544
Hdr-E
4-F-Bnzl
i-Bu
1.21
390
I


IF-545
i-Pnt
Ph-Et
4-OH-Bnzl
1.36
462
I


IF-546
i-Pnt
Hxy
i-Bu
1.61
392
I


IF-547
i-Pnt
4-F-Bnzl
Bnzl
1.58
450
I


IF-548
i-Pnt
4-F-Bnzl
i-Bu
1.48
416
I


IF-549
Ph-Et
4-F-Bnzl
Bnzl
1.62
484
I


IF-550
Ph-Et
4-F-Bnzl
i-Bu
1.56
450
I


IF-551
Chm
Np-M
i-Bu
1.75
474
I


IF-552
4-F-Bnzl
Np-M
4-OH-Bnzl
1.48
536
I


IF-553
Hdr-E
Ph-Et
i-Pnt
1.37
400
I


IF-554
i-Pnt
Hxy
Ph-Et
1.77
440
I






















TABLE 4-19







IF-555
i-Pnt
Hxy
Np-M
1.84
476
I


IF-556
Ph-Et
4-F-Bnzl
i-Pnt
1.66
464
I


IF-557
Chm
4-F-Bnzl
i-Pnt
1.66
456
I


IF-558
4-F-Bnzl
Np-M
i-Pnt
1.73
500
I


IF-559
Bnzl
Hxy
Bnzl
1.70
446
I


IF-560
Bnzl
Hxy
i-Bu
1.63
412
I


IF-561
Bnzl
4-F-Bnzl
Bnzl
1.55
470
I


IF-562
Bnzl
Hxy
i-Pnt
1.67
426
I


IF-563
Bnzl
Hxy
Ph-Et
1.74
460
I


IF-564
Bnzl
Cbm-E
Ph-Et
1.31
447
I


IF-565
Bnzl
4-OH-Bnzl
Ph-Et
1.45
482
I


IF-566
Bnzl
4-OH-Bnzl
Np-M
1.53
518
I


IF-567
i-Bu
Ph-Et
4-OH-Bnzl
1.33
448
I


IF-568
i-Bu
Np-M
4-OH-Bnzl
1.42
484
I


IF-569
i-Bu
Hxy
i-Bu
1.53
378
I


IF-570
i-Bu
Np-M
i-Pnt
1.61
448
I


IF-571
i-Bu
Hxy
i-Pnt
1.61
392
I


IF-572
i-Bu
Hxy
Ph-Et
1.66
426
I


IF-573
i-Bu
Hxy
Np-M
1.83
462
I


IF-574
i-Bu
4-F-Bnzl
Np-M
1.67
486
I


IF-575
i-Bu
Cbm-E
Ph-Et
1.19
413
I


IF-576
i-Bu
4-OH-Bnzl
Ph-Et
1.31
448
I


IF-577
4-OH-Bnzl
Ph-Et
Bnzl
1.44
482
I


IF-578
4-OH-Bnzl
Np-M
i-Bu
1.47
484
I


IF-579
4-OH-Bnzl
Hdr-E
Ph-Et
1.59
436
I


IF-580
4-OH-Bnzl
Ph-Et
Np-M
1.61
532
I


IF-581
Np-M
4-OH-Bnzl
Ph-Et
1.64
532
I


IF-582
Np-M
4-OH-Bnzl
Np-M
1.80
568
I


IF-583
i-Pnt
Hxy
4-OH-Bnzl
1.50
442
I


IF-584
4-F-Bnzl
i-Pnt
Bnzl
1.65
450
I


IF-585
4-F-Bnzl
i-Pnt
i-Bu
1.57
416
I


IF-586
4-F-Bnzl
Ph-Et
Bnzl
1.69
484
I


IF-587
4-F-Bnzl
Hxy
Bnzl
1.79
464
I


IF-588
Chm
4-F-Bnzl
Np-M
1.79
526
I


IF-589
4-F-Bnzl
i-Pnt
Np-M
1.82
500
I


IF-590
4-OH-Bnzl
Ph-Et
i-Bu
1.40
448
I


IF-591
i-Pnt
Bnzl
Cbx-E
1.23
414
I


IF-592
Ph-Et
Bnzl
Cbx-E
1.31
448
I


IF-593
Np-M
i-Pnt
Cbx-E
1.51
464
I


IF-594
Cbx-E
i-Bu
Np-M
1.43
450
I


IF-595
Bnzl
Bnzl
Cbx-E
1.19
434
I


IF-596
Np-M
i-Pr
Np-M
1.81
504
I


IF-597
i-Pnt
Hdr-E
i-Bu
1.13
352
I


IF-598
i-Pnt
Hdr-E
4-OH-Bnzl
0.61
402
I


IF-599
i-Pnt
Hxy
Bnzl
1.67
426
I


IF-600
Ph-Et
Hdr-E
i-Bu
1.23
386
I






















TABLE 4-20







IF-601
Ph-Et
Hdr-E
4-OH-Bnzl
1.01
436
I


IF-602
Ph-Et
Hxy
Bnzl
1.75
460
I


IF-603
Np-M
Hdr-E
Bnzl
1.49
456
I


IF-604
Np-M
Hdr-E
i-Bu
1.35
422
I


IF-605
Np-M
Hxy
Bnzl
1.92
496
I


IF-606
Chm
Hdr-E
i-Bu
1.23
378
I


IF-607
Chm
Hdr-E
4-OH-Bnzl
0.99
428
I


IF-608
Chm
4-F-Bnzl
Bnzl
1.61
476
I


IF-609
4-F-Bnzl
Hdr-E
i-Bu
1.17
390
I


IF-610
Hdr-E
Ph-Et
Np-M
1.48
470
I


IF-611
i-Pnt
Hdr-E
Np-M
1.45
436
I


IF-612
Ph-Et
Hdr-E
Np-M
1.44
470
I


IF-613
Np-M
Hdr-E
i-Pnt
1.43
436
I


IF-614
Np-M
Hdr-E
Np-M
1.59
506
I


IF-615
Np-M
Hxy
Ph-Et
1.96
510
I


IF-616
Np-M
Hxy
Np-M
2.10
546
I


IF-617
Chm
Hdr-E
i-Pnt
1.35
392
I


IF-618
Chm
Hdr-E
Ph-Et
1.39
426
I


IF-619
Chm
Hdr-E
Np-M
1.46
462
I


IF-620
4-F-Bnzl
Hdr-E
Np-M
1.43
474
I


IF-621
Bnzl
Hdr-E
Bnzl
1.22
406
I


IF-622
Bnzl
Hdr-E
4-OH-Bnzl
0.75
422
I


IF-623
Bnzl
Hdr-E
Ph-Et
1.31
420
I


IF-624
Bnzl
Hdr-E
Np-M
1.42
456
I


IF-625
i-Bu
Hdr-E
Np-M
1.33
422
I


IF-627
Hdr-E
Bnzl
i-Pnt
1.34
386
I


IF-628
Hdr-E
Bnzl
Bnzl
1.30
406
I


IF-629
Hdr-E
Bnzl
i-Bu
1.25
372
I


IF-630
Hdr-E
Bnzl
4-OH-Bnzl
1.22
422
I


IF-631
Hdr-E
i-Bu
i-Bu
1.15
338
I


IF-632
i-Pnt
Bnzl
Ph-Et
1.62
446
I


IF-634
i-Pnt
Bnzl
4-OH-Bnzl
1.31
448
I


IF-635
i-Pnt
i-Bu
Ph-Et
1.54
412
I


IF-636
i-Pnt
i-Bu
i-Bu
1.42
364
I


IF-637
i-Pnt
i-Bu
4-OH-Bnzl
1.30
414
I


IF-638
Ph-Et
Bnzl
i-Pnt
1.66
446
I


IF-639
Ph-Et
Bnzl
i-Bu
1.56
432
I


IF-640
Ph-Et
Bnzl
4-OH-Bnzl
1.40
482
I


IF-641
Ph-Et
i-Bu
Bnzl
1.58
432
I


IF-642
Np-M
Bnzl
i-Bu
1.73
468
I


IF-643
Chm
Bnzl
Ph-Et
1.66
472
I


IF-644
Chm
Bnzl
i-Bu
1.59
424
I


IF-645
Chm
Bnzl
4-OH-Bnzl
1.34
474
I


IF-646
Chm
i-Bu
Np-M
1.76
474
I


IF-647
Chm
i-Bu
4-OH-Bnzl
1.35
440
I


IF-648
4-F-Bnzl
Bnzl
Ph-Et
1.68
484
I






















TABLE 4-21







IF-649
4-F-Bnzl
Bnzl
Bnzl
1.60
470
I


IF-650
4-F-Bnzl
Bnzl
i-Bu
1.57
436
I


IF-651
4-F-Bnzl
Bnzl
4-OH-Bnzl
1.32
486
I


IF-652
4-F-Bnzl
i-Bu
Ph-Et
1.59
450
I


IF-653
4-F-Bnzl
i-Bu
Bnzl
1.52
436
I


IF-654
4-F-Bnzl
i-Bu
i-Bu
1.48
402
I


IF-655
4-F-Bnzl
i-Bu
4-OH-Bnzl
1.29
452
I


IF-656
Hdr-E
i-Pnt
Bnzl
1.36
386
I


IF-657
Ph-Et
i-Pnt
i-Bu
1.62
412
I


IF-658
Chm
i-Pnt
Bnzl
1.65
438
I


IF-659
Chm
i-Pnt
i-Bu
2.29
404
I


IF-660
Hdr-E
i-Pnt
Np-M
1.53
436
I


IF-661
Np-M
i-Pnt
Ph-Et
1.91
496
I


IF-662
Chm
i-Pnt
Ph-Et
1.72
452
I


IF-663
Chm
i-Pnt
Np-M
1.83
488
I


IF-664
4-F-Bnzl
i-Pnt
Ph-Et
1.68
464
I


IF-665
Bnzl
i-Pnt
Bnzl
1.61
432
I


IF-666
Bnzl
i-Pnt
4-OH-Bnzl
1.36
448
I


IF-667
Bnzl
i-Pnt
Ph-Et
1.65
446
I


IF-670
Bnzl
i-Bu
Ph-Et
1.54
432
I


IF-671
i-Bu
i-Pnt
i-Bu
1.44
364
I


IF-672
i-Bu
i-Pnt
4-OH-Bnzl
1.30
414
I


IF-673
i-Bu
i-Pnt
Ph-Et
1.56
412
I


IF-674
i-Bu
i-Pnt
Np-M
1.71
448
I


IF-675
i-Bu
Bnzl
i-Pnt
1.53
398
I


IF-678
i-Bu
Bnzl
4-OH-Bnzl
1.23
434
I


IF-679
i-Bu
i-Bu
Ph-Et
1.48
398
I


IF-680
i-Bu
i-Bu
Np-M
1.59
434
I


IF-683
i-Bu
i-Bu
4-OH-Bnzl
1.23
400
I


IF-684
4-OH-Bnzl
i-Pnt
Np-M
1.62
498
I


IF-686
i-Pnt
Cbm-E
Ph-Et
1.28
427
I


IF-687
Np-M
i-Pnt
4-OH-Bnzl
1.56
498
I


IF-688
Chm
4-F-Bnzl
i-Bu
1.56
442
I


IF-689
4-F-Bnzl
Hxy
4-OH-Bnzl
1.47
480
I


IF-690
Ph-Et
Hdr-E
i-Pnt
1.30
400
I


IF-691
Bnzl
i-Pnt
i-Bu
1.54
398
I


IF-692
Bnzl
Hxy
4-OH-Bnzl
1.45
462
I


IF-693
Cbx-E
Bnzl
Bnzl
1.30
434
I


IF-694
Cbx-E
Bnzl
i-Bu
1.24
400
I


IF-695
Bnzl
i-Pnt
Cbx-E
1.26
414
I


IF-696
i-Pnt
Cbm-E
Np-M
1.46
463
I


IF-697
i-Pnt
Cbm-E
Bnzl
1.28
413
I


IF-698
Ph-Et
Cbm-E
Bnzl
1.36
447
I


IF-699
Ph-Et
Cbm-E
i-Bu
1.24
413
I


IF-700
Chm
Cbm-E
Ph-Et
1.43
453
I


IF-701
Chm
Cbm-E
Bnzl
1.36
439
I






















TABLE 4-22







IF-702
4-F-Bnzl
Cbm-E
Bnzl
1.27
451
I


IF-703
4-F-Bnzl
Cbm-E
i-Bu
1.23
417
I


IF-704
Hdr-E
Ph-Et
i-Bu
1.31
386
I


IF-705
i-Pnt
Np-M
i-Bu
1.69
448
I


IF-706
i-Pnt
Np-M
4-OH-Bnzl
1.50
498
I


IF-707
Ph-Et
i-Pnt
4-OH-Bnzl
1.47
462
I


IF-708
Np-M
Ph-Et
4-OH-Bnzl
1.57
532
I


IF-709
Chm
i-Pnt
4-OH-Bnzl
1.40
454
I


IF-710
Chm
Ph-Et
Bnzl
1.72
472
I


IF-711
Chm
Ph-Et
i-Bu
1.69
438
I


IF-712
Chm
Np-M
4-OH-Bnzl
1.58
524
I


IF-713
4-F-Bnzl
i-Pnt
4-OH-Bnzl
1.38
466
I


IF-714
4-F-Bnzl
Ph-Et
i-Bu
1.62
450
I


IF-715
4-F-Bnzl
Ph-Et
4-OH-Bnzl
1.42
500
I


IF-716
4-F-Bnzl
Np-M
i-Bu
1.71
486
I


IF-717
Chm
Ph-Et
i-Pnt
1.76
452
I


IF-718
Chm
Ph-Et
Np-M
1.94
522
I


IF-719
Chm
Np-M
i-Pnt
1.81
488
I


IF-720
4-F-Bnzl
Ph-Et
i-Pnt
1.68
464
I


IF-721
Bnzl
Ph-Et
i-Bu
1.58
432
I


IF-722
Bnzl
Ph-Et
4-OH-Bnzl
1.41
482
I


IF-723
Bnzl
Ph-Et
i-Pnt
1.68
446
I


IF-724
Bnzl
Cbm-E
Bnzl
1.24
433
I


IF-725
i-Bu
Ph-Et
i-Bu
1.51
398
I


IF-726
i-Bu
Np-M
i-Bu
1.62
434
I


IF-727
i-Bu
Ph-Et
i-Pnt
1.62
412
I


IF-728
i-Bu
Cbm-E
Np-M
1.37
449
I


IF-730
4-OH-Bnzl
Np-M
i-Pnt
1.62

I


IF-731
4-OH-Bnzl
Cbm-E
Np-M
1.29
499
I


IF-732
i-Pnt
Bnzl
Np-M
1.72
482
I


IF-733
i-Pnt
Bnzl
i-Bu
1.49
398
I


IF-734
i-Pnt
i-Bu
Np-M
1.66
448
I


IF-735
i-Pnt
i-Bu
Bnzl
1.50
398
I


IF-736
Ph-Et
Bnzl
Np-M
1.76
516
I


IF-737
Ph-Et
Bnzl
Bnzl
1.61
466
I


IF-738
Ph-Et
i-Bu
i-Bu
1.49
398
I


IF-739
Np-M
i-Bu
i-Bu
1.66
434
I


IF-740
Chm
Bnzl
i-Pnt
1.69
438
I


IF-742
Chm
i-Bu
i-Bu
1.49
390
I


IF-743
4-F-Bnzl
Bnzl
i-Pnt
1.64
450
I


IF-744
Ph-Et
i-Pnt
Bnzl
1.65
446
I


IF-746
Bnzl
Bnzl
Ph-Et
1.58
466
I


IF-747
Bnzl
Bnzl
Np-M
1.72
502
I


IF-751
Bnzl
i-Bu
4-OH-Bnzl
1.26
434
I


IF-752
i-Bu
i-Pnt
Bnzl
1.50
398
I


IF-753
i-Bu
Bnzl
Np-M
1.64
468
I






















TABLE 4-23







IF-755
4-OH-Bnzl
Bnzl
i-Pnt
1.42
448
I


IF-756
Ph-Et
Cbm-E
Np-M
1.48
497
I


IF-757
Ph-Et
i-Pr
Np-M
1.65
468
I


IF-758
Hdr-E
Np-M
Bnzl
1.46
456
I


IF-759
i-Pnt
Np-M
Bnzl
1.72
482
I


IF-760
Ph-Et
Np-M
i-Bu
1.71
482
I


IF-761
Ph-Et
Np-M
4-OH-Bnzl
1.57
532
I


IF-762
Np-M
i-Pnt
Bnzl
1.86
482
I


IF-763
Np-M
Np-M
i-Bu
1.95
518
I


IF-764
Chm
Np-M
Bnzl
1.77
508
I


IF-765
4-F-Bnzl
Np-M
Bnzl
1.76
520
I


IF-766
Ph-Et
Np-M
i-Pnt
1.74
497
I


IF-767
Np-M
Np-M
i-Pnt
1.96
532
I


IF-768
Np-M
4-F-Bnzl
Np-M
2.03
570
I


IF-769
Chm
Np-M
Ph-Et
1.85
522
I


IF-770
Chm
Np-M
Np-M
1.95
558
I


IF-771
4-F-Bnzl
Np-M
Ph-Et
1.80
534
I


IF-772
4-F-Bnzl
Np-M
Np-M
1.95
570
I


IF-773
Bnzl
Np-M
i-Bu
1.67
468
I


IF-774
Bnzl
Np-M
i-Pnt
1.73
482
I


IF-775
Bnzl
4-F-Bnzl
Np-M
1.75
520
I


IF-776
Bnzl
Cbm-E
Np-M
1.42
483
I


IF-777
i-Bu
Np-M
Ph-Et
1.71
482
I


IF-778
i-Bu
Np-M
Np-M
1.81
518
I


IF-779
4-OH-Bnzl
Np-M
Np-M
1.71
568
I


IF-780
Hdr-E
i-Bu
Ph-Et
1.34
386
I


IF-781
Hdr-E
i-Bu
4-OH-Bnzl
1.12
388
I


IF-782
Ph-Et
i-Bu
4-OH-Bnzl
1.44

I


IF-783
Ph-Et
Cbm-E
4-OH-Bnzl
1.03
463
I


IF-784
Np-M
Bnzl
i-Pnt
1.84
482
I


IF-785
Np-M
Bnzl
Ph-Et
1.88
516
I


IF-786
Np-M
Bnzl
Np-M
2.03
552
I


IF-787
Np-M
i-Bu
4-OH-Bnzl
1.40
484
I


IF-788
Np-M
Cbm-E
Np-M
1.65
533
I


IF-789
Np-M
i-Pr
Ph-Et
1.69
468
I


IF-790
Np-M
i-Pr
Bnzl
1.67
454
I


IF-791
Chm
Bnzl
Np-M
1.80
508
I


IF-792
Hdr-E
i-Pnt
i-Bu
1.30
352
I


IF-793
Ph-Et
Np-M
Bnzl
1.80
516
I


IF-794
Np-M
Np-M
Bnzl
2.05
552
I


IF-795
Np-M
4-F-Bnzl
Bnzl
1.89
520
I


IF-796
Hdr-E
i-Pnt
Ph-Et
1.44
400
I


IF-797
Hdr-E
Np-M
i-Pnt
1.50
436
I


IF-798
Hdr-E
Np-M
Ph-Et
1.50
470
I


IF-799
i-Pnt
Np-M
Ph-Et
1.78
496
I


IF-800
i-Pnt
4-F-Bnzl
Ph-Et
1.63
464
I






















TABLE 4-24







IF-801
i-Pnt
4-F-Bnzl
Np-M
1.71
500
I


IF-802
Ph-Et
i-Pnt
Np-M
1.77
496
I


IF-803
Ph-Et
Np-M
Np-M
1.93
566
I


IF-804
Ph-Et
4-F-Bnzl
Np-M
1.84
534
I


IF-805
Bnzl
Np-M
Bnzl
1.72
502
I


IF-806
Bnzl
Np-M
4-OH-Bnzl
1.45
518
I


IF-807
Bnzl
4-F-Bnzl
i-Bu
1.55
436
I


IF-808
Bnzl
4-F-Bnzl
4-OH-Bnzl
1.39
486
I


IF-809
Bnzl
i-Pnt
Np-M
1.79
482
I


IF-810
Bnzl
Np-M
Ph-Et
1.81
516
I


IF-811
Bnzl
4-F-Bnzl
i-Pnt
1.60
450
I


IF-812
Bnzl
i-Pr
Np-M
1.54
454
I


IF-814
i-Bu
Hxy
Bnzl
1.62
412
I


IF-815
i-Bu
4-F-Bnzl
Bnzl
1.52
436
I


IF-816
4-OH-Bnzl
i-Pnt
Ph-Et
1.51
462
I


IF-817
4-OH-Bnzl
Bnzl
Ph-Et
1.43
482
I


IF-818
4-OH-Bnzl
Bnzl
i-Bu
1.32
434
I


IF-819
4-OH-Bnzl
i-Bu
i-Bu
1.25
400
I


IF-820
i-Pnt
Cbx-E
Bnzl
0.70
414
C


IF-821
Ph-Et
Cbx-E
i-Pnt
0.73
428
C


IF-822
Chm
Cbx-E
Bnzl
0.72
440
C


IF-823
4-OH-Bnzl
Cbx-E
i-Pnt
0.61
430
C


IF-824
4-OH-Bnzl
Cbx-E
Ph-Et
0.65
464
C


IF-825
Bnzl
Cbx-E
i-Bu
0.67
400
C


IF-826
Bnzl
Cbx-E
i-Pnt
0.70
414
C


IF-827
Bnzl
Cbx-E
Ph-Et
0.71
448
C


IF-828
i-Bu
Cbx-E
Ph-Et
0.67
414
C


IF-829
i-Bu
Cbx-E
4-OH-Bnzl
0.70
416
C


IF-830
i-Pnt
Cbx-E
Ph-Et
0.72
428
C


IF-831
i-Pnt
Cbx-E
4-OH-Bnzl
0.59
430
C


IF-832
Chm
Cbx-E
Ph-Et
0.74
454
C


IF-833
Chm
Cbx-E
4-OH-Bnzl
0.62
456
C


IF-835
Ph-Et
Cbx-E
i-Bu
0.69
414
C


IF-836
4-OH-Bnzl
Cbx-E
i-Bu
0.58
416
C






1) (M-H)-














TABLE 4-25









embedded image



















Compound




Retention
Mass
Measurement


number
R1
R2
R3
R4
RT (min)
(M + H)+
condition





IF-837
Bnzl
Np-M
i-Bu
H
1.127
468
B


IF-838
Bnzl
4-(trifluoromethyl)benzyl
i-Bu
H
1.14
486
B























TABLE 4-26







IF-839
4-Cl-Bnzl
Bnzl
i-Bu
H
1.13
452
B


IF-840
3-Cl-Bnzl
Bnzl
i-Bu
H
1.14
452
B


IF-841
4-methoxybenzyl
Bnzl
i-Bu
H
1.072
448
B


IF-842
4-methylbenzyl
Bnzl
i-Bu
H
1.097
432
B


IF-843
i-Pnt
i-Bu
Bnzl
H
1.278
398
B


IF-844
i-Bu
i-Bu
4-Cl-Bnzl
H
1.275
418
B


IF-845
i-Bu
i-Pnt
Bnzl
H
1.082
398
B


IF-846
i-Bu
4-Cl-Bnzl
i-Bu
H
1.085
418
B


IF-847
4-hydroxybenzyl
Bnzl
i-Bu
H
1.187
434
B


IF-848
4-(dimethylamino)benzyl
Bnzl
i-Bu
H
1.097
461
B


IF-849
4-(tert-butyl)benzyl
Bnzl
i-Bu
H
1.175
474
B


IF-850
i-Bu
Bnzl
i-Pnt
H
1.075
398
B


IF-851
i-Pnt
Bnzl
i-Bu
H
1.29
398
B


IF-852
4-(trifluoromethyl)benzyl
Bnzl
i-Bu
H
1.18
502
B


IF-853
4-ethoxybenzyl
Bnzl
i-Bu
H
1.112
462
B


IF-854
Bnzl
naphthalen-2-ylmethyl
i-Bu
H
1.142
468
B


IF-855
4-methylbenzyl
Bnzl
i-Bu
ethyl
1.172
460
B


IF-856
4-methylbenzyl
Bnzl
i-Bu
i-Bu
1.303
488
B


IF-857
4-methylbenzyl
Bnzl
i-Bu
acetyl
1.187
474
B


IF-858
4-methylbenzyl
Bnzl
i-Bu
3-methylbutanoyl
1.247
516
B


IF-859
4-methylbenzyl
Bnzl
i-Bu
2-phenylacetyl
1.253
550
B


IF-860
4-methylbenzyl
Bnzl
i-Bu
methoxycarbonyl
1.23
490
B


IF-861
4-methylbenzyl
Bnzl
i-Bu
2-methylpropoxycarbonyl
1.292
532
B


IF-862
4-methylbenzyl
Bnzl
i-Bu
benzyloxycarbonyl
1.297
566
B


IF-863
4-methylbenzyl
Bnzl
i-Bu
aminocarbonyl
1.157
475
B























TABLE 4-27







IF-864
4-methylbenzyl
Bnzl
i-Bu
N-benzylaminocarbonyl
1.252
565
B


IF-865
Bnzl
pyridin-4-ylmethyl
i-Bu
H
1.11
419
B


IF-866
4-(dimethylamino)benzyl
3-hydroxybenzyl
i-Bu
H
1.223
477
B


IF-867
4-(dimethylamino)benzyl
4-hydroxybenzyl
i-Bu
H
1.208
477
B


IF-868
2-hydroxyethyl
4-fluorobenzyl
Np-M
H
0.76
474
C


IF-869
4-methoxybenzyl
Bnzl
Bnzl
H
0.83
482
C


IF-870
4-methoxybenzyl
Bnzl
Bnzl
tert-butoxycarbonyl
1.01
582
C


IF-871
ethyl
Bnzl
Bnzl
tert-butoxycarbonyl
0.94
490
C


IF-872
phenethyl
Bnzl
2-(tert-butyldimethylsilyloxy)
H
0.95
534
C





ethyl






IF-873
cyclopentylmethyl
4-(tert-butoxy)benzyl
2-(tert-butoxycarbonyl)ethyl
H
0.93
554
C


IF-874
4-nitrobenzyl
4-(tert-butoxy)
2-(tert-butoxycarbonyl)ethyl
H
0.97
607
C




benzyl







IF-875
phenethyl
Bnzl
2-hydroxyethyl
H
0.72
420
C


IF-876
cyclopentylmethyl
4-(tert-butoxy)benzyl
2-(tert-butoxycarbonyl)ethyl
methoxycarbonyl
1.03
612
C


IF-877
cyclopentylmethyl
4-hydroxybenzyl
2-carboxyethyl
methoxycarbonyl
0.71
500
C


IF-878
cyclopentylmethyl
4-hydroxybenzyl
2-carboxyethyl
H
0.64
442
C


IF-879
phenethyl
Bnzl
2-hydroxyethyl
methoxycarbonyl
0.8
478
C


IF-880
4-aminobenzyl
4-(tert-butoxy)benzyl
2-(tert-butoxycarbonyl)ethyl
formyl
0.89
605
C


IF-881
4-(cyclopentylcarbonylamino)
4-(tert-butoxy)benzyl
2-(tert-butoxycarbonyl)ethyl
formyl
1
701
C



benzyl








IF-882
4-(cyclopentylmethylamino)
4-(tert-butoxy)benzyl
2-(tert-butoxycarbonyl)ethyl
formyl
1.07
687
C



benzyl























TABLE 4-28







IF-
4-(cyclopentylmethylamino)
4-
2-
H
0.81
561
C


883
benzyl
hydroxybenzyl
methoxycarbonylethyl






IF-
4-(cyclopentylmethylamino)
4-
2-
H
0.75
547
C


884
benzyl
hydroxybenzyl
carboxylethyl
















TABLE 4-29







Formula XXIF




embedded image




















Compound





Retention
Mass
Measurement


number
R1
R2A
R2B
R3
R4
RT (min)
(M + H)+
condition





IF-885
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
1.99
466
 B1


IF-886
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
1.98
466
 B1


IF-887
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
1.75
462
 B1


IF-888
i-Bu
H
4-Me-Bnzl
Ph-Et
H
1.92
446
 B1


IF-889
i-Bu
H
2-Npm
Ph-Et
H
2.07
482
 B1


IF-890
i-Bu
H
Bnzl
Ph-Pr
H
1.89
446
B


IF-891
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
1.16
480
B


IF-892
i-Bu
H
3-F-Bnzl
Ph-Pr
H
1.14
464
B


IF-893
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
1.13
460
B


IF-894
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
1.10
476
B


IF-895
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
1.16
494
B


IF-896
i-Bu
H
3-F-Bnzl
Ph-Bu
H
1.12
478
B


IF-897
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
1.16
474
B


IF-898
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
1.12
491
B


IF-899
i-Bu
H
Bnzl
Ph-Bu
H
1.13
460
B


IF-900
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
1.14
478
B


IF-901
1-Npm
H
pentyl
Ph-Et
H
0.92
496
C


IF-902
1-Npm
H
cyclohexyl
Ph-Et
H
0.92
508
C


IF-903
1-Npm
H
cyclopentyl
Ph-Et
H
0.90
494
C


IF-904
1-Npm
H
Hxy
4-methylphenethyl
H
0.99
524
C


IF-905
1-Npm
H
Hxy
2-(naphthalen-2-yl)ethyl
H
1.02
560
C


IF-906
1-Npm
H
heptyl
Ph-Et
H
1.00
524
C


IF-907
1-Npm
H
Hxy
4-isopropylphenethyl
H
1.05
552
C


IF-908
1-Npm
H
Hxy
cyclohexylethyl
H
1.03
516
C
























TABLE 4-30







IF-909
i-Bu
H
Ph-Et
Ph-Et
H
1.87
444
B1


IF-910
Chm
H
tBuO-E
1-Npm
H
0.87
518
C


IF-911
tBuO-E
H
Ph-Et
1-Npm
H
0.88
526
C


IF-912
Ph-Et
H
Hxy
1-Npm
H
0.95
510
C


IF-913
tBuO-E
H
4-fluorophenethyl
1-Npm
H
0.89
544.4
C


IF-914
Hdr-E
H
4-fluorophenethyl
1-Npm
H
0.77
488.3
C


IF-915
3-tert-butoxypropyl
H
4-F-Bnzl
1-Npm
H
0.89
544.4
C


IF-916
tBuO-E
H
4-Cl-Bnzl
1-Npm
H
0.9
546.3
C


IF-917
3-hydroxypropyl
H
4-F-Bnzl
1-Npm
H
0.76
488.3
C


IF-918
Hdr-E
H
4-Cl-Bnzl
1-Npm
H
0.78
490.3
C


IF-919
1-Npm
H
Hxy
3-methylphenethyl
H
0.99
524.4
C


IF-920
1-Npm
H
β-hydroxyphenethyl
Ph-Et
H
0.84
546.4
C


IF-921
1-Npm
H
α-hydroxymethylphenethyl
Ph-Et
H
0.88
560.4
C


IF-922
1-Npm
H
α-hydroxymethylphenethyl
Ph-Et
H
0.85
560.4
C


IF-923
4-Nt-Bnzl
H
Bnzl
tBOC-E
H
0.86
535
C


IF-924
4-Nt-Bnzl
H
Bnzl
tBOC-E
ethoxycarbonyl
0.94
607
C


IF-925
1-Npm
H
4-F-Bnzl
2-OH-Et
H
0.73
474.3
C


IF-926
4-tBuO-Bnzl
H
Bnzl
i-Bu
H
0.91
490.4
C


IF-927
4-tBuO-Bnzl
H
i-Bu
Bnzl
H
0.88
490.4
C


IF-928
2-OtBu-Et
H
Bnzl
1-Npm
H
0.85
512.4
C


IF-929
2-OH-Et
H
Bnzl
1-Npm
H
0.74
456.3
C


IF-930
4-OH-Bnzl
H
i-Bu
Bnzl
H
0.73
434.3
C


IF-931
1-Npm
H
4-F-Bnzl
2-OTBS-Et
H
1.01
588.4
C









Example 2: Assay Method for Anti-Rabies Virus Activity

Each tested compound prepared as a 10 mM with DMSO was first diluted to 100 μM or 40 μM with 10% fetal bovine serum-supplemented Eagle's minimal essential medium (hereinafter, medium), and further diluted with the medium to the final concentration of interest. Fifty microlitter of the diluted medium was added dropwise to each well of a 96-well plate. Furthermore, 50 μL of medium comprising 4×102 infectious units of the recombinant rabies virus 1088 strain expressing Gaussia Luciferase (GLuc) (1088/GLuc) and 4×104 Neuro-2a cells were added to each well. The plate was shaken for 30 seconds with a multiple microplate mixer NS-4P (AS ONE Corporation) and then cultured for 3 days at 37° C. in the presence of 5% CO2. After incubation, 25 μL of coelenterazine, which is a substrate of the luciferase, was added dropwise to each well of the plate, and the plate was immediately loaded into a luminescent plate reader LuMate (Awareness Technology) and shaken for 10 seconds. The relative light unit (RLU) was then measured.


The synthesized compounds were tested. It was found that the compounds described in Table 5 exhibited the higher anti-rabies virus activity compared to T-705 (generic name: Favipiravir) (IC50=30 μM), which is examined as an anti-rabies antiviral drug.


The compounds are classified as A if ICH is 5 μM or less, B if greater than 5 μM and less than or equal to 10 μM, and C if greater than 10 μM and less than 30 μM. The ‘na’ indicates not applicable.











TABLE 5-1





Compound

IC50


number
Name of compound
(μM)







IB-3 
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1-
19.6



diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-4 
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-
19.2



diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-5 
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1,7-
18.2



diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-9 
(3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-1-
17.0



isopentyloctahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-12
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7-isobutyl-N-
15.5



phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-13
(3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(3-
14.3



methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IB-15
(3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-
15.9



methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide


















TABLE 5-2







IF-1 
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-1-
12.6



isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-6 
(3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl-N-
16.3



isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-7 
(3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-7-
8.5



isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-9 
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-1-
15.6



isopentyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-11
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7-
17.5



phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-13
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(3-
13.1



methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-14
(3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(4-
14.1



methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-15
(3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-
17.1



methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IF-20
(3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N-(3,4-
11.6



dichlorobenzyl)-7-isobutyloctahydro-6H-3,6-




methanopyrrolo[3,2-c]pyridine-6-carboxamide



IF-69
(3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-4-ethyl-1-
16.5



isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-




c]pyridine-6-carboxamide



IIB-4 
(3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-dilsobutyl-
8.9



1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-




b]pyridine-3a-carboxamide



IIF-16
(3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-1-isobutyl-N-(4-
28.7



methylbenzyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6-




methanopyrrolo[3,2-c]pyridine-6-carboxamide
















TABLE 5-3







Table. Anti-rabies activity of compound of formula IB












Compound




Anti-rabies


number
R1
R2
R3
R4
activity





IB-3 
i-Bu
i-Bu
Bnzl
H
C


IB-4 
Bnzl
i-Bu
i-Bu
H
C


IB-5 
i-Bu
Bnzl
i-Bu
H
C


IB-9 
i-Pnt
Bnzl
Bnzl
H
C


IB-12
i-Bu
phenethyl
Bnzl
H
C


IB-13
i-Bu
Bnzl
3-methylbenzyl
H
C


IB-15
i-Bu
3-methylbenzyl
Bnzl
H
C


IB-42
Np-M
Bnzl
Bnzl
H
C


IB-81
carbamoylmethyl
1-naphthylmethyl
i-Bu
H
C


IB-82
carbamoylmethyl
1-naphthylmethyl
Bnzl
H
C


IB-83
carbamoylmethyl
1-naphthylmethyl
4-hydroxybenzyl
H
C


IB-84
carbamoylmethyl
1-naphthylmethyl
i-Pnt
H
C


IB-86
carbamoylmethyl
2-phenylethyl
i-Bu
H
C


IB-87
carbamoylmethyl
2-phenylethyl
Bnzl
H
A


IB-89
carbamoylmethyl
2-phenylethyl
i-Pnt
H
A





(A: IC50 ≤ 5 μM,B: 5 μM < IC50 ≤ 10 μM,C: 10 μM < IC50 < 30 μM)


















TABLE 5-4







IB-90
carbamoylmethyl
1-naphthylmethyl
1-naphthylmethyl
H
A


IB-92
carbamoylmethyl
4-fluorobenzyl
Bnzl
H
C


IB-95
carbamoylmethyl
4-fluorobenzyl
2-phenylethyl
H
A


IB-96
carbamoylmethyl
4-fluorobenzyl
1-naphthylmethyl
H
C


IB-97
carbamoylmethyl
2-phenylethyl
1-naphthylmethyl
H
A


IB-102
carbamoylmethyl
i-Pnt
2phenylethyl-
H
A


IB-103
carbamoylmethyl
i-Pnt
1-naphthylmethyl
H
C


IB-105
carbamoylmethyl
hexyl
Bnzl
H
C


IB-108
carbamoylmethyl
hexyl
i-Pnt
H
C


IB-109
carbamoylmethyl
hexyl
2-phenylethyl
H
C


IB-110
carbamoylmethyl
hexyl
1-naphthylmethyl
H
A


IB-130
carbamoylmethyl
Bnzl
2-phenylethyl
H
C


IB-164
3-guanidinopropyl
1-naphthylmethyl
i-Bu
H
A


IB-174
3-guanidinopropyl
hexyl
2-phenylethyl
H
C


IB-176
3-guanidinopropyl
isopropyl
i-Bu
H
C


IB-179
3-guanidinopropyl
isopropyl
2-phenylethyl
H
C


IB-182
3-guanidinopropyl
4-fluorobenzyl
Bnzl
H
C


IB-187
i-Bu
i-Bu
3-guanidinopropyl
H
C


IB-192
i-Bu
i-Pnt
3-guanidinopropyl
H
A


IB-198
Bnzl
i-Bu
3-guanidinopropyl
H
C


IB-203
4-hydroxybenzyl
i-Bu
3-guanidinopropyl
H
C


IB-207
4-hydroxybenzyl
4-fluorobenzyl
3-guanidinopropyl
H
C


IB-247
Bnzl
phenethyl
3-guanidinopropyl
H
C


IB-249
Bnzl
hexyl
3-guanidinopropyl
H
C


IB-250
Bnzl
4-fluorobenzyl
3-guanidinopropyl
H
C


IB-256
phenethyl
hexyl
3-guanidinopropyl
H
C


IB-260
4-fluorobenzyl
Bnzl
3-guanidinopropyl
H
C


IB-262
4-fluorobenzyl
phenethyl
3-guanidinopropyl
H
C


IB-274
Bnzl
3-amino-3-oxopropyl
i-Pnt
H
C





















TABLE 5-5







IB-276
Bnzl
3-
Bnzl
H
C




guanidinopropyl





IB-279
Bnzl
3-
phenethyl
H
C




guanidinopropyl





IB-280
Bnzl
3-
Np-M
H
C




guanidinopropyl





IB-300
3-
Bnzl
Np-M
H
C



guanidinopropyl






IB-327
3-
phenethyl
Np-M
H
C



guanidinopropyl






IB-342
phenethyl
3-amino-3-
i-Pnt
H
C




oxopropyl





IB-344
phenethyl
3-
Bnzl
H
C




guanidinopropyl





IB-346
phenethyl
3-
i-Pnt
H
C




guanidinopropyl





IB-347
phenethyl
3-
Np-M
H
C




guanidinopropyl





IB-349
Np-M
3-amino-3-
i-Pnt
H
A




oxopropyl





IB-350
Np-M
3-
i-Bu
H
C




guanidinopropyl





IB-351
Np-M
3-
Bnzl
H
C




guanidinopropyl





IB-353
Np-M
3-
i-Pnt
H
A




guanidinopropyl





IB-354
Np-M
3-
phenethyl
H
A




guanidinopropyl





IB-357
cyclohexylmethyl
3-amino-3-
i-Pnt
H
C




oxopropyl





IB-361
cyclohexylmethyl
3-
i-Pnt
H
C




guanidinopropyl





IB-362
cyclohexylmethyl
3-
phenethyl
H
A




guanidinopropyl





IB-365
4-
3-amino-3-
i-Pnt
H
C



fluorobenzyl
oxopropyl





IB-369
4-
3-
i-Pnt
H
C



fluorobenzyl
guanidinopropyl





IB-372
2-
i-Bu
i-Pnt
H
C



hydroxyethyl






IB-378
i-Bu
i-Bu
i-Pnt
H
A


IB-381
i-Pnt
2-
Np-M
H
C




carboxyethyl





IB-384
4-
2-
Np-M
H
C



fluorobenzyl
carboxyethyl





IB-386
i-Pnt
4-
2-
H
C




fluorobenzyl
carboxyethyl




IB-389
cyclohexylmethyl
Np-M
2-
H
C





carboxyethyl





















TABLE 5-6







IB-390
4-
Np-M
2-
H
C



fluorobenzyl

carboxyethyl




IB-392
2-
Np-M
i-Bu
H
C



carboxyethyl






IB-394
2-
4-
Bnzl
H
C



carboxyethyl
fluorobenzyl





IB-398
2-
Np-M
i-Pnt
H
C



carboxyethyl






IB-399
2-
4-
i-Pnt
H
C



carboxyethyl
fluorobenzyl





IB-402
2-
4-
i-Pnt
H
C



carboxyethyl
hydroxybenzyl





IB-410
4-
2-
Np-M
H
C



hydroxybenzyl
carboxyethyl





IB-417
Np-M
4-
Np-M
H
C




hydroxybenzyl





IB-425
2-
Np-M
2-
H
C



hydroxyethyl

carboxyethyl




IB-426
i-Pnt
Np-M
hydroxymethyl
H
A


IB-430
2-
i-Bu
phenethyl
H
A



carboxyethyl






IB-431
2-
i-Bu
hydroxymethyl
H
C



carboxyethyl






IB-449
phenethyl
4-
i-Bu
H
C




hydroxybenzyl





IB-458
4-
4-
i-Bu
H
C



fluorobenzyl
hydroxybenzyl





IB-459
Np-M
2-
4-
H
C




hydroxyethyl
hydroxybenzyl




IB-461
phenethyl
2-
i-Pnt
H
C




hydroxyethyl





IB-464
Bnzl
4-
i-Bu
H
A




hydroxybenzyl





IB-465
i-Bu
4-
i-Pnt
H
C




hydroxybenzyl





IB-470
2-
4-
Np-M
H
C



hydroxyethyl
hydroxybenzyl





IB-476
2-
hexyl
Bnzl
H
A



hydroxyethyl






IB-477
2-
hexyl
i-Bu
H
A



hydroxyethyl






IB-478
2-
hexyl
4-
H
C



hydroxyethyl

hydroxybenzyl




IB-479
2-
4-
Bnzl
H
C



hydroxyethyl
fluorobenzyl





IB-481
i-Pnt
4-
4-
H
A




fluorobenzyl
hydroxybenzyl




IB-484
cyclohexylmethyl
phenethyl
Bnzl
H
A


IB-490
2-
hexyl
i-Pnt
H
A



hydroxyethyl






IB-492
2-
4-
phenethyl
H
A



hydroxyethyl
fluorobenzyl





















TABLE 5-7







IB-495
i-Bu
phenethyl
i-Bu
H
A


IB-498
i-Bu
4-
4-
H
A




fluorobenzyl
hydroxybenzyl




IB-499
4-
4-
i-Bu
H
A



hydroxybenzyl
fluorobenzyl





IB-501
4-
isopropyl
i-Pnt
H
A



hydroxybenzyl






IB-502
4-
isopropyl
Np-M
H
A



hydroxybenzyl






IB-505
i-Pnt
Bnzl
2-
H
C





carboxyethyl




IB-508
phenethyl
i-Bu
2-
H
C





carboxyethyl




IB-510
cyclohexylmethyl
i-Bu
2-
H
C





carboxyethyl




IB-515
2-
4-
phenethyl
H
C



carboxyethyl
hydroxybenzyl





IB-516
2-
4-
Np-M
H
C



carboxyethyl
hydroxybenzyl





IB-520
Np-M
3-amino-3-
i-Bu
H
A




oxopropyl





IB-521
Np-M
3-amino-3-
4-
H
C




oxopropyl
hydroxybenzyl




IB-522
cyclohexylmethyl
3-amino-3-
Np-M
H
C




oxopropyl





IB-525
4-
3-amino-3-
Np-M
H
C



fluorobenzyl
oxopropyl





IB-527
2-
Np-M
4-
H
C



hydroxyethyl

hydroxybenzyl




IB-531
2-
phenethyl
i-Pnt
H
C



hydroxyethyl






IB-535
Bnzl
3-amino-3-
phenethyl
H
C




oxopropyl





IB-536
i-Bu
phenethyl
4-
H
C





hydroxybenzyl




IB-539
i-Bu
3-amino-3-
phenethyl
H
C




oxopropyl





IB-540
4-
phenethyl
i-Bu
H
C



hydroxybenzyl






IB-541
4-
Np-M
i-Bu
H
A



hydroxybenzyl






IB-544
4-
phenethyl
i-Pnt
H
C



hydroxybenzyl






IB-549
2-
4-
4-
H
C



hydroxyethyl
fluorobenzyl
hydroxybenzyl




IB-551
i-Pnt
hexyl
i-Bu
H
A


IB-553
i-Pnt
4-
i-Bu
H
A




fluorobenzyl





IB-562
Bnzl
hexyl
Bnzl
H
C


IB-568
Bnzl
4-
phenethyl
H
C




fluorobenzyl





IB-574
4-
i-Pnt
Bnzl
H
C



hydroxybenzyl





















TABLE 5-8







IB-575
2-
i-Bu
Np-M
H
C



carboxyethyl






IB-576
i-Pnt
4-
phenethyl
H
C




hydroxybenzyl





IB-577
i-Pnt
4-
Bnzl
H
C




hydroxybenzyl





IB-581
cyclohexylmethyl
4-
i-Bu
H
C




hydroxybenzyl





IB-582
4-
4-
i-Pnt
H
C



fluorobenzyl
hydroxybenzyl





IB-583
4-
4-
Bnzl
H
C



fluorobenzyl
hydroxybenzyl





IB-585
2-
Np-M
i-Bu
H
C



hydroxyethyl






IB-588
Np-M
2-
Bnzl
H
A




hydroxyethyl





IB-593
phenethyl
2-
Np-M
H
C




hydroxyethyl





IB-602
Bnzl
2-
Np-M
H
C




hydroxyethyl





IB-610
2-
2-
Np-M
H
C



hydroxyethyl
carboxyethyl





IB-611
i-Pnt
2-
i-Bu
H
C




carboxyethyl





IB-613
cyclohexylmethyl
2-
i-Pnt
H
C




carboxyethyl





IB-614
cyclohexylmetyl
2-
Np-M
H
C




carboxyethyl





IB-616
Bnzl
2-
Np-M
H
C




carboxyethyl





IB-618
2-
Bnzl
phenethyl
H
A



hydroxyethyl






IB-619
2-
Bnzl
Bnzl
H
C



hydroxyethyl






IB-621
2-
i-Bu
Np-M
H
A



hydroxyethyl






IB-625
phenethyl
i-Bu
4-
H
C





hydroxybenzyl




IB-630
4-
i-Bu
i-Bu
H
A



fluorobenzyl






IB-631
4-
i-Bu
4-
H
C



fluorobenzyl

hydroxybenzyl




IB-633
i-Bu
i-Bu
phenethyl
H
A


IB-636
i-Pnt
3-amino-3-
phenethyl
H
C




oxopropyl





IB-637
cyclohexylmethyl
3-amino-3-
Bnzl
H
A




oxopropyl





IB-640
phenethyl
2-
Bnzl
H
A




hydroxyethyl





IB-641
phenethyl
2-
i-Bu
H
C




hydroxyethyl





















TABLE 5-9







IB-642
phenethyl
4-
4-
H
A




fluorobenzyl
hydroxybenzyl




IB-643
Np-M
2-
i-Bu
H
C




hydroxyethyl





IB-646
cyclohexylmethyl
2-
i-Bu
H
C




hydroxyethyl





IB-648
cyclohexylmethyl
i-Pnt
4-
H
C





hydroxybenzyl




IB-649
4-
2-
Bnzl
H
C



fluorobenzyl
hydroxyethyl





IB-650
4-
2-
i-Bu
H
C



fluorobenzyl
hydroxyethyl





IB-656
4-
hexyl
4-
H
A



fluorobenzyl

hydroxybenzyl




IB-657
2-
4-
i-Pnt
H
C



hydroxyethyl
fluorobenzyl





IB-658
i-Pnt
2-
phenethyl
H
C



hydroxyethyl






IB-659
i-Pnt
2-
Np-M
H
A




hydroxyethyl





IB-663
cyclohexylmethyl
2-
phenethyl
H
A




hydroxyethyl





IB-668
4-
2-
i-Pnt
H
A



fluorobenzyl
hydroxyethyl





IB-669
4-
2-
phenethyl
H
C



fluorobenzyl
hydroxyethyl





IB-676
Bnzl
2-
Bnzl
H
C




hydroxyethyl





IB-678
Bnzl
i-Pnt
4-
H
A





hydroxybenzyl




IB-680
Bnzl
2-
i-Pnt
H
C




hydroxyethyl





IB-681
Bnzl
2-
phenethyl
H
C




hydroxyethyl





IB-684
i-Bu
i-Pnt
4-
H
C





hydroxybenzyl




IB-687
i-Bu
2-
Np-M
H
C




hydroxyethyl





IB-688
i-Bu
i-Pnt
phenethyl
H
A


IB-694
2-
Bnzl
i-Pnt
H
C



carboxyethyl






IB-703
i-Pnt
3-amino-3-
Np-M
H
A




oxopropyl





IB-707
phenethyl
3-amino-3-
Bnzl
H
A




oxopropyl





IB-708
phenethyl
3-amino-3-
i-Bu
H
A




oxopropyl





IB-710
cyclohexylmethyl
3-amino-3-
phenethyl
H
A




oxopropyl





















TABLE 5-10







IB-712
4-
3-amino-3-
Bnzl
H
A



fluorobenzyl
oxopropyl





IB-714
2-
i-Pnt
Bnzl
H
A



hydroxyethyl






IB-725
4-
phenethyl
i-Bu
H
A



fluorobenzyl






IB-727
2-
i-Pnt
Np-M
H
A



hydroxyethyl






IB-729
Np-M
phenethyl
Np-M
H
A


IB-734
Bnzl
3-amino-3-
Bnzl
H
C




oxopropyl





IB-737
i-Bu
3-amino-3-
Np-M
H
C




oxopropyl





IB-739
4-
i-Pnt
i-Bu
H
C



hydroxybenzyl






IB-743
4-
3-amino-3-
Np-M
H
A



hydroxybenzyl
oxopropyl





IB-749
i-Pnt
Bnzl
4-
H
C





hydroxybenzyl




IB-753
i-Pnt
i-Bu
i-Bu
H
A


IB-757
phenethyl
Bnzl
i-Bu
H
A


IB-759
phenethyl
i-Bu
Bnzl
H
A


IB-760
phenethyl
i-Bu
i-Bu
H
A


IB-762
Np-M
i-Bu
i-Bu
H
A


IB-763
Np-M
i-Bu
4-
H
C





hydroxybenzyl




IB-770
cyclohexylmethyl
i-Bu
4-
H
C





hydroxybenzyl




IB-772
4-
Bnzl
Bnzl
H
A



fluorobenzyl






IB-773
4-
Bnzl
i-Bu
H
A



fluorobenzyl






IB-774
4-
i-Bu
phenethyl
H
A



fluorobenzyl






IB-777
Bnzl
Bnzl
Np-M
H
A


IB-780
i-Bu
i-Pnt
Bnzl
H
A


IB-783
i-Bu
Bnzl
4-
H
C





hydroxybenzyl




IB-786
4-
Bnzl
i-Pnt
H
C



hydroxybenzyl






IB-787
4-
Bnzl
i-Bu
H
C



hydroxybenzyl






IB-804
Np-M
Np-M
phenethyl
H
A


IB-813
Bnzl
3-amino-3-
Np-M
H
A




oxopropyl





IB-831
2-
4-
Np-M
H
A



hydroxyethyl
fluorobenzyl





IB-864
4-C1-Bnzl
Bnzl
i-Bu
H
B


IB-865
3-C1-Bnzl
Bnzl
i-Bu
H
B


IB-866
4-
Bnzl
i-Bu
H
B



methoxybenzyl





















TABLE 5-11







IB-867
4-
Bnzl
i-Bu
H
B



methylbenzyl






IB-870
i-Bu
i-Pnt
Bnzl
H
C


IB-871
i-Bu
4-Cl-Bnzl
i-Bu
H
C


IB-873
4-
Bnzl
i-Bu
H
B



(dimethylamino)-







benzyl






IB-874
4-(tert-
Bnzl
i-Bu
H
B



butyl)benzyl






IB-875
i-Bu
Bnzl
i-Pnt
H
C


IB-876
i-Pnt
Bnzl
i-Bu
H
C


IB-877
4-
Bnzl
i-Bu
H
B



(trifluoromethyl)-







benzyl






IB-878
4-
Bnzl
i-Bu
H
C



ethoxybenzyl






IB-879
Bnzl
naphthalen-
i-Bu
H
A




2-ylmethyl





IB-880
4-
Bnzl
i-Bu
ethyl
A



methylbenzyl






IB-881
4-
Bnzl
i-Bu
i-Bu
A



methylbenzyl






IB-883
4-
Bnzl
i-Bu
3-
A



methylbenzyl


methylbutanoyl



IB-884
4-
Bnzl
i-Bu
2-
A



methylbenzyl


phenylacetyl



IB-885
4-
Bnzl
i-Bu
methoxy-
B



methylbenzyl


carbonyl



IB-886
4-
Bnzl
i-Bu
2-
B



methylbenzyl


methylpropoxy-







carbonyl



IB-887
4-
Bnzl
i-Bu
benzyloxy-
B



methylbenzyl


carbonyl



IB-888
4-
Bnzl
i-Bu
aminocarbonyl
C



methylbenzyl






IB-889
4-
Bnzl
i-Bu
N-
B



methylbenzyl


benzylamino-







carbonyl



IB-891
4-
3-
i-Bu
H
C



(dimethylamino)-
hydroxybenzyl






benzyl






IB-892
4-
4-
i-Bu
H
C



(dimethylamino)-
hydroxybenzyl






benzyl
















TABLE 5-12







Anti-rabies activity of compounds of formula XXIB













Compound





Anti-rabies


number
R1
R2A
R2B
R3
R4
activity





IB-924
4-Me-
H
Bnzl
i-Bu
N-isobutylamino-
na



Bnzl



carbonyl



IB-925
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
A


IB-926
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
A


IB-927
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
A


IB-928
i-Bu
H
4-Me-Bnzl
Ph-Et
H
A


IB-929
i-Bu
H
2-Npm
Ph-Et
H
A


IB-930
i-Bu
H
Bnzl
Ph-Pr
H
A


IB-931
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
A


IB-932
i-Bu
H
3-F-Bnzl
Ph-Pr
H
A


IB-933
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
A


IB-934
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
A


IB-935
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
A


IB-936
i-Bu
H
3-F-Bnzl
Ph-Bu
H
A


IB-937
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
A


IB-938
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
A


IB-939
i-Bu
H
Bnzl
Ph-Bu
H
A


IB-940
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
A


IB-957
i-Bu
H
Ph-Et
Ph-Et
H
A


IB-958
i-Bu
H
1-Npm
Ph-Et
H
A
















TABLE 5-13







Table. Anti-rabies activity of compounds of formula IF












Compound




Anti-rabies


number
R1
R2
R3
R4
activity





IF-1 
i-Bu
Bnzl
Bnzl
H
C


IF-6 
Bnzl
i-Bu
Bnzl
H
C


IF-7 
Bnzl
Bnzl
i-Bu
H
B


IF-9 
i-Pnt
Bnzl
Bnzl
H
C


IF-11
i-Bu
Bnzl
phenethyl
H
C


IF-13
i-Bu
Bnzl
3-methylbenzyl
H
C


IF-14
i-Bu
Bnzl
4-methylbenzyl
H
C





(A: IC50 ≤ 5 μM,B: 5 μM < IC50 ≤ 10 μM,C: 10 μM < IC50 < 30 μM)


















TABLE 5-14







IF-15 
i-Bu
3-
Bnzl
H
C




methylbenzyl





IF-20 
Bnzl
3,4-
i-Bu
H
C




dichlorobenzyl





IF-38 
i-Bu
Bnzl
cyclohexylmethyl
H
C


IF-42 
Np-M
Bnzl
Bnzl
H
C


IF-69 
i-Bu
Bnzl
Bnzl
ethyl
C


IF-81 
2-amino-2-
Np-M
i-Bu
H
C



oxoethyl






IF-82 
2-amino-2-
Np-M
Bnzl
H
C



oxoethyl






IF-84 
2-amino-2-
Np-M
i-Pnt
H
C



oxoethyl






IF-85 
2-amino-2-
Np-M
phenethyl
H
C



oxoethyl






IF-90 
2-amino-2-
phenethyl
Np-M
H
C



oxoethyl






IF-91 
2-amino-2-
Np-M
Np-M
H
A



oxoethyl






IF-95 
2-amino-2-
4-
i-Pnt
H
C



oxoethyl
fluorobenzyl





IF-97 
2-amino-2-
4-
Np-M
H
C



oxoethyl
fluorobenzyl





IF-109
2-amino-2-
hexyl
phenethyl
H
C



oxoethyl






IF-110
2-amino-2-
hexyl
Np-M
H
A



oxoethyl






IF-137
2-amino-2-
4-
Np-M
H
A



oxoethyl
hydroxybenzyl





IF-214
i-Pnt
isopropyl
3-
H
C





guanidinopropyl




IF-219
phenethyl
3-amino-
2-amino-2-
H
C




3-oxopropyl
oxoethyl




IF-223
phenethyl
Np-M
2-amino-2-
H
C





oxoethyl




IF-226
Np-M
i-Bu
2-amino-2-
H
C





oxoethyl




IF-230
Np-M
2-
2-amino-2-
H
C




hydroxyethyl
oxoethyl




IF-235
Np-M
i-Bu
3-
H
C





guanidinopropyl




IF-236
Np-M
Bnzl
3-
H
C





guanidinopropyl




IF-239
Np-M
2-
3-
H
C




hydroxyethyl
guanidinopropyl




IF-243
Np-M
hexyl
3-
H
A





guanidinopropyl




IF-244
Np-M
isopropyl
3-
H
A





guanidinopropyl





















TABLE 5-15







IF-245
Np-M
4-
3-
H
A




fluoro-
guanidinopropyl






benzyl





IF-246
cyclohexyl-
Bnzl
2-amino-2-
H
C



methyl

oxoethyl




IF-247
cyclohexyl-
4-
2-amino-2-
H
C



methyl
hydroxy-
oxoethyl






benzyl





IF-251
cyclohexyl-
phenethyl
2-amino-2-
H
C



methyl

oxoethyl




IF-260
cyclohexyl-
hexyl
3-
H
C



methyl

guanidinopropyl




IF-262
4-
i-Bu
2-amino-2-
H
A



fluorobenzyl

oxoethyl




IF-269
4-
phenethyl
2-amino-2-
H
C



fluorobenzyl

oxoethyl




IF-274
4-
isopropyl
3-
H
C



fluorobenzyl

guanidinopropyl




IF-284
Bnzl
Np-M
3-
H
C





guanidinopropyl




IF-285
Bnzl
hexyl
3-
H
C





guanidinopropyl




IF-297
4-
Np-M
3-
H
C



fluorobenzyl

guanidinopropyl




IF-298
4-
hexyl
3-
H
C



fluorobenzyl

guanidinopropyl




IF-300
i-Bu
3-
i-Pnt
H
C




amino-







3-







oxopropyl





IF-356
3-
i-Pnt
Np-M
H
C



guanidino-







propyl






IF-359
3-
phenethyl
4-hydroxybenzyl
H
C



guanidino-







propyl






IF-384
Np-M
3-
i-Pnt
H
C




amino-







3-







oxopropyl





IF-386
Np-M
3-
Bnzl
H
C




guanidino-







propyl





IF-389
Np-M
3-
phenethyl
H
A




guanidino-







propyl





IF-390
Np-M
3-
Np-M
H
C




guanidino-







propyl





IF-411
Bnzl
i-Bu
i-Pnt
H
A


IF-412
i-Bu
i-Bu
i-Pnt
H
A


IF-413
i-Pnt
2-
Np-M
H
C




carboxy-







ethyl





IF-416
cyclohexyl-
2-
Np-M
H
C



methyl
carboxy-







ethyl





IF-417
4-
2-
Np-M
H
C



fluorobenzyl
carboxy-







ethyl





IF-419
cyclohexyl-
Np-M
2-carboxyethyl
H
C



methyl






IF-422
2-
Np-M
i-Pnt
H
C



carboxyethyl






IF-428
i-Bu
2-
Np-M
H
C




carboxy-







ethyl





IF-435
Np-M
3-
4-hydroxybenzyl
H
A




amino-







3-







oxopropyl





IF-437
i-Pnt
phenethyl
i-Bu
H
C





















TABLE 5-16







IF-439
cyclohexyl-
phenethyl
4-hydroxybenzyl
H
A



methyl






IF-444
2-
2-
Np-M
H
C



hydroxyethyl
carboxy-







ethyl





IF-445
i-Pnt
4-
2-carboxyethyl
H
C




hydroxy-







benzyl





IF-447
cyclohexyl-
4-
2-carboxyethyl
H
C



methyl
hydroxy-







benzyl





IF-452
2-
2-
Np-M
H
C



carboxyethyl
hydroxy-







ethyl





IF-454
2-
i-Bu
phenethyl
H
C



carboxyethyl






IF-455
2-
i-Bu
4-hydroxybenzyl
H
C



carboxyethyl






IF-458
2-
4-
i-Pnt
H
C



carboxyethyl
hydroxy-







benzyl





IF-464
i-Pnt
4-
phenethyl
H
C




hydroxy-







benzyl





IF-465
i-Pnt
4-
Np-M
H
C




hydroxy-







benzyl





IF-466
i-Pnt
4-
Bnzl
H
C




hydroxy-







benzyl





IF-468
phenethyl
4-
i-Pnt
H
C




hydroxy-







benzyl





IF-469
phenethyl
4-
Bnzl
H
C




hydroxy-







benzyl





IF-470
phenethyl
4-
i-Bu
H
C




hydroxy-







benzyl





IF-472
Np-M
4-
Bnzl
H
A




hydroxy-







benzyl





IF-473
Np-M
4-
i-Bu
H
A




hydroxy-







benzyl





IF-474
cyclohexyl-
4-
i-Pnt
H
A



methyl
hydroxy-







benzyl





IF-475
cyclohexyl-
4-
phenethyl
H
C



methyl
hydroxy-







benzyl





IF-477
cyclohexyl-
4-
Bnzl
H
A



methyl
hydroxy-







benzyl





IF-478
cyclohexyl-
4-
i-Bu
H
A



methyl
hydroxy-







benzyl





IF-479
4-
4-
i-Pnt
H
A



fluorobenzyl
hydroxy-







benzyl





IF-481
4-
4-
Bnzl
H
C



fluorobenzyl
hydroxy-







benzyl





IF-482
4-
4-
i-Bu
H
C



fluorobenzyl
hydroxy-







benzyl





IF-486
cyclohexyl-
2-
Bnzl
H
C



methyl
hydroxy-







ethyl





















TABLE 5-17







IF-490
4-
2-
i-Pnt
H
C



fluorobenzyl
hydroxyethyl





IF-493
Bnzl
4-
i-Pnt
H
A




hydroxybenzyl





IF-494
Bnzl
4-
Bnzl
H
C




hydroxybenzyl





IF-500
i-Bu
4-
Np-M
H
C




hydroxybenzyl





IF-503
4-
isopropyl
i-Pnt
H
A



hydroxybenzyl






IF-504
4-
isopropyl
Np-M
H
C



hydroxybenzyl






IF-505
Np-M
Bnzl
4-hydroxybenzyl
H
A


IF-508
2-
4-
Bnzl
H
C



hydroxyethyl
fluorobenzyl





IF-514
cyclohexyl-
hexyl
4-hydroxybenzyl
H
A



methyl






IF-516
2-
4-
phenethyl
H
A



hydroxyethyl
fluorobenzyl





IF-525
i-Bu
4-
phenethyl
H
C




fluorobenzyl





IF-536
cyclohexyl-
3-amino-
Np-M
H
A



methyl
3-







oxopropyl





IF-539
4-
3-amino-
Np-M
H
A



fluorobenzyl
3-







oxopropyl





IF-542
2-
Np-M
i-Bu
H
A



hydroxyethyl






IF-543
2-
Np-M
4-hydroxybenzyl
H
C



hydroxyethyl






IF-545
i-Pnt
phenethyl
4-hydroxybenzyl
H
C


IF-546
i-Pnt
hexyl
i-Bu
H
C


IF-547
i-Pnt
4-
Bnzl
H
A




fluorobenzyl





IF-548
i-Pnt
4-
i-Bu
H
C




fluorobenzyl





IF-560
Bnzl
hexyl
i-Bu
H
A


IF-561
Bnzl
4-
Bnzl
H
A




fluorobenzyl





IF-565
Bnzl
4-
phenethyl
H
A




hydroxybenzyl





IF-567
i-Bu
phenethyl
4-hydroxybenzyl
H
C


IF-568
i-Bu
Np-M
4-hydroxybenzyl
H
A


IF-569
i-Bu
hexyl
i-Bu
H
C


IF-576
i-Bu
4-
phenethyl
H
C




hydroxybenzyl





IF-578
4-
Np-M
i-Bu
H
A



hydroxybenzyl






IF-580
4-
phenethyl
Np-M
H
C



hydroxybenzyl





















TABLE 5-18







IF-583
i-Pnt
hexyl
4-hydroxybenzyl
H
A


IF-584
4-
i-Pnt
Bnzl
H
A



fluorobenzyl






IF-585
4-
i-Pnt
i-Bu
H
A



fluorobenzyl






IF-586
4-
phenethyl
Bnzl
H
C



fluorobenzyl






IF-596
Np-M
isopropyl
Np-M
H
C


IF-599
i-Pnt
hexyl
Bnzl
H
C


IF-602
phenethyl
hexyl
Bnzl
H
C


IF-603
Np-M
2-
Bnzl
H
C




hydroxy-







ethyl





IF-604
Np-M
2-
i-Bu
H
C




hydroxy-







ethyl





IF-606
cyclohexyl-
2-
i-Bu
H
C



methyl
hydroxy-







ethyl





IF-610
2-
phenethyl
Np-M
H
C



hydroxyethyl






IF-611
i-Pnt
2-
Np-M
H
C




hydroxy-







ethyl





IF-612
phenethyl
2-
Np-M
H
C




hydroxy-







ethyl





IF-613
Np-M
2-
i-Pnt
H
C




hydroxy-







ethyl





IF-614
Np-M
2-
Np-M
H
C




hydroxy-







ethyl





IF-619
cyclohexyl-
2-
Np-M
H
C



methyl
hydroxy-







ethyl





IF-620
4-
2-
Np-M
H
A



fluorobenzyl
hydroxy-







ethyl





IF-624
Bnzl
2-
Np-M
H
C




hydroxy-







ethyl





IF-635
i-Pnt
i-Bu
phenethyl
H
C


IF-639
phenethyl
Bnzl
i-Bu
H
A


IF-640
phenethyl
Bnzl
4-hydroxybenzyl
H
C


IF-641
phenethyl
i-Bu
Bnzl
H
A


IF-644
cyclohexyl-
Bnzl
i-Bu
H
A



methyl






IF-645
cyclohexyl-
Bnzl
4-hydroxybenzyl
H
C



methyl






IF-646
cyclohexyl-
i-Bu
Np-M
H
A



methyl






IF-649
4-
Bnzl
Bnzl
H
A



fluorobenzyl






IF-650
4-
Bnzl
i-Bu
H
A



fluorobenzyl






IF-652
4-
i-Bu
phenethyl
H
A



fluorobenzyl






IF-653
4-
i-Bu
Bnzl
H
C



fluorobenzyl






IF-654
4-
i-Bu
i-Bu
H
A



fluorobenzyl





















TABLE 5-19







IF-656
2-
i-Pnt
Bnzl
H
C



hydroxyethyl






IF-657
phenethyl
i-Pnt
i-Bu
H
A


IF-658
cyclohexyl-
i-Pnt
Bnzl
H
A



methyl






IF-659
cyclohexyl-
i-Pnt
i-Bu
H
C



methyl






IF-660
2-
i-Pnt
Np-M
H
C



hydroxyethyl






IF-665
Bnzl
i-Pnt
Bnzl
H
A


IF-670
Bnzl
i-Bu
phenethyl
H
A


IF-673
i-Bu
i-Pnt
phenethyl
H
A


IF-674
i-Bu
i-Pnt
Np-M
H
C


IF-675
i-Bu
Bnzl
i-Pnt
H
A


IF-679
i-Bu
i-Bu
phenethyl
H
A


IF-680
i-Bu
i-Bu
Np-M
H
C


IF-684
4-
i-Pnt
Np-M
H
C



hydroxybenzyl






IF-691
benzyl
i-Pnt
i-Bu
H
C


IF-692
Bnzl
hexyl
4-hydroxybenzyl
H
A


IF-699
phenethyl
3-
i-Bu
H
C




amino-







3-







oxopropyl





IF-705
i-Pnt
Np-M
i-Bu
H
A


IF-706
i-Pnt
Np-M
4-hydroxybenzyl
H
A


IF-707
phenethyl
i-Pnt
4-hydroxybenzyl
H
A


IF-708
Np-M
phenethyl
4-hydroxybenzyl
H
A


IF-709
cyclohexyl-
i-Pnt
4-hydroxybenzyl
H
C



methyl






IF-710
cyclohexyl-
phenethyl
Bnzl
H
A



methyl






IF-711
cyclohexyl-
phenethyl
i-Bu
H
C



methyl






IF-714
4-
phenethyl
i-Bu
H
A



fluorobenzyl






IF-715
4-
phenethyl
4-hydroxybenzyl
H
A



fluorobenzyl






IF-717
cyclohexyl-
phenethyl
i-Pnt
H
A



methyl






IF-718
cyclohexyl-
phenethyl
Np-M
H
A



methyl






IF-721
Bnzl
phenethyl
i-Bu
H
A


IF-722
Bnzl
phenethyl
4-hydroxybenzyl
H
A


IF-723
Bnzl
phenethyl
i-Pnt
H
C


IF-725
i-Bu
phenethyl
i-Bu
H
C


IF-726
i-Bu
Np-M
i-Bu
H
C


IF-727
i-Bu
phenethyl
i-Pnt
H
A


IF-730
4-
Np-M
i-Pnt
H
C



hydroxybenzyl





















TABLE 5-20







IF-733
i-Pnt
Bnzl
i-Bu
H
A


IF-734
i-Pnt
i-Bu
Np-M
H
A


IF-735
i-Pnt
i-Bu
Bnzl
H
C


IF-738
phenethyl
i-Bu
i-Bu
H
C


IF-739
Np-M
i-Bu
i-Bu
H
A


IF-740
cyclohexyl-
Bnzl
i-Pnt
H
C



methyl






IF-742
cyclohexyl-
i-Bu
i-Bu
H
C



methyl






IF-743
4-
Bnzl
i-Pnt
H
C



fluorobenzyl






IF-744
phenethyl
i-Pnt
Bnzl
H
A


IF-753
i-Bu
Bnzl
Np-M
H
C


IF-758
2-
Np-M
Bnzl
H
A



hydroxyethyl






IF-778
i-Bu
Np-M
Np-M
H
A


IF-779
4-
Np-M
Np-M
H
C



hydroxybenzyl






IF-789
Np-M
isopropyl
phenethyl
H
C


IF-805
Bnzl
Np-M
Bnzl
H
C


IF-807
Bnzl
4-
i-Bu
H
A




fluorobenzyl





IF-815
i-Bu
4-
Bnzl
H
A




fluorobenzyl





IF-830
i-Pnt
2-
phenethyl
H
C




carboxy-







ethyl





IF-837
Bnzl
Np-M
i-Bu
H
B


IF-838
Bnzl
4-
i-Bu
H
C




(trifluoro-







methyl)-







benzyl





IF-839
4-Cl-Bnzl
Bnzl
i-Bu
H
B


IF-840
3-Cl-Bnzl
Bnzl
i-Bu
H
B


IF-841
4-
Bnzl
i-Bu
H
B



methoxybenzyl






IF-842
4-
Bnzl
i-Bu
H
A



methylbenzyl






IF-845
i-Bu
i-Pnt
Bnzl
H
C


IF-846
i-Bu
4-Cl-
i-Bu
H
C




Bnzl





IF-848
4-
Bnzl
i-Bu
H
B



(dimethylamino)-







benzyl






IF-849
4-(tert-
Bnzl
i-Bu
H
B



butyl)benzyl






IF-850
i-Bu
Bnzl
i-Pnt
H
B


IF-851
i-Pnt
Bnzl
i-Bu
H
C


IF-852
4-
Bnzl
i-Bu
H
B



(trifluoro-







methyl)benzyl





















TABLE 5-21







IF-853
4-
Bnzl
i-Bu
H
B



ethoxybenzyl






IF-854
Bnzl
naphthalen-
i-Bu
H
B




2-







ylmethyl





IF-855
4-
Bnzl
i-Bu
ethyl
B



methylbenzyl






IF-856
4-
Bnzl
i-Bu
i-Bu
A



methylbenzyl






IF-859
4-
Bnzl
i-Bu
2-
B



methylbenzyl


phenylacetyl



IF-860
4-
Bnzl
i-Bu
methoxy-
C



methylbenzyl


carbonyl



IF-861
4-
Bnzl
i-Bu
2-
B



methylbenzyl


methyl-







propoxy-







carbonyl



IF-862
4-
Bnzl
i-Bu
benzyloxy-
B



methylbenzyl


carbonyl



IF-864
4-
Bnzl
i-Bu
N-
C



methylbenzyl


benzyl-







amino-







carbonyl



IF-866
4-
3-
i-Bu
H
C



(dimethyl-
hydroxy-






amino)benzyl
benzyl





IF-867
4-
4-
i-Bu
H
C



(dimethyl-
hydroxy-






amino)benzyl
benzyl
















TABLE 5-22







Anti-rabies activity of compounds of formula XXIF













Compound





Anti-rabies


number
R1
R2A
R2B
R3
R4
activity





IF-885
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
A


IF-886
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
A


IF-887
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
A


IF-888
i-Bu
H
4-Me-Bnzl
Ph-Et
H
A


IF-889
i-Bu
H
2-Npm
Ph-Et
H
A


IF-890
i-Bu
H
Bnzl
Ph-Pr
H
B


IF-891
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
A


IF-892
i-Bu
H
3-F-Bnzl
Ph-Pr
H
A


IF-893
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
B


IF-894
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
A


IF-895
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
A


IF-896
i-Bu
H
3-F-Bnzl
Ph-Bu
H
A


IF-897
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
A


IF-898
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
B


IF-899
i-Bu
H
Bnzl
Ph-Bu
H
B


IF-900
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
A


IF-909
i-Bu
H
Ph-Et
Ph-Et
H
A
















TABLE 5-23







Anti-rabies activity of compounds of formula IIB


(A: IC50 ≤ 5 μM, B: 5 μM < IC50 ≤ 10 μM, C: 10 μM < IC50 < 30 μM)















Anti-


Compound



rabies


number
R1
R2
R3
activity





IIB-4
Bnzl
i-Bu
i-Bu
B


IIB-83
4-Cl-Bnzl
Bnzl
i-Bu
A


IIB-84
3-Cl-Bnzl
Bnzl
i-Bu
A


IIB-85
4-methoxybenzyl
Bnzl
i-Bu
B


IIB-86
4-methylbenzyl
Bnzl
i-Bu
B


IIB-94
4-(dimethylamino)benzyl
Bnzl
i-Bu
B


IIB-95
4-(tert-butyl)benzyl
Bnzl
i-Bu
B


IIB-96
4-(trifluoromethoxy)benzyl
Bnzl
i-Bu
B


IIB-97
4-ethoxybenzyl
Bnzl
i-Bu
C


IIB-101
4-hydroxybenzyl
Bnzl
i-Pnt
B


IIB-102
Bnzl
naphthalen-2-
i-Bu
A




ylmethyl




IIB-103
i-Pnt
4-Cl-Bnzl
i-Bu
B


IIB-104
i-Pnt
4-fluorobenzyl
i-Bu
B
















TABLE 5-24







Anti-rabies activity of compounds of formula XXIIB

















Anti-


Compound




rabies


number
R1
R2A
R2B
R3
activity





IIF-325
i-Pnt
H
3-Cl-Bnzl
Bnzl
A


IIF-328
i-Pnt
H
4-Me-Bnzl
Bnzl
A


IIF-329
i-Pnt
H
4-MeO-Bnzl
Bnzl
A


IIB-329
Me
H
quinolin-8-ylethyl
Bnzl
A


IIB-330
Me
H
quinolin-5-ylethyl
Bnzl
A


IIB-331
i-Bu
H
4-Cl-Bnzl
Ph-Et
A


IIB-332
i-Bu
H
3-Cl-Bnzl
Ph-Et
A


IIB-333
i-Bu
H
4-MeO-Bnzl
Ph-Et
A


IIB-334
i-Bu
H
4-Me-Bnzl
Ph-Et
A


IIB-335
i-Bu
H
2-Npm
Ph-Et
A


IIB-336
i-Bu
H
Bnzl
Ph-Pr
A


IIB-337
i-Bu
H
3-Cl-Bnzl
Ph-Pr
A


IIB-338
i-Bu
H
3-F-Bnzl
Ph-Pr
A


IIB-339
Cpm
H
4-OH-Bnzl
2-Cbx-Et
na


IIB-340
i-Bu
H
3-Me-Bnzl
Ph-Pr
A


IIB-341
i-Bu
H
3-MeO-Bnzl
Ph-Pr
A


IIB-342
i-Bu
H
3-Cl-Bnzl
Ph-Bu
B


IIB-343
i-Bu
H
3-F-Bnzl
Ph-Bu
A


IIB-344
i-Bu
H
3-Me-Bnzl
Ph-Bu
A


IIB-345
i-Bu
H
3-MeO-Bnzl
Ph-Bu
A


IIB-346
i-Bu
H
Bnzl
Ph-Bu
A


IIB-347
i-Pnt
H
3-F-Bnzl
Ph-Pr
A


IIF-327
i-Pnt
H
4-F-Bnzl
Bnzl
A


IIF-370
i-Pnt
H
Ph-Et
Bnzl
A


IIF-371
i-Pnt
H
1-Npm
Bnzl
A


IIB-374
i-Bu
H
4-F-Bnzl
Ph-Et
A


IIB-375
i-Bu
H
Ph-Et
Ph-Et
A


IIB-376
i-Bu
H
1-Npm
Ph-Et
A


IIB-378
4-F-Bnzl
H
1-Npm
i-Bu
A
















TABLE 5-25







Anti-rabies activity of compounds of formula IIF


(A: IC50 ≤ 5 μM, B: 5 μM < IC50 ≤ 10 μM, C: 10 μM < IC50 < 30 μM)















Anti-


Compound



rabies


number
R1
R2
R3
activity





IIF-16
i-Bu
4-Me-Bnzl
Bnzl
C


IIF-83
4-Cl-Bnzl
Bnzl
i-Bu
A


IIF-84
3-Cl-Bnzl
Bnzl
i-Bu
B


IIF-85
4-methoxybenzyl
Bnzl
i-Bu
B


IIF-86
4-methylbenzyl
Bnzl
i-Bu
A


IIF-94
4-(dimethylamino)benzyl
Bnzl
i-Bu
B


IIF-95
4-(tert-butyl)benzyl
Bnzl
i-Bu
A


IIF-96
4-(trifluoromethoxy)benzyl
Bnzl
i-Bu
B


IIF-97
4-ethoxybenzyl
Bnzl
i-Bu
C


IIF-101
4-hydroxybenzyl
Bnzl
i-Pnt
B


IIF-102
Bnzl
naphthalen-2-
i-Bu
A




ylmethyl




IIF-103
i-Pnt
4-Cl-Bnzl
i-Bu
B


IIF-104
i-Pnt
4-fluorobenzyl
i-Bu
B
















TABLE 5-26







Anti-rabies activity of compounds of formula XXIIF












Compound




Anti-rabies


number
R1
R2A
R2B
R3
activity





IIF-325
i-Pnt
H
3-Cl-Bnzl
Bnzl
A


IIF-326
i-Pnt
H
4-Cl-Bnzl
Bnzl
A


IIF-327
i-Pnt
H
4-F-Bnzl
Bnzl
A


IIF-328
i-Pnt
H
4-Me-Bnzl
Bnzl
A


IIF-329
i-Pnt
H
4-MeO-Bnzl
Bnzl
A


IIF-330
i-Bu
H
4-Cl-Bnzl
Ph-Et
A


IIF-331
i-Bu
H
3-Cl-Bnzl
Ph-Et
A


IIF-332
i-Bu
H
4-MeO-Bnzl
Ph-Et
A


IIF-333
i-Bu
H
4-Me-Bnzl
Ph-Et
A


IIF-334
i-Bu
H
2-Npm
Ph-Et
A


IIF-335
i-Bu
H
Bnzl
Ph-Pr
A


IIF-336
i-Bu
H
3-Cl-Bnzl
Ph-Pr
A


IIF-337
i-Bu
H
3-F-Bnzl
Ph-Pr
A


IIF-338
Cpm
H
4-OH-Bnzl
2-Cbx-Et
na


IIF-339
i-Bu
H
3-Me-Bnzl
Ph-Pr
A


IIF-340
i-Bu
H
3-MeO-Bnzl
Ph-Pr
A


IIF-341
i-Bu
H
3-Cl-Bnzl
Ph-Bu
A


IIF-342
i-Bu
H
3-F-Bnzl
Ph-Bu
A


IIF-343
i-Bu
H
3-Me-Bnzl
Ph-Bu
A


IIF-344
i-Bu
H
3-MeO-Bnzl
Ph-Bu
A


IIF-345
i-Bu
H
Bnzl
Ph-Bu
A


IIF-346
i-Pnt
H
3-F-Bnzl
Ph-Pr
A


IIF-370
i-Pnt
H
Ph-Et
Bnzl
A


IIF-371
i-Pnt
H
1-Npm
Bnzl
A


IIF-372
i-Bu
H
4-F-Bnzl
Ph-Et
A


IIF-373
i-Bu
H
Ph-Et
Ph-Et
A


IIF-374
i-Bu
H
1-Npm
Ph-Et
A


IIF-376
4-F-Bnzl
H
1-Npm
i-Bu
A









Example 3: Efficacy in a Mouse Model of Rabies

In this example, it was tested whether the compound of the present disclosure is effective in a rabies mouse model.


(Materials and Methods)


Recombinant rabies virus 1088 strain expressing Red Firefly Luciferase (RFLuc) (1088/RFLuc) was generated by replacing the E2Cr gene of the recombinant virus 1088/E2Cr with the RFLuc gene (Isomura M, Yamada K, Noguchi K, Nishizono A. Near-infrared fluorescent protein iRFP720 is optimal for in vivo fluorescence imaging of rabies virus infection. J Gen Virol. 2017, 98(11): 2689-2698. doi: 10.1099/jgv.0.000950.). Hairless mice (Hos: HR-1, 6-week old, female; Hoshino Laboratory Animals) were inoculated with 1×105 infectious units of 1088/RFLuc intramuscularly into the right hindlimb and administered the test compound intraperitoneally for 6 days (Day 0 to Day 6), beginning 1 hour after inoculation. Actually, 0.5 mL of the solution (2% DMSO, 2% Solutol HS 15, and penicillin/streptomycin-added Dulbecco's phosphate buffered saline, available from Nacalai tesque, Sigma-Aldrich, etc.) supplemented with/without the compound (25 mg/kgBW) was administered twice daily with a 6-hour interval between doses. The inoculated mice were monitored for clinical signs and weighed everyday. The viral dynamics in the treated mice were observed longitudinally using in vivo imaging as follows; mice were administered D-Luciferin solution (150 mg/kgBW; Wako Pure Chemical Industry) intraperitoneally and then imaged (exposure time of 2 minutes and electron-multiplying gain of 300) with the Lumazone imaging system (Nippon Roper) under 2% isoflurane inhalation anesthesia after 15 minutes of substrate injection. The obtained images (16-bit TIFF) were processed and analysed using the ImageJ software. The compounds listed in Table 5 that were evaluated in Example 2 were tested as the test compounds.


(Results)


On days 6 and 8 after virus inoculation, the viral dynamics and the effect of the test compounds were observed in the mice, where the virus-driven luciferase luminescence served as an indicator. It was observed that the viral propagation and dissemination in the brain and spinal cord were significantly suppressed in three of four infected mice that were given the test compound at 50 mg/kgBW/day for 6 days (Days 0 to 5) compared to the solvent administered group, indicating that the antiviral effect of the test compounds on rabies virus was also confirmed in the infected mouse model. In other words, the compounds listed in Table 5 that were evaluated in Example 2 were confirmed to attain a significant therapeutic/prophylactic effect. For the nucleic acid analog drug favipiravir (product name: Avigan tablet/Toyama Chemical), which was confirmed to be effective on rabies virus, a significant prophylactic effect was confirmed in ddY mice given in a dose of 300 mg/kgBW/day, but not 100 mg/kgBW/day, for 7 days immediately after viral inoculation (Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2016, 213(8): 1253-1261.doi:10.1093/infdis/jiv586.). Therefore, the present compound can be provided as a novel and highly effective rabies therapeutic agent that has a different mechanism of action from favipiravir.


Example 4: Anti-Cancer Cell Activity Evaluation Method

The minimum inhibitory concentration (MIC) with respect to cells was evaluated for compounds in Example 2 with which cell death of the host, i.e., mouse neuroblastoma cell strain Neuro-2A, was observed.


Each tested compound prepared as a 10 mM with DMSO was first diluted to 100 μM or 40 μM with 10% fetal bovine serum-supplemented medium, and further diluted with the medium to the final concentration of interest. Fifty microlitter of the diluted medium was added dropwise to each well of a 96-well plate. Furthermore, 50 μL of medium comprising 4×102 infectious units of 1088/GLuc and 4×104 Neuro-2a cells were added to each well. The plate was shaken for 30 seconds with the microplate mixer NS-4P and then cultured for 3 days at 37° C. in the presence of 5% CO2. After incubation, 25 μL of coelenterazine was added dropwise to each well of the plate, and the plate was immediately loaded into the luminescent plate reader LuMate and shaken for 10 seconds. The relative light unit (RLU) was then measured, and entries in which a cell death caused due to virus infection were excluded.


The following tables show the results of evaluating the compounds. Some compounds were evaluated as a mixture as shown in the following tables. The compounds are classified as a if the minimum inhibitory concentration (MIC) is 10 μM or less, b if greater than 10 μM and less than or equal to 20 μM, and c if greater than 20 μM and less than or equal to 40 μM. The ‘na’ indicates not applicable.









TABLE 6-1







Anti-cancer cell activity of compounds of formula XXIB













Compound





Anti-cancer


number
R1
R2A
R2B
R3
R4
cell activity





IB-924
4-Me-
H
Bnzl
i-Bu
N-isobutyl-
na



Bnzl



aminocarbonyl



IB-925
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
c


IB-926
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
b


IB-927
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
c


IB-928
i-Bu
H
4-Me-Bnzl
Ph-Et
H
c


IB-929
i-Bu
H
2-Npm
Ph-Et
H
b


IB-930
i-Bu
H
Bnzl
Ph-Pr
H
c


IB-931
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
c


IB-932
i-Bu
H
3-F-Bnzl
Ph-Pr
H
c


IB-933
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
b


IB-934
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
b


IB-935
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
c


IB-936
i-Bu
H
3-F-Bnzl
Ph-Bu
H
b


IB-937
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
c


IB-938
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
c


IB-939
i-Bu
H
Bnzl
Ph-Bu
H
c


IB-940
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
c


IB-957
i-Bu
H
Ph-Et
Ph-Et
H
c


IB-958
i-Bu
H
1-Npm
Ph-Et
H
b





(a: MIC ≤ 10 μM,


b: 10 μM < MIC ≤ 20 μM,


c: 20 μM < MIC ≤ 40 μM)













TABLE 6-2







Anti-cancer cell activity of compounds of formula XXIF













Compound





Anti-cancer


number
R1
R2A
R2B
R3
R4
cell activity





IF-885
i-Bu
H
4-Cl-Bnzl
Ph-Et
H
c


IF-886
i-Bu
H
3-Cl-Bnzl
Ph-Et
H
c


IF-887
i-Bu
H
4-MeO-Bnzl
Ph-Et
H
c


IF-888
i-Bu
H
4-Me-Bnzl
Ph-Et
H
na


IF-889
i-Bu
H
2-Npm
Ph-Et
H
b


IF-890
i-Bu
H
Bnzl
Ph-Pr
H
c


IF-891
i-Bu
H
3-Cl-Bnzl
Ph-Pr
H
b


IF-892
i-Bu
H
3-F-Bnzl
Ph-Pr
H
c


IF-893
i-Bu
H
3-Me-Bnzl
Ph-Pr
H
c


IF-894
i-Bu
H
3-MeO-Bnzl
Ph-Pr
H
c


IF-895
i-Bu
H
3-Cl-Bnzl
Ph-Bu
H
b


IF-896
i-Bu
H
3-F-Bnzl
Ph-Bu
H
b


IF-897
i-Bu
H
3-Me-Bnzl
Ph-Bu
H
b


IF-898
i-Bu
H
3-MeO-Bnzl
Ph-Bu
H
c


IF-899
i-Bu
H
Bnzl
Ph-Bu
H
c


IF-900
i-Pnt
H
3-F-Bnzl
Ph-Pr
H
c


IF-909
i-Bu
H
Ph-Et
Ph-Et
H
na
















TABLE 6-3







Anti-cancer cell activity of compounds of formula XXIIB and


formula XXIIF












Compound




Anti-cancer


number
R1
R2A
R2B
R3
cell activity





Mixture of
i-Pnt
H
3-Cl-Bnzl
Bnzl
c


IIB-326 and







IIF-325







Mixture of
i-Pnt
H
4-Me-Bnzl
Bnzl
c


IIB-327 and







IIF-328







Mixture of
i-Pnt
H
4-MeO-Bnzl
Bnzl
na


IIB-328 and







IIF-329







IIB-329
Me
H
quinolin-8-
Bnzl
na





ylethyl




IIB-330
Me
H
quinolin-5-
Bnzl
na





ylethyl




IIB-331
i-Bu
H
4-Cl-Bnzl
Ph-Et
c


IIB-332
i-Bu
H
3-Cl-Bnzl
Ph-Et
b


IIB-333
i-Bu
H
4-MeO-Bnzl
Ph-Et
na


IIB-334
i-Bu
H
4-Me-Bnzl
Ph-Et
c


IIB-335
i-Bu
H
2-Npm
Ph-Et
c


IIB-336
i-Bu
H
Bnzl
Ph-Pr
c


IIB-337
i-Bu
H
3-Cl-Bnzl
Ph-Pr
c


IIB-338
i-Bu
H
3-F-Bnzl
Ph-Pr
c


IIB-339
Cpm
H
4-OH-Bnzl
2-Cbx-Et
na


IIB-340
i-Bu
H
3-Me-Bnzl
Ph-Pr
c


IIB-341
i-Bu
H
3-MeO-Bnzl
Ph-Pr
c


IIB-342
i-Bu
H
3-Cl-Bnzl
Ph-Bu
b


IIB-343
i-Bu
H
3-F-Bnzl
Ph-Bu
c


IIB-344
i-Bu
H
3-Me-Bnzl
Ph-Bu
b


IIB-345
i-Bu
H
3-MeO-Bnzl
Ph-Bu
c


IIB-346
i-Bu
H
Bnzl
Ph-Bu
b


IIB-347
i-Pnt
H
3-F-Bnzl
Ph-Pr
c


Mixture of
i-Pnt
H
4-F-Bnzl
Bnzl
b


IIB-371 and







IIF-327







Mixture of
i-Pnt
H
Ph-Et
Bnzl
na


IIB-372 and







IIF-370







Mixture of
i-Pnt
H
1-Npm
Bnzl
c


IIB-373 and







IIF-371







IIB-374
i-Bu
H
4-F-Bnzl
Ph-Et
c


IIB-375
i-Bu
H
Ph-Et
Ph-Et
na


IIB-376
i-Bu
H
1-Npm
Ph-Et
c


IIB-378
4-F-Bnzl
H
1-Npm
i-Bu
b
















TABLE 6-4







(continuation)












Compound




Anti-cancer


number
R1
R2A
R2B
R3
cell activity





IIF-326
i-Pnt
H
4-Cl-Bnzl
Bnzl
b


IIF-330
i-Bu
H
4-Cl-Bnzl
Ph-Et
c


IIF-331
i-Bu
H
3-Cl-Bnzl
Ph-Et
c


IIF-332
i-Bu
H
4-MeO-Bnzl
Ph-Et
na


IIF-333
i-Bu
H
4-Me-Bnzl
Ph-Et
c


IIF-334
i-Bu
H
2-Npm
Ph-Et
c


IIF-335
i-Bu
H
Bnzl
Ph-Pr
na


IIF-336
i-Bu
H
3-Cl-Bnzl
Ph-Pr
c


IIF-337
i-Bu
H
3-F-Bnzl
Ph-Pr
b


IIF-338
Cpm
H
4-OH-Bnzl
2-Cbx-Et
na


IIF-339
i-Bu
H
3-Me-Bnzl
Ph-Pr
c


IIF-340
i-Bu
H
3-MeO-Bnzl
Ph-Pr
na


IIF-341
i-Bu
H
3-Cl-Bnzl
Ph-Bu
b


IIF-342
i-Bu
H
3-F-Bnzl
Ph-Bu
c


IIF-343
i-Bu
H
3-Me-Bnzl
Ph-Bu
c


IIF-344
i-Bu
H
3-MeO-Bnzl
Ph-Bu
c


IIF-345
i-Bu
H
Bnzl
Ph-Bu
c


IIF-346
i-Pnt
H
3-F-Bnzl
Ph-Pr
c


IIF-372
i-Bu
H
4-F-Bnzl
Ph-Et
c


IIF-373
i-Bu
H
Ph-Et
Ph-Et
c


IIF-374
i-Bu
H
1-Npm
Ph-Et
c


IIF-376
4-F-Bnzl
H
1-Npm
i-Bu
c









[Note]


As disclosed above, the present disclosure is exemplified by the use of its preferred embodiments. However, it is understood that the scope of the present disclosure should be interpreted based solely on the Claims. It is also understood that any patent, any patent application, and any other references cited herein should be incorporated herein by reference in the same manner as the contents are specifically described herein. The present application is a continuation-in-part application that claims priority to Japanese Patent Application No. 2018-153227 filed on Aug. 16, 2018 and International Publication No. PCT/JP2019/032032 filed on Aug. 15, 2019 with the Japan Patent Office. The entire content thereof is incorporated herein by reference.


INDUSTRIAL APPLICABILITY

The present disclosure is useful in the field of rabies and cancer treatment and prophylaxis.

Claims
  • 1. A compound represented by formula XXIF:
  • 2. A compound represented by formula XXIB:
  • 3. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R1, R3, and R4 are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, andthe alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R2A and R2B, and the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.
  • 4. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R1, R3, and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,optionally substituted aryl,optionally substituted heteroaryl, oroptionally substituted carbonyl,R2A and R2B are each independently, hydrogen,optionally substituted alkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,optionally substituted aryl,optionally substituted heteroaryl, oroptionally substituted carbonyl, orR2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted-, or(2) wherein(2) wherein R1, R3, and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted heteroarylcarbonyl,optionally substituted heteroaryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl,optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl,wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II,R2A and R2B are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted heteroarylcarbonyl,optionally substituted heteroaryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl,optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl,wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, orR2A and R2B together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.
  • 5. (canceled)
  • 6. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R1 and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl,optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III; or(2) wherein R1 and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,carbamoyl, oroptionally alkylcarbamoyl,wherein the croups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III; or(3) wherein R1 and R4 are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro,formyl,substituted carbonyl, orsubstituted oxycarbonyl,wherein the substituted amino, substituted oxy, substituted alkyl, substituted, carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV; or(4) wherein R1 and R4 are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy,formyl,alkylcarbonyl,arylalkylcarbonyl,arylalkyloxycarbonyl,alkoxycarbonyl,arylcarbonyl,carbamoyl,alkylcarbamoyl, orarylalkylcarbamoyl,wherein the substituted aminos each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
  • 7-9. (canceled)
  • 10. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R3 is hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy,wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R3 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV; or(2) wherein R3 is hydrogen, alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consist of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy, or(3) wherein R3 is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.
  • 11. (canceled)
  • 12. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R2A and R2B are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy,heteroarylalkyl,substituted heteroarylalkyl,cycloalkyl, orsubstituted cycloalkyl,wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, orR2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI; or(2) wherein R2A and R2B are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy,heteroarylalkyl,alkoxycarbonyl-substituted heteroarylalkyl, orcycloalkyl, orR2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or(3) wherein R2A is hydrogen,R2B is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl haloalkyl, alkoxy, and hydroxy, orcycloalkyl.
  • 13. (canceled)
  • 14. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim wherein R1 is alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy,wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
  • 15.-16. (canceled)
  • 17. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, wherein R4 is hydrogen,alkyl,alkylcarbonyl,arylalkylcarbonyl,arylalkyloxycarbonyl,alkoxycarbonyl,carbamoyl, orarylalkylcarbamoyl.
  • 18.-40. (canceled)
  • 41. A method for the prophylaxis or treatment of rabies, comprising administering a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
  • 42. A method for the prophylaxis or treatment of cancer, comprising administering a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
  • 43. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R1, R3, and R4 are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, andthe alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R2A and R2B, and the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.
  • 44. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R1, R3, and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,optionally substituted aryl,optionally substituted heteroaryl, oroptionally substituted carbonyl,R2A and R2B are each independently, hydrogen,optionally substituted alkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,optionally substituted aryl,optionally substituted heteroaryl, oroptionally substituted carbonyl, orR2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted, or(2) wherein R1, R3, and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted heteroarylcarbonyl,optionally substituted heteroaryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl,optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1, R3, and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II,R2A and R2B are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,optionally substituted heterocycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted heteroarylcarbonyl,optionally substituted heteroaryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl, optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl, wherein the groups of R2A and R2B are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, orR2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.
  • 45. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R1 and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,optionally substituted cycloalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,optionally substituted cycloalkylcarbonyl,optionally substituted cycloalkyloxycarbonyl,optionally substituted heterocycloalkylcarbonyl,optionally substituted heterocycloalkyloxycarbonyl,carbamoyl,optionally substituted alkylcarbamoyl,optionally substituted alkoxycarbamoyl,optionally substituted arylcarbamoyl,optionally substituted heteroarylcarbamoyl,optionally substituted cycloalkylcarbamoyl, oroptionally substituted heterocycloalkylcarbamoyl, wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or(2) wherein R1 and R4 are each independently, hydrogen,optionally substituted alkyl,optionally substituted arylalkyl,formyl,optionally substituted alkylcarbonyl,optionally substituted alkoxycarbonyl,optionally substituted arylcarbonyl,optionally substituted aryloxycarbonyl,carbamoyl, oroptionally substituted alkylcarbamoyl,wherein the groups of R1 and R4 are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or(3) wherein R1 and R4 are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro,formyl,substituted carbonyl, orsubstituted oxycarbonyl,wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R1 and R4 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or(4) wherein R1 and R4 are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy,formyl,alkylcarbonyl,arylalkylcarbonyl,arylalkyloxycarbonyl,alkoxycarbonyl,arylcarbonyl,aryloxycarbonyl,carbamoyl,alkylcarbamoyl, orarylalkylcarbamoyl,wherein the substituted aminos each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
  • 46. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R3 is hydrogen, alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy,wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R3 each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or(2) wherein R3 is hydrogen, alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy, or(3) wherein R3 is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.
  • 47. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R2A and R2B are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy,heteroarylalkyl,substituted heteroarylalkyl,cycloalkyl, orsubstituted cycloalkyl,wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R2A and R2B each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, orR2A and R2B, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or(2) wherein R2A and R2B are each independently, hydrogen,alkyl,alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy,heteroarylalkyl,alkoxycarbonyl-substituted heteroarylalkyl, orcycloalkyl, orR2A and R2B, together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or(3) wherein R2A is hydrogen,R2B is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl,arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, orcycloalkyl.
  • 48. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein R1 is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl,arylalkyl, orarylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy,wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
  • 49. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein R4 is hydrogen, alkyl,alkylcarbonyl,arylalkylcarbonyl,arylalkyloxycarbonyl,alkoxycarbonyl,carbamoyl, orarylalkylcarbamoyl.
  • 50. A method for the prophylaxis or treatment of rabies, comprising administering a therapeutically effective amount of the compound according to claim 2, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
  • 51. A method for the prophylaxis or treatment of cancer, comprising administering a therapeutically effective amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
Priority Claims (1)
Number Date Country Kind
2018-153227 Aug 2018 JP national
Continuation in Parts (1)
Number Date Country
Parent PCT/JP2019/032032 Aug 2019 US
Child 16791715 US